



US008283148B2

(12) **United States Patent**
Sorge et al.(10) **Patent No.:** **US 8,283,148 B2**
(45) **Date of Patent:** ***Oct. 9, 2012**(54) **DNA POLYMERASE COMPOSITIONS FOR
QUANTITATIVE PCR AND METHODS
THEREOF**(75) Inventors: **Joseph A. Sorge**, Wilson, WY (US);
Reinhold Dietrich Mueller, San Diego,
CA (US); **Gothami Padmabandu**, San
Diego, CA (US); **Nick Roelofs**, San
Diego, CA (US); **Holly H. Hogrefe**, San
Diego, CA (US)(73) Assignee: **Agilent Technologies, Inc.**, Santa Clara,
CA (US)(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 2021 days.This patent is subject to a terminal dis-
claimer.(21) Appl. No.: **10/734,563**(22) Filed: **Dec. 12, 2003**(65) **Prior Publication Data**

US 2005/0069908 A1 Mar. 31, 2005

Related U.S. Application Data(63) Continuation-in-part of application No. 10/408,601,
filed on Apr. 7, 2003, now abandoned, which is a
continuation-in-part of application No. 10/298,680,
filed on Nov. 18, 2002, now abandoned, which is a
continuation-in-part of application No. 10/280,962,
filed on Oct. 25, 2002, now abandoned.(51) **Int. Cl.**
C12N 9/12 (2006.01)
C12P 19/34 (2006.01)(52) **U.S. Cl.** **435/194**; 435/91.1(58) **Field of Classification Search** None
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**5,489,523 A 2/1996 Mathur 435/194
6,333,183 B1 12/2001 Evans et al. 435/194
6,395,526 B1 5/2002 Uemori et al. 435/194
6,607,883 B1 8/2003 Frey et al. 435/6**FOREIGN PATENT DOCUMENTS**EP 0 870 832 A1 10/1998
EP 0 693 078 B1 6/1999
EP 0 922 765 A1 6/1999
EP 1 088 891 A1 4/2001
EP 1 132 474 A1 9/2001
JP 2001-269188 10/2001
WO WO 01/23583 A2 4/2001
WO 0132887 5/2001
WO WO 01/92501 A1 12/2001
WO WO03/060144 7/2003
WO WO03/089637 10/2003**OTHER PUBLICATIONS**Ngo et al., Computational Complexity, Protein Structure Prediction,
and the Levinthal Paradox, in *The Protein Folding Problem and*
Tertiary Structure Prediction, 1994, Merz et al. (ed.), Birkhauser,
Boston, MA, pp. 433 and 492-495.*Arezi, B. et al., "Amplification efficiency of thermostable DNA
polymerases", *Analytical Biochemistry*, 2003, 321:226-235.Fogg, M.J. et al., "The Structural Basis for Template Strand Uracil
Recognition by Archaeal DNA Polymerases", *FASEB Summer*
Research Conference, poster abstract, Jun. 2002, (20).Hogrefe, H.H. et al., "Archaeal dUTPase enhances PCR amplifica-
tions with archaeal DNA polymerases by preventing dUTP incorpo-
ration", *PNAS*, 2002, 99(2):596-601.Pavlov, A.R. et al., "Helix-hairpin-helix motifs confer salt resistance
and processivity on chimeric DNA polymerases", *PNAS*, 2002,
99(21):13510-13515.Evans, S.J. et al., "Improving dideoxynucleotide-triphosphate
utilisation by the hyper-thermophilic DNA polymerase from the
archaeon *Pyrococcus furiosus*", *Nucleic Acids Research*, 2000,
28(5):1059-1066.Greagg, M.A. et al., "A read-ahead function in archaeal DNA
polymerases detects promutagenic template-strand uracil", *Proceed-
ings of the National Academy of Sciences USA*, 1999, 96(16):9045-
9050.Sakaguchi, A.Y. et al., "Cautionary Note on the Use of dUMP-Con-
taining PCR Primers with *Pfu* and *Vent*_® DNA Polymerases", 1996,
BioTechniques, 21:368-370.Slupphaug, G. et al., "Low Incorporation of dUMP by Some
Thermostable DNA Polymerases May Limit Their Use in PCR
Amplifications", 1993, *Anal. Biochem.*, 211:164-169.Longo, M.C. et al., "Use of uracil DNA glycosylase to control carry-
over contamination in polymerase chain reactions", 1990, *Gene*,
93:125-128.International Search Report for PCT/US03/33997, dated Dec. 10,
2004.Evans, et al. Improving dideoxynucleotide-triphosphate utilisation
by the hyper-thermophilic DNA polymerase from the archaeon
Pyrococcus furiosus. *Nucleic Acids Research*. Mar. 2000, vol. 28,
No. 5, pp. 1059-1066.Connolly et al., "Uracil Recognition by Archaeal Family B DNA
Polymerase", *Biochemical Society Transactions* (2003), V. 31, Part 3,
pp. 699-702.Fogg et al., "Structural Basis for Uracil Recognition by Archaeal
Family B DNA Polymerases", *Nature Structural Biology* (2002), V.
9, No. 12, pp. 922-927.Gardner et al., "Determinants of Nucleotide Sugar Recognition in an
Archaeon DNA Polymerase", *Nucleic Acids Research* (1999), V. 27,
No. 12, pp. 2545-2553.Supplementary European Search Report based on EP 03809647
dated Sep. 22, 2005.Guo, et al. "Protein Tolerance to Random Amino Acid Change",
(2004) *Proc. Natl. Acad. Sci.*, vol. 101(25), pp. 9205-9210.

(Continued)

Primary Examiner — Richard Hutson(57) **ABSTRACT**The invention relates to the generation and characterization of
Archaeal DNA polymerase mutants with deficient 3'-5' exo-
nuclease activity and reduced base analog detection activity.
The invention further provides for Archaeal DNA polymerase
mutants with deficient 3'-5' exonuclease activity and reduced
base analog detection activity containing additional muta-
tions that modulate other DNA polymerase activities includ-
ing DNA polymerization or reverse transcriptase activity. The
invention also discloses methods and applications of DNA
polymerases with deficient 3'-5' exonuclease activity and
reduced base analog detection activity.**25 Claims, 62 Drawing Sheets**

OTHER PUBLICATIONS

Bonnin, et al. "A Single Tyrosine Prevents Insertion of Ribonucleotides in the Eukaryotic-type Phi29 DNA Polymerase" (1999) J.Mol.Biol., vol. 291(1), pp. 241-251.

International Search Report received in PCT/US04/41899, dated Nov. 30, 2007.

Savino, C. et al., "Insights Into DNA Replication: The Crystal Structure of DNA Polymerase B1 from the Archaeon *Sulfolobus solfataricus*", Structure, vol. 12, 2001-2008, Nov. 2004.

* cited by examiner

Figure 1. Oligonucleotide Primers for QuikChange Mutagenesis

V93E#15'-gAACATCCCCAAGATgAACCCACTATTAgAgAAAAAg-3' (SEQ ID NO: 6)**V93E#2**

5'-CTTTTCTCTAATAgTgggTTCATCTTggggATgTTC-3' (SEQ ID NO: 7)

V93R#15'-gAACATCCCCAAGATAgAACCCACTATTAgAgAAAAAg-3' (SEQ ID NO: 8)**V93R#2**

5'-CTTTTCTCTAATAgTgggTCTATCTTggggATgTTC-3' (SEQ ID NO: 9)

V93N#15'-gAACATCCCCAAGATAACCCCACTATTAgAgAAAAAg-3' (SEQ ID NO: 10)**V93N#2**

5'-CTTTTCTCTAATAgTggggTTATCTTggggATgTTC-3' (SEQ ID NO: 11)

V93H#15'-gAACATCCCCAAGATCACCCCACTATTAgAgAAAAAg-3' (SEQ ID NO: 12)**V93H#2**

5'-CTTTTCTCTAATAgTggggTgATCTTggggATgTTC-3' (SEQ ID NO: 13)

V93X (for saturation mutagenesis; obtained V93G and V93L mutants from library)5'-(Phosphate)gAACATCCCCAAGATNNKCCCACTATTAgAgAAAAAg-3'
(SEQ ID NO: 14)**V93K#1**5'-gAACATCCCCAAGATAAACCCACTATTAgAg-3' (SEQ ID NO: 43)**V93K#2**

5'-CTCTAATAgTgggTTTATCTTggggATgTTC-3' (SEQ ID NO: 44)

QCM#1 5'-(Phosphate)gAACATCCCCAAGATgCACCCACTATTAgAgAAAAAg-
(SEQ ID NO: 45)'

Alanine

QCM#2 5'-(Phosphate)gAACATCCCCAAGATgACCCCACTATTAgAgAAAAAg-3'
(SEQ ID NO: 46)

Aspartic Acid

QCM#3 5'-(Phosphate)gAACATCCCCAAGATTgCCCCCACTATTAgAgAAAAAg-3'
(SEQ ID NO: 47)

Cysteine

QCM#4 5'-
(Phosphate)gAACATCCCCAAGATATACCCACTATTAgAgAAAAAg-3'
(SEQ ID NO: 48)

Isoleucine

QCM#5 5'-(Phosphate)gAACATCCCCAAGATATgCCCACTATTAgAgAAAAAg-3'
(SEQ ID NO: 49)

Methionine

QCM#6 5'-(Phosphate)gAACATCCCCAAGATTTCCTCCCACTATTAgAgAAAAAg-3'
(SEQ ID NO: 50)

Phenylalanine

QCM#7 5'-(Phosphate)gAACATCCCCAAGATCCTCCCACTATTAgAgAAAAAg-3'
(SEQ ID NO: 51)

Proline

QCM#8 5' Phosphate)gAACATCCCCAAGATAgCCCACTATTAgAgAAAAAg-3'
(SEQ ID NO: 52)

Serine

QCM#9 5'-(Phosphate)gAACATCCCCAAGATACACCCACTATTAgAgAAAAAg- 3'
(SEQ ID NO: 53)

Threonine


QCM#10 5' - (Phosphate) gAACATCCCCAagATTACCCCACTATTAgAgAAAAAg-3 '
(SEQ ID NO: 54)

Tyrosine

QCM#11 5' - (Phosphate) gAACATCCCCAagATTggCCCACTATTAgAgAAAAAg-3 '
(SEQ ID NO: 55)

Tryptophan

a.)



b.)




Figure 2

Figure 3: Protein concentration, unit concentration, and specific activity of the purified Pfu V93R and V93E mutants.

<i>Pfu</i> mutant	Protein concentration	PCR Unit concentrati	Specific activity (U/mg)
<i>Pfu</i>	0.0258 µg/µl	2.5U/µl	9.7×10^4
<i>Pfu</i> V93R	45 µg/µl	<u>6250U/µl</u>	<u>1.4×10^5</u>
<i>Pfu</i> V93E	35 µg/µl	<u>6250U/µl</u>	<u>1.8×10^5</u>




Figure 4




Figure 5

FIGURE 6A

PFU DNA POLYMERASE (SEQ ID NO: 17)

V93R MUTANT: GTT CAN BE MODIFIED TO BE = AGA, AGG, CGA, CGC, CGG, CGT (ALL POSSIBLE CODONS FOR ARGININE)V93E MUTANT: GTT CAN BE MODIFIED TO BE = GAA, GAG (ALL CODONS FOR GLUTAMIC ACID)V93D MUTANT: GTT CAN BE MODIFIED TO BE = GAT, GAC (ALL CODONS FOR ASPARTIC ACID)V93K MUTANT: GTT CAN BE MODIFIED TO BE = AAA, AAG (ALL CODONS FOR LYSINE)V93N MUTANT: GTT CAN BE MODIFIED TO BE = AAC, AAU (ALL CODONS FOR ASPARAGINE)

```
ATGATTTTAG ATGTGGATTA CATAACTGAA GAAGGAAAAC CTGTTATTAG GCTATTCAAA 60
AAAGAGAACG GAAAATTTAA GATAGAGCAT GATAGAACTT TTAGACCATA CATTACGCT 120
CTTCTCAGGG ATGATTCAAA GATTGAAGAA GTTAAGAAAA TAACGGGGGA AAGGCATGGA 180
AAGATTGTGA GAATTGTTGA TGTAGAGAAG GTTGAGAAAA AGTTTCTCGG CAAGCCTATT 240
ACCGTGTGGA AACTTTATTT GGAACATCCC CAAGATGTTT CCACTATTAG AGAAAAAGTT 300
AGAGAACATC CAGCAGTTGT GGACATCTTC GAATACGATA TTCCATTTGC AAAGAGATAC 360
CTCATCGACA AAGGCCTAAT ACCAATGGAG GGGGAAGAAG AGCTAAAGAT TCTTGCCTTC 420
GATATAGAAA CCCTCTATCA CGAAGGAGAA GAGTTTGGAA AAGGCCCAAT TATAATGATT 480
AGTTATCGAG ATGAAAATGA AGCAAAGGTG ATTACTTGGA AAAACATAGA TCTTCCATAC 540
GTTGAGGTTG TATCAAGCGA GAGAGAGATG ATAAAGAGAT TTCTCAGGAT TATCAGGGAG 600
AAGGATCCTG ACATTATAGT TACTTATAAT GGAGACTCAT TCGCATTCCC ATATTTAGCG 660
AAAAGGGCAG AAAAAGCTTG GATTAAATTA ACCATTGGAA GAGATGGAAG CGAGCCCAAG 720
ATGCAGAGAA TAGGCGATAT GACGGCTGTA GAAGTCAAGG GAAGAATACA TTTCGACTTG 780
TATCATGTAA TAACAAGGAC AATAAATCTC CCAACATACA CACTAGAGGC TGTATATGAA 840
GCAATTTTGT GAAAGCCAAA GGAGAAGGTA TACGCCGACG AGATAGCAAA AGCCTGGGAA 900
AGTGGAGAGT ACCTTGAGAG AGTTGCCAAA TACTCGATGG AAGATGCAAA GGCAACTTAT 960
GAACTCGGGA AAGAATTCTT TCCAATGGAA ATTCAGCTTT CAAGATTAGT TGGACAACCT 1020
TTATGGGATG TTTCAAGGTC AAGCACAGGG AACCTTGTAG AGTGGTTCTT ACTTAGGAAA 1080
GCCTACGAAA GAAACGAAGT AGCTCCAAAC AAGCCAAGTG AAGAGGAGTA TCAAAGAAGG 1140
CTCAGGGAGA GCTACACAGG TGGATTCTGT AAAGAGCCAG AAAAGGGGTT GTGGGAAAAC 1200
ATAGTATACC TAGATTTTAG AGCCCTATAT CCCTCGATTA TAATTACCCA CAATGTTTCT 1260
CCCGATACTC TAAATCTTGA GGGATGCAAG AACTATGATA TCGCTCCTCA AGTAGGCCAC 1320
AAGTTCTGCA AGGACATCCC TGGTTTTATA CCAAGTCTCT TGGGACATTT GTTAGAGGAA 1380
AGACAAAAGA TTAAGACAAA AATGAAGGAA ACTCAAGATC CTATAGAAAA AATACTCCTT 1440
GACTATAGAC AAAAAGCGAT AAAACTCTTA GCAAATCTT TCTACGGATA TTATGGCTAT 1500
GCAAAAGCAA GATGGTACTG TAAGGAGTGT GCTGAGAGCG TTACTGCCTG GGAAGAAAAG 1560
TACATCGAGT TAGTATGGAA GGAGCTCGAA GAAAAGTTTG GATTTAAAGT CCTCTACATT 1620
GACACTGATG GTCTCTATGC AACTATCCCA GGAGGAGAAA GTGAGGAAAT AAAGAAAAAG 1680
GCTCTAGAAT TTGTAAAATA CATAAATTCA AAGCTCCCTG GACTGCTAGA GCTTGAATAT 1740
GAAGGGTTT ATAAGAGGGG ATTCTTCGTT ACGAAGAAGA GGTATGCAGT AATAGATGAA 1800
GAAGGAAAAG TCATTACTCG TGGTTTAGAG ATAGTTAGGA GAGATTGGAG TGAAATTGCA 1860
AAAGAACTC AAGCTAGAGT TTTGGAGACA ATACTAAAAC ACGGAGATGT TGAAGAAGCT 1920
GTGAGAATAG TAAAAGAAGT AATACAAAAG CTTGCCAATT ATGAAATTCC ACCAGAGAAG 1980
CTCGCAATAT ATGAGCAGAT AACAAGACCA TTACATGAGT ATAAGGCGAT AGGTCTCTAC 2040
GTAGCTGTTG CAAAGAACT AGCTGCTAAA GGAGTTAAAA TAAAGCCAGG AATGGTAATT 2100
GGATACATAG TACTTAGAGG CGATGGTCCA ATTAGCAATA GGGCAATTCT AGCTGAGGAA 2160
TACGATCCCA AAAAGCACAA GTATGACGCA GAATATTACA TGGAGAACCA GGTCTTCCA 2220
GCGGTACTTA GGATATTGGA GGGATTGGA TACAGAAAGG AAGACCTCAG ATACCAAAAG 2280
ACRAGACAAG TCGGCCTAAC TTCCTGGCTT AACATTAAAA AATCCTAG 2328
```

KOD DNA POLYMERASE (SEQ ID NO: 18)

V93R MUTANT: GTC CAN BE MODIFIED TO BE = AGA, AGG, CGA, CGC, CGG, CGT (ALL POSSIBLE CODONS FOR ARGININE)

V93E MUTANT: GTC CAN BE MODIFIED TO BE = GAA, GAG (ALL CODONS FOR GLUTAMIC ACID)

V93D MUTANT: GTC CAN BE MODIFIED TO BE = GAT, GAC (ALL CODONS FOR ASPARTIC ACID)

V93K MUTANT: GTC CAN BE MODIFIED TO BE = AAA, AAG (ALL CODONS FOR LYSINE)

V93Q MUTANT: GTC CAN BE MODIFIED TO BE = CAA, CAG (ALL CODONS FOR GLUTAMINE)

V93N MUTANT: GTC CAN BE MODIFIED TO BE = AAC, AAU (ALL CODONS FOR ASPARAGINE)

```
ATGATCCTCG  ACACTGACTA  CATAACCGAG  GATGGAAAGC  CTGTCATAAG  AATTTTCAAG  60
AAGGAAAACG  GCGAGTTTAA  GATTGAGTAC  GACCGGACTT  TTGAACCTTA  CTTCTACGCC  120
CTCCTGAAGG  ACGATTCTGC  CATTGAGGAA  GTCAGAAGA  TAACCGCCGA  GAGGCACGGG  180
ACGGTTGTAA  CGGTTAAGCG  GGTGAAAAG  GTTCAGAAGA  AGTTCCTCGG  GAGACCAGTT  240
GAGGTCTGGA  AACTCTACTT  TACTCATCCG  CAGGACGTC  CAGCGATAAG  GGACAAGATA  300
CGAGAGCATC  CAGCAGTTAT  TGACATCTAC  GAGTACGACA  TACCCTTCGC  CAAGCGCTAC  360
CTCATAGACA  AGGGATTAGT  GCCAATGGAA  GGCACGAGG  AGCTGAAAAT  GCTCGCCTTC  420
GACATTGAAA  CTCTCTACCA  TGAGGGCGAG  GAGTTCGCCG  AGGGGCCAAT  CCTTATGATA  480
AGCTACGCCG  ACGAGGAAGG  GGCCAGGGTG  ATAACCTGGA  AGAACGTGGA  TCTCCCTAC  540
GTTGACGTCG  TCTCGACGGA  GAGGGAGATG  ATAAAGCGCT  TCCTCCGTGT  TGTGAAGGAG  600
AAAGACCCGG  ACGTTCTCAT  AACCTACAAC  GGCACAACT  TCGACTTCGC  CTATCTGAAA  660
AAGCGCTGTG  AAAAGCTCGG  AATAAACTTC  GCCCTCGGAA  GGGATGGAAG  CGAGCCGAAG  720
ATTTCAGAGG  TGGGCGACAG  GTTTGCCGTC  GAAGTGAAGG  GACGGATACA  CTTGATCTC  780
TATCCTGTGA  TAAGACGGAC  GATAAACCTG  CCCACATACA  CGCTTGAGGC  CGTTTATGAA  840
GCCGTCTTCG  GTCAGCCGAA  GGAGAAGGTT  TACGCTGAGG  AAATAACCAC  AGCCTGGGAA  900
ACCGGCGAGA  ACCTTGAGAG  AGTCGCCCCG  TACTCGATGG  AAGATGCGAA  GGTACATAC  960
GAGCTTGGGA  AGGAGTTCCT  TCCGATGGAG  GCCCAGCTTT  CTCGCTTAAT  CGGCCAGTCC  1020
CTCTGGGACG  TCTCCCGCTC  CAGCACTGGC  AACCTCGTTG  AGTGGTTCCT  CCTCAGGAAG  1080
GCCTATGAGA  GGAATGAGCT  GGCCCCGAAC  AAGCCCGATG  AAAAGGAGCT  GGCCAGAAGA  1140
CGGCAGAGCT  ATGAAGGAGG  CTATGTAAAA  GAGCCCGAGA  GAGGGTTGTG  GGAGAACATA  1200
GTGTACCTAG  ATTTTAGATC  CCTGTACCCC  TCAATCATCA  TCACCCACAA  CGTCTCGCCG  1260
GATACGCTCA  ACAGAGAAGG  ATGCAAGGAA  TATGACGTTG  CCCCACAGGT  CGGCCACCGC  1320
TTCTGCAAGG  ACTTCCCAGG  ATTTATCCCG  AGCCTGCTTG  GAGACCTCCT  AGAGGAGAGG  1380
CAGAAGATAA  AGAAGAAGAT  GAAGGCCACG  ATTGACCCGA  TCGAGAGGAA  GCTCCTCGAT  1440
TACAGGCAGA  GGGCCATCAA  GATCCTGGCA  AACAGCTACT  ACGGTTACTA  CGGCTATGCA  1500
AGGGCGCGCT  GGTACTGCAA  GGAGTGTGCA  GAGAGCGTAA  CGGCCTGGGG  AAGGGAGTAC  1560
ATAACGATGA  CCATCAAGGA  GATAGAGGAA  AAGTACGGCT  TTAAGGTAAT  CTACAGCGAC  1620
ACCGACGGAT  TTTTGGCCAC  AATACCTGGA  GCCGATGCTG  AAACCGTCAA  AAAGAAGGCT  1680
ATGGAGTTCC  TCAAGTATAT  CAACGCCAAA  CTTCCGGGCG  CGCTTGAGCT  CGAGTACGAG  1740
GGCTTCTACA  AACGCGGCTT  CTTGCTCAG  AAGAAGAAGT  ATGCGGTGAT  AGACGAGGAA  1800
GGCAAGATAA  CAACGCGCGG  ACTTGAGATT  GTGAGGCGTG  ACTGGAGCGA  GATAGCGAAA  1860
GAGACGCAGG  CGAGGGTTCT  TGAAGCTTTG  CTAAAGGACG  GTGACGTCGA  GAAGGCCGTG  1920
AGGATAGTCA  AAGAAGTTAC  CGAAAAGCTG  AGCAAGTACG  AGGTTCCGCC  GGAGAAGCTG  1980
GTGATCCACG  AGCAGATAAC  GAGGGATTTA  AAGGACTACA  AGGCAACCGG  TCCCCACGTT  2040
GCCGTTGCCA  AGAGGTTGGC  CGCGAGAGGA  GTCAAAATAC  GCCCTGGAAC  GGTGATAAGC  2100
TACATCGTGC  TCAAGGGCTC  TGGGAGGATA  GGCACAGGG  CGATACCGTT  CGACGAGTTC  2160
GACCCGACGA  AGCACAAAGT  CGACGCCGAG  TACTACATTG  AGAACCGGT  TCTCCAGCC  2220
GTTGAGAGAA  TTCTGAGAGC  CTTGCGTTAC  CGCAAGGAAG  ACCTGCGCTA  CCAGAAGACG  2280
AGACAGGTTG  GTTTGAGTGC  TTGGCTGAAG  CCGAAGGGAA  CTTGA  2325
```

Vent DNA POLYMERASE (SEQ ID NO: 19)

V93R MUTANT: GTT CAN BE MODIFIED TO BE = AGA, AGG, CGA, CGC, CGG, CGT (ALL POSSIBLE CODONS FOR ARGININE)

V93E MUTANT: GTT CAN BE MODIFIED TO BE = GAA, GAG (ALL CODONS FOR GLUTAMIC ACID)

V93D MUTANT: GTT CAN BE MODIFIED TO BE = GAT, GAC (ALL CODONS FOR ASPARTIC ACID)

V93K MUTANT: GTT CAN BE MODIFIED TO BE = AAA, AAG (ALL CODONS FOR LYSINE)

V93Q MUTANT: GTT CAN BE MODIFIED TO BE = CAA, CAG (ALL CODONS FOR GLUTAMINE)

V93N MUTANT: GTT CAN BE MODIFIED TO BE = AAC, AAU (ALL CODONS FOR ASPARAGINE)

```
ATGATACTGG  ACACTGATTA  CATAACAAAA  GATGGCAAGC  CTATAATCCG  AATTTTAAAG  60
AAAGAGAACG  GGGAGTTTAA  AATAGAACTT  GACCCTCATT  TTCAGCCCTA  TATATATGCT  120
CTTCTCAAAG  ATGACTCCGC  TATTGAGGAG  ATAAAGGCAA  TAAAGGGCGA  GAGACATGGA  180
AAAACGTGTA  GAGTGCTCGA  TGCAGTGAAA  GTCAGGAAAA  AATTTTGGG  AAGGGAAGTT  240
GAAGTCTGGA  AGCTCATTTT  CGAGCATCCC  CAAGACGTTT  CAGCTATGCG  GGGCAAAATA  300
AGGGAACATC  CAGCTGTGGT  TGACATTTAC  GAATATGACA  TACCCTTTGC  CAAGCGTTAT  360
CTCATAGACA  AGGGCTTGAT  TCCCATGGAG  GGAGACGAGG  AGCTTAAGCT  CCTTGCCTTT  420
GATATTGAAA  CGTTTTATCA  TGAGGGAGAT  GAATTTGGAA  AGGGCGAGAT  AATAATGATT  480
AGTTATGCCC  ATGAAGAAGA  GGCCAGAGTA  ATCACATGGA  AAAATATCGA  TTTGCCGTAT  540
GTCGATGTTG  TGTCCAAATG  AAGAGAAATG  ATAAAGCGTT  TTGTTCAAGT  TGTTAAAGAA  600
AAAGACCCCG  ATGTGATAAT  AACTTACAAT  GGGGACAATT  TTGATTTGCC  GTATCTCATA  660
AAACGGGCAG  AAAAGCTGGG  AGTTCGGCTT  GTCTTAGGAA  GGGACAAAGA  ACATCCCGAA  720
CCCAGATTTC  AGAGGATGGG  TGATAGTTTT  GCTGTGGAAG  TCAAGGGTAG  AATCCACTTT  780
GATCTTTTCC  CAGTTGTGCG  AAGGACGATA  AACCTCCCAA  CGTATACGCT  TGAGGCAGTT  840
TATGAAGCAG  TTTTAGGAAA  AACCAAAAGC  AAATTAGGAG  CAGAGGAAAT  TGCCGCTATA  900
TGGGAAACAG  AAGAAAGCAT  GAAAAAATA  GCCCAGTACT  CAATGGAAGA  TGCTAGGGCA  960
ACGTATGAGC  TCGGGAAGGA  ATTCTTCCCC  ATGGAAGCTG  AGCTGGCAAA  GCTGATAGGT  1020
CAAAGTGTAT  GGGACGTCTC  GAGATCAAGC  ACCGGCAACC  TCGTGGAGTG  GTATCTTTTA  1080
AGGCTGGCAT  ACGCGAGGAA  TGAAGTTGCA  CCGAACAAAC  CTGATGAGGA  AGAGTATAAA  1140
CGGCGCTTAA  GAACAACCTA  CCTGGGAGGA  TATGTAAAAG  AGCCAGAAAA  AGGTTTGTGG  1200
GAAAATATCA  TTTATTTGGA  TTTCCGCACT  CTGTACCCTT  CAATAATAGT  TACTCACAAC  1260
GTATCCCGAG  ATACCCTTGA  AAAAGAGGGC  TGTAAGAATT  ACGATGTTGC  TCCGATAGTA  1320
GGATATAGGT  TCTGCAAGGA  CTTTCCGGGC  TTTATTCCCT  CCATACTCGG  GGACTTAATT  1380
GCAATGAGGC  AAGATATAAA  GAAGAAAATG  AAATCCACAA  TTGACCCGAT  CGAAAAGAAA  1440
ATGCTCGATT  ATAGGCAAG  GGCTATTAAA  TTGCTTGCAA  ACAGCTATTA  CGGCTATATG  1500
GGGTATCCTA  AGGCAAGATG  GTACTCGAAG  GAATGTGCTG  AAAGCGTTAC  CGCATGGGGG  1560
AGACACTACA  TAGAGATGAC  GATAAGAGAA  ATAGAGGAAA  AGTTCGGCTT  TAAGGTTCTT  1620
TATGCGGACA  CTGACGGCTT  TTATGCCACA  ATACCCGGGG  AAAAGCCTGA  ACTCATTAAA  1680
AAGAAAGCCA  AGGAATTCCT  AAATACATA  AACTCCAAAC  TTCCAGGTCT  GCTTGAGCTT  1740
GAGTATGAGG  GCTTTTACTT  GAGAGGATTC  TTTGTTACAA  AAAAGCGCTA  TGCAGTCATA  1800
GATGAAGAGG  GCAGGATAAC  AACAAGGGGC  TTGGAAGTAG  TAAGGAGAGA  TTGGAGTGAG  1860
ATAGCTAAGG  AGACTCAGGC  AAAGGTTTAA  GAGGCTATAC  TTAAAGAGGG  AAGTGTTGAA  1920
AAAGCTGTAG  AAGTTGTTAG  AGATGTTGTA  GAGAAAATAG  CAAAATACAG  GGTTCCACTT  1980
GAAAAGCTTG  TTATCCATGA  GCAGATTACC  AGGGATTTAA  AGGACTACAA  AGCCATTGGC  2040
CCTCATGTCG  CGATAGCAAA  AAGACTTGCC  GCAAGAGGGA  TAAAAGTGAA  ACCGGGCACA  2100
ATAATAGCT  ATATCGTTCT  CAAAGGGAGC  GGAAAGATAA  GCGATAGGGT  AATTTTACTT  2160
ACAGAATACG  ATCCTAGAAA  ACACAAGTAC  GATCCGGACT  ACTACATAGA  AAACCAAGTT  2220
TTGCCGCGAG  TACTTAGGAT  ACTCGAAGCG  TTTGATACA  GAAAGGAGGA  TTTAAGGTAT  2280
CAAAGCTCAA  AACAAACCGG  CTTAGATGCA  TGGCTCAAGA  GGTAG  2325
```

Deep Vent (SEQ ID NO: 20)

V93R MUTANT: GTT CAN BE MODIFIED TO BE = AGA, AGG, CGA, CGC, CGG, CGT (ALL POSSIBLE CODONS FOR ARGININE)

V93E MUTANT: GTT CAN BE MODIFIED TO BE = GAA, GAG (ALL CODONS FOR GLUTAMIC ACID)

V93D MUTANT: GTT CAN BE MODIFIED TO BE = GAT, GAC (ALL CODONS FOR ASPARTIC ACID)

V93K MUTANT: GTT CAN BE MODIFIED TO BE = AAA, AAG (ALL CODONS FOR LYSINE)

V93Q MUTANT: GTT CAN BE MODIFIED TO BE = CAA, CAG (ALL CODONS FOR GLUTAMINE)

V93N MUTANT: GTT CAN BE MODIFIED TO BE = AAC, AAU (ALL CODONS FOR ASPARAGINE)

ATGATACTTG	ACGCTGACTA	CATCACCGAG	GATGGGAAGC	CGATTATAAG	GATTTTCAAG	60
AAAGAAAACG	GCGAGTTTAA	GGTTGAGTAC	GACAGAAACT	TTAGACCTTA	CATTTACGCT	120
CTCCTCAAAG	ATGACTCGCA	GATTGATGAG	GTTAGGAAGA	TAACCGCCGA	GAGGCATGGG	180
AAGATAGTGA	GAATTATAGA	TGCCGAAAAG	GTAAGGAAGA	AGTTCCTGGG	GAGGCCGATT	240
GAGGTATGGA	GGCTGTACTT	TGAACACCCT	CAGGACGTTT	CCGCAATAAG	GGATAAGATA	300
AGAGAGCATT	CCGCAGTTAT	TGACATCTTT	GAGTACGACA	TTCCGTTTCG	GAAGAGGTAC	360
CTAATAGACA	AAGGCCTAAT	TCCAATGGAA	GGCGATGAAG	AGCTCAAGTT	GCTCGCATTT	420
GACATAGAAA	CCCTCTATCA	CGAAGGGGAG	GAGTTCGCGA	AGGGGCCCAT	TATAATGATA	480
AGCTATGCTG	ATGAGGAAGA	AGCCAAAGTC	ATAACGTGGA	AAAAGATCGA	TCTCCCGTAC	540
GTCGAGGTAG	TTTCCAGCGA	GAGGGAGATG	ATAAAGCGGT	TCCTCAAGGT	GATAAGGGAG	600
AAAGATCCCG	ATGTTATAAT	TACCTACAAC	GGCGATTCTT	TCGACCTTCC	CTATCTAGTT	660
AAGAGGGCCG	AAAAGCTCGG	GATAAAGCTA	CCCCTGGGAA	GGGACGGTAG	TGAGCCAAAG	720
ATGCAGAGGC	TTGGGGATAT	GACAGCGGTG	GAGATAAAGG	GAAGGATACA	CTTTGACCTC	780
TACCACGTGA	TTAGGAGAAC	GATAAACCTC	CCAACATACA	CCCTCGAGGC	AGTTTATGAG	840
GCAATCTTCG	GAAAGCCAAA	GGAGAAAGTT	TACGCTCACG	AGATAGCTGA	GGCCTGGGAG	900
ACTGGAAGG	GACTGGAGAG	AGTTGCAAAG	TATTCAATGG	AGGATGCAAA	GGTAACGTAC	960
GAGTCTGGTA	GGGAGTTCTT	CCCAATGGAG	GCCCAGCTTT	CAAGGTTAGT	CGGCCAGCCC	1020
CTGTGGGATG	TTTCTAGGTC	TTCAACTGGC	AACCTGGTGG	AGTGGTACCT	CCTCAGGAAG	1080
GCGTACGAGA	GGAAATGAATT	GGCTCCAAAC	AAGCCGGATG	AGAGGGAGTA	CGAGAGAAGG	1140
CTAAGGGAGA	GCTACGCTGG	GGGATACGTT	AAGGAGCCGG	AGAAAGGGCT	CTGGGAGGGG	1200
TTAGTTTCCC	TAGATTTCAG	GAGCCTGTAC	CCCTCGATAA	TAATCACCCA	TAACGTCTCA	1260
CCGGATACGC	TGAACAGGGA	AGGGTGTAGG	GAATACGATG	TCGCCCCAGA	GGTTGGGCAC	1320
AAGTTCTGCA	AGGACTTCCC	GGGGTTTATC	CCGAGCCTGC	TCAAGAGGTT	ATTGGATGAA	1380
AGGCAAGAAA	TAAAAAGGAA	GATGAAAGCT	TCTAAAGACC	CAATCGAGAA	GAAGATGCTT	1440
GATTACAGGC	AACGGGCAAT	CAAATCCTG	GCAAACAGCT	ATTATGGGTA	TTATGGGTAC	1500
GCAAAAGCCC	GTTGGTACTG	TAAGGAGTGC	GCAGAGAGCG	TTACGGCCTG	GGGGAGGGAA	1560
TATATAGAGT	TCGTAAGGAA	GGAAGTGGAG	GAAAAGTTTC	GGTTCAAAGT	CTTATACATA	1620
GACACAGATG	GACTCTACGC	CACAATTCCT	GGGGCAAAAC	CCGAGGAGAT	AAAGAAGAAA	1680
GCCCTAGAGT	TCGTAGATTA	TATAAACGCC	AAGCTCCCAG	GGCTGTTGGA	GCTTGAGTAC	1740
GAGGGCTTCT	ACGTGAGAGG	GTTCTTCGTG	ACGAAGAAGA	AGTATGCGTT	GATAGATGAG	1800
GAAGGGAAGA	TAATCACTAG	GGGGCTTGAA	ATAGTCAGGA	GGGACTGGAG	CGAAATAGCC	1860
AAAGAAACCC	AAGCAAAAGT	CCTAGAGGCT	ATCCTAAAGC	ATGGCAACGT	TGAGGAGGCA	1920
GTAAAGATAG	TTAAGGAGGT	AACTGAAAAG	CTGAGCAAGT	ACGAAATACC	TCCAGAAAAG	1980
CTAGTTATTT	ACGAGCAGAT	CACGAGGCC	CTTACAGAGT	ACAAGGCTAT	AGGTCCGCAC	2040
GTTGCCGTGG	CAAAAAGGTT	AGCCGCTAGA	GGAGTAAAGG	TGAGGCCTGG	CATGGTGATA	2100
GGGTACATAG	TGCTGAGGGG	AGACGGGCCA	ATAAGCAAGA	GGGCTATCCT	TGCAGAGGAG	2160
TTCGATCTCA	GGAAGCATAA	GTATGACGCT	GAGTATTACA	TAGAAAATCA	GGTTTACCT	2220
GCCGTTCTTA	GAATATTAGA	GGCCTTTGGG	TACAGGAAAG	AAGACCTCAG	GTGGCAGAAG	2280
ACTAAACAGA	CAGGTCTTAC	GGCATGGCTT	AACATCAAGA	AGAAGTAA		2328

V93R MUTANT: GTT CAN BE MODIFIED TO BE = AGA, AGG, CGA, CGC, CGG, CGT (ALL POSSIBLE CODONS FOR ARGININE)

V93E MUTANT: GTT CAN BE MODIFIED TO BE = GAA, GAG (ALL CODONS FOR GLUTAMIC ACID)

V93D MUTANT: GTT CAN BE MODIFIED TO BE = GAT, GAC (ALL CODONS FOR ASPARTIC ACID)

V93K MUTANT: GTT CAN BE MODIFIED TO BE = AAA, AAG (ALL CODONS FOR LYSINE)

V93Q MUTANT: GTT CAN BE MODIFIED TO BE = CAA, CAG (ALL CODONS FOR GLUTAMINE)

V93N MUTANT: GTT CAN BE MODIFIED TO BE = AAC, AAU (ALL CODONS FOR ASPARAGINE)

ATGATCCTTGACGTTGATTACATCACCGAGAATGGAAAGCCCGTCATCAGGGTCTTCAAGAAGGAGAACGGCGAGTT
CAGGATTGAATACGACCGCGAGTTCGAGCCCTACTTCTACGCGCTCCTCAGGGACGACTCTGCCATCGAAGAAATCA
AAAAGATAACCGCGGAGAGGCACGGCAGGGTCGTTAAGGTTAAGCGCGCGGAGAAAGTGAAGAAAAAGTTCTTCGGC
AGGTCTGTGGAGGTCTGGGTCTTACTTACGACCCCGCAGGACGTTCCGGCAATCCGCGACAAAATAAGGAAGCA
CCCCGCGGTATCGACATCTACGAGTACGACATACCCCTTCGCCAAGCGCTACCTCATAGACAAGGGCCTAATCCCGA
TGGAAGGTGAGGAAGAGCTTAAACTCATGTCTTCCGACATCGAGCGCTCTACCACGAGGGAGAGAGTTTGGAACC
GGGCCGATTCTGATGATAAGCTACGCCGATGAAAGCGAGGCGCGCTGATAACCTGGAAGAAGATCGACCTTCTCTTA
CGTTGAGGTTGTCTCCACCGAGAAGGAGATGATTAAGCGCTTCTTGAGGGTCGTTAAGGAGAAGGACCCGCGAGTGC
TGATAACATACAAACCGCGACAACTTCGACTTCGCCTACTGAAAAGCGCTGTGAGAAGCTTGGCGTGAGCTTTACC
CTCGGGAGGACCGGAGCGAGCCGAAGATACAGCGCATGGGGACAGGTTTGCGGTGAGGTGAAGGGCAGGGTACA
CTTCGACCTTTATCGAGTCATAAGGCGCACCATAAACCTCCCGACCTACACCCTTGAGGCTGTATACGAGGCGGTTT
TCGGCAAGCCCAAGGAGAAGGTCTACGCCGAGGAGATAGCCACCGCTGGGAGACCGGCGAGGGGCTTGAGAGGGTC
GCGCGCTACTCGATGGAGGACGCGAGGGTTACCTACGAGCTTGGCAGGGAGTTCTTCCGATGGAGGCCAGCTTTC
CAGGCTCATCGGCCAAGGCCTCTGGGACGTTTCCCGCTCCAGCACCGGCAACCTCGTCGAGTGGTTCTCTCTAAGGA
AGGCCTACGAGAGGAACGAACTCGCTCCCAACAAGCCCGACGAGAGGGAGCTGGCGAGGAGAAGGGGGGCTACGcC
GGTGCTACGTCAAGGAGCCGGAGCGGGGACTGTGGGACAATATCGTGTATCTAGACTTTCGTAGTCTCTAQCCTTC
AATCATAATCACCCACAACGTCCTCGCCAGATACGCTCAACCGCGAGGGGTGTAGGAGCTACGACGTTGCCCCCGAGG
TCGGTCACAAGTTCTGCAAGGACTTCCCCGGCTTCATTCGAGCCTGCTCGGAACCTGCTGGAGGAAGGCAGAAG
ATAAGAGGAAGATGAAGGCAACTCTCGACCCGCTGGAGAAGAATCTCCTCGATTACAGGCAACCGCTCCTATCAAGAT
TCTCGCCAAACAGCTACTACGGCTACTACGGCTATGCCAGGGCAAGATGGTACTGCAGGGAGTGCGCGAGAGCGTTA
CGGCATGGGGAAGGGAGTACATCGAAATGGTCATCAGAGAGCTTGAGGAAAAGTTTCGGTTTTAAAGTCTCTATGCA
GACACAGACGGTCTCCATGCCACCATTCCTGGAGCGGACGCTGAAAACAGTCAAGAAAAAGGCAATGGAGTTCTTAAA
CTATATCAATCCCAAACCTGCCCGGCTTCTCGAACTCGAATACGAGGGCTTCTACGTACGGGGCTTCTCTCGTCACGA
AGAAAAAGTACGCGGTCTCGACGAGGAGGGCAAGATAACCACGCGCGGGCTTGAGATAGTCAGGCGCGACTGGAGC
GAGATAGCGAAGGAGACGAGGCGAGGGTTTTGGAGGGCATACTCAGGCACGGTGACGTTGAAGAGGCCGTGAGAAAT
TGTCAGGGAGTCACCGAAAAGCTGAGCAAGTACGAGGTTCCGCGGAGAAGCTGGTTATCCACGAGCAGATAACGC
GCGAGCTCAAGGACTACAAGGCCACCGGCGCACGTAGCCATAGCGAAGcGTTTGGCCGCGAGAGGTGTTAAATC
CGGCCCGGAACTGTGATAAGCTACATCGTTCTGAAGGGCTCCGGAAGGATAGGCGACAGGGCGATTCCCTTCGACGA
GTTTCGACCCGACGAAGCACAGTACGATGCGGACTACTACATCGAGAACCAGGTTCTGCCGCGAGTTGAGAGAATCC
TCAGGGCCTTCGGCTACCGCAAGGAAGACCTGCGCTACCAGAAGACGAGGCAGGTGCGGCTTGGCGCGTGGCTGAAG
CCGAAGGGGAAGAAGAAGTGA

Tgo (SEQ ID NO: 22)

V93R MUTANT: GTT CAN BE MODIFIED TO BE = AGA, AGG, CGA, CGC, CGG, CGT (ALL POSSIBLE CODONS FOR ARGININE)

V93E MUTANT: GTT CAN BE MODIFIED TO BE = GAA, GAG (ALL CODONS FOR GLUTAMIC ACID)

V93D MUTANT: GTT CAN BE MODIFIED TO BE = GAT, GAC (ALL CODONS FOR ASPARTIC ACID)

V93K MUTANT: GTT CAN BE MODIFIED TO BE = AAA, AAG (ALL CODONS FOR LYSINE)

V93Q MUTANT: GTT CAN BE MODIFIED TO BE = CAA, CAG (ALL CODONS FOR GLUTAMINE)

V93N MUTANT: GTT CAN BE MODIFIED TO BE = AAC, AAU (ALL CODONS FOR ASPARAGINE)

ATGATCCTCGATACAGACTACATAAAGTGGAGATGGAAAGCCCGTCATCAGGATCTTCAAGAAGGAGAACGGCGAGTT
CAAAATAGACTACGACAGAACTTTGAGCCATACATCTACGCGCTCTTGAAGGACGACTCTGCGATTGAGGACGTCA
AGAAGATAACTGCCGAGAGGCACGGCACTACCGTTAGGGTTGTCAGGGCCGAGAAAGTGAAGAAGAAGTTCTTAGGC
AGGCCGATAGAGGTCTGGAAGCTCTACTTCACTACCCCCAGGACGTTCCCGCAATCAGGGACAAGATAAAGGAGCA
TCCTGCCGTTGTGGACATCTACGAGTACGACATCCCCCTTCGCGAAGCGCTACCTCATAGACAAAGGCTTAATCCCGA
TGGAGGGCGACGAGGAACCTTAAGATGCTCGCCTTCGACATCGAGACGCTCTATCAGGAGGGCGAGGAGTTCCGCGAA
GGGCTATCTCGATGATAAGCTACGCCGACGAGGAAGGGCGCGCGTTATTACCTGGAAGAATATCGACCTTCCCTA
TGTCGACGTCGTTTCCACCGAGAAGGAGATGATAAAGCGCTTCTCAAGGTCGTCAAGGAAAGGATCCCCGACGTCC
TCATAACCTACAACGGCGACAACCTTCGACTTCGCCTACCTCAAGAAGCGCTCCGAGAAGCTCGGAGTCAAGTTTCATC
TTCGGAAGGGGAAGGGAGCGAGCCGAAATCCAGCGCATGGGCGATCGCTTTCGCGTGGAGGTCAAGGGAAGGATTCA
CTTCGACCTCTACCCCGTCATTAGGAGAACGATTAACTTCCCACTTACACCTTGAGGCAGTATATGAAGCCATCT
TTGGACAGCCGAAGGAGAAGGTCTACGCTGAGGAGATAGCGCAGGCCTGGGAAACGGGCGAGGGATTAGAAAGGGTG
GCCCCGTACTCGATGGAGGACGCAAGGTAACTATGAACTCGGAAAGAGTTCTTCCCTATGGAAGCCAGCTCTC
GCGCCTCGTAGGCCAGAGCCTCTGGGATGTATCTCGCTCGAGTACCGGAAACCTCGTCGAGTGGTTTTTGTCTGAGGA
AGGCCTACGAGAGGAATGAACCTTGACCAACAAGCCGGACGAGAGGGAGCTGGCAAGAAGAAGGGAGAGCTACGCG
GGTGATACGTCAAGGAGCCCGAAAGGGGACTGTGGGAGAACATCGTGTATCTGGACTTCCGCTCCCTGTATCCTTC
GATAAATACCCATAACGTCTCCCTGATACACTCAACAGGGAGGGTTGTGAGGAGTACGACGTGGCTCCTCAGG
TAGGCCATAAGTTCTGCAAGGACTTCCCGGCTTCAATCCCAAGCCTCCTCGGAGACCTCTTGAGGAGAGACAGAAG
GTAAAGAAGAAGATGAAGGCCACTATAGACCCAATCGAGAAGAACTCCTCGATTACAGGCAACGAGCAATCAAAAT
CCTTGCTAATAGCTTCTACGGTTACTACGGCTATGCAAAGGCCCGCTGGTACTGCAAGGAGTGCGCCGAGAGCGTTA
CCGCTTGGGGCAGGCAGTACATCGAGACCACGATAAGGGAAATAGAGGAGAAATTTGGCTTTAAAGTCTCTACGCG
GACACAGATGATTTTTTCGCAACAATACCTGGAGCGGACGCCGAACCGTCAAAAAGAAGGCAAGGAGTTCTTGGA
CTACATCAACGCCAACTGCCCGGCTGCTCGAATCGAATACGAGGGCTTCTACAAGCGCGGCTTCTTCGTGACGA
AGAAGAAGTACGCGGTTATAGACGAGGAGGACAAGATAACGACGCGCGGCTTGAAATAGTTAGGCGTGACTGGAGC
GAGATAGCGAAGGAGACGCGAGGCGAGGTTCTTGAGGCGATACTAAAGCACGGTGACGTTGAAGAAGCGGTAAGGAT
TGTCAAAGAGGTTACGGAGAAGCTGAGCAAGTACGAGGTTCCACCGGAGAAGCTGGTCATCTACGAGCAGATAACCC
CGGACCTGAAGGACTACAAGGCCACCGGGCCGATGTGGCTGTTGCAAAACGCTCGCCGCAAGGGGATAAAAATC
CGGCCCGGAACGGTCATAAGCTACATCGTGCTCAAAGGCTCGGGAAGGATTGGGGACAGGGCTATACCTTTGACGA
ATTTGACCCGGCAAAGCACAGTACGATGCAGAATACTACATCGAGAACCAGGTTCTTCAGCTGTGGAGAGGATTTC
TGAGGGCCTTTGGTTACCGTAAGAAGATTTAAGGTATCAGAAAACGCGGACGTTGGCTTGGGGCGTGCTAAAA
CCTAAGACATGA

PFU DNA POLYMERASE (SEQ ID NO: 23)

G387P Mutant (CCN is the codon for Proline where N = C, G, A, or T)

V93R MUTANT: GTT CAN BE MODIFIED TO BE = AGA, AGG, CGA, CGC, CGG, CGT (ALL POSSIBLE CODONS FOR ARGININE)

V93E MUTANT: GTT CAN BE MODIFIED TO BE = GAA, GAG (ALL CODONS FOR GLUTAMIC ACID)

V93D MUTANT: GTT CAN BE MODIFIED TO BE = GAT, GAC (ALL CODONS FOR ASPARTIC ACID)

V93K MUTANT: GTT CAN BE MODIFIED TO BE = AAA, AAG (ALL CODONS FOR LYSINE)

V93N MUTANT: GTT CAN BE MODIFIED TO BE = AAC, AAU (ALL CODONS FOR ASPARAGINE)

ATGATTTTAG ATGTGGATTA CATAACTGAA GAAGGAAAAC CTGTTATTAG GCTATTCAAA 60
AAAGAGAACG GAAAAATTTAA GATAGAGCAT GATAGAACTT TTAGACCATA CATTTACGCT 120
CTTCTCAGGG ATGATTCAAA GATTGAAGAA GTTAAGAAAA TAACGGGGGA AAGGCATGGA 180
AAGATTGTGA GAATTGTTGA TGTAGAGAAG GTTGAGAAAA AGTTTCTCGG CAAGCCTATT 240
ACCGTGTGGA AACTTTATTT GGAACATCCC CAAGATGTTT CCACTATTAG AGAAAAAGTT 300
AGAGAACATC CAGCAGTTGT GGACATCTTC GAATACGATA TTCCATTTCG AAAGAGATAC 360
CTCATCGACA AAGGCCAAT ACCAATGGAG GGGGAAGAAG AGCTAAAGAT TCTGCTCTC 420
GATATAGAAA CCCTCTATCA CGAAGGAGAA GAGTTTGGAA AAGGCCCAAT TATAATGATT 480
AGTTATGCAG ATGAAAATGA AGCAAAGGTG ATTACTTGGA AAAACATAGA TCTTCCATAC 540
GTTGAGGTTG TATCAAGCGA GAGAGAGATG ATAAGAGAGT TTCTCAGGAT TATCAGGGAG 600
AAGGATCCTG ACATTATAGT TACTTATAAT GGAGACTCAT TCGCATTTCC ATATTTAGCG 660
AAAAGGGCAG AAAAACTTGG GATTAAATTA ACCATTGGAA GAGATGGAAG CGAGCCCAAG 720
ATGCAGAGAA TAGGCGATAT GACGGCTGTA GAAGTCAAGG GAAGAATACA TTTCGACTTG 780
TATCATGTAA TAACAAGGAC AATAAATCTC CCAACATACA CACTAGAGG TGTATATGAA 840
GCAATTTTGG GAAAGCCAAA GGAGAAGGTA TACGCCGACG AGATAGCAAA AGCCTGGGAA 900
AGTGGAGAGA ACCTTGAGAG AGTTGCCAAA TACTCGATGG AAGATGCAAA GGCAACTTAT 960
GAACTCGGGA AAGAATTCCT TCCAATGGAA ATTCAAGCTT CAAGATTAGT TGGACAACCT 1020
TTATGGGATG TTTCAAGGTC AAGCACAGGG AACCTTGTA AGTGGTTCTT ACTTAGGAAA 1080
GCCTACGAAA GAAACGAAGT AGCTCCAAAC AAGCCAAGTG AAGAGGAGTA TCAAAGAAGG 1140
CTCAGGGAGA GCTACACACC NGGATTTCGT AAAGAGCCAG AAAAGGGGTT GTGGGAAAAC 1200
ATAGTATACC TAGATTTTAG AGCCCTATAT CCCTCGATTA TAATTACCCA CAATGTTTCT 1260
CCCGATACTC TAAATCTTGA GGGATGCAAG AACTATGATA TCGCTCCTCA AGTAGGCCAC 1320
AAGTTCTGCA AGGACATCCC TGGTTTTATA CCAAGTCTCT TGGGACATTT GTTAGAGGAA 1380
AGACAAAAGA TTAAGACAAA AATGAAGGAA ACTCAAGATC CTATAGAAAA AATACTCCTT 1440
GACTATAGAC AAAAAGCGAT AAAACTCTTA GCAAATCTT TCTACGGATA TTATGGCTAT 1500
GCAAAAGCAA GATGGTACTG TAAGGAGTGT GCTGAGAGCG TTACTGCCTG GGAAGAAAAG 1560
TACATCGAGT TAGTATGGAA GGAGCTCGAA GAAAAGTTT GATTAAAGT CCTCTACATT 1620
GACACTGATG GTCTCTATGC AACTATCCCA GGAGGAGAAA GTGAGGAAAT AAAGAAAAAG 1680
GCTCTAGAAT TTGTAAAATA CATAAATTCA AAGCTCCCTG GACTGCTAGA GCTTGAATAT 1740
GAAGGGTTTT ATAAGAGGGG ATTCTTCGTT ACGAAGAAGA GGTATGCAGT AATAGATGAA 1800
GAAGGAAAAG TCATTACTCG TGGTTTAGAG ATAGTTAGGA GAGATTGGAG TGAAATTGCA 1860
AAAGAAACTC AAGCTAGAGT TTTGGAGACA ATACTAAAAC ACGGAGATGT TGAAGAAGCT 1920
GTGAGAATAG TAAAAGAAGT AATACAAAAG CTTGCCAATT ATGAATTCC ACCAGAGAAG 1980
CTCGCAATAT ATGAGCAGAT AACAAAGACCA TTACATGAGT ATAAGGCGAT AGGTCCTCAC 2040
GTAGCTGTTG CAAAGAAACT AGCTGCTAAA GGAGTTAAAA TAAAGCCAGG AATGGTAATT 2100
GGATACATAG TACTTAGAGG CGATGGTCCA ATTAGCAATA GGGCAATTCT AGCTGAGGAA 2160
TACGATCCCA AAAAGCACAA GTATGACGCA GAATATTACA TGGAGAACCA GGTCTCTCCA 2220
GCGGTACTTA GGATATTGGA GGGATTGGA TACAGAAAGG AAGACCTCAG ATACCAAAAG 2280
ACAAGACAAG TCGGCCTAAC TTCCTGGCTT AACATTAAAA AATCCTAG 2328

PFU DNA POLYMERASE (SEQ ID NO: 24)

D141A/E143A Mutant (GCN is the codon for alanine where N = C, G, A, or T)

V93R MUTANT: GTT CAN BE MODIFIED TO BE = AGA, AGG, CGA, CGC, CGG, CGT (ALL POSSIBLE CODONS FOR ARGININE)

V93E MUTANT: GTT CAN BE MODIFIED TO BE = GAA, GAG (ALL CODONS FOR GLUTAMIC ACID)

V93D MUTANT: GTT CAN BE MODIFIED TO BE = GAT, GAC (ALL CODONS FOR ASPARTIC ACID)

V93K MUTANT: GTT CAN BE MODIFIED TO BE = AAA, AAG (ALL CODONS FOR LYSINE)

V93N MUTANT: GTT CAN BE MODIFIED TO BE = AAC, AAU (ALL CODONS FOR ASPARAGINE)

ATGATTTTAG ATGTGGATTA CATAACTGAA GAAGGAAAAC CTGTTATTAG GCTATTCAAA 60
AAAGAGAACG GAAAATTTAA GATAGAGCAT GATAGAACTT TTAGACCATA CATTTACGCT 120
CTTCTCAGGG ATGATTCAAA GATTGAAGAA GTTAAGAAAA TAACGGGGGA AAGGCATGGA 180
AAGATTGTGA GAATTGTTGA TGTAGAGAAG GTTGAGAAAA AGTTTCTCGG CAAGCCTATT 240
ACCGTGTGGA AACTTTATTT GGAACATCCC CAAGATGTTT CCACTATTAG AGAAAAAGTT 300
AGAGAACATC CAGCAGTTGT GGACATCTTC GAATACGATA TTCCATTTGC AAAGAGATAC 360
CTCATCGACA AAGGCCTAAT ACCAATGGAG GGGGAAGAAG AGCTAAAGAT TCTTGCCTTC 420
GCMATAGCNA CCCTCTATCA CGAAGGAGAA GAGTTTGGAA AAGGCCCAAT TATAATGATT 480
AGTTATGCAG ATGAAAATGA AGCAAAGGTG ATTACTTGGA AAAACATAGA TCTTCCATAC 540
GTTGAGGTTG TATCAAGCGA GAGAGAGATG ATAAAGAGAT TTCTCAGGAT TATCAGGGAG 600
AAGGATCCTG ACATTATAGT TACTTATAAT GGAGATCAT TCGCATTTCC ATATTAGCG 660
AAAAGGGCAG AAAAAGTTGG GATTAAATTA ACCATTGGAA GAGATGGAAG CGAGCCCAAG 720
ATGCAGAGAA TAGGCGATAT GACGGCTGTA GAAGTCAAGG GAAGAATACA TTTCGACTTG 780
TATCATGTAA TAACAAGGAC AATAAATCTC CCAACATACA CACTAGAGGC TGTATATGAA 840
GCAATTTTGG GAAAGCCAAA GGAGAAGGTA TACGCCGACG AGATAGCAAA AGCCTGGGAA 900
AGTGGAGAGA ACCTTGAGAG AGTTGCCAAA TACTCGATGG AAGATGCAAA GGCAACTTAT 960
GAACTCGGGA AAGAATTCCT TCCAATGGAA ATTCAGCTTT CAAGATTAGT TGGACAACCT 1020
TTATGGGATG TTTCAAGGTC AAGCACAGGG AACCTTGTAG AGTGGTTCTT ACTTAGGAAA 1080
GCCTACGAAA GAAACGAAGT AGCTCCAAAC AAGCCAAGTG AAGAGGAGTA TCAAAGAAGG 1140
CTCAGGGAGA GCTACACAGG TGGATTCTGT AAAGAGCCAG AAAAGGGGTT GTGGGAAAAC 1200
ATAGTATACC TAGATTTTAG AGCCCTATAT CCCTCGATTA TAATTACCCA CAATGTTTCT 1260
CCCGATACCT TAAATCTTGA GGGATGCAAG AACTATGATA TCGCTCCTCA AGTAGGCCAC 1320
AAGTTCTGCA AGGACATCCC TGGTTTTATA CCAAGTCTCT TGGGACATTT GTTAGAGGAA 1380
AGACAAAAGA TTAAGACAAA AATGAAGGAA ACTCAAGATC CTATAGAAAA AATACTCCTT 1440
GACTATAGAC AAAAAGCGAT AAAACTCTTA GCAAATTCCT TCTACGGATA TTATGGCTAT 1500
GCAAAAGCAA GATGGTACTG TAAGGAGTGT GCTGAGAGCG TTACTGCCTG GGGGAAGAAAG 1560
TACATCGAGT TAGTATGGAA GGAGCTCGAA GAAAAGTTTG GATTTAAAGT CCTCTACATT 1620
GACACTGATG GTCTCTATGC AACTATCCCA GGAGGAGAAA GTGAGGAAAT AAAGAAAAAG 1680
GCTCTAGAAT TTGTAAAATA CATAAATTC AAGCTCCCTG GACTGCTAGA GCTTGAATAT 1740
GAAGGGTTTT ATAAGAGGGG ATTCTTCGTT ACGAAGAAGA GGTATGCAGT AATAGATGAA 1800
GAAGGAAAAG TCATTACTCG TGGTTTAGAG ATAGTTAGGA GAGATGGAG TGAAATTGCA 1860
AAAGAACTC AAGCTAGAGT TTTGGAGACA ATACTAAAAC ACGGAGATGT TGAAGAAGCT 1920
GTGAGAATAG TAAAAGAAGT AATACAAAAG CTTGCCAATT ATGAAATTCC ACCAGAGAAG 1980
CTCGCAATAT ATGAGCAGAT AACAAAGACCA TTACATGAGT ATAAGGCGAT AGGTCCTCAC 2040
GTAGCTGTTG CAAAGAACT AGCTGCTAAA GGAGTTAAAA TAAAGCCAGG AATGGTAATT 2100
GGATACATAG TACTTAGAGG CGATGGTCCA ATTAGCAATA GGGCAATTCT AGCTGAGGAA 2160
TACGATCCCA AAAAGCACAA GTATGACGCA GAATATTACA TGGAGAACCA GGTTCTTCCA 2220
GCGGTACTTA GGATATTGGA GGGATTGGA TACAGAAAGG AAGACCTCAG ATACCAAAAG 2280
ACAAGACAAG TCGGCCTAAC TTCTGGCTT AACATTAAAA AATCCTAG 2328

PFU DNA POLYMERASE (SEQ ID NO: 25)

V93 DELETION MUTANT

```
ATGATTTTAG ATGTGGATTA CATAACTGAA GAAGGAAAAC CTGTTATTAG GCTATTCAAA 60
AAAGAGAACG GAAAATTTAA GATAGAGCAT GATAGAACTT TTAGACCATA CATTACGCT 120
CTTCTCAGGG ATGATTCAAA GATTGAAGAA GTTAAGAAAA TAACGGGGGA AAGGCATGGA 180
AAGATTGTGA GAATTGTTGA TGTAAGAGAAG GTTGAGAAAA AGTTTCTCGG CAAGCCTATT 240
ACCGTGTGGA AACTTTATTT GGAACATCCC CAAGAT---C CCACTATTAG AGAAAAAGTT 300
AGAGAACATC CAGCAGTTGT GGACATCTTC GAATACGATA TTCCATTGTC AAAGAGATAC 360
CTCATCGACA AAGGCCTAAT ACCAATGGAG GGGGAAGAAG AGCTAAAGAT TCTTGCCTTC 420
GATATAGAAA CCCTCTATCA CGAAGGAGAA GAGTTTGGA AAGGCCCAAT TATAATGATT 480
AGTTATGCAG ATGAAAATGA AGCAAAGGTG ATTACTTGGA AAAACATAGA TCTTCCATAC 540
GTTGAGGTTG TATCAAGCGA GAGAGAGATG ATAAAGAGAT TTCTCAGGAT TATCAGGGAG 600
AAGGATCCTG ACATTATAGT TACTTATAAT GGAGACTCAT TCGCATTCCT ATATTTAGCG 660
AAAAGGGCAG AAAAAGCTGG GATTAAATTA ACCATTGGAA GAGATGGAAG CGAGCCCAAG 720
ATGCAGAGAA TAGGCGATAT GACGGCTGTA GAAGTCAAGG GAAGAATACA TTTCGACTTG 780
TATCATGTAA TAACAAGGAC AATAAATCTC CCAACATACA CACTAGAGGC TGTATATGAA 840
GCAATTTTGG GAAAGCCAAA GAGAGAGGTA TACGCCGACG AGATAGCAAA AGCCTGGGAA 900
AGTGAGAGAG ACCTTGAGAG AGTTGCCAAA TACTCGATGG AAGATGCAAA GGCAACTTAT 960
GAACTCGGGA AAGAATTCCT TCCAATGGAA ATTCAGCTTT CAAGATTAGT TGGACAACCT 1020
TTATGGGATG TTTCAAGGTC AAGCACAGGG AACCTTGTAG AGTGGTTCTT ACTTAGGAAA 1080
GCCTACGAAA GAAACGAAGT AGCTCCAAAC AAGCCAAGTG AAGAGGAGTA TCAAAGAAGG 1140
CTCAGGGAGA GCTACACAGG TGGATTTCGT AAAGAGCCAG AAAAGGGGTT GTGGGAAAAC 1200
ATAGTATACC TAGATTTTAG AGCCCTATAT CCCTCGATTA TAATTACCCA CAATGTTTCT 1260
CCGATACTC TAAATCTTGA GGGATGCAAG AACTATGATA TCGCTCCTCA AGTAGGCCAC 1320
AAGTTCTGCA AGGACATCCC TGGTTTTATA CCAAGTCTCT TGGGACATTT GTTAGAGGAA 1380
AGACAAAAGA TTAAGACAAA AATGAAGGAA ACTCAAGATC CTATAGAAAA AATACTCCTT 1440
GACTATAGAC AAAAAGCGAT AAAACTCTTA GCAAAATCTT TCTACGGATA TTATGGCTAT 1500
GCAAAAGCAA GATGGTACTG TAAGGAGTGT GCTGAGAGCG TTACTGCCTG GGAAGAAAG 1560
TACATCGAGT TAGTATGGAA GGAGCTCGAA GAAAAGTTTG GATTTAAAGT CCTCTACATT 1620
GACACTGATG GTCTCTATGC AACTATCCCA GGAGGAGAAA GTGAGGAAAT AAAGAAAAAG 1680
GCTCTAGAA TGTAAAATA CATAAATCCA AAGCTCCCTG GACTGCTAGA GCTTGAATAT 1740
GAAGGGTTTT ATAAGAGGGG ATTCTTCGTT ACGAAGAAGA GGTATGCAGT AATAGATGAA 1800
GAAGGAAAAG TCATTACTCG TGGTTTAGAG ATAGTTAGGA GAGATTGGAG TGAATTTGCA 1860
AAAGAACTC AAGCTAGAGT TTTGGAGACA ATACTAAAAC ACGGAGATGT TGAAGAAGCT 1920
GTGAGAATAG TAAAAGAAGT AATACAAAAG CTTGCCAATT ATGAAATCC ACCAGAGAAG 1980
CTCGCAATAT ATGAGCAGAT AACAAAGCCA TTACATGAGT ATAAGGCGAT AGGTCCCTCAC 2040
GTAGCTGTTG CAAAGAACT AGCTGCTAAA GGAGTTAAAA TAAAGCCAGG AATGGTAATT 2100
GGATACATAG TACTTAGAGG CGATGGTCCA ATTAGCAATA GGGCAATTCT AGCTGAGGAA 2160
TACGATCCCA AAAAGCAGCA GTATGACGCA GAATATTACA TGGAGAACCA GGTCTTTCCA 2220
GCGGTACTTA GGATATTGGA GGGATTGGA TACAGAAAGG AAGACCTCAG ATACCAAAAG 2280
ACAAAGACAAG TCGGCCTAAC TTCCTGGCTT AACATTAAAA AATCCTAG 2328
```

PFU DNA POLYMERASE (SEQ ID NO: 26)

D92-V93-P94 DELETION MUTANT

```
ATGATTTTAG ATGTGGATTA CATAACTGAA GAAGGAAAAC CTGTTATTAG GCTATTCAAA 60
AAAGAGAACG GAAAATTTAA GATAGAGCAT GATAGAACTT TTAGACCATA CATTACGCT 120
CTTCTCAGGG ATGATTCAAA GATTGAAGAA GTTAAGAAAA TAACGGGGGA AAGGCATGGA 180
AAGATTGTGA GAATTGTTGA TGTAAGAGAAG GTTGAGAAAA AGTTTCTCGG CAAGCCTATT 240
ACCGTGTGGA AACTTTATTT GGAACATCCC CAA ACTATTAG AGAAAAAGTT 300
AGAGAACATC CAGCAGTTGT GGACATCTTC GAATACGATA TTCCATTGTC AAAGAGATAC 360
CTCATCGACA AAGGCCTAAT ACCAATGGAG GGGGAAGAAG AGCTAAAGAT TCTTGCCTTC 420
GATATAGAAA CCCTCTATCA CGAAGGAGAA GAGTTTGGA AAGGCCCAAT TATAATGATT 480
```

AGTTATGCAG ATGAAAATGA AGCAAAGGTG ATTACTTGGA AAAACATAGA TCTTCCATAC 540
GTTGAGGTTG TATCAAGCGA GAGAGAGATG ATAAAGAGAT TTCTCAGGAT TATCAGGGAG 600
AAGGATCCTG ACATTATAGT TACTTATAAT GGAGACTCAT TCGCATTCCC ATATTTAGCG 660
AAAAGGGCAG AAAAAGCTTG GATTAAATTA ACCATTGGAA GAGATGGAAG CGAGCCCAAG 720
ATGCAGAGAA TAGGCGATAT GACGGCTGTA GAAGTCAAGG GAAGAATACA TTTCGACTTG 780
TATCATGTAA TAACAAGGAC AATAAATCTC CCAACATACA CACTAGAGGC TGTATATGAA 840
GCAATTTTTG GAAAGCCAAA GGAGAAGGTA TACGCCGACG AGATAGCAAA AGCCTGGGAA 900
AGTGAGAGAG ACCTTGAGAG AGTTGCCAAA TACTCGATGG AAGATGCAAA GGCAACTTAT 960
GAACTCGGGA AAGAATTCCT TCCAATGGAA ATTCAGCTTT CAAGATTAGT TGGACAACCT 1020
TTATGGGATG TTTCAAGGTC AAGCACAGGG AACCTTGTA AGTGGTTCTT ACTTAGGAAA 1080
GCCTACGAAA GAAACGAAGT AGCTCCAAAC AAGCCAAGTG AAGAGGAGTA TCAAAGAAGG 1140
CTCAGGGAGA GCTACACAGG TGGATTCTGT AAAGAGCCAG AAAAGGGGTT GTGGGAAAAC 1200
ATAGTATACC TAGATTTTAG AGCCCTATAT CCCTCGATTA TAATTACCCA CAATGTTTCT 1260
CCCGATACTC TAAATCTTGA GGGATGCAAG AACTATGATA TCGCTCCTCA AGTAGGCCAC 1320
AAGTTCTGCA AGGACATCCC TGGTTTTATA CCAAGTCTCT TGGGACATTT GTTAGAGGAA 1380
AGACAAAAGA TTAAGACAAA AATGAAGGAA ACTCAAGATC CTATAGAAAA AATACTCCTT 1440
GACTATAGAC AAAAAGCGAT AAAACTCTTA GCAAATTCTT TCTACGGATA TTATGGCTAT 1500
GCAAAAGCAA GATGGTACTG TAAGGAGTGT GCTGAGAGCG TTAGTGCCTG GGGAAGAAAG 1560
TACATCGAGT TAGTATGGAA GGAGCTCGAA GAAAAGTTTG GATTTAAAGT CCTCTACATT 1620
GACACTGATG GTCTCTATGC AACTATCCCA GGAGGAGAAA GTGAGGAAAT AAAGAAAAAG 1680
GCTCTAGAAT TTGTAAAATA CATAAATTCA AAGCTCCCTG GACTGCTAGA GCTTGAATAT 1740
GAAGGGTTTT ATAAGAGGGG ATTCCTTCGTT ACGAAGAAGA GGTATGCAGT AATAGATGAA 1800
GAAGGAAAAG TCATTACTCG TGGTTTAGAG ATAGTTAGGA GAGATTGGAG TGAAATTGCA 1860
AAAGAACTC AAGCTAGAGT TTTGGAGACA ATACTAAAAC ACGGAGATGT TGAAGAAGCT 1920
GTGAGAATAG TAAAAGAAGT AATACAAAAG CTTGCCAATT ATGAAATTCC ACCAGAGAAG 1980
CTCGCAATAT ATGAGCAGAT AACAAGACCA TTACATGAGT ATAAGGCGAT AGGTCTCTAC 2040
GTAGCTGTTG CAAAGAACT AGCTGCTAAA GGAGTTAAAA TAAAGCCAGG AATGGTAATT 2100
GGATACATAG TACTTAGAGG CGATGGTCCA ATTAGCAATA GGGCAATTCT AGCTGAGGAA 2160
TACGATCCCA AAAAGCACAA GTATGACGCA GAATATTACA TGGAGAACCA GGTTCCTCCA 2220
GCGGTACTTA GGATATTGGA GGGATTGGA TACAGAAAGG AAGACCTCAG ATACCAAAAG 2280
ACAAGACAAG TCGGCCTAAC TTCCTGGCTT AACATTAAAA AATCCTAG 2328

Figure 6B

>Pfu (SEQ ID NO: 27)

VALINE AT POSITION 93 MAY BE SUBSTITUTED BY ONE OF: R, E, D, K, OR N

MILDVDYITEEGKPVIRLFKKENGKFKIEHRTFRPYIYALLRDDSKEEVKKITGERHKGKIVRIVDVEKVEKKFLG
KPITVWKLYLEHPQDVPTIREKVREHPAVVDIFEYDIPFAKRYLIDKGLIPMEGEEELKILAFDIETLYHEGEEFGK
GPIIMISYADENEAKVITWKNIDLPYEVVSSEREMIKRFLRIIREKDPDIIVTYNGDSFDFPYLAKRAEKLGIKLT
IGRDGSEPKMQRIGDMTAVEVKGRIHFDLYHVIITRTINLPTYTLEAVYEAIFGKPKKVKYADEIAKAWESGENLERV
AKYSMEDAKATYELGKEFLPMEIQLSRLVGQPLWDVSRSSSTGNLVEWFLLRKAYERNEVAPNKPSEEEYQRRLRRESY
TGGFVKEPEKGLWENIVYLDLFRALYPSIIITHNVSPDTLNLEGCKNYDIAPOVGHKFKCKDIPGFIPSLLGHLLERQ
KIKTKMKETQDPIEKILLDYRQKAIKLLANSFYGYGYAKARWYCKEACSVTAWGRKYIELVWKELEBKFGFKVLY
IDTDGLYATIPGGESEBIIKKKALEFVKYINSKLPGLLELEYEGFYKRGFFVTKKRYAVIDEKGKIVITRGLIIVRRDW
SEIAKETQARVLEITLKHGDVEEAVRIVKEVIQKLANYEIPPEKLAIYEQITRPLHEYKAIGPHVAVAKLAAGVK
IKPGMVIGYIVLRGDPISNRAILAEYDPPKKHKYDAEYYIENQVLPVAVLRILEGFGYRKEDLRYQKTRQVGLTSWL
NIKKK

>DEEP VENT (SEQ ID NO: 28)

VALINE AT POSITION 93 MAY BE SUBSTITUTED BY ONE OF: R, E, D, K, Q, OR N

MILDADYITEDGKPIIRIFKKENGGEFKVEYDRNFRPYIYALLKDDSQIDEVRKITAERHKGKIVRIIDAQKVRKKFLG
RPIEVWRLYFEHPQDVPAIROKIREHSAVIDIFEYDIPFAKRYLIDKGLIPMEGDEELKLLAFDIETLYHEGEEFAK
GPIIMISYADEEEAKVITWKKIDLPYEVVSSEREMIKRFLKVIREKDPDVIITYNGDSFDFPYLVKRAEKLGIKLP
LGRDGSEPKMQRLGDMTAVEIKGRIHFDLYHVIITRTINLPTYTLEAVYEAIFGKPKKVKYAEHIAEAWETGKGLERV
AKYSMEDAKVTYELGREFFPMEAQLSRLVGQPLWDVSRSSSTGNLVEWYLLRKAYERNELAPNKPDEREYERRLRRESY
AGGYVKEPEKGLWGLVSLDFRSLYPSIIITHNVSPDTLNREGCREYDVAPEVGHKFKCKDFPGFIPSLLKRLDERQ
EIKRKMKASKDPIEKMLDYRQRAIKILANSYGYGYAKARWYCKEACSVTAWGREYIEFVRKELEBKFGFKVLY
IDTDGLYATIPGAKPEEIKKKALEFVDYINAKLPGLLELEYEGFYVRGFFVTKKKYALIDEEGKIITRGLIIVRRDW
SEIAKETQAKVLEAILKHGNVVEAVKIVKEVTEKLSKYEIPPEKLVIYEQITRPLHEYKAIGPHVAVAKRLAAGVK
VRPGMVIGYIVLRGDPISKRAILAEFDPKHKHYDAEYYIENQVLPVAVLRILEAFGYRKEDLRWQKTQGTGLTAWL
NIKKK

>TGO (SEQ ID NO: 29)

VALINE AT POSITION 93 MAY BE SUBSTITUTED BY ONE OF: R, E, D, K, Q, OR N

MILDTDYITEDGKPVIRIFKKENGFKIDYDRNFEPYIYALLKDDSAIEDVKKITAERHGTTVRVVRAEKVKKKFLG
RPIEVWKLIFYTHPQDVPAIRDKIKEHPAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELKMLAFDIETLYHEGEEFAE
GPILMISYADEEGARVITWKNIDLPYVDVSTEEKMIKRLKVVEKDPDVLITYNGDNDFAYLKKRSEKLGVKFI
LREGSEPKIQRMGDRFAVEVKGRIHFDLYPVIRRTINLPTYTLEAVYEAIFGQPKKVKYAEHIAQAWETGEGLERV
ARYSMEDAKVTYELGKEFFPMEAQLSRLVGQSLWDVSRSSSTGNLVEWFLLRKAYERNELAPNKPDERELARRRESYA
GGYVKEPERGLWENIVYLDLFRSLYPSIIITHNVSPDTLNREGCEEYDVAPOVGHKFKCKDFPGFIPSLLGLDLEERQK
VKKMKATIDPIEKLLDYRQRAIKILANSFYGYGYAKARWYCKEACSVTAWGRQYIETIREIEEKFGFKVLYA

DTDGFFATIPGADAETVKKKAKEFLDYINAKLPGLLELEYEGFYKRGFFVTKKKYAVIDEEDKITTRGLEIVRRDWS
EIAKETQARVLEAILKHGDVEEAVRIVKEVTEKLSKYEVPPPEKLVIEHQITRDLKDYKATGPHVAVAKRLAARGIKI
RPGTVISYIVLKGSGRIGDRAIPFDEFDPKHKYDAEYYIENQVLPAPERILRAFGRKEDLRYQKTRQVGLGAWLK
PKT

>KOD (SEQ ID NO: 30)

VALINE AT POSITION 93 MAY BE SUBSTITUTED BY ONE OF: R, E, D, K, Q, OR N

MILDTDYITEDGKPVIRIFKKEGFEKIEYDRTFEPYFYALLKDDSAIEEVKKITAERHGTVVTVKRVKQKKFLG
RPVEVWKLYFTHPQDVPAPKIREHGAVIDIYEYDIPFAKRYLIDKGLVPMEGDEELKMLAFDIQTLYHGEFEFAG
GPILMISYADEEGARVITWKNVDLPYVDVSTEREMIKRFLRVVKEKDPDVLITYNGDNFDFAYLKKRCEKLGINPA
LGRDGSEPKIQRMGDRFAVEVKGRIHFDLYPVIRRTINLPTYTLEAVYEAVFGQPKKQVYAEIEITPAWETGENLERV
ARYSMEDAKVTYELGKEFLPMEAQLSRLIGQSLWDVSRSTGNLVEWFLLRKAYERNELAPNKPDEKELARRQSYE
GGYVKEPERGLWENIVYLDFRSLYPSIIITHNVSPDTLNREGCKEYDVAPQVGHFRFCKDFPGFIPSLGLDLEERQK
IKKKMKATIDPIERKLLDYRQRAIKILANSYGYGYGARARWYCKECAESVTAWGREYITMTIKEIEEKYGFVKIYS
DTDGFFATIPGADAETVKKKAMEFLNYINAKLPGALELEYEGFYKRGFFVTKKKYAVIDEEGKITTRGLEIVRRDWS
EIAKETQARVLEALLKGDVEKAVRIVKEVTEKLSKYEVPPPEKLVIEHQITRDLKDYKATGPHVAVAKRLAARGVKI
RPGTVISYIVLKGSGRIGDRAIPFDEFDPKHKYDAEYYIENQVLPAPERILRAFGRKEDLRYQKTRQVGLSAWLK
PKGT

>VENT (SEQ ID NO: 31)

VALINE AT POSITION 93 MAY BE SUBSTITUTED BY ONE OF: R, E, D, K, Q, OR N

MILDTDYITKDGKPIIRIFKKEGFEKIEIDPHFPQYIYALLKDDSAIEEIKAIKGERHGTVRVLDVAVKVRKKFLG
REVEVWKLYFEHPQDVPAMRGKIREHPAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELKLLAFDIETFYHGEDEFK
GEIIMISYADEEEARVITWKNIDLPHYVDVVSNEREMIKRFVQVVEKDPDVIITYNGDNFDFAYLKKRAEKLGVRLV
LGRDKEHPEPKIQRMGDSFAVEIKGRIHFDLPVVRRTINLPTYTLEAVYEAVLGKTKSKLGAEEIAATWETESMK
KLAQYSMEDARATYELGKEFFPMEAEALIGQSVWDVSRSTGNLVEWYLLRVAYARNELAPNKPDEEYKRRRLRT
TYLGGYVKEPEKGLWENIYLDFRSLYPSIIITHNVSPDTLEKEGCKNYDVAPIVGYRCKDFPGFIPSLGLDIAM
RQDIKKMKSTIDPIEKMLDYRQRAIKLLANSYGYMGYPKARWYSKECAESVTAWGRHYIEMTIREIEEKFGFKV
LYADTDGFFATIPGKEPELIKKAKEFLNYINSLKPLGLELEYEGFYLRGFFVTKKRYAVIDEEGKITTRGLEIVRR
DWSEIAKETQARVLEAILKEGSVEKAVEVVRDVVEKIAKYRVPLEKLVIEHQITRDLKDYKAIGPHVAIAKRLAARG
IKVKPGTIISYIVLKGSGKISDRVILLTEYDPRKHKYPDYIENQVLPVLRILEAFGRKEDLRYQSSKQTGLDA
WLKR

>JDF-3 (SEQ ID NO: 32)

VALINE AT POSITION 93 MAY BE SUBSTITUTED BY ONE OF: R, E, D, K, Q, OR N

MILDVDYITENGKPVIRVFKKEGFEFRIEYDREFEPYFYALLRDDSAIEEIKITAERHGRVVKVRAEKVKKKFLG
RSVEVWVLYFTHPQDVPAPKIREHGAVIDIYEYDIPFAKRYLIDKGLIPMEGEEELKMLSF^{DIET}LYHGEFEFGT
GPILMISYADESEARVITWKKIDLPHYVEVSTEREMIKRFLRVVKEKDPDVLITYNGDNFDFAYLKKRCEKLGVSFT
LGRDGSEPKIQRMGDRFAVEVKGRIHFDLYPVIRRTINLPTYTLEAVYEAVFGKPKKQVYAEIEIATAWETGEGLERV
ARYSMEDARVTYELGREFFPMEAQLSRLIGQGLWDVSRSTGNLVEWFLLRKAYERNELAPNKPDERELARRRGGYA
GGYVKEPERGLWONIVYLDFRSLY^{PSII}ITHNVSPDTLNREGCRSYDVAPVGHKFKCKDFPGFIPSLGLNLLEERQK
IKKKMKATLDPLEKNLLDYRQRA^{IK}ILANSYGYGYGARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYA
DTDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEEGKITTRGLEIVRRDWS
EIAKETQARVLEAILRHGDVEEAVRIVREVTEKLSKYEVPPPEKLVIEHQITRELKDYKATGPHVAIAKRLAARGVKI
RPGTVISYIVLKGSGRIGDRAIPFDEFDPKHKYDADYIENQVLPAPERILRAFGRKEDLRYQKTRQVGLGAWLK
PKGKKK

>Pfu V93/G387P (SEQ ID NO: 33)

VALINE AT POSITION 93 MAY BE SUBSTITUTED BY ONE OF: R, E, D, K, OR N

MILDVDYITEEGKPVIRLFPKKENGKFKIEHDRTRFRPIYIALLRDDS KIEEVKKITGERHGKIVRIVDVEKVEKKFLG
KPITVWKLYLEHPQDVPTIREKVREHPAVVDIFEYDIPFAKRYLIDKGLIPMEGEEELKILAFDIETLYHEGEEFGK
GPIIMISYADENEAKVITWKNIDLPHYEVVSSEREMIKRFLRIIREKDPDIIVTYNGDSFDFPYLAKRAEKLGIKLT
IGRDGSEPKMQRIGDMTAVEVKGRIHFDLYHVITRTINLPTYTLEAVYEAIFGKPKKVKYADEIAKAWESGENLERV
AKYSMEDAKATYELGKEFLPMEIQLSRLVGQPLWDVSRSTGNLVEWFLLRKAYERNEVAPNKPSEEEYQRRRLRESY
TPGFVKEPEKGLWENIVYLDLFRALYPSIIITHNVSPDTLNLGCKNYDIAPQVGHKFKCDIPGFIPSLGLHLEERQ
KIKTKMKETQDPIEKILLDYRQKAIKLLANSFYGYGYAKARWYCKECAESVTAWGRKYIELVWKELEEKFGFKVLY
IDTDGLYATIPGGESEEEKKALEFVKYINSKLPGLLELEYEGFYKRGFFVTKKRYAVIDEEGKVITRGLIVRRDW
SBIAKETQARVLETILKHGDVEEAVRIVKEVIQKLANYEIPPEKLAIYEQITRPLHEYKAIGPHVAVAKKLAAGVK
IKPGMVIGYIVLRGDGPISNRAILAEYDPPKKHKYDAEYYIENQVLPVAVLRILEGFGYRKEDLRYQKTRQVGLTSLW
NIKKS

>Pfu V93/D141A/E143A (SEQ ID NO: 34)

VALINE AT POSITION 93 MAY BE SUBSTITUTED BY ONE OF: R, E, D, K, OR N

MILDVDYITEEGKPVIRLFPKKENGKFKIEHDRTRFRPIYIALLRDDS KIEEVKKITGERHGKIVRIVDVEKVEKKFLG
KPITVWKLYLEHPQDVPTIREKVREHPAVVDIFEYDIPFAKRYLIDKGLIPMEGEEELKILAFDIETLYHEGEEFGK
GPIIMISYADENEAKVITWKNIDLPHYEVVSSEREMIKRFLRIIREKDPDIIVTYNGDSFDFPYLAKRAEKLGIKLT
IGRDGSEPKMQRIGDMTAVEVKGRIHFDLYHVITRTINLPTYTLEAVYEAIFGKPKKVKYADEIAKAWESGENLERV
AKYSMEDAKATYELGKEFLPMEIQLSRLVGQPLWDVSRSTGNLVEWFLLRKAYERNEVAPNKPSEEEYQRRRLRESY
TGGFVKEPEKGLWENIVYLDLFRALYPSIIITHNVSPDTLNLGCKNYDIAPQVGHKFKCDIPGFIPSLGLHLEERQ
KIKTKMKETQDPIEKILLDYRQKAIKLLANSFYGYGYAKARWYCKECAESVTAWGRKYIELVWKELEEKFGFKVLY
IDTDGLYATIPGGESEEEKKALEFVKYINSKLPGLLELEYEGFYKRGFFVTKKRYAVIDEEGKVITRGLIVRRDW
SEIAKETQARVLETILKHGDVEEAVRIVKEVIQKLANYEIPPEKLAIYEQITRPLHEYKAIGPHVAVAKKLAAGVK
IKPGMVIGYIVLRGDGPISNRAILAEYDPPKKHKYDAEYYIENQVLPVAVLRILEGFGYRKEDLRYQKTRQVGLTSLW
NIKKS

>Pfu delta V93 (SEQ ID NO: 35)

MILDVDYITEEGKPVIRLFPKKENGKFKIEHDRTRFRPIYIALLRDDS KIEEVKKITGERHGKIVRIVDVEKVEKKFLG
KPITVWKLYLEHPQDVPTIREKVREHPAVVDIFEYDIPFAKRYLIDKGLIPMEGEEELKILAFDIETLYHEGEEFGK
PIIMISYADENEAKVITWKNIDLPHYEVVSSEREMIKRFLRIIREKDPDIIVTYNGDSFDFPYLAKRAEKLGIKLT
IGRDGSEPKMQRIGDMTAVEVKGRIHFDLYHVITRTINLPTYTLEAVYEAIFGKPKKVKYADEIAKAWESGENLERV
AKYSMEDAKATYELGKEFLPMEIQLSRLVGQPLWDVSRSTGNLVEWFLLRKAYERNEVAPNKPSEEEYQRRRLRESY
TGGFVKEPEKGLWENIVYLDLFRALYPSIIITHNVSPDTLNLGCKNYDIAPQVGHKFKCDIPGFIPSLGLHLEERQ
KIKTKMKETQDPIEKILLDYRQKAIKLLANSFYGYGYAKARWYCKECAESVTAWGRKYIELVWKELEEKFGFKVLY
IDTDGLYATIPGGESEEEKKALEFVKYINSKLPGLLELEYEGFYKRGFFVTKKRYAVIDEEGKVITRGLIVRRDW
SEIAKETQARVLETILKHGDVEEAVRIVKEVIQKLANYEIPPEKLAIYEQITRPLHEYKAIGPHVAVAKKLAAGVK
IKPGMVIGYIVLRGDGPISNRAILAEYDPPKKHKYDAEYYIENQVLPVAVLRILEGFGYRKEDLRYQKTRQVGLTSLW
NIKKS //

>Pfu delta D92-V93-P94 (SEQ ID NO: 36)

MILDVDYITEEGKPVIRLFKKENGKFKIEHRTFRPYIYALLRDDSKIEEVKKITGERHGKIVRIVDVEKVEKKFLG
KPITVWKLYLEHPQTIREKVRHPAVVDIFEYDIPFAKRYLIDKGLIPMEGEEELKILAFDIETLYHEGEEFGKGPI
IMISYADENEAKVITWKNIDLPYVEVVSSEREMIKRFLRIIREKDPDIVTYNGDSFDFPYLAKRAEKLGIKLTIGR
DGSEPKMQRIGDMTAVEVKGRIFDLYHVITRTINLPTYTLEAVYBAIFGKPKEKVYADEIAKAWESGENLERVAKY
SMEDAKATYELGKEFLPMEIQLSRLVGQPLWDVSRSSGTGNLVEWFLLRKAYERNEVAPNKPSEEEYQRRRESYTGG
FVKEPEKGLWENIVYLDLFRALYPSIIITHNVSPDTLNLEGCKNYDIAPQVGHKFKCDIPGFIPSLLGHLLEERQKIK
TKMKETQDPIEKILLDYRQKAIKLLANSFYGYGYAKARWYCKECAESVTAWGRKYIELVWKELEKFGFKVLYIDT
DGLYATIPGGESEEEKKALEFVKYINSKLPGLLELEYEGFYKRGFFVTKKRYAVIDEEGKVITRGLEIVRRDWSEI
AKETQARVLETILKHGDVEEAVRIVKEVIQKLANYEIPPEKLAIYEQITRPLHEYKAIGPHVAVAKKLAAGVKIKP
GMVIGYIVLRGDGPISNRILAEEYDPKKHKYDABYYIENQVLPVLRILEGFGYRKEDLRYQKTRQVGLTSWLNK
KS >Pfu

Figure 6C-1 (SEQ ID NOS: 37[nt] and 38[aa])

5'

atg atc ctc gat aca gac tac ata act gag gat gga aag ccc gtc atc 48

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile

1 5 10 15

agg atc ttc aag aag gag aac ggc gag ttc aaa ata gac tac gac aga 96

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Asp Tyr Asp Arg

20 25 30

aac ttt gag cca tac atc tac gcg ctc ttg aag gac gac tct gcg att 144

Asn Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile

35 40 45

gag gac gtc aag aag ata act gcc gag agg cac ggc act acc gtt agg 192

Glu Asp Val Lys Lys Ile Thr Ala Glu Arg His Gly Thr Thr Val Arg

50 55 60

gtt gtc agg gcc gag aaa gtg aag aag aag ttc cta ggc agg ccg ata 240

Val Val Arg Ala Glu Lys Val Lys Lys Lys Phe Leu Gly Arg Pro Ile

65 70 75 80

gag gtc tgg aag ctc tac ttc act cac ccc cag gac nnn ccc gca atc 288

Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Xaa Pro Ala Ile

85 90 95

agg gac aag ata aag gag cat cct gcc gtt gtg gac atc tac gag tac 336

Arg Asp Lys Ile Lys Glu His Pro Ala Val Val Asp Ile Tyr Glu Tyr

100

105

110

gac atc ccc ttc gcg aag cgc tac ctc ata gac aaa ggc tta atc ccg 384

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro

115

120

125

atg gag ggc gac gag gaa ctt aag atg ctc gcc ttc gac atc gag acg 432

Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr

130

135

140

ctc tat cac gag ggc gag gag ttc gcc gaa ggg cct atc ctg atg ata 480

Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile

145

150

155

160

agc tac gcc gac gag gaa ggg gcg cgc gtt att acc tgg aag aat atc 528

Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Ile

165

170

175

gac ctt ccc tat gtc gac gtc gtt tcc acc gag aag gag atg ata aag 576

Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys

180

185

190

cgc ttc ctc aag gtc gtc aag gaa aag gat ccc gac gtc ctc ata acc 624

Arg Phe Leu Lys Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr

195

200

205

tac aac ggc gac aac ttc gac ttc gcc tac ctc aag aag cgc tcc gag 672

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Ser Glu
210 215 220

aag ctc gga gtc aag ttc atc ctc gga agg gaa ggg agc gag ccg aaa 720
Lys Leu Gly Val Lys Phe Ile Leu Gly Arg Glu Gly Ser Glu Pro Lys
225 230 235 240

atc cag cgc atg ggc gat cgc ttt gcg gtg gag gtc aag gga agg att 768
Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
245 250 255

cac ttc gac ctc tac ccc gtc att agg aga acg att aac ctc ccc act 816
His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

tac acc ctt gag gca gta tat gaa gcc atc ttt gga cag ccg aag gag 864
Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Gln Pro Lys Glu
275 280 285

aag gtc tac gct gag gag ata gcg cag gcc tgg gaa acg ggc gag gga 912
Lys Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Thr Gly Glu Gly
290 295 300

tta gaa agg gtg gcc cgc tac tcg atg gag gac gca aag gta acc tat 960
Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305 310 315 320

gaa ctc gga aaa gag ttc ttc cct atg gaa gcc cag ctc tcg cgc ctc 1008

Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
325 330 335

gta ggc cag agc ctc tgg gat gta tct cgc tcg agt acc gga aac ctc 1056
Val Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340 345 350

gtc gag tgg ttt ttg ctg agg aag gcc tac gag agg aat gaa ctt gca 1104
Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
355 360 365

cca aac aag ccg gac gag agg gag ctg gca aga aga agg gag agc tac 1152
Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Arg Glu Ser Tyr
370 375 380

gcg ggt gga tac gtc aag gag ccc gaa agg gga ctg tgg gag aac atc 1200
Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Asn Ile
385 390 395 400

gtg tat ctg gac ttc cgc tcc ctg tat cct tcg ata ata atc acc cat 1248
Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
405 410 415

aac gtc tcc cct gat aca ctc aac agg gag ggt tgt gag gag tac gac 1296
Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Glu Glu Tyr Asp
420 425 430

gtg gct cct cag gta ggc cat aag ttc tgc aag gac ttc ccc ggc ttc 1344

Val Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe
435 440 445

atc cca agc ctc ctc gga gac ctc ttg gag gag aga cag aag gta aag 1392
Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Val Lys
450 455 460

aag aag atg aag gcc act ata gac cca atc gag aag aaa ctc ctc gat 1440
Lys Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Lys Lys Leu Leu Asp
465 470 475 480

tac agg caa cga gca atc aaa atc ctt gct aat agc ttc tac ggt tac 1488
Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly Tyr
485 490 495

tac ggc tat gca aag gcc cgc tgg tac tgc aag gag tgc gcc gag agc 1536
Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
500 505 510

gtt acc gct tgg ggc agg cag tac atc gag acc acg ata agg gaa ata 1584
Val Thr. Ala Trp Gly Arg Gln Tyr Ile Glu Thr Thr Ile Arg Glu Ile
515 520 525

gag gag aaa ttt ggc ttt aaa gtc ctc tac gcg gac aca gat gga ttt 1632
Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
530 535 540

ttc gca aca ata cct gga gcg gac gcc gaa acc gtc aaa aag aag gca 1680

Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala

545

550

555

560

aag gag ttc ctg gac tac atc aac gcc aaa ctg ccc ggc ctg ctc gaa 1728

Lys Glu Phe Leu Asp Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu Glu

565

570

575

ctc gaa tac gag ggc ttc tac aag cgc ggc ttc ttc gtg acg aag aag 1776

Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys

580

585

590

aag tac gcg gtt ata gac gag gag gac aag ata acg acg cgc ggc ctt 1824

Lys Tyr Ala Val Ile Asp Glu Glu Asp Lys Ile Thr Thr Arg Gly Leu

595

600

605

gaa ata gtt agg cgt gac tgg agc gag ata gcg aag gag acg cag gcg 1872

Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala

610

615

620

agg gtt ctt gag gcg ata cta aag cac ggt gac gtt gaa gaa gcg gta 1920

Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val

625

630

635

640

agg att gtc aaa gag gtt acg gag aag ctg agc aag tac gag gtt cca 1968

Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro

645

650

655

ccg gag aag ctg gtc atc tac gag cag ata acc cgc gac ctg aag gac 2016

Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Asp Leu Lys Asp

660

665

670

tac aag gcc acc ggg ccg cat gtg gct gtt gca aaa cgc ctc gcc gca 2064

Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala

675

680

685

agg ggg ata aaa atc cgg ccc gga acg gtc ata agc tac atc gtg ctc 2112

Arg Gly Ile Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu

690

695

700

aaa ggc tcg gga agg att ggg gac agg gct ata ccc ttt gac gaa ttt 2160

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe

705

710

715

720

gac ccg gca aag cac aag tac gat gca gaa tac tac atc gag aac cag 2208

Asp Pro Ala Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln

725

730

735

gtt ctt cca gct gtg gag agg att ctg agg gcc ttt ggt tac cgt aaa 2256

Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys

740

745

750

gaa gat tta agg tat cag aaa acg cgg cag gtt ggc ttg ggg gcg tgg 2304

Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp

755

760

765

cta aaa cct aag aca tga 2322

Leu Lys Pro Lys Thr

Tgo93 (R): nnn = AGA, AGG, CGA, CGC, CGG, CGT (R)

Tgo 93 (R) amino acid sequence

Tgo 93 (E): nnn = GAA, GAG (E)

Tgo 93 (E) amino acid sequence

Tgo93 (D): nnn = GAT, GAC (D)

Tgo 93 (D) amino acid sequence

Tgo93 (K): nnn = AAA, AAG (K)

Tgo 93 (K) amino acid sequence

Tgo93 (Q): nnn = CAA, CAG (Q)

Tgo 93 (Q) amino acid sequence

Tgo93 (N): nnn = AAC, AAU (N)

Tgo 93 (N) amino acid sequence

Figure 7A

ACCESSION AAA72101 Vent Thermococcus litoralis

mildtdyitk dgkpiirfk kengefkiel dphfqpyiya llkddsaiee ikaikgerhg ktrrvldavk vrkkflgrev
evwklifehp qdvpamrgki rehpaavdiy eydipfakry lidkglipme gdeelklaf dietfyhegd efgkgeiimi
syadeeeav itwknidlpv vdvvsnerem ikrfvqvve kdpdviityn gdnfdlpyli kraeklgvrl vlgrdkehpe
pkiqrmgdsf aveikgrihf dlfpvvrtri nlptyleav yeavlgkts klgaeeiaai weteesmkkl aqysmedara
tyelgkeffp meaelaklig qsvwdvsrss tgnlvewyll rvayarnela pnkpdeeyk rrlrttylgg yvkepekglw
eniylldfrs lypsiivthn vspdtlekeg cknvdvaviv gyrfckdfpg fipsilgdli amrqdikkkm kstidpiekk
mldyrqraik llansygygm gypkarwysk ecaesvtawg rhyientire iekfsgfklv yadtdgfyat ipgekpelik
kkakeflnyi nskplgllel eyegfylrgf fvtkkryavi deegrittrg levvrddwse iaketqakvl eailkegsve
kavevrvdvv ekiakyrvpl eklviheqit rdldykaig phvaiaakra argikvkpgt iisyivlks gkisdrrvll
teydrkhky dpdyienqv lpavlrilea fgyrkedlry qsskqtglda wlkr (SEQ ID NO. 83)

ACCESSION O33845 THEST THERMOCOCCUS SP.

mildtdyitk dgkpiirfk kengefkiel dphfqpyiya llkddsaide ikaikgerhg kivrvldavk vkkklgrdv
evwklifehp qdvpalrgki rehpaavdiy eydipfakry lidkglipme gdeelklmaf dietfyhegd efgkgeiimi
syadeeeav itwknidlpv vdvvsnerem ikrfvqvve kdpdvlityn gdnfdlpyli kraeklgvrl vlgrdkehpe
pkihrmgdsf aveikgrihf dlfpvvrtri nlptyleav yeavlgkts klgaeeiaai weteesmkkl aqysmedara
tyelgkeffp meaelaklig qsvwdvsrss tgnlvewyll rvayarnela pnkpdeeyr rrlrttylgg yvkeperglw
eniayldfrc hpadtkvivk gkgivnisdv kegdyilgid gwqrvkkvkw yhyegklini ngkctpnhk vpvvtendrq
trirdslaks flsgkvkiki itklfekia efeknpsee eilkgelgi ilaegtllrk dieyfdssrg kkrishqyrv citigeneke
llerilyifd klfgirpsvk kkgdtnalki ttakkavylq ieellknies lyapavlrgr ferdatvni rstivvtqgt nnkwkidiva
kllldslgipy sryeykyien gkelthile itgrdgilf qtlvgfisse knealekaie vrenmrlnn sfynlstfev
sseykygevy dltlepnpyy fangilthns lypsiivthn vspdtlereg cknvdvaviv gykfckdfpg fipsilgeli
tmrqeikkkm katidpiekk mldyrqavk llansilpne wlpieengev kfvkigefid rymeeqkdqv rtdntevle
vdrifafsln keskkseikk vkalrhkyk geayeevelns grkihitrg slftimgki keiwgeevkv gdliivpkkv
knekeavin ipelisklpe edtdvmtt pvkgrknffk gmlrtlkwif geeskrttf nrylfhlee gfvklprgy
evtdweglkr yrqlyeklv nlryngkre ylvrfndikd svscfprkel eewkigtgk frxkcilkvd edfgkflgyy
vsegyagaqk nktggmsysv klynenpnvl kdmkniaekf fgkvrvgknc vdiplkmayl lkslcvta enkripsiif
dssepvrwaf lrayfvgdgd ihpskrllrs tksellanql vflnslgvs sikigfdsgv yrvyinedlp flqtsrqknt
yypnlipkev lecifgrkf qnifekfke ladsgkldkr kvklldfln gdivldrvkn vekreyeyv ydlsvednen
flvgfglly hnsygygmgy pkarwyskcc aesvtawgrh yientikeie ekfsgfklv dsvtgdteii vkmgriefv
pieklfervd yrigekeyci ledvealtld nrgkliwkv pyvmhrakk kvyrwitns wyidvtedhs livaedglke
arpmeiegks liatkdldsg veyikphaie eisyngyvyd ievgthrff angilvhntd gfyatipgek petikkake
flkyinsklp glleleyegf ylgffvakk ryavideegr ittrglevvr rdwseiaket qakvleailk edsvekavei
vkdvveeik yqvplekvi heqitkdlse ykaighvai akrlaakgik vrpgtiisi ylrsgskisd rvillseydp
kkhkypdyy ienqvlpavl rileafgyrk edlkyqsskq vglawlk (SEQ ID NO. 84)

ACCESSION P77916 Pab Pyrococcus abyssi

miidadyite dgkpiirifk kekgefkev dtrfpyiya llkddsaide vkkitærhg kivritevek vqkkflgrpi evwklylehp qdvpaireki rehpavvdif eydipfakry lidkgltpme gneeltflav dietlyhege efgkgpiimi syadeegakv itwksidlpv vevvsserem ikrivkvire kdpdviityn gdnfdpyll kraeklgikl plgrdnsepk mqrmgdsav eikgrihfdl fpvirrtinl ptytleavve aifgkskekv yaheiaaeawe tggklervak ysmedakvtf elgkeffpme aqlarlvqgp vwdvsrsstg nlvewflrk ayemelapn kpdereyerr lresyeggyv kepekglweg ivsldfrsly psiiithnvs pdtlnrenck eydvapqvgf rfckdfpgfi psllgnlee rqkikkrmk skdpvekkll dyrqraikil ansyygygyg akarwyckec aesvtawgrq yidlvrrle srgfkvlyid tdglyatipg akheieikea lkfveyinsk lpglleleye gfyargffvt kkkyalidee gkivtrglei vrrdwseia etqakvleai lkhgnvdeav kivkevtekl skyeppekl viyeqitrpl seykaigphv avakrlaakg kvkpgmvig yivlrgdgpi skraiaieef dpkhhkydae yyienqvlpa verilrafgy rkedlryqkt kvqvglawlk f (SEQ ID NO. 85)

ACCESSION O59610 PYRHO *Pyrococcus horikoshii*

mildadyite dgkpiirifk kengefkev dmrpyiya llrddsaide ikkitaqrhg kvrvivetek iqrkflgrpi evwklylehp qdvpairedki rehpavvdif eydipfakry lidkgltpme gneeltflav dietlyhege efgkgpvimi syadeegakv itwkkidlpv vevvsserem ikrirvike kdpdviityn gdnfdpyll kraeklgikl llgrdnsepk mqkmgdsav eikgrihfdl fpvirrtinl ptytleavve aifgkpkkev yadeiakawe tggklervak ysmedakvty elgreffpme aqlarlvqgp vwdvsrsstg nlvewflrk ayemelapn kpdekeyerr lresyeggyv kepekglweg ivsldfrsly psiiithnvs pdtlnregce eydvapkvgh rfckdfpgfi psllgqlee rqkikkrmk skdpvekkll dyrqraikil ansilpdewl pivenekvrf vkigdfidre ieenaervkr dgeteilevk dlkalsfnre tkkselkkvk alirhrysgk vysikksgr rikitsghsl fsvkngklvk vrgdelkpgd lvvvpgrlkl peskqvlnlv ellklpee tsnivmmipv kgrknffkgm lktlywifge gerprtagry lkhlerlgyv klkrrgecvl dweslkryrk lyetliknlk yngnsraymv efnsldrsvs lmpieelkew iigepgpk gtfidvdsf akllgyyiss gdvekdrykf hskdqnvled iaklaeklfk kvrrgrgyie vsgekishaif rvlaegkrip efiftspmdi kvafklng naeeltfstk sellvnqll llnsigvsdi kiehekgvyr vyinkkessn gdivdsves ievkyeggyv ydlsvednen flvgfgllya hnsyygygyg akarwyckec aesvtawgrq yidlvrrle argfkvlyid tdglyatipg vkdweevkrr alefvdvins klpgvleley egfyargffv tkkkyalide egkivtrgle ivrrdwseia ketqarvlea ilkhgnveea kvikdvtek ltnyevpek lviyeqitrp ineykaigph vavakrlmar gikvkpgmvi gyivlrgdgp iskraisiee fdprkhkyda eyyienqvlp averilkafg ykredlrwqk tkqvglgawi kvkks (SEQ ID NO. 86)

ACCESSION P77932 PYRSE *PYROCOCCUS SP.*

miidadyite dgkpiirifk kekgefkev dtrfpyiya llkddsaide vkkitærhg kivritevek vqkkflgrpi evwklylehp qdvpaireki rehpavvdif eydipfakry lidkgltpme gneeltflav dietlyhege efgkgpiimi syadeegakv itwksidlpv vevvsserem ikrivkvire kdpdviityn gdnfdpyll kraeklgikl plgrdnsepk mqrmgdsav eikgrihfdl fpvirrtinl ptytleavve aifgkskekv yaheiaaeawe tggklervak ysmedakvtf elgkeffpme aqlarlvqgp vwdvsrsstg nlvewflrk ayemelapn kpdereyerr lresyeggyv kepekglweg ivsldfrsly psiiithnvs pdtlnrenck eydvapqvgf rfckdfpgfi psllgnlee rqkikkrmk skdpvekkll dyrqraikil ansyygygyg akarwyckec aesvtawgrq yidlvrrle ssgfkvlyid tdglyatipg akpneikea lkfveyinsk lpglleleye gfyargffvt kkkyalidee gkivtrglei vrrdwseia etqakvleai lkhgnvdeav kivkevtekl skyeppekl viyeqitrpl seykaigphv avakrlaakg kvkpgmvig yivlrgdgpi skraiaieef dpkhhkydae yyienqvlpa verilrafgy rkedlryqkt kvqvglawlk f (SEQ ID NO. 87)

ACCESSION AAA67131 DeepVent Pyrococcus sp.

mildadyite dgkpiirifk kengefkvey dnmfrpyiya llkddsqide vrkitaerhg kivriidaek vrkkflgrpi
evwrylyfep qdvpairdki rehsavidif eydipfakry lidkglipme gdeelklaf dietlyhege efakgpiimi
syadeeeakv itwkkidlpv vevvsserem ikrflkvire kdpdviityn gdsfdlpvlv kraeklgikl plgrdgsepk
mqrlgdmav eikgrihfdl yhvirtinl ptytleavye aifgkpkkev yaheiaeawe tgkglervak ysmedakvty
elgreffpme aqlsrlvgqp lwdvsrsstg nlvewyllrk ayernelapn kpdereyerr lresyaggyv kepekgllweg
lvsldfrsly psiiithnvs pdtlnregcr eydvapevgh kfckdfpgfi psllkrllde rqeikrkmka skdpiekkml
dyrqaikil ansygygygy akarwyckec aesvtawgre yiefvrkele ekfgfkvlyi dtdglyatip gakpeeikkk
alefvdyna klpglleley egfyvrgffv tkkkyalide egkiitrgle ivrrdwseia ketqakvlea ilkhgnveea
vkivkevtek lskyeippekk lviyeqitrp lheykaigh vavakraar gvkvrpgmvi gyivlrgdgp iskralae
fdlrkhkyda eyyienqvlv avlrileafg yrkedlrwqk tkqtgtawl nikkk (SEQ ID NO. 88)

ACCESSION P80061 Pfu Pyrococcus furiosus

mildvdyite egkpvirflk kengkfkieh drtfrpyiya llrddskiee vkkitgerhg kivrivdvek vekkflgkpi
tvwklylehp qdvpitirekv rehpaavdif eydipfakry lidkglipme geeelkilaf dietlyhege efgkgpiimi
syadeneakv itwknidlpv vevvsserem ikrflriire kdpdiityn gdsfdfpyla kraeklgikl tigrdgsepk
mqrigdmav evkgrihfdl yhvitrinl ptytleavye aifgkpkkev yadeiakawe sgenlervak ysmedakaty
elgkeflpme iqslrlvgqp lwdvsrsstg nlvewflrk ayernevapn kpseeeyqrr lresyaggfv kepekgllwen
ivyldfraly psiiithnvs pdtlnlegck nydiapqvgf kfckdipgfi psllghllle rqkiktkmke tqdpickill
dyrqaikil ansfygygygy akarwyckec aesvtawgrk yielvwkele ekfgfkvlyi dtdglyatip ggeseiikkk
alefvyins klpglleley egfykrffv tkkryavide egkvitrgle ivrrdwseia ketqarvlet ilkhgdveea
vrivkeviqk lanyeippekk laiyeqitrp lheykaigh vavaklaak gvkikpgmvi gyivlrgdgp isnrailae
ydpkkhkyda eyyienqvlv avlrilefg yrkedlryqk trqvgltswl nikks (SEQ ID NO. 89)

> JDF-3 Thermococcus sp.

mildvdyitengkpvirvfkkengefriedrefepfyfyllrddsaieeikkitaerhgrvvkvkraekvkkkflgrsvevwlyfthp
qdvpairdkirkhpavidiyeydipfakrylidkglipmegeeelklmsfdietlyhegeefgtgpilmsiyadesearvitwkkidlpv
vevvstekemikrflrvvkekdpdlityngdnfdafylkrckelgvsftlgrdgsepkiqrmgdrfavevkgvrhfdlpyvirtinl
ptytleavyeavfgkpkkevyaeeiatawetgeglervarysmedarvtyelgreffpmeaqlsrligqglwdvsrsstgnlvewflrk
ayernelapnkpderelarrggyaggyvkeperglwdnivldfrslypsiiithnvspdtlnregcrsydvapevghkfckdfpgfip
slgnlleerqkikrkmkatldpleknldyrqaikilansygygygyararwycreaesvtawgreiyemvireleekfgfkvlyadt
dglhatipgadaetvkkkameflnyinpkpglleleyegfyvrgffvtkkkyavideegkitttrgleivrrdwseiaketqarvleailrh
gdveeavrivrevteklskyevppeklviheqitrelkdykatgphvaiakraargvkirpgtvisyivlkgsgrigdraipfdefdptkh
kydadyyienqvlpaverilrafgyrkedlryqktrqvlgawlkpgkghk (SEQ ID NO. 90)

ACCESSION Q56366 9degN THERMOCOCCUS SP. (STRAIN 9°N-7).

mildtdyite ngkpvirvfk kengefkicy drtfepyfya llkddsaied vkkvtakrhg tvvkvkraek vqkkflgrpi evwklyfnhp qdvpairdri rahpavvdiy eydipfakry lidkglipme gdeeltmlaf dietlyhege efgtgpilmi syadgsearv itwkkidlpv vdvvstekem ikrflrvvre kdpdvlityn gdnfd Faylk krceelgikf tlgdrgsepk iqrmgdrfav evkgrihfdl ypvirrtinl ptytleavve avfgkpkkev yaeeiaqawe sgeglervar ysmedakvty elgreffpme aqlsrligqs lwdvsrsstg nlvewflrk ayknelapn kpderelarr rggyaggyvk eperglwdni vyldfrslyp siiithnvsp dtlnregcke ydvapevghk fckdfpgfip slldlleer qkikrkmkat vdplekklld yrqraikila nsfygygya karwyckeca esvtawgrey iemvirelee kfgfkvlyad tdlghatipg adaetvkkka keflkyinpk lpglleeye gfyvrgffvt kkkyavidee gkittrglei vrrdwseiak etqarvleai lkhgdveeav rivkevtekl skyevppekl viheqitrdl rdykatgphv avakrlaarg vkirpgtvis yivlkgsgri gdraipadef dptkhrydae yyienqvlpa verilkafty rkedlryqkt qkvglgawlk vkgkk (SEQ ID NO. 91)

ACCESSION BAA06142 KOD *Pyrococcus* sp.

mildtdyite dgkpvirfkk kengefkicy drtfepyfya llkddsaiee vkkitaerhg tvvtvkrvek vqkkflgrpv evwklyfthp qdvpairdki rehpaividiy eydipfakry lidkglvpme gdeelkmlaf dietlyhege efaegpilmi syadeegarv itwknvdipv vdvvsterem ikrflrvvke kdpdvlityn gdnfd Faylk krceklginf algrdgsepk iqrmgdrfav evkgrihfdl ypvirrtinl ptytleavve avfgqpkkev yaeeittawe tgenlervar ysmedakvty elgkeflpme aqlsrligqs lwdvsrsstg nlvewflrk ayernelapn kpdekelarr rqsyeggyvk eperglweni vyldfrchpa dtkvvvkgkg iinisevqeg dyvlgidgwq rvrvvweydy kgelvningl kctpnhklpv vtnerqtri rdsllaksflt kvkvgkiitt plfyieigrat senipeeevl kgelagilla egtllrkdv ydssrkkrr ishgyrveit igkdeeeefrd rityiferlf gitpsisekk gtnavtlkva kknvylkvke imdnieslha psvlrgffeg dgsvnrvrs ivatqgtkne wkiklvskll sqlgiphqty tyqyqengkd rsryileitg kdglilfql igfiserkna llnkaisqre mnnlenngfy rlsefnvste yyegkvdytl legtpyyfan gilthnslyp siiithnvsp dtlnregcke ydvapqvghr fckdfpgfip slldlleer qkikrkmkat idpieklld yrqraikila nsilpeewlp vleegevhfv rigelidrmn eenagkvkre getevlevsg levpsfnrrt nkaelkrvka lrrhdysgkv ytirllksgr ikitsghslf svrngellev tgdelpkpgd vavprrelp emhvlnlve lllgtpeeet ldivmtipvk gkknffkgml rtlrwifgee krprtarryl rhledlgyvr lkkigyevld wdsllknyrrl yealvenvry ngnkreylve fnsirdavgi mplkelkewk igtngfmr klievdesla klgyyvseg yarkqmpkn gwsysvklvnl edpevlldme rlasrffgkv rrgmyveip kkigyllfen mcgvlaenkr ipefvftspk gvrlafleg yfigdgvhpn krlrlstkse llanqlvlll nsvgvsavkl ghdsyvryv ineelpfvkl dkkknayysh vipkevlsev fgkvfqknvs pqtfrkmved grldpekaqr lswliegdvv ldrvesvdve dydgyvydls vednenflvg fglvyahnsy ygygyarar wyckecaesv tawgreyitm tikeieekyg fkviysdtgd ffatipgada etvkkkamef lkyinaklp aleleyegfy krgffvtkkk yavideegki ttrgleivrr dwseiaketq arvleallkd gdvekavriv kevteklsky evppeklvih eqitrdlkdy katgphvava krlaargvki rpgtvisyiv lkgsgrigdr aipdfdefdt khkydaeyyi enqvlpaver ilrafgyrke dlryqktrqv glsawlkpkg t (SEQ ID NO. 92)

ACCESSION 4699806 Tgo *Thermococcus gorgonarius*.

mildtdyite dgkpvirfkk kengefkidy drmfepiya llkddsaied vkkitaerhg tvrvvraek vkkkflgrpi evwklyfthp qdvpairdki kehpaividiy eydipfakry lidkglipme gdeelkmlaf dietlyhege efaegpilmi syadeegarv itwknidlpv vdvvstekem ikrflrvvke kdpdvlityn gdnfd Faylk krseklgvkf ilgregsepk iqrmgdrfav evkgrihfdl ypvirrtinl ptytleavve aifgqpkkev yaeeiaqawe tgeglervar ysmedakvty elgkeffpme aqlsrlvgqs lwdvsrsstg nlvewflrk ayernelapn kpderelarr resyaggyvk eperglweni vyldfrslyp siiithnvsp dtlnregcee ydvapqvghk fckdfpgfip slldlleer qkvkkkmkat idpieklld

yrqraikila nsfygygya karwyckeca esvtawgrqy iettireiee kfgfkvlyad tdgffatipg adaetvkkka
kefldyina kpglleeye gfykrffvt kkkyavidee dkittgrlei vrrdwseia etqarvleai lkhgdveeav
rivkevtekl skyevppekl viyeqitrdl kdykatgphv avakrlaarg ikirpgtvis yivlkgsgri gdraipfdef
dpakhkydae yyienqvlpa verilrafy rkedlryqkt qvlgawlk pkt (SEQ ID NO. 93)

ACCESSION P74918 THEFM *Thermococcus fumicolans*

mildtdyite dgrpvirvfk kengefkicy drdfepyya llkddsaied vkkitasrhg ttvrvragk vkkkflgrpi
evwklyfthp qdvpairdki rehpaavdiy eydipfakry lidkglipme gdeelkmlaf dietlyhege efaegpilm
syadeegarv itwkkidlpy vdvstekem ikrlfkvvke kdpdvlityn gdnfdafylk krseklgvkf ilgrdgsep
iqrmgdrfav evkgrihfdl ypvirhtinl ptytleavve aifgqpkv yaeeiaqawe tgeglervar ysmedakvty
elgreffpme aqlsrlvgqs fwdvsrsstg nlvewyllrk ayernelapn kpsgreler rgyaggyvk eperglweni
ayldfrchpa dtkvivkgk vvnisevreg dyvlgidgwq kvqrvweydy egelvningl kctpnhklpv vrrterqtai
rdslaksflt kkvgklitt plfekigkie redvpeeeil kgelagiila egtllrkdv yfdssrgkk vshqyrveit
vgaqeedfqr rivyiferlf gvtpsvyrkk ntnaitfkva kkevylrvre imdgienlha psvlrgffeg dgsvnkvrkt
vvvnqgtne wkievvskll nklgiphrry tydyterekt mtthileiag rdglilfqi vgfisteknm aleaairne
vnrlennafy tladftakte yykgvydlt legtpyyfan gilthnslyp siiishnvsp dtlnregcge ydeapqvghr
fckdfpgfip slldllder qkvkhhmkat vdpiekkld yrqraikila nsfygygya karwyckeca esvtawgrqy
iettmreiee kfgfkvlyad svtgdevti rmgriefvp ieklfervdh rvekeycvl ggvealtldn rgrlvwkvvp
yvmrhktdkr iyrwvftsw yldvtedhsl igylntskvk pgkplkerlv evkpeelggk vkslitpnrp iartikanpi
avklweligl lvgdgnwggq snwakyyvvl scgldkaeie rkvlnporea svisnyydk kkgdvsilsk wlagfmvkyf
kdengkaip sfmfnlprey icaflrglfs adgtvslrrg ipeirltsvn relsdavrkl lwlvgvsnl ftekpnrlyl ekesgthsih
vriknhrfa driglilrk stklseilgg htnkkrayky dfdlvyrki ecitydgyvy dievegthrf fangilvhnt
dgffatipga daetvkkar eflnyinplk pglleeyeg fyrrgffvk kkyavidee kittgrleiv rrdwseavake
tqarvleail rhgdveeavr ivkevtekl kyevppeklv iheqitrelk dykatgphva iakrlaargi kvrpgtvisy
ivlkgsgri drtipfdefd ptkhrydaey yienqvlpav erikafgyk kedlryqkt qvlgawlk gkk (SEQ ID
NO. 94)

ACCESSION O27276 METTH *Methanobacterium thermoautotrophicum*

medyrmvld idyvtvdevp virfkgdks ggnepiihd rsfrpyyai ptdldeclre leelelekle vkemrdlgrp
teviriefrih pqdvpkird irdlesvrdi rehdpfyr ylidksivpm eelefggvev dsapsvtdv rtvevtgrvq
stgsgahld ilsdievrn phgmpdpek eivmigvagn mgyesvista gdhldfvev ederellerf aeividkkpd
ilvgynsdnf dfpyitrra ilgaeldlgw dgskirtmrr gfanataikg tvhvdlypvm rymnldryt lervyqelfg
eekidlpgr lweywdrdel rdelfrysld dvvathria kilpnllelt rlvqplfdi smatgqae wflvrkayqy
gelvpnkpsq sdfssrrgr avgyvkepe kglhenivqf dfrslypsii isknispdtl tdeesecyv apegyrfrk
sprgfvpsvi geilservi keemkgsddp merklnvqq ealkrlantm ygyvgyrfr wysmecaeai tawgrdyikk
tiktaeefgf htvyadtgdg yatyr (SEQ ID NO. 95)

ACCESSION Q58295 Metja

Methanococcus jannaschii

mgmsmgkiki dalidntykt iedkaviyly linsilkdrd fkyfyvelh kekvenedie kikeflknd llkfveniev
vkkilrkek evikiiathp qkvplrkik eceivkeiye hdiplakryl idneiipmty wdfenkkpvs iepklksva
fdmevynrdt epnperdpil masfwdengg kvitykefnh pnievvknek elikkietl keydviytyn gdnfdfpylk
arakiygidi nlgdgeelk ikrgrmeyrs yipgrvhiidl ypisrllkl tkytledvvy nlfgieklki phtkivdywa
nndktlieys lqdakytyki gkyffplevm fsrivnqtpf eitrmssgqm veyllmkraf kenmivpnkp deeeeyrrvl
tтыeggyvke pekgmfedii smdfrchpkg tkvvvkgkgi vniedvkegn yvlgidgwqk vkkvwykye gelinvnglk
ctpnhkiplr ykikhkkink ndylvrdiya kslltkfke gklilckdfe tignyekyin dmdedfilks eligillaeg
hlrrdieyf dssrgkkris hqyrveitvn edekdfieki kyifklfny elyvrrkkgt kaitlgcakk diylkieeil
knkekylpna ilrgffegdg yvntvrravv vnqgtynydk ikfiaslldr lgikysfyty syeergkkkl ryviefiskg
dlikfsilis fisrrknnll neiirqktly kigdygyfndl ddvcslesy kgevydltle grpyyfangi lthnslypsi iisynispdt
ldceckdvs ekilghwfck kkeglipkti nlierrini krmkkmaei geineeynll dyeqskilil ansilpdeyl
tiieedgikv kvigeyiddl mrkhkdkikf sgiseiletk nlktsfdki tkkceikkvk alirhpyfgk aykiklrsg
tikvtrghsl fkyengkive vkgddvrfgd livvpkkltc vdeevinip krlinadeee ikdlvitkhk dkaffvklkk
tlediennkl kvifddcily lkelglidyn iikkinkvdi kildeekfka ykkyfdtvie hgnfkkgren iqyikikdyi
anipdkfed ceigaysgki nallkldek akflgffvtr grlkkqklkg etveyisvyk slpeyqkeia etfkevfgag
smvkdktvmd nkivylvly ifkcgdkdkk hipeelflas esviksfldg flkakknshk gtstfmakde klynqlmifl
nlvgiptrft pvknkgyklt lnpkygtvkd lmldevkeie afeysgyvyd lsvednenfl vnnyahnsy ygylafprar
fysrecaeiv tylgrkyile tvkeakfgf kvlyidtdgf yaiwkekisk eelikkamef veyinsklpg tmelefegyf
krgifvtkkr yalidengrv tvkglefvr dwsniakitq rrvleallve gsiekakkii qdvikdlrek kikkedliiy
tqltkdpkey kttaphveia kklmregkri kvgdiigyii vkgtksiser aklpeevdid didvnyyidn qilppvlrim
eavgysknel kkegaqltld kfkf (SEQ ID NO. 96)

ACCESSION B56277 POC Pyrodictium occultum

mtetiefvll dssyeilgke pvvilwgitl dgkrvllldh rfrpyfyali argyedmvee iaasirrlsv vkspiidakp
ldkryfgrpr kavkittmip esvrhyreav kkiegvedsl eadrfamry lidkrylpft vyripvedag mngfvrdrv
ykvagdpepl aditridlpp mrlvafdiev ysrrgspna rdpviivslr dsegkerlie aeghddrrvl refveyvraf
dpdiivgyns nhfdwpylme rarrlgikld vtrvgaapt tsygyhvsq grlnvldydy aeempeikmk tleeaeylg
vmkkservii ewwripeywd dekkqrller yalddvraty glaekmlpfa iqlstvtgvp ldqvgamgvg frlewylnra
aydmnelvsn rverrgesyk gavvlkplkg vhenvvldf smmypsimek ynvdpdtivd dpsecpkygg cyvapevghr
firspgffk tvlenllkl rqvkekmkef ppspeyrly derqkalkvl anasygymgw sharwyckrc aeavtawgrn
liltaieyar klglkviygd tdsfvydyd ekvekliefv ekelgfeiki dkiykvfft eakkryvgll edgridivgf
eavrgdwcel akevqekaae ivlntgnvdk aisyyevik qlregkvpit klliwktlsk rieeyhdap hvmaarmke
agyevspgdk vgyvivkgsg svssraypyf mvdpstidvn yyidhqivpa alrilsyfgv tekqlkaaat vqrsldffa skk
(SEQ ID NO. 97)

ACCESSION BAA81109 ApeI Aeropyrum pernix

mrpstpvii wrgadgsrv vvygefrpy fyvlpdgsvg ldqlaamirr lsrpsspils vervrfrfig revealkvtt
lvpasvreyr eavrlggvr dvleadipla lrfiidfny pmrwyvaevr evavphgysv draytlsgdi redetriqed
plklrvmaf dievyskmrt pdpkdpvim iglqqagei eileadrsd kkviagfver vksidpdviv gynqrndwp
ylverarvlg vklavgrsv epqpglyghy svsglnvdl ldfaeelhev kvktleevad ylgvvkiger vtlewwqige
ywddpskrei lrkylrddvr stmglaekfl pfgaelsqvs glpldqvmaa svgrflewrl ireaaklgel vprnrverseg

ryagaivlrp kpgvhediav ldfasmypni mvkynvgpdt lvrpgeeyge eevytapevg hkfrksppgf fkkilerfls
wrrqirsemk khppdspeyk llderqkaik llanasygym gwpharwycr ecaeavtawg rsiirtairk agelgleviy
gdtdslfvkn dpekvrlir fveeelgfdi kvdkvyrrvf fteakkryvg ltvdkidvv gfeavrgdws elaketqfkv
aeivlktgsv deavdyvni ieklrrgqvd mrklviwktl trppsmyear qphvtaallm eragikvepg akigyvvtkg
sgplytrakp yfmaskeevd veyyvdkqv vpaalrilqyf gvtekrkkg grqstlldfm rrgk (SEQ ID NO. 98)

ACCESSION O29753 ARCFU Archaeoglobus fulgidus

mervegwlid adyetiggka vvrwckddq gifvaydynf dpyfyvigvd edilknaats trrevikls fekaqlktlg
revegyivya hhpqhvpklr dylsqfgdvr eadipfayry lidkdlacmd giaiegekqg gvirsykiek veriprmefp
elkmlvfdce mlssfgmpep ekdpiiivsv ktndddeiil tgderkiisd fvkliksydp diivgynqda fdwpylrkra
erwnipldvgr dgsnvvfrg grpkitgrln vdlydiamri sdikikklen vaeflgtkie iadieakdiy rywsrgekek
vlnyarq dai ntyliakell pmhyelskmi rlpvddvtrm grgkqvdlw lseakkigei apnppehaes yegafvlepe
rglhenvacl dfasmypsim iafnispdty gerddceyap evghkfrksp dgffkrilrm liekrrelkv elknspess
eyklldikqq tlkvltnsfy gymgwnlarw ychpcaeatt awgrhfirts akiaesmgfk vlygdtdsif vtkagmtked
vdrldiklhe elpiqievde yysaiffvek kryagltedg rlvvkglevr rgdwcelakk vqrevievil keknpekals
lvkdvilrik egkvsleevv iykgltkps kyeshmqahv aalkaremgi iypvsskigy vivkgsgnig draypidlie
dfdenlrik tksgieikkl dkdyidnqi ipsvlriler fgyteaslkq ssqmsldsff s (SEQ ID NO. 99)

ACCESSION 6435708 Desulfurococcus sp. Tok.

mildadyite dgkpvirvfk kekgefkidy drdfepyyia llkddsaied ikkitaerhg ttvrvtraer vkkkflgrpv
evwklyfthp qdvpairdki rehpaavdiy eydipfakry lidrglipme gdeelmrlaf dietlyhege efgegpilmi
syadeegarv itwknidlpv vesvstekem ikfrlqvqe kdpdvlityn gdnfdafaylk krsemlgvkf ilgrdgsepk
iqrmgdrfav evkgrihfdl ypvirtinl pytletvyve pvfgqpkkev yaeeiarawe sgeglervar ysmedakaty
elgkeffpme aqlsrivgqs lwdvsrsstg nlvewflrk ayerndvapn kpderelarr tesyaggyvk epekglweni
vyldyslyp siiithnvsp dtlnregcre ydvapqvgfr fckdfpgfip slldlleer qkvkkkmkat vdpierklld
yrqraikila nsyygyyaya narwycra esvtawgrqy iettmreiee kfgfkvlyad tdgffatipg adaetvknka
keflnyinpr lpglleeye gfyrrgffvt kkkyavidee dkittgrlei vrrdwseiak etqarvleai lkhgdveeav
rivkevtekl srhevpekl viyeqitrdl rsyratgphv avakrlaarg ikirpgtvis yivlkgpgrv gdraipfdef
dpakhrydae yyienqvlp verilrafgy rkedlryqkt kqaglgawlk pkt (SEQ ID NO. 100)

ACCESSION Q56366 9oN-7

mildtdyite ngkpvirvfk kengefkicy drtfepyyia llkddsaied vkkvtakrhg tvkvkraek vqkkflgrpi
evwklyfnhp qdvpairdri rahpaavdiy eydipfakry lidkglipme gdeeltmlaf dietlyhege efgtgpilmi
syadgsearv itwkidlpv ydvstekem ikfrlvvre kdpdvlityn gdnfdafaylk krceelgikf tlgrdgsepk
iqrmgdrfav evkgrihfdl ypvirtinl pytleavve avfgkpkkev yaeeiaqawe sgeglervar ysmedakaty
elgreffpme aqlsrilgqs lwdvsrsstg nlvewflrk aykrelapn kpderelarr rggyaggyvk eperglwdni
vyldfrslyp siiithnvsp dtlnregcke ydvapevghk fckdfpgfip slldlleer qkikrkmkat vdpieklld
yrqraikila nsfygyygya karwyckeca esvtawgrey iemvirelee kfgfkvlyad tdgllhatipg adaetvkkka
keflkyinpk lpglleeye gfyvrgffvt kkkyavidee gkittgrlei vrrdwseiak etqarvleai lkhgdveeav

rivkevtel skyevppekl viheqitrld rdykatgphv avakrlaarg vkirpgtvis yivlkgsgri gdraipadef
dptkhrydae yyienqvlpa verilkafigy rkedlryqkt kvvglgawlk vkggk (SEQ ID NO. 101)

ACCESSION O29753 Afu

mervegwlid adyetiggka vvrwckddq gifvaydynf dpyfyvigvd edilknaats trrevikls fekaqlktlg
revegyivya hhpqhvpklr dylsqfgdvr eadipfayry lidkdlaamd giaiegekqg gvirsykiek veriprmeff
elkmlvfdce mlssfgmpep ekdpiiisv ktndddeil tgderkiisd fvkliksydp diivgynqda fdwpylrkra
erwnipldvg rdgsnvvfrg grpkitgrln vdlydiamri sdikikklen vaeflgtkie iadieakdiy rywsrgekek
vlnyarqai ntyliakell pmhyelskmi rlpvddvtrm grgkqvdlwll lseakkigei apnppehaes yegafvlepe
rglhenvacl dfasmypsim iafnispdty gcrddceyap evghkfrksp dgffkrilrm liekrrelkv elknlspeess
eyklldikqq tlkvltnsfy gymgwnlarw ychpcaeatt awgrhfirts akiaesmgfk vlygdttsif vtkagmtked
vdrlidklhe elpiqievde yysaiffvek kryagltedg rlvvkglevr rgdwcelakk vqrevievil keknpekals
lvkdvilrik egkvsleevv iykgltkkps kyesmqahvk aalkaremgi iypvsskigy vivkgsgnig draypidlie
dfdenlrik tksgieikkkl dkdyidnqi ipsvlriler fgyteaslkq ssqmsldsf s (SEQ ID NO. 102)

ACCESSION P52025 Mvo

mdldynskdl cidmyyknog lkkpeinlqk ecefkpyfyv dtsepkeiyd yldglneid lkklepefen ntslkvqdli
tnieiekiv ysyilngkd isevsdfknk kerkickvyv kypnhvkiir eyfkefgksy efdipflrry midqdivpsa
kysednkidn sipelnciaf dmelyckkep nakkdpiimv nlfskdyqkv itykkfense yngcvdyvkd ekeliqkie
ilkqydivyt yngdnfdpy lkraniyei eldfdnasns qppqiikisk gginrkskip giidhlypi arklnltky
klenvvqelf kinkeavdyg dipkmweted tllryayed alytykmgnv flpleimfsr invqplydts rmnssqmvef
lllksrfeqn misprpss syrerakfsy eggyvrepk giqedivsd fmslypsili shnispetvi yeekerenme
lgiipktlne llsrkhikm llkdkiqkne fdeysrleh eqsikvian shygylafpm arwysdkcae mvtglgrkyi
qetiekaef gfkviyaddt gfyakwdydk lqkgkkeeend ksdkslnpk lskeeliit kkflkginee lpegmelefe
ghfkrgrlft kkyaliied ghivvkglev vrrdwsniak dtqqaviral ledgdvnlak kiikntidnl kkgnidkndl
lihtqltkni eeykstaphi evakkikqrg dsrvvgdvis yivkgssri sraelleya gdydinyid nqvlppviri
meslgisese lknsqkqkl dqfm (SEQ ID NO. 103)

ACCESSION AAF27815

melkvwpldi tyavvgsvpe irifgilssg ervvlidrsf kpyfyvdcav cepaalktal srvapiddvq iverflgrs
kkflkviaki pedvrklrea amsiprvsgv yeadirfymr ymidmgvvpw swnvaeveeg grlggiptyv vsqwygideg
fppslkvmaf dievyners pdpirdpvm laikndghe evfeasgkdd rgvvravvdf irsydpdiv gynsngfdwp
ylverakavg vplkvdrln ppqsvyghw sivgranvdl yniveespei klktldrae yfgvmkreer vlipghkiye
ywkdpnkrpl lkryvlddr stlgldkl pfliqlssvs glpldqvaa svgnrvewml lryayrlgev apnreereye
pykgaivlep kpgmyedvlv ldfssmynpi mmkynlspdt ylepepdpp egvnvapevg hrfrsppgf vpqvkslve
lrkavreeak kyppdspefk ilderqralk vmanaiygy gwvgarwykr evaesvtafa railkdvieq arlgivvvy
gdtldslfvkk hgdvdliky veekygidik vdkdyakvlf teakkryagl lrdgridivg fevvrgdwse lakdvqlrvi
eiilksrdiv earhgvikiy reierlkny kfndidliw ktldkeldey kaypphvhay qilkrhgyrv gkggtigyvi
vkgekvser alpyilldi kkididyie rqiipaali aevigkesd lktgmrsi ldfis (SEQ ID NO. 104)

ACCESSION AAC62712 Csy

mtvqdaveip psllvsatyed sqagavvlkf yepesqkivh wtdntghkpy cytrqppsel gelegredvl gteqvmrhdl
iadkdvpvtpk itvadplaig gtseksirn imdtwesdik yyenlydks lvgryysvs ggkviphdmp isdevklalk
sllwdkvvde gmadrkefre fiagwadlln qpiprirrls fdievdseeg ripdpkisdr rvtavgfaat dgikqvfvlr
sgaeegengv tpgvevvfyd keadmirdal svigsypfvl tyngddfdmp ymlnrarrlg vsdsdiplym mrdsatlrhg
vhldlyrtfs nrsfqlyafa akytdyslms vtkamlgegk vdygvklgdl tlyqtanycy hdarltlels tfgneilmdl
lvvtsriarm piddmsrmgv sqwirsilly ehrsmlip rrelegrsr evsndavikd kkfrgglvve peegihfdvt
vmdfaslyps iikvrnlsye tvrcvhaeck kntipdtnhw vctknnglts miigslrldr vnnykslsks tsiteeqrqq
ytvisqalkv vlnasygvmg aeifplyflp aaeattavgr yiimqtishc eqmgvrvlyg dtdslfikdp eerqiheive
hakkehgvcl evdkeyryvv lsnrknyfg vtragkvdkv gltgkkshtp pfikelfysl ldilsgvese defesakmri
skaiaacgkr leerqiplvd lafnvmiska pseyyktvpq hiraarllen arevkkgdii sykvmmnktg vkpvmearag
evdtskylef mestldqlts smglfdfeil gkpkqtgmeq fffk (SEQ ID NO. 105)

ACCESSION P95690 Sac

mskqatldf sikkneskeq ntqesvevpk qtanrtkiew ikeaedgvky flqvdydg ksravcklyd kegkkiyimq
desghkpyfl ttdidpkvkn itkvrdpsf dhlelinkvd pytgkkirlt kivvkdplav rrmrsslpa yeahikyynn
yyvndglip liyvknkgkl tqlnpelke eineikklsd ayemtketvn dwipiletev pdikrvsldi evytpnrgri
pdperaefpi isvalagndg skivlalkre dvnsdfskkd gvqveifde kklarlfei ireypmltf ngddfdipyi
yfralrnfs peevpldvvs gegkflagih idlykfffr avsiyafegk yseyslyava tallgiskvk ldtfifindi
dklieynlrd acitklttf nnnlvklmv llarisklgl eeltrtevt wiknlyyweh rknwliplk eelvrnsqv
ktaavikgk ykgavvidpp agvyfnvvvl dfaslypsii knwnisyeti eidectkkvw vedetgeklh yvcmdkpgit
avyqglirdf rvkvvykkak ysniseeqrs lydvvqramk vfinatygvf gaenflyap avaesvtaig ryiitttykq
aeklnlviy gtdslifly ptkdkleeli kfvkqnfld levdytykv aysglkknfy gvypdgktei kgmlakmrnt
pifikkefae iknmlaslns pndipevkn leikikdiyy klrnkgynld dlafrimlsk pldsytknt qhvkagqlr
afgvnlprd vimfvkvsk dgvkayqlak iseidiekyv etlrrtfeqi lkafgiswde ivstisidsf fgskk (SEQ ID
NO. 106)

ACCESSION BAA23994 Soh

marqitldf tlkkeqnkde srkeephann ineerrkpe wikeaegks yflqvdydg kkskaickly dketkkiyil
ydnthkpyf ltidpekvk kipkvrdps fdhletviki dpysgnkikl tkivvkdpla vrrmrnsvpk ayeahikyfn
nyiydlglip gpyvvkkgk leqlpelkg eevdeirkaf adsdemtkea vndwipifes evpdvkrvai dievytpikg
ripdpekaef piisislagn dgtrvllv redvnsqitk hdvivetfks erelirffd iildypiiit fngddfdipy iyralklnf
tpeepfdii ndegkylagi hidlykfffr rairnyafeg kyneynldav atallgmskv kldtlisfld ldklieynsr daeitkltt
fnnnlvwlk illariskmg leeltrtevs twiknlyywe hrrnwlipl keeiltrssq iktaaiikgk rykgavvidp
pagvffnvvv ldfaslypsi irwnnisyet vdencknke yvrdetgevl hyickdkpgi tavitglld frkvvykka
ksqniseeqr svydvqram kvfinatygv fgaenflya pavaesvtai gryvittvn yersigqlv ygdtdsmflw
npskekleei ikfvkkgkgl dlevdkvykf vafsglkknfy lgvypdgktd ikgmllakrn tpefikkefn evkqlvttin
spddipkird qleykikeiy eklrhkgynl delafrvmls kplesytknt pqhvkaalql rsygvmlpr diimfvkvks
kdgvkpvqla klseidvdky idavrstfeq ilkafgliga nllqlsils lt (SEQ ID NO. 107)

ACCESSION P26811 Sso

mtkqltldi psskpakseq ntqqsqqsap veekkvvrre wleeaqenki yflqvdydg kkgkavcklf dketqkiyal
ydnthgkpyf lvdlepdkgv kipkivrdps fdhietvski dpytwnkfkl tkivvrdpla vrrlndvpk ayeahikyfn
nymydgilip gmpyvknkgk lesvylsde kdveeikkaf adsdemtrqm avdwlpiet eipkikrvai dievytpvkg
ripdsqkaef piisialags dglkkvln rmdvnegsvk ldgisverfn teyellgrff dilleypivl tfngddfdlp yiyfralkg
yfpeeipdv agkdeakyla glhidlykff fnkavnyaf egkyneynld avakallgts kvkvdltisf ldveklieyn
frdaeitlql ttfndltmk livlfsrisr lgieelrte istwvknlyy wehrkrnwli plkeeilaks snirtsalik gkgykgavvi
dppagiffni tvldfaslyp siirtwnlsy etvdiqqckk pyevkdetge vlhivcmdrp gitavitgll rdrvkiykk
kaknpnnsee qkllydvvr amkvfinaty gvfgaetfpl yapavaesvt algryvitst vkkarecglv vlygdtdslf
llnppknsle niikwvktff nldlevdkty kfvaefsglkk nyfgvyqdgk vdikgmvlkk ntpfevkkv fnevkelmis
inspndvkei krkivdvkkg syeklknkg nldelafkvm lskpldaykk ntpqhvkaal qlrpfgvnl prdiiyykv
rskdgvkpvq lakvteidae kylealrstf eqilrafgvs wdeiaatmsi dsffsyyskg ns (SEQ ID NO. 108)

Figure 7B

Alignment (DIALIGN format):

Pfu	1	MILDVDYITE	EKGPVIRLFK	KENGFKIEH	DRTFRPYIYA	LLRDSKIEE
Tgo	1	MILDTDYITE	DGKPVIRIFK	KENGFKIDY	DRNFEPYIYA	LLKDDSAIED
KOD	1	MILDTDYITE	DGKPVIRIFK	KENGFKIEY	DRTFEPYFYA	LLKDDSAIEE
Vent	1	MILDTDYITK	DGKPIIRIFK	KENGFKIEL	DPHFQPYIYA	LLKDDSAIEE
Deep	1	MILDADYITE	DGKPIIRIFK	KENGFKVEY	DRNFRPYIYA	LLKDDSQIDE
JDF-3	1	MILDVDYITE	NGKPVIRVFK	KENGFRIEY	DREFEPYFYA	LLRDDSAIEE

V93

Pfu	51	VKKITGERHG	KIVRIVDVEK	VEKKFLGKPI	TVWKLYLEHP	QVPTIREKV
Tgo	51	VKKITAERHG	TTVRVVRAEK	VKKKFLGRPI	EVWKLYFTHP	QVPAIRDKI
KOD	51	VKKITAERHG	TVTVKRVK	VQKKFLGRPV	EVWKLYFTHP	QVPAIRDKI
Vent	51	IKAIKGERHG	KTVRVLDVAV	VRKKFLGREV	EVWKLIFEHP	QVPAIRGKI
Deep	51	VRKITAERHG	KIVRIIDAEK	VRKKFLGRPI	EVWRLYFEHP	QVPAIRDKI
JDF-3	51	IKKITAERHG	RVVKVKRAEK	VKKKFLGRSV	EVWVLYFTHP	QVPAIRDKI

DXE (exo I)

Pfu	101	REHPAVVDIF	EYDIPFAKRY	LIDKGLIPME	GEEELKILAF	DIETLYHEGE
Tgo	101	KEHPAVVDIY	EYDIPFAKRY	LIDKGLIPME	GDEELKMLAF	DIETLYHEGE
KOD	101	REHGAVIDIY	EYDIPFAKRY	LIDKGLVPME	GDEELKMLAF	DIETLYHEGE
Vent	101	REHPAVVDIY	EYDIPFAKRY	LIDKGLIPME	GDEELKLLAF	DIETLYHEGD
Deep	101	REHSAVIDIF	EYDIPFAKRY	LIDKGLIPME	GDEELKLLAF	DIETLYHEGE
JDF-3	101	RKHPAVIDIY	EYDIPFAKRY	LIDKGLIPME	GDEELKLSF	DIETLYHEGE

11 12 13 14-143

Pfu	151	EFKGPIIMI	SYADENEAKV	ITWKNIDLPI	VEVVSSEREM	IKRFLRIIRE
Tgo	151	EFAEGPILMI	SYADEEGARV	ITWKNIDLPI	VDVVSTEKEM	IKRFLKVVKE
KOD	151	EFAEGPILMI	SYADEEGARV	ITWKNVDLPI	VDVVSTEREM	IKRFLRVVKE
Vent	151	EFKGGEIIMI	SYADEEEARV	ITWKNIDLPI	VDVVSNEREM	IKRFVQVVKE
Deep	151	EFAKGPIIMI	SYADEEEAKV	ITWKKIDLPI	VEVVSSEREM	IKRFLKVIRE
JDF-3	151	EPGTGPILMI	SYADESEARV	ITWKKIDLPI	VEVVSSTEKEM	IKRFLRVVKE

NX₂₃FD (exo II)

Pfu	201	KDPDIIVTYN	GDSFDLPYLA	KRAEKLGIKL	TIGRDGS-E	PKMQRIGDMT
Tgo	201	KDPDVLITYN	GDNFDLAYLK	KRSEKLGVKF	ILGREGS-E	PKIQRMGDRF
KOD	201	KDPDVLITYN	GDNFDLAYLK	KRCEKLGINF	ALGRDGS-E	PKIQRMGDRF
Vent	201	KDPDVIITYN	GDNFDLPYLI	KRAEKLGVRL	VLGRDkehpe	PKIQRMGDSF
Deep	201	KDPDVIITYN	GDSFDLPYLV	KRAEKLGIKL	PLGRDGS-E	PKMQRLGDMT
JDF-3	201	KDPDVLITYN	GDNFDLAYLK	KRCEKLGVSF	TLGRDGS-E	PKIQRMGDRF

210-215 231 239

Pfu	249	AVEVKGRIHF	DLYHVITRTI	NLPTYTLEAV	YEAIFGKPKE	KVYADEIAKA
Tgo	249	AVEVKGRIHF	DLYPVIRRTI	NLPTYTLEAV	YEAIFGQPKE	KVYAEEDIAQA
KOD	249	AVEVKGRIHF	DLYPVIRRTI	NLPTYTLEAV	YEAIFGQPKE	KVYAEEDIAQA

Vent	251	AVEIKGRIHF	DLFPVVRTI	NLPTYTLEAV	YEAVLGKTKS	KLGAEEIAAI
Deep	249	AVEIKGRIHF	DLYHVIRRTI	NLPTYTLEAV	YEAIFGKPKE	KVYAHEIAEA
JDF-3	249	AVEVKG RVHF	DLYPVIRRTI	NLPTYTLEAV	YEAVFGKPKE	KVYAEIATA

γ X₃D (exo III)

Pfu	299	WESGENLERV	AKYSMEDAKA	TYELGKEFLP	MEIQLSRLVG	QPLWDVSRSS
Tgo	299	WETGGLERV	ARYSMEDAKV	TYELGKEFFP	MEAQLSRLVG	QSLWDVSRSS
KOD	299	WETGENLERV	ARYSMEDAKV	TYELGKEFLP	MEAQLSRLIG	QSLWDVSRSS
Vent	301	WETEESMKKL	AQYSMEDARA	TYELGKEFFP	MEAEALAKLIG	QSVWDVSRSS
Deep	299	WETGGLERV	AKYSMEDAKV	TYELGREFFP	MEAQLSRLVG	QPLWDVSRSS
JDF-3	299	WETGGLERV	ARYSMEDARV	TYELGREFFP	MEAQLSRLIG	QGLWDVSRSS

311-315

Pfu	349	TGNLVEWFLL	RKAYERNEVA	PNKPSEEEYQ	RRLRESYTGG	FVKEPEKGLW
Tgo	349	TGNLVEWFLL	RKAYERNELA	PNKPDERELA	RR-RESYAGG	YVKEPERGLW
KOD	349	TGNLVEWFLL	RKAYERNELA	PNKPDEKELA	RR-RQSYEGG	YVKEPERGLW
Vent	351	TGNLVEWYLL	RVAYARNELA	PNKPDEEEYK	RRLRTTYLGG	YVKEPEKGLW
Deep	349	TGNLVEWYLL	RKAYERNELA	PNKPDEREYE	RRLRESYAGG	YVKEPEKGLW
JDF-3	349	TGNLVEWFLL	RKAYERNELA	PNKPDERELA	RR-RggYAGG	YVKEPERGLW

Pfu	399	ENIVYLD FRA	LYPSIIITHN	VSPDTLNLEG	CKNYDIAPQV	GHKFCKDIPG
Tgo	398	ENIVYLD FRS	LYPSIIITHN	VSPDTLNREG	CEEYDVAPQV	GHKFCKDFPG
KOD	398	ENIVYLD FRS	LYPSIIITHN	VSPDTLNREG	CKEYDVAPQV	GHRFCKDFPG
Vent	401	ENIYLD FRS	LYPSIIIVTHN	VSPDTLEKEG	CKNYDVAPIV	GYRFCKDFPG
Deep	399	EGLVSLDFRS	LYPSIIITHN	VSPDTLNREG	CREYDVAVEP	GHKFCKDFPG
JDF-3	398	DNIVYLD FRS	LYPSIIITHN	VSPDTLNREG	CRSYDVAVEP	GHKFCKDFPG

Pfu	449	FIPSL LGHLL	EERQKI KTKM	KETQDPIEKI	LLDYRQKAIK	LLANSFYGYG
Tgo	448	FIPSL LGDLL	EERQKV KKKM	KATIDPIEKK	LLDYRQRAIK	ILANSFYGYG
KOD	448	FIPSL LGDLL	EERQKI KKKM	KATIDPIERK	LLDYRQRAIK	ILANSFYGYG
Vent	451	FIPSL ILGLI	AMRQDI KKKM	KSTIDPIEKK	MLDYRQRAIK	LLANSFYGYM
Deep	449	FIPSL LKRL	DERQEIKRKM	KASKDPIEKK	MLDYRQRAIK	ILANSFYGYG
JDF-3	448	FIPSL LGNLL	EERQKI KKKM	KATLDPLEKN	LLDYRQRAIK	ILANSFYGYG

Pfu	499	GYAKARWYCK	ECAESVTAWG	RKYIELVWKE	LEEKFGFKVL	YIDTDGLYAT
Tgo	498	GYAKARWYCK	ECAESVTAWG	RQYIETTIRE	IEEKFGFKVL	YADTDGFFAT
KOD	498	GYARARWYCK	ECAESVTAWG	REYITMTIKE	IEEKYGFVKV	YSDTDGFFAT
Vent	501	GYPKARWYCK	ECAESVTAWG	RHYIEMTIRE	IEEKFGFKVL	YADTDGFIAT
Deep	499	GYAKARWYCK	ECAESVTAWG	REYIEFVRKE	LEEKFGFKVL	YIDTDGLYAT
JDF-3	498	GYARARWYCR	ECAESVTAWG	REYIEMVIRE	LEEKFGFKVL	YADTDGLHAT

Pfu	549	IPGGESEEEK	KKALEFVKYI	NSKLPGLLEL	EYEGFYKRGF	FVTKKRYAVI
Tgo	548	IPGADAETVK	KKAKEFLDYI	NAKLPGLLEL	EYEGFYKRGF	FVTKKKYAVI

KOD	548	IPGADAETVK	KKAMEFLNYI	NAKLPGAEL	EYEGFYKRGF	FVTKKKYAVI
Vent	551	IPGEKPELIK	KKAKEFLNYI	NSKLPGLLEL	EYEGFYLRGF	FVTKKKYAVI
Deep	549	IPGAKPEEIK	KKALEFVDYI	NAKLPGLEL	EYEGFYVRGF	FVTKKKYALI
JDF-3	548	IPGADAETVK	KKAMEFLNYI	NPKLPGLLEL	EYEGFYVRGF	FVTKKKYAVI

Pfu	599	DEEGKVITRG	LEIVRRDWSE	IAKETQARVL	ETILKHGDVE	EAVRIVKEVI
Tgo	598	DEEDKITTRG	LEIVRRDWSE	IAKETQARVL	EAILKHGDVE	EAVRIVKEVT
KOD	598	DEEGKITTRG	LEIVRRDWSE	IAKETQARVL	EALLKGDVE	KAVRIVKEVT
Vent	601	DEEGRITTRG	LEVRRDWSE	IAKETQAKVL	EAILKEGSVE	KAVEVVRDVV
Deep	599	DEEGKIITRG	LEIVRRDWSE	IAKETQAKVL	EAILKHGNE	EAVKIVKEVT
JDF-3	598	DEEGKITTRG	LEIVRRDWSE	IAKETQARVL	EAILRHGDVE	EAVRIVREVT

Pfu	649	QKLANYEIPP	EKLAIYEQIT	RPLHEYKAIG	PHVAVAKKLA	AGGVKIKPGM
Tgo	648	EKLSKYEVP	EKLVIYEQIT	RELKDYKATG	PHVAVAKRLA	ARGIKIRPGT
KOD	648	EKLSKYEVP	EKLVIHEQIT	RELKDYKATG	PHVAVAKRLA	ARGVKIRPGT
Vent	651	EKIAKYRVPL	EKLVIHEQIT	RELKDYKAIG	PHVAIAKRLA	ARGIKVKPGT
Deep	649	EKLSKYEIPP	EKLVIYEQIT	RPLHEYKAIG	PHVAVAKRLA	ARGVKVRPGM
JDF-3	648	EKLSKYEVP	EKLVIHEQIT	RELKDYKATG	PHVAIAKRLA	ARGVKIRPGT

Pfu	699	VIGYIVLRGD	GPISNRAILA	EEYDPKKHKY	DAEYYIENQV	LPAVLRILEG
Tgo	698	VISYIVLKGS	GRIGDRAIPF	DEFDPAKHKY	DAEYYIENQV	LPAVERILRA
KOD	698	VISYIVLKGS	GRIGDRAIPF	DEFDPTKHKY	DAEYYIENQV	LPAVERILRA
Vent	701	IISYIVLKGS	GKISDRVILL	TEYDPRKHKY	DPDYIENQV	LPAVLRILEA
Deep	699	VIGYIVLRGD	GPISKRAILA	EEFDLRKHKY	DAEYYIENQV	LPAVLRILEA
JDF-3	698	VISYIVLKGS	GRIGDRAIPF	DEFDPTKHKY	DADYYIENQV	LPAVERILRA

Pfu	749	FGYRKEDLRY	QKTRQVGLTS	WLNKKs---
Tgo	748	FGYRKEDLRY	QKTRQVGLGA	WLKPKt---
KOD	748	FGYRKEDLRY	QKTRQVGLSA	WLKPKgt---
Vent	751	FGYRKEDLRY	QSSKQTGLDA	WLKr-----
Deep	749	FGYRKEDLRW	QKTKQTGLTA	WLNKKk---
JDF-3	748	FGYRKEDLRY	QKTRQVGLGA	WLKPKGkkk

Alignment (FASTA format):

>Pfu
MILDVDYITEEGKPVIRLFKKENGKFKIEHRTFRPYIYALLRDSKIEE
VKKITGERHGKIVRIVDVEKVEKKFLGKPIVWKLYLEHPQDVPTIREKV
REHPAVVDIFEYDIPFAKRYLIDKGLIPMEGEEELKILAFDIETLYHEGE
EFGKGPIIMISYADENEAKVITWKNIDL PYVEVVSSEREMIKRFLRIIRE
KDPDIIVTYNGDSFDFPYLAKRAEKLGIKLTIGRDGS--EPKMQRIGDMT
AVEVKGRIFDLYHVITRTINLPTYTLEAVYEAIFGKPKKEKVYADEIAKA

WESGENLERVAKYSMEDAKATVELGKEFLPMEIQLSRLVGQPLWDVSRSS
TGNLVEWFLLRKAYERNEVAPNKPSEEEYQRRRLRESYTTGGFVKEPEKGLW
ENIVYLDLFRALYPSIIITHNVSPDTLNLEGCKNYDIAPQVGHKFKCDIPG
FIPSLLGHLLEERQKIKTKMKETQDPIEKILLDYRQKAIKLLANSFYGY
GYAKARWYCKECAESVTAWGRKYIELVWKELEEKFGFKVLYIDTDGLYAT
IPGGESEEEKKALEFVKYINSKLPGLLELEYEGFYKRGFFVTKKRYAVI
DEEGKVITRGLEIVRRDWSEIAKETQARVLETILKHGDVEEAVRIVKEVI
QKLANYEIPPEKLAIEYEQITRPLHEYKAIGHVAVAKKLAAGVKIKPGM
VIGYIVLRGDGPISNRAILAEYDPKKHKYDAEYYIENQVLPVLRILEG
FGYRKEDLRYQKTRQVGLTSWLNKKs—

>Tgo

MILDTDYITEDGKPVIRIFKKENGFEKIDYDRNFEPYIYALLKDDSAIED
VKKITAERHGTTRVVRRAEKVKKFLGRPIEVWKLYFTHPQDVPDIRDKI
KEHPAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELKMLAFDIETLYHEGE
EFAEGPILMISYADEEGARVITWKNIDL PYVDVSTEKEMIKRFLKVVKE
KDPDVLITYNGDNDFAYLKKRSEKLGKVFILGREGS—EPKIQRMGDRF
AVEVKGRIFHDLYPVIRRTINLPTYTLEAVYEAIFGQPKKVEYAEIAQA
WETGEGLERVARYSMEDAKVTYELGKEFFPMEQLSRLVGQSLWDVSRSS
TGNLVEWFLLRKAYERNELAPNKPDERELARR—RESYAGGYVKEPERGLW
ENIVYLDLFRSLYPSIIITHNVSPDTLNREGCEEYDVAPQVGHKFKCDFPG
FIPSLGDLLEERQKVKKKMKATIDPIEKLLDYRQRAIKILANSFYGY
GYAKARWYCKECAESVTAWGRQYIETIREIEEEKFGFKVLYADTDGFFAT
IPGADAETVKKKAKEFLDYINAKLPGLLELEYEGFYKRGFFVTKKRYAVI
DEEDKITRGLEIVRRDWSEIAKETQARVLEAILKHGDVEEAVRIVKEVT
EKLSKYEVPEKLVIEYEQITRDLKDYKATGPHVAVAKRLAARGIKIRPGT
VISYIVLKGSGRIGDRAIPFDEFDPAKHKYDAEYYIENQVLPVAILRA
FGYRKEDLRYQKTRQVGLGAWLKPKt—

>KOD

MILDTDYITEDGKPVIRIFKKENGFEKIEYDRTFEPYFYALLKDDSAIEE
VKKITAERHGTTRVTVKRVEKVQKKFLGRPVEVWKLYFTHPQDVPDIRDKI
REHGAVIDIYEYDIPFAKRYLIDKGLVPMEGDEELKMLAFDIETLYHEGE
EFAEGPILMISYADEEGARVITWKNVDLPYVDVSTEREMIKRFLRVVKE
KDPDVLITYNGDNDFAYLKKRCEKLGINFALGRDGS—EPKIQRMGDRF
AVEVKGRIFHDLYPVIRRTINLPTYTLEAVYEAIFGQPKKVEYAEITPA
WETGENLERVARYSMEDAKVTYELGKEFLPMEQLSRLIGQSLWDVSRSS
TGNLVEWFLLRKAYERNELAPNKPDEKELARR—RQSYEGGYVKEPERGLW
ENIVYLDLFRSLYPSIIITHNVSPDTLNREGCKEYDVAPQVGHKFKCDFPG
FIPSLGDLLEERQKIKKKMKATIDPIERKLLDYRQRAIKILANSYGY
GYARARWYCKECAESVTAWGREYITMTIKEIEEKYGFVKIYSDTDGFFAT
IPGADAETVKKKAMEFLNYINAKLPGALELEYEGFYKRGFFVTKKRYAVI
DEEGKITRGLEIVRRDWSEIAKETQARVLEALLKGDVEKAVRIVKEVT
EKLSKYEVPEKLVIEYEQITRDLKDYKATGPHVAVAKRLAARGVKIRPGT
VISYIVLKGSGRIGDRAIPFDEFDPTKHKYDAEYYIENQVLPVAILRA
FGYRKEDLRYQKTRQVGLSAWLKPKGt—

>Vent

MILDTDYITKDGPPIIRIFKKENGFEKIELDPHFPQYIYALLKDDSAIEE
IKAIKGERHGKTVRVLDVAVKVRKKFLGREVEVWKLIFEHPQDVPAMRGKI
REHPAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELKMLAFDIETLYHEGD
EFGKGEIIMISYADEEEARVITWKNIDL PYVDVVSNEREMIKRFVQVKE
KDPDVIITYNGDNDFLPYLKRAEKLGVRLVLRDKEHPKIQRMGDSF
AVEIKGRIFHDLYPVVVRTINLPTYTLEAVYEAIVLGKTSKLGAEIAAI
WETEESMKKLAQYSMEDARATYELGKEFFPMEALAKLIGQSVWDVSRSS
TGNLVEWYLLRVAYARNELAPNKPDEEYKRRLRTTYLGGYVKEPEKGLW
ENIYLDLFRSLYPSIIIVTHNVSPDTLEKEGCKNYDVAPIVGYRFGCDFPG
FIPSILGDLIAMRQDIKKMKSTIDPIEKKMLDYRQRAIKLLANSYGYM
GYPKARWYSKECAESVTAWGRHYIEMTIREIEEEKFGFKVLYADTDGFIAT

IPGEKPELIKKKAKEFLNYINSKLPGLLELEYEGFYLRGFFVTKKRYAVI
 DEEGRITTRGLEVVRRDWSEIAKETQAKVLEAILKEGSVEKAVEVVRDVV
 EKIAYRVPLEKLVIEHQITRDLKDYKAIGPHVAIAKRLAARGIKVKPGT
 IISYIVLKSGSGKISDRVILLTEYDPRKHKYDPDYIENQVLPVLRILEA
 FGyrkedlryqsskqtglawlk_r-----

>Deep

MILDADYITEDGKPIIRIFKKENGFEKVEYDRNFRPYIYALLKDDSQIDE
 VRKITAERHGKIVRIIDA EKVRKKFLGRPIEVWRLYFEHPQDVPAIRDKI
 REHSAVIDIFEYDIPFAKRYLIDKGLIPMEGDEELKLLAFDIETLYHEGE
 EFAKGPIIMISYADEEEAKVITWKKIDLPYVEVVSSEMIKRFVKVIRE
 KDPDVIITYNGDSFDLPYLVKRAEKLGIKLPLGRDGS—EPKMQRLGDMT
 AVEIKGRIHFDLYHVIRRTINLPTYTLEAVYEATFGKPKEKVYAEIAEA
 WETGGLERVAKYSMEDAKVTYELGREFFPMEAQLSRLVGQPLWDVSRSS
 TGNLVEWYLLRKAYERNELAPNKPDEREYERRLRESYAGGYVKEPEKGLW
 EGLVSLDFRSLYPSIIITHNVSPDTLNREGCREYDVAPEVGHKFCDFPG
 FIPSLKRLDERQEIKRKMASKDPIEKKMLDYRQRAIKILANSYGYG
 GYAKARWYCKEAE SVTAWGREYIEFVRKELEEKFGFKVLYIDTDGLYAT
 IPGAKPEEIKKKALEFVDYINAKLPGLLELEYEGFYVRGFFVTKKRYALI
 DEEGKIITRGLEIVRRDWSEIAKETQAKVLEAILKHGNVEEAVKIVKEVT
 EKLSKYEIPPEKLVIEHQITRPLHEYKAIGPHVAVAKRLAARGVKVRPGM
 VIGYIVLRGDPISKRAILAEFDLRKHKYDAEYIENQVLPVLRILEA
 FGyrkedlRWQKTRQTGLTAWLNikk--

>JDF-3

MILDVDYITENGKPVIRVFKKENGFEFRIEYDREFEPFYALLRDDS AIEE
 IKKITAERHGRVVKVRAEKVKKFLGRSVEVWVLYFTHPQDVPAIRDKI
 RKHPAVIDIYEYDIPFAKRYLIDKGLIPMEGEEELKLSFDIETLYHEGE
 EFGTGPIIMISYADESEARVITWKKIDLPYVEVVSSTEKEMIKRFLRVVKE
 KDPDVLITYNGDNDFAYLKKRCEKLGVSFTLGRDGS—EPKIQRMGDRF
 AVEVKG RVHFDLYPVIRRTINLPTYTLEAVYEAVFGKPKEKVYAEIATA
 WETGGLERVARYSMEDARVTYELGREFFPMEAQLSRLIGQGLWDVSRSS
 TGNLVEWFLRKAYERNELAPNKPDERELARR—RggYAGGYVKEPERGLW
 DNIIVYLDFRSLYPSIIITHNVSPDTLNREGCRSYDVAPEVGHKFCDFPG
 FIPSLGNLLEERQKIKRKMATLDPLEKNLLDYRQRAIKILANSYGYG
 GYARARWYCREAE SVTAWGREYIEMVIRELEEKFGFKVLYADTDGLHAT
 IPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKRYAVI
 DEEGKITTRGLEIVRRDWSEIAKETQARVLEAILRHGDVEEAVRIVREVT
 EKLSKYEVPPEKLVIEHQITRELKDYKATGPHVAIAKRLAARGVKIRPGT
 VISYIVLKSGRIGDRAIPFDEFDPTKHKYDADYIENQVLPVAVRILRA
 FGyrkedlryqktrqvglawlkpgk_{kkk}

Sequence tree:

Tree constructed using UPGMA

((Pfu :0.000998,
 Deep :0.000998):0.000080,
 ((Tgo :0.000905,
 KOD :0.000905):0.000032,
 JDF-3 :0.000937):0.000141):0.000067,
 Vent :0.001144);

Alignment (DIALIGN format):

Pfu	1	MILDVDYITE	EGKPVIRLFK	KENGKFKIEH	DRTFRPYIYA	LLRDDSKEIE
Tgo	1	MILDTDYITE	DGKPVIRIFK	KENGEFKIDY	DRNFEPYIYA	LLKDDSAIED
KOD	1	MILDTDYITE	DGKPVIRIFK	KENGEFKIEY	DRTFEPYFYA	LLKDDSAIEE
Vent	1	MILDTDYITK	DGKPIIRIFK	KENGEFKIEL	DPHFQPYIYA	LLKDDSAIEE
Deep	1	MILDADYITE	DGKPIIRIFK	KENGEFKVEY	DRNFRPYIYA	LLKDDSQIDE
JDF-3	1	MILDVDYITE	NGKPVIRVFK	KENGEFRIEY	DREFEPYFYA	LLRDDSAIEE

Pfu	51	VKKITGERHG	KIVRIVDVEK	VEKKFLGKPI	TVWKLYLEHP	QDVPTIREKV
Tgo	51	VKKITAERHG	TTVRVVRAEK	VKKKFLGRPI	EVWKLYFTHP	QDVPAlRDKI
KOD	51	VKKITAERHG	TVTVKRVKVEK	VQKKFLGRPV	EVWKLYFTHP	QDVPAlRDKI
Vent	51	IKAIKGERHG	KTVRVLDVAV	VRKKFLGREV	EVWKLIFEHP	QDVPAMRGKI
Deep	51	VRKITAERHG	KIVRIIDAEK	VRKKFLGRPI	EVWRLYFEHP	QDVPAlRDKI
JDF-3	51	IKKITAERHG	RVVKVKRAEK	VKKKFLGRSV	EVWVLYFTHP	QDVPAlRDKI

Pfu	101	REHPAVVDIF	EYDIPFAKRY	LIDKGLIPME	GEEELKILAF	DIETLYHEGE
Tgo	101	KEHPAVVDIY	EYDIPFAKRY	LIDKGLIPME	GDEELKMLAF	DIETLYHEGE
KOD	101	REHGAVIDIY	EYDIPFAKRY	LIDKGLVPM	GDEELKMLAF	DIQTLYHEGE
Vent	101	REHPAVVDIY	EYDIPFAKRY	LIDKGLIPME	GDEELKLLAF	DIETFYHEGD
Deep	101	REHSAVIDIF	EYDIPFAKRY	LIDKGLIPME	GDEELKLLAF	DIETLYHEGE
JDF-3	101	RKHPAVIDIY	EYDIPFAKRY	LIDKGLIPME	GEEELKLMSF	DIETLYHEGE

Pfu	151	EFGKGPIIMI	SYADENEAKV	ITWKNIDLPI	VEVVSSEREM	IKRFLRIIRE
Tgo	151	EFAEGPILMI	SYADEEGARV	ITWKNIDLPI	VDVVSTEKEM	IKRFLKVVKE
KOD	151	EFAEGPILMI	SYADEEGARV	ITWKNVDLPY	VDVVSTEREM	IKRFLRVVKE
Vent	151	EFGKGPIIMI	SYADEEEARV	ITWKNIDLPI	VDVVSNEREM	IKRFLQVVKE
Deep	151	EFAKGPIIMI	SYADEEEAKV	ITWKKIDLPI	VEVVSSEREM	IKRFLKVIRE
JDF-3	151	EFGTGPIIMI	SYADESEARV	ITWKKIDLPI	VEVVSTEKEM	IKRFLRVVKE

Pfu	201	KDPDIIVTYN	GDSFDFPYLA	KRAEKLGIKL	TIGRDGS—E	PKMQRIGDMT
Tgo	201	KDPDVLITYN	GNFDFAYLK	KRSEKLGVKF	ILGREGS—E	PKIQRMGDRF
KOD	201	KDPDVLITYN	GNFDFAYLK	KRCEKLGINF	ALGRDGS—E	PKIQRMGDRF
Vent	201	KDPDVIITYN	GNFDFLPYLI	KRAEKLGVRL	VLGRDkehpe	PKIQRMGDSF
Deep	201	KDPDVIITYN	GDSFDFLPYLV	KRAEKLGIKL	PLGRDGS—E	PKMQRLGDMT
JDF-3	201	KDPDVLITYN	GNFDFAYLK	KRCEKLGVSF	TLGRDGS—E	PKIQRMGDRF

Pfu	249	AVEVKGRIHF	DLYHVITRTI	NLPTYTLEAV	YEAIFGKPKE	KVYADEIAKA
Tgo	249	AVEVKGRIHF	DLYPVIRRTI	NLPTYTLEAV	YEAIFGQPKE	KVYAEETIAQA
KOD	249	AVEVKGRIHF	DLYPVIRRTI	NLPTYTLEAV	YEAIFGQPKE	KVYAEETIPA

Vent	251	AVEIKGRIHF	DLFPVVRRTI	NLPTYTLEAV	YEAVLGKTKS	KLGAEEIAAI
Deep	249	AVEIKGRIHF	DLYHVIRRTI	NLPTYTLEAV	YEAIFGKPKE	KVYAHEIAEA
JDF-3	249	AVEVKGRVHF	DLYPVIRRTI	NLPTYTLEAV	YEAVFGKPKE	KVYAEEIATA

Pfu	299	WESGENLERV	AKYSMEDAKA	TYELGKEFLP	MEIQLSRLVG	QPLWDVSRSS
Tgo	299	WETGGLERV	ARYSMEDAKV	TYELGKEFFP	MEAQLSRLVG	QSLWDVSRSS
KOD	299	WETGENLERV	ARYSMEDAKV	TYELGKEFLP	MEAQLSRLIG	QSLWDVSRSS
Vent	301	WETEESMKKL	AQYSMEDARA	TYELGKEFFP	MEAEALAKLIG	QSVWDVSRSS
Deep	299	WETGGLERV	AKYSMEDAKV	TYELGREFFP	MEAQLSRLVG	QPLWDVSRSS
JDF-3	299	WETGGLERV	ARYSMEDARV	TYELGREFFP	MEAQLSRLIG	QGLWDVSRSS

Pfu	349	TGNLVEWFLL	RKAYERNEVA	PNKPSEEEYQ	RRLRESYTGG	FVKEPEKGLW
Tgo	349	TGNLVEWFLL	RKAYERNELA	PNKPDERELA	RR-RESYAGG	YVKEPERGLW
KOD	349	TGNLVEWFLL	RKAYERNELA	PNKPDEKELA	RR-RQSYEGG	YVKEPERGLW
Vent	351	TGNLVEWYLL	RVAYARNELA	PNKPDEEEYK	RRLRTTYLGG	YVKEPEKGLW
Deep	349	TGNLVEWYLL	RKAYERNELA	PNKPDEREYE	RRLRESYAGG	YVKEPEKGLW
JDF-3	349	TGNLVEWFLL	RKAYERNELA	PNKPDERELA	RR-RggYAGG	YVKEPERGLW

DOXSLPSII (Region II)

Pfu	399	ENIVYLD	FRA	LYPSII	I	THN	VSPDTLNLEG	CKNYDIAPQV	GHKFCKDIPG
Tgo	398	ENIVYLD	FRS	LYPSII	I	THN	VSPDTLNREG	CEEYDVAPQV	GHKFCKDFPG
KOD	398	ENIVYLD	FRS	LYPSII	I	THN	VSPDTLNREG	CKEYDVAPQV	GHRFCKDFPG
Vent	401	ENIYYLD	FRS	LYPSII	I	THN	VSPDTLEKEG	CKNYDVAPIV	GYRFCKDFPG
Deep	399	EGLVSLD	FRS	LYPSII	I	THN	VSPDTLNREG	CREYDVAVEP	GHKFCKDFPG
JDF-3	398	DNIVYLD	FRS	LYPSII	I	THN	VSPDTLNREG	CRSYDVAVEV	GHKFCKDFPG

Pfu	449	FIPSLLGHL	EERQIKTKM	KETQDPIEKI	LLDYRQKAIK	LLANSFYGGY
Tgo	448	FIPSLLGDL	EERQKVKKKM	KATIDPIEKK	LLDYRQRAIK	ILANSFYGGY
KOD	448	FIPSLLGDL	EERQIKKKM	KATIDPIERK	LLDYRQRAIK	ILANSYGGY
Vent	451	FIPSLGDLI	AMRQDIKKM	KSTIDPIEKK	MLDYRQRAIK	LLANSYGYM
Deep	449	FIPSLKRL	DERQEIKRM	KASKDPIEKK	MLDYRQRAIK	ILANSYGGY
JDF-3	448	FIPSLGNLL	EERQIKRKM	KATLDPLEKN	LLDYRQRAIK	ILANSYGGY

Pfu	499	GYAKARWYCK	ECAESVTAWG	RKYIELVWKE	LEEKFGFKVL	YIDTDGLYAT
Tgo	498	GYAKARWYCK	ECAESVTAWG	RQYIETTIRE	IEEKFGFKVL	YADTDGFFAT
KOD	498	GYARARWYCK	ECAESVTAWG	REYITMTIKE	IEEKYGFVKVI	YSDTDGFFAT
Vent	501	GYPKARWYCK	ECAESVTAWG	RHYIEMTIRE	IEEKFGFKVL	YADTDGFTAT
Deep	499	GYAKARWYCK	ECAESVTAWG	REYIEFVRKE	LEEKFGFKVL	YIDTDGLYAT
JDF-3	498	GYARARWYCR	ECAESVTAWG	REYIEMVIRE	LEEKFGFKVL	YADTDGLHAT

Pfu	549	IPGGESEEEK	KKALEFVKYI	NSKLPGLLEL	EYEGFYKRGF	FVTKKRYAVI
Tgo	548	IPGADAETVK	KKAKEFLDYI	NAKLPGLLEL	EYEGFYKRGF	FVTKKRYAVI

KOD	548	IPGADAETVK	KKAMEFLNYI	NAKLPGALEL	EYEGFYKRGF	FVTKKKYAVI
Vent	551	IPGEKPELIK	KKAKEFLNYI	NSKLPGLLEL	EYEGFYLRGF	FVTKKRYAVI
Deep	549	IPGARPEEIK	KKALEFVDYI	NAKLPGLLEL	EYEGFYVRGF	FVTKKRYALI
JDF-3	548	IPGADAETVK	KKAMEFLNYI	NPKLPGLLEL	EYEGFYVRGF	FVTKKKYAVI

Pfu	599	DEEGKVITRG	LEIVRRDWSE	IAKETQARVL	ETILKHGDVE	EAVRIVKEVI
Tgo	598	DEEDKITTRG	LEIVRRDWSE	IAKETQARVL	EAILKHGDVE	EAVRIVKEVT
KOD	598	DEEGKITTRG	LEIVRRDWSE	IAKETQARVL	EALLKGDGVE	KAVRIVKEVT
Vent	601	DEEGRITTRG	LEVRRDWSE	IAKETQAKVL	EAILKEGSVE	KAVEVVRDVG
Deep	599	DEEGKIITRG	LEIVRRDWSE	IAKETQAKVL	EAILKHGNGVE	EAVKIVKEVT
JDF-3	598	DEEGKITTRG	LEIVRRDWSE	IAKETQARVL	EAILRHGDVE	EAVRIVREVT

Pfu	649	QKLANYEIPP	EKLAIYEQIT	RPLHEYKAIG	PHVAVAKKLA	AKGVKIKPGM
Tgo	648	EKLSKYEVP	EKLVIYEQIT	RDLKDYKATG	PHVAVAKRLA	ARGIKIRPGT
KOD	648	EKLSKYEVP	EKLVIHEQIT	RDLKDYKATG	PHVAVAKRLA	ARGVKIRPGT
Vent	651	EKIAKYRVP	EKLVIHEQIT	RDLKDYKAIG	PHVAIAKRLA	ARGIKVKPGT
Deep	649	EKLSKYEIPP	EKLVIYEQIT	RPLHEYKAIG	PHVAVAKRLA	ARGVKVRPGM
JDF-3	648	EKLSKYEVP	EKLVIHEQIT	RELKDYKATG	PHVAIAKRLA	ARGVKIRPGT

Pfu	699	VIGYIVLRGD	GPISNRAILA	EEYDPKKHKY	DAEYYIENQV	LPAVLRILEG
Tgo	698	VISYIVLKGS	GRIGDRAIPF	DEFDPAKHKY	DAEYYIENQV	LPAVERILRA
KOD	698	VISYIVLKGS	GRIGDRAIPF	DEFDPTKHKY	DAEYYIENQV	LPAVERILRA
Vent	701	IISYIVLKGS	GKISDRVILL	TEYDPRKHKY	DPDYIENQV	LPAVLRILEA
Deep	699	VIGYIVLRGD	GPISKRAILA	EEFDLRKHKY	DAEYYIENQV	LPAVLRILEA
JDF-3	698	VISYIVLKGS	GRIGDRAIPF	DEFDPTKHKY	DADYYIENQV	LPAVERILRA

Pfu	749	FGYRKEDLRY	QKTRQVGLTS	WLNIKKs---
Tgo	748	FGYRKEDLRY	QKTRQVGLGA	WLKPkt---
KOD	748	FGYRKEDLRY	QKTRQVGLSA	WLKPGt---
Vent	751	FGYRKEDLRY	QSSKQTGLDA	WLKt-----
Deep	749	FGYRKEDLRW	QKTKQTGLTA	WLNIKKk---
JDF-3	748	FGYRKEDLRY	QKTRQVGLGA	WLKPGkkk

Alignment (FASTA format):

```
>Pfu
MILDVDYITEEGKPVIRLFKKENGKFKIEHDRTFRPYIYALLRDDS KIEE
VKKITGERHGKIVRIVDVEKVEKKFLGKPITVWKLYLEHPQDVPTIREKV
REHPAVVDIFEYDIPFAKRYLIDKGLIPMEGEEELKILAFDIETLYHEGE
EFGKGPIIMISYADENEAKVITWKNIDLPHYEVVSSEREMIKRFLRIIRE
KDPDIIIVTYNGDSFDPYLAKEKLGIKLTIGRDGS--EPKMRIGDMT
AVEVKGRIHFDLYHVITRTINLPTYTLEAVYEAIFGKPKKVKYADEIAKA
```

WESGENLERVAKYSMEDAKATYELGKEFLPMEIQLSRLVGQPLWDVSRSS
TGNLVEWFLLRKAYERNEVAPNKPSEEEYQRLRESYTGGFVKEPEKGLW
ENIYVLDLFRSLYPSIIITHNVSPDTLNLEGCKNYDIAPQVGHKFKCDIPG
FIPSLGLLLEERQKIKTKMKETQDPIEKILLDYRQKAIKLLANSFYGY
GYAKARWYCKEACSVTAWGRKYIELVWKELEKFGFKVLYIDTDGLYAT
IPGGESEEEKKALEFVKYINSKLPGLLELEYEGFYKRGFFVTKKRYAVI
DEEGKVITRGLEIVRRDWSEIAKETQARVLETILKHGDVEEAVRIVKEVI
QKLANYEIPPEKLAIEYEQITRPLHEYKAIGPHVAVAKKLAAGVKIKPGM
VIGYIVLRGDPISNRAILAEEDPKKKHYDAEYYIENQVLPVLRILEG
FGYRKEDLRYQKTRQVGLTSWLNKKs—

>Tgo

MILDTDYITEDGKPVIRIFKKENGFEKIDYDRNFEPYIYALLKDDSAIED
VKKITAERHGTTRVVRRAEKVKKFLGRPIEVWKLFTHPQDVPPIRDKI
KEHPAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELKMLAFDIETLYHEGE
EFAEGPILMISYADEEGARVITWKNIDLPYVDVSTEKEMIKRFLKVVE
KDPDVLITYNGDNFDFAYLKKRSEKLGKVFILGREGS—EPKIQRMGDRF
AVEVKGRIHFDLYPVIRRTINLPTYTLEAVYEAIFGQPKKVVAAEIAQA
WETGGLERVARYSMEDAKVTYELGKEFFPMEAQLSRLVGQSLWDVSRSS
TGNLVEWFLLRKAYERNELAPNKPDERELARR—RESYAGGYVKEPERGLW
ENIYVLDLFRSLYPSIIITHNVSPDTLNREGCEEYDVAPQVGHKFKCDFPG
FIPSLGLLLEERQKVKKKMKATIDPIEKLLDYRQRAIKILANSFYGY
GYAKARWYCKEACSVTAWGRQYIETTIREIEEKFGFKVLYADTDGFFAT
IPGADAETVKKKAKEFLDYINAKLPGLLELEYEGFYKRGFFVTKKRYAVI
DEEDKITRTRGLEIVRRDWSEIAKETQARVLEAILKHGDVEEAVRIVKEVT
EKLKYEVPPEKLVIEYEQITRDLKDYKATGPHVAVAKRLAARGIKIRPGT
VISYIVLKGSGRIGDRAIPDFEFDPAKKHYDAEYYIENQVLPVERILRA
FGYRKEDLRYQKTRQVGLGAWLKPKt—

>KOD

MILDTDYITEDGKPVIRIFKKENGFEKIEYDRTFEPYFYALLKDDSAIEE
VKKITAERHGTTRVVRKEVKQKFLGRPIEVWKLFTHPQDVPPIRDKI
REHGAVIDIYEYDIPFAKRYLIDKGLVPMEGDEELKMLAFDIQTLYHEGE
EFAEGPILMISYADEEGARVITWKNVDLPYVDVSTEREMIKRFLRVVKE
KDPDVLITYNGDNFDFAYLKKRCEKLGINFALGRDGS—EPKIQRMGDRF
AVEVKGRIHFDLYPVIRRTINLPTYTLEAVYEAIFGQPKKVVABEITPA
WETGENLERVARYSMEDAKVTYELGKEFLPMEAQLSRLIGQSLWDVSRSS
TGNLVEWFLLRKAYERNELAPNKPDEKELARR—RQSYEGGYVKEPERGLW
ENIYVLDLFRSLYPSIIITHNVSPDTLNREGCKEYDVAPQVGHKFKCDFPG
FIPSLGLLLEERQKIKKKMKATIDPIERKLLDYRQRAIKILANSYYGY
GYARARWYCKEACSVTAWGREYITMTIKEIEEKYGFVLYSDTDGFFAT
IPGADAETVKKKAMEFLNYINAKLPGALELEYEGFYKRGFFVTKKRYAVI
DEEGKITRTRGLEIVRRDWSEIAKETQARVLEALLKGDVEKAVRIVKEVT
EKLKYEVPPEKLVIEYEQITRDLKDYKATGPHVAVAKRLAARGVKIRPGT
VISYIVLKGSGRIGDRAIPDFEFDPTKHKYDAEYYIENQVLPVERILRA
FGYRKEDLRYQKTRQVGLSAWLKPKGt—

>Vent

MILDTDYITKDGKPIIRIFKKENGFEKIELDPHFQPYIYALLKDDSAIEE
IKAIKGERHCKTVRVLDAVKVRKKFLGREVEVWKLIFEHPQDVPAMRGKI
REHPAVVDIYEYDIPFAKRYLIDKGLIPMEGDEELKMLAFDIETFYHEGD
EFGKGEIIMISYADEEEARVITWKNIDLPYVDVVSNEREMIKRFVQVVE
KDPDVIITYNGDNFDPYLIKRAEKLGVRLVLRGDKhepEPKIQRMGDSF
AVEIKGRIHFDLPVVRRTINLPTYTLEAVYEAFLGKTKSKLGAEEIAAI
WETEESMKKLAQYSMEDARATYELGKEFFPMEALAKLIGQSVWDVSRSS
TGNLVEWYLLRVAYARNELAPNKPDEEYKRRRTTYLGGYVKEPEKGLW
ENIYVLDLFRSLYPSIIIVTHNVSPDTLEKEGCKNYDVAPIVGYRCKDFPG
FIPSLGLDLIAMRQDIKKMKSTIDPIEKMLDYRQRAIKILANSYYGYM
GYPKARWYSKEACSVTAWGRHYIEMTIREIEEKFGFKVLYADTDGFIAT

IPGEKPELIKKAKEFLNYINSKLPGLLELEYEGFYLRGFFVTKRYAVI
 DEEGRITTRGLEVVRRDWSEIAKETQAKVLEAILKEGSVEKAVEVVRDVV
 EKIAYRVPLEKLVIEHQITRDLKDYKAIGPHVAIAKRLAARGIKVKPGT
 IISYIVLKGSGKISDRVILLTEYDPRKHKYDPDYIENQVLPVLRILEA
 FGVRKEDLRYQSSKQTGLDAWLK—

>Deep

MILDADYITEDGKPIIRIFKKENGFEKVEYDRNFRPYIYALLKDDSQIDE
 VRKITAERHGKIVRIIDAOKVRKKFLGRPIEVWRLYFEHPQDVPAIRDKI
 REHSAVIDIFEYDIPFAKRYLIDKGLIPMEGDEELKLLAFDIETLYHEGE
 EFAKGPIMISYADEEEAKVITWKKIDLPYVEVVSSEMIKRFLKVIRE
 KDPDVIITYNGDSFDLPYLVKRAEKLGIKPLGRDGS—EPKMQR LGDMT
 AVEIKGRIHFDLYHVIRRTINLPTYTLEAVYEAIFGKPKVKVYAEIAEA
 WETGKGLERVAKYSMEDAKVTYELGREFFPMEAQLSRLVGQPLWDVSRSS
 TGNLVEWYLLRKAYERNELAPNKPDEREYERRLRESYAGGYVKEPEKGLW
 EGLVSLDFRSLYPSIIITHNVSPDTLNREGCREYDVAPEVGHKFKCDFPG
 FIPSLKRLDERQEIKRKMKASKDPIEKMLDYRQRAIKILANSYYGY
 GYAKARWYCKEABSVTAWGREYIEFVRKELEEKFGFKVLYIDTGLYAT
 IPGAKPEEIKKALEFVDYINAKLPGLLELEYEGFYVRGFFVTKKYALI
 DEEGKIITRGLEIVRRDWSEIAKETQAKVLEAILKHGNEEAVKIVKEVT
 EKLSKYEIPPEKLVIEHQITRPLHEYKAIGPHVAVAKRLAARGVKVRPGM
 VIGYIVLRGDPISKRAILAEFDRKHKYDAEYIENQVLPVLRILEA
 FGVRKEDLRWQKTKQTGLTAWLNKK—


>JDF-3

MILDVDYITENGKPVIRVFKENGFEFRIEYDREFEPYFYALLRDDSIAIEE
 IKKITAERHGRVVKVRAEKVKKFLGRSVEVWVLYFTHPQDVPAIRDKI
 RKHPAVIDIYEYDIPFAKRYLIDKGLIPMEGDEELKLLMSFDIETLYHEGE
 EFGTGPILMISYADESEARVITWKKIDLPYVEVVSSEMIKRFLRVVKE
 KDPDVLITYNGDNFDFAYLKKRCEKLGVSFTLCRDGS—EPKIQRMGDRF
 AVEVKG RVHFDLYPVIRRTINLPTYTLEAVYEAIFGKPKVKVYAEIATA
 WETGGLERVARYSMEDARVTYELGREFFPMEAQLSRLIGQGLWDVSRSS
 TGNLVEWFLRKAYERNELAPNKPDERELARR—RggYAGGYVKEPERGLW
 DNIVYLDFRSLYPSIIITHNVSPDTLNREGCRSYDVAPEVGHKFKCDFPG
 FIPSLGNLLEERQIKRKMKATLDPLEKNLLDYRQRAIKILANSYYGY
 GYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYADTDGLHAT
 IPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKYAVI
 DEEGKITRGLEIVRRDWSEIAKETQARVLEAILRHGDVEEAVRIVREVT
 EKLSKYEVPPEKLVIEHQITRELKDYKATGPHVAIAKRLAARGVKIRPGT
 VISYIVLKGSGRIGDRAIPDEFDPTKHKYDADYIENQVLP AVERILRA
 FGVRKEDLRYQKTRQVGLGAWLKPKGkkk

Sequence tree:


Tree constructed using UPGMA

((Pfu :0.000998,
 Deep :0.000998):0.000080,
 ((Tgo :0.000905,
 KOD :0.000905):0.000032,
 JDF-3 :0.000937):0.000141):0.000067,
 Vent :0.001144);




Results: *Pfu* V93K and V93R mutants show significantly improved dUTP incorporation compared to wild type *Pfu*. In contrast, the *Pfu* V93W, V93Y, and V93M mutants show little-to-no improvement in dUTP incorporation.

Figure 8A



Results: The *Pfu* V93D and V93R mutants show significantly improved dUTP incorporation compared to wild type *Pfu*.

Figure 8B



Results: The *Pfu* V93N mutant shows a very small improvement in dUTP incorporation compared to wild type *Pfu*. In contrast, the *Pfu* V93G mutant shows little-to-no improvement.

Figure 8C

Figure 9: Polymerase activity and Temperature optimum of Pfu N terminal truncation mutants

Pfu clone #	Truncated after Pfu residue	Relative DNA polymerase activity	Temperature Optimum
61	H30	Moderate	65°
72	V66	Similar to wild type	70°
81	P128	Low	Not tested
92	I158	Low	Not tested
3	G125	Similar to wild type	Not tested
13/14	K201	low	65°

Figure 10. Oligonucleotide Primers for QuikChange Mutagenesis

KOD V93 mutations

V93Q KOD 5'- CTCATCCG CAGGACCAGC CAGCGATAAG GGACAAG-3' (SEQ ID NO: 56)

V93R KOD 5'- CTCATCCG CAGGACCGTC CAGCGATAAG GGACAAG-3' (SEQ ID NO: 57)

V93K KOD 5'- CTCATCCG CAGGACAAAC CAGCGATAAG GGACAAG-3' (SEQ ID NO: 58)

V93N KOD 5'- CTCATCCG CAGGACAATC CAGCGATAAG GGACAAG-3' (SEQ ID NO: 59)

V93E KOD 5'- CTCATCCG CAGGACGAGC CAGCGATAAG GGACAAG-3' (SEQ ID NO: 60)

V93D KOD 5'- CTCATCCG CAGGACGATC CAGCGATAAG GGACAAG-3' (SEQ ID NO: 61)

Tgo V93 mutations

(SEQ ID NO: 62)

V93Q Tgo 5'-CAC CCC CAG GAC CAA CCC GCA ATC AGG GAC AAG G-3'

(SEQ ID NO: 63)

V93R Tgo 5'-CAC CCC CAG GAC AGA CCC GCA ATC AGG GAC AAG G-3'

(SEQ ID NO: 64)

V93N Tgo 5'-CAC CCC CAG GAC AAT CCC GCA ATC AGG GAC AAG G-3'

(SEQ ID NO: 65)

V93K Tgo 5'-CAC CCC CAG GAC AAA CCC GCA ATC AGG GAC AAG G-3'

(SEQ ID NO: 66)

V93E Tgo 5'-CAC CCC CAG GAC GAA CCC GCA ATC AGG GAC AAG G-3'

(SEQ ID NO: 67)

V93D Tgo 5'-CAC CCC CAG GAC GAC CCC GCA ATC AGG GAC AAG G-3'

JDF-3 V93 mutations

(SEQ ID NO: 68)

V93Q JDF-3 5'-ACG CAC CCG CAG GAC  CCG GCA ATC CGC GAC 3'

(SEQ ID NO: 69)

V93R JDF-3 5'-ACG CAC CCG CAG GAC  CCG GCA ATC CGC GAC 3'

(SEQ ID NO: 70)

V93E JDF-3 5'-ACG CAC CCG CAG GAC  CCG GCA ATC CGC GAC 3'

(SEQ ID NO: 71)

V93D JDF-3 5'-ACG CAC CCG CAG GAC  CCG GCA ATC CGC GAC 3'

(SEQ ID NO: 72)

V93K JDF-3 5'-ACG CAC CCG CAG GAC  CCG GCA ATC CGC GAC 3'

Pfu deletions

(SEQ ID NO: 73)


Δ93 Pfu : 5'- GAA CAT CCC CAA GAT CCC ACT ATT AGA G-3'

(SEQ ID NO: 74)

Δ92-94 Pfu : 5'- GAA CAT CCC CAA ACT ATT AGA G-3'

Fig. 11. Uracil Insensitivity of KOD V93 mutants

T-/dU-primers and dUTP/TTP incorporation:



	With regular primers		With U primers	
	dNTP	dGCAU	dNTP	dGCAU
KOD WT	+	-	-	-
KOD V93D	+	-	+	-
KOD V93E	+	-	+	-
KOD V93K	+	+	+	+
KOD V93N	+	-	-	-
KOD V93Q	+	-	+	-
KOD V93R	+	+	+	+

Fig. 12. Uracil Insensitivity of Tgo V93 mutants

T-primers and dUTP/TTP incorporation:





Fig. 13. Uracil Insensitivity of JDF-3 V93 mutants

T-primers and dUTP/TTP incorporation:



T-/dU-primers and dUTP/TTP incorporation:






Fig. 14. Uracil Sensitivity of *Pfu* deletion mutants

T-primers and dUTP/TTP incorporation:




Amplification Plot for Comparison of Three Polymerases in QRT-PCR



* FM = FEN-1

Figure 15


Semi-log Amplification Plots Comparing Pfu V93R and Pfu V93R exo- Containing QPCR Reactions



	V93R exo-	V93R exo-	V93R	V93R	PlatinumTaq	AmpliTaq
Units	1.25	2.5	1.25	2.5	1.25	1.25
Avg Ct	22.2	22.2	23.5	23.2	24.3	23.6

Figure 16

Pfn V93R^{exo} -Multiplex-ATP2B1 and Tfr



	Target amt	Tfr	ATP2B1	Tfr + ATP2B1
Pfn V93R ^{exo}	100ng	22.8		22.7
			30.9	30.8
ABIMM	100ng	24.6		25.3
(TaqMan)			30.3	30.1

Figure 17

1

DNA POLYMERASE COMPOSITIONS FOR QUANTITATIVE PCR AND METHODS THEREOF

RELATED APPLICATIONS

The present application claims priority under 35 U.S.C. §120 as a continuation in part of U.S. patent application with Ser. No. 10/408,601, filed Apr. 7, 2003, which is a continuation in part of U.S. application Ser. No. 10/298,680, filed Nov. 18, 2002, which is a continuation in part of U.S. application Ser. No. 10/280,962, Filed Oct. 25, 2002. The entirety of each of the above applications is hereby incorporated by reference.

FIELD OF THE INVENTION

The invention relates to mutant Archaeal DNA polymerases with deficient 3'-5' exonuclease activity and/or reduced base analog detection activity, and the uses thereof.

BACKGROUND

DNA polymerases synthesize DNA molecules in the 5' to 3' direction from deoxynucleoside triphosphates (nucleotides) using a complementary template DNA strand and a primer by successively adding nucleotides to the free 3'-hydroxyl group of the growing strand. The template strand determines the order of addition of nucleotides via Watson-Crick base pairing. In cells, DNA polymerases are involved in DNA repair synthesis and replication (Kornberg, 1974, In DNA Synthesis. W. H. Freeman, San Francisco).

Archaeal DNA polymerases have a 3' to 5' exonuclease activity and a DNA synthesis activity. Many molecular cloning techniques and protocols involve the synthesis of DNA in *in vitro* reactions catalyzed by DNA polymerases. Sometimes, mutant forms of DNA polymerases are desired for particular uses. For example, DNA polymerases are used in DNA labelling and DNA sequencing reactions, using either 35S-, 32P- or 33P-labelled nucleotides. Most of these enzymes require a template and primer, and synthesize a product whose sequence is complementary to that of the template. The 5' to 3' exonuclease activity of an Archaeal DNA polymerase is often troublesome in these reactions because it degrades the 5' terminus of primers that are bound to the DNA templates and removes 5' phosphates from the termini of DNA fragments that are to be used as substrates for ligation. The use of DNA polymerase for these labelling and sequencing reactions thus may depend upon the removal of the 5' to 3' exonuclease activity.

DNA processivity is performed by heat denaturation of a DNA template containing the target sequence, annealing of a primer to the DNA strand and extension of the annealed primer with a DNA polymerase. The concept of net DNA processivity is the ratio of DNA synthesis activity versus 3'-5' exonuclease activity (for reviews, see, e.g., Kelman et al., 1998 *Processivity of DNA polymerases: two mechanisms, one goal*. Structure 6(2):121-5; Wyman and Botchan, 1995, *DNA replication. A familiar ring to DNA polymerase processivity*. Curr Biol. 5(4):334-7; and Von Hippel et al., 1994, *On the processivity of polymerases*. Ann NY Acad Sci. 726:118-31). DNA synthesis activity acts to polymerize nucleotides while 3'-5' exonuclease has an editing or proof-reading function to enhance the fidelity of the synthesis. Thus highly efficient DNA synthesis is generally achieved at the expense of high fidelity and vice versa. The 3'-to-5' exonuclease activity of many DNA polymerases may, therefore, be disadvantageous

2

in situations where one is trying to achieve net synthesis of DNA and/or where fidelity is not of primary concern.

Archaeal family B DNA polymerases are uniquely able to recognize unrepaired uracil in a template strand and stall polymerization upstream of the lesion, thereby preventing the irreversible fixation of an G-C to A-T mutation (Fogg et al., 2002, Nat Struct Biol. 9(12):922-7). Uracil detection is thought to represent the first step in a pathway to repair DNA cytosine deamination (dCMP→dUMP) in archaea (Greagg et al., 1999, PNAS USA, 96:9405). Stalling of DNA synthesis opposite uracil has significant implications for high-fidelity PCR amplification with Archaeal DNA polymerases. Techniques requiring dUTP (e.g., dUTP/UDG decontamination methods, Longo et al. 1990, Gene, 93:125) or uracil-containing oligonucleotides can not be performed with proofreading DNA polymerases (Slupphaug et al. 1993, Anal. Biochem., 211:164; Sakaguchi et al. 1996, Biotechniques, 21:368). But more importantly, uracil stalling has been shown to compromise the performance of Archaeal DNA polymerases under standard PCR conditions (Hogrefe et al. 2002, PNAS USA, 99:596).

During PCR amplification, a small amount of dCTP undergoes deamination to dUTP (% dUTP varies with cycling time), and is subsequently incorporated by Archaeal DNA polymerases. Once incorporated, uracil-containing DNA inhibits Archaeal DNA polymerases, limiting their efficiency. We found that adding a thermostable dUTPase (dUTP→dUMP+PP_i) to amplification reactions carried out with Pfu, KOD, Vent, and Deep Vent DNA polymerases significantly increases PCR product yields by preventing dUTP incorporation (Hogrefe et al. 2002, Supra). Moreover, the target-length capability of Pfu DNA polymerase is dramatically improved in the presence of dUTPase (from <2 kb to 14 kb), indicating that uracil poisoning severely limits long-range PCR due to the use of prolonged extension times (1-2 min per kb @72° C.) that promote dUTP formation.

In addition to dUTP incorporation, uracil may also arise as a result of cytosine deamination in template DNA. The extent to which cytosine deamination occurs during temperature cycling has not been determined; however, any uracil generated would presumably impair the PCR performance of Archaeal DNA polymerases. Uracil arising from cytosine deamination in template DNA is unaffected by adding dUTPase, which only prevents incorporation of dUTP (created by dCTP deamination). Adding enzymes such as uracil DNA glycosylase (UGD), which excise uracil from the sugar backbone of DNA, or mismatch-specific UDGs (MUG), which additionally excise G:T mismatches, is one way to eliminate template uracil that impedes polymerization.

Alternatively, the problem of uracil stalling may be overcome by introducing mutations or deletions in Archaeal DNA polymerases that reduce, or ideally, eliminate uracil detection, and therefore, allow synthesis to continue opposite incorporated uracil (non-mutagenic uracil) and deaminated cytosine (pro-mutagenic uracil). Such mutants would be expected to produce higher product yields and amplify longer targets compared to wild type Archaeal DNA polymerases. Moreover, mutants that lack uracil detection should be compatible with dUTP/UNG decontamination methods employed in real-time Q-PCR.

It is sometimes desired for a DNA polymerase or a reverse transcriptase to have a high processivity. Processivity is a measurement of the ability of a DNA polymerase to incorporate one or more deoxynucleotides into a primer template molecule without the DNA polymerase dissociating from that molecule. DNA polymerases having low processivity, such as the Klenow fragment of DNA polymerase I of *E. coli*, will

dissociate after about 5-40 nucleotides are incorporated on average. Other polymerases, such as T7 DNA polymerase in the presence of thioredoxin, are able to incorporate many thousands of nucleotides prior to dissociating. In the absence of thioredoxin such a T7 DNA polymerase has a much lower processivity. Processivity factors have been identified to increase the processivity of a DNA polymerase (e.g., see Carson D R, Christman M F. 2001, Proc Natl Acad Sci U S A. 98(15):8270-5).

U.S. Pat. No. 5,972,603 teaches a chimeric DNA polymerase having a DNA polymerase domain and a processivity factor binding domain not naturally associated with the DNA polymerase domain, where the processivity factor binding domain binds thioredoxin.

U.S. patent application with Ser. No. 2002/0119467 describes a method for increasing the processivity of reverse transcriptase (RT) *E. coli* DNA polymerase and T7 DNA polymerase using a polynucleotide binding protein such as Ncp7, recA, SSB and T4gp32.

There is therefore a need for thermostable DNA polymerases that can amplify DNA in the presence of dUTP without compromising proofreading or polymerization activity and efficiency. There is also a need for thermostable DNA polymerases that can amplify DNA efficiently without the proof checking function of 3'-5' exonuclease activity so that the thermostable DNA polymerase exhibits increased processivity.

SUMMARY OF THE INVENTION

The present invention provides an Archaeal DNA polymerase comprising an amino acid sequence selected from SEQ ID NOs. 83-108, and further comprising at least one amino acid mutation in exoI motif and another amino acid mutation at V93, where the Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

The present invention provides an Archaeal DNA polymerase comprising an amino acid sequence selected from SEQ ID NOs. 83-108, and further comprising at least one amino acid mutation in exoII motif and another amino acid mutation at V93, where the Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

The present invention also provides an Archaeal DNA polymerase comprising an amino acid sequence selected from SEQ ID NOs. 83-108, and further comprising at least one amino acid mutation in exo III motif and another amino acid mutation at V93, where the Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

The present invention further provides an Archaeal DNA polymerase comprising an amino acid sequence selected from SEQ ID NOs. 83-108, and further comprising at least one amino acid mutation in each of exo I and exo III motifs and another amino acid mutation at V93, where the Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

In addition, the present invention provides an Archaeal DNA polymerase comprising an amino acid sequence selected from SEQ ID NOs. 83-108, and further comprising at least one amino acid mutation in each of exo II and exo III motifs and another amino acid mutation at V93, where the Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

The present invention provides an Archaeal DNA polymerase comprising an amino acid sequence selected from SEQ ID NOs. 83-108, and further comprising at least one amino acid mutation in each of exo I and exoII motifs and another amino acid mutation at V93, where the Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

The present invention provides an Archaeal DNA polymerase comprising an amino acid sequence selected from SEQ ID NOs. 83-108, and further comprising at least one amino acid mutation in each of exoI, exo II, and exoIII motifs and another amino acid mutation at V93, where the Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

Preferably, the mutant Archaeal DNA polymerase of the present invention is selected from the group consisting of: KOD, Pfu, and JDF-3 DNA polymerase.

Also preferably, the mutation at position V93, is a Valine to Arginine substitution, a Valine to Glutamic acid substitution, a Valine to Lysine substitution, a Valine to Aspartic acid substitution, a Valine to Glutamine substitution, or a Valine to Asparagine substitution.

Preferably, the mutation in exo I motif is selected from the group consisting of: aspartic acid (D) to threonine (T), aspartic acid (D) to alanine (A) and glutamic acid (E) to alanine (A).

The present invention provides an isolated polynucleotide comprising a nucleotide sequence encoding a mutant Archaeal DNA polymerase of the present invention as described above.

The present invention provides a composition comprising a mutant Archaeal DNA polymerase as described above.

Preferably, the composition of the present invention also contains an enzyme with reverse transcriptase activity.

The present invention provides a kit comprising a mutant Archaeal DNA polymerase as described above and packaging material therefor.

The kit may further contain an enzyme with reverse transcriptase activity.

Preferably, the enzyme with reverse transcriptase is a second mutant DNA polymerase.

More preferably, the enzyme with reverse transcriptase is the mutant Archaeal DNA polymerase which contains an increased reverse transcriptase activity.

The composition or kit of the present invention may further comprise a PCR additive.

The present invention provides a method for DNA synthesis comprising: (a) providing a mutant Archaeal DNA polymerase; and (b) contacting the mutant Archaeal DNA polymerase with a polynucleotide template to permit DNA synthesis. The present invention further provides a method for determining the abundance of a polynucleotide template, comprising (a) providing a mutant Archaeal DNA polymerase; (b) contacting the mutant Archaeal DNA polymerase with the polynucleotide template to produce amplified product; and (c) determining the abundance of the amplified product, where the abundance of the amplified product is indicative of the abundance of the polynucleotide template.

Preferably, the polynucleotide template is a RNA molecule, and where the RNA molecule is reverse transcribed into cDNA before the contacting step (b).

Also preferably, the RNA is reverse transcribed by an enzyme with reverse transcriptase activity.

More preferably, the RNA is reverse transcribed by the mutant Archaeal DNA polymerase which also contains an increased reverse transcriptase activity.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Oligonucleotide Primers for QuikChange Mutagenesis (SEQ ID Nos: 6-14, 43-55) according to one embodiment of the invention.

FIG. 2: (a) dUTP incorporation of V93E and V93R exo-mutants compared to wild type Pfu DNA polymerase according to one embodiment of the invention.

(b) PCR Amplification of Pfu V93R exo-mutant extract in the presence of 100% dUTP according to one embodiment of the invention.

FIG. 3: Protein concentration, unit concentration, and specific activity of the purified Pfu V93R and V93E exo-mutants according to one embodiment of the invention.

FIG. 4: Comparison of the efficacy of PCR amplification of Pfu DNA polymerase mutants and wt enzyme in the presence of different TTP:dUTP concentration ratios.

FIG. 5: Comparison of the efficacy of "long" PCR amplification of Pfu DNA polymerase mutants and wt enzyme.

FIG. 6: 6A. DNA sequence of example mutant Archaeal DNA polymerases according to one embodiment of the invention.

6B. Amino acid sequence of example mutant Archaeal DNA polymerases according to one embodiment of the invention

6C. DNA and Amino acid sequence of mutant Tgo DNA polymerase according to one embodiment of the invention

FIG. 7: 7A. Amino acid sequence of example wild type DNA polymerase according to one embodiment of the invention (SEQ ID NOs. 83-108).

7B Amino acid sequence alignment of example wild-type Archaeal DNA polymerases according to one embodiment of the invention: Pfu: SEQ ID NO: 27; Tgo: SEQ ID NO: 29; KOD: SEQ ID NO: 30; Vent: SEQ ID NO: 31; Deep: SEQ ID NO: 28; JDF-3: SEQ ID NO: 32.

FIG. 8: dUTP incorporation of Pfu mutants compared to wild type Pfu DNA polymerase according to one embodiment of the invention.

8A. dUTP incorporation of Pfu mutants V93W, V93Y, V93M, V93K and V93R compared to wild type Pfu DNA polymerase

8B. dUTP incorporation of the Pfu V93D and V93R mutants compared to wild type Pfu DNA polymerase.

8C. dUTP incorporation of the Pfu V93N and V93G mutant compared to wild type Pfu DNA polymerase

FIG. 9: DNA polymerase activity of N-terminal Pfu DNA polymerase truncation mutants according to one embodiment of the invention.

FIG. 10: Oligonucleotide Primers for QuikChange Mutagenesis (SEQ ID Nos: 56-74).

FIG. 11: DNA polymerase activity of KOD V93 exo-polymerase mutants according to one embodiment of the invention.

FIG. 12: DNA polymerase activity of Tgo V93 exo-DNA polymerase mutants and comparison with JDF-3 V93 exo-polymerase mutants according to one embodiment of the invention.

FIG. 13: DNA polymerase activity of JDF-3 polymerase mutants according to one embodiment of the invention.

FIG. 14: DNA polymerase activity of Pfu polymerase deletion mutants according to one embodiment of the invention.

FIG. 15: An amplification plot for comparison of three polymerases in RT-QPCR according to one embodiment of the invention.

FIG. 16: A semi-log amplification plot comparing Pfu V93R and Pfu V93R exo-QPCR according to one embodiment of the invention.

FIG. 17: An amplification plot comparing Pfu V93R and other DNA polymerase in multiplexing QPCR according to one embodiment of the invention.

DETAILED DESCRIPTION

Definitions

The invention contemplates A mutant DNA polymerase that exhibits deficient 3'-5' exonuclease activity and/or reduced base analog detection (for example, reduced detection of a particular base analog such as uracil or inosine or reduced detection of at least two base analogs).

Unless defined otherwise, the scientific and technological terms and nomenclature used herein have the same meaning as commonly understood by a person of ordinary skill to which this invention pertains. Generally, the procedures for molecular biology methods and the like are common methods used in the art. Such standard techniques can be found in reference manuals such as for example Sambrook et al. (1989, *Molecular Cloning—A Laboratory Manual*, Cold Spring Harbor Laboratories) and Ausubel et al. (1994, *Current Protocols in Molecular Biology*, Wiley, N.Y.).

As used herein, "Archaeal" DNA polymerase refers to DNA polymerases that belong to either the Family B/pol I-type group (e.g., Pfu, KOD, Pfx, Vent, Deep Vent, Tgo, Pwo) or the pol II group (e.g., *Pyrococcus furiosus* DP1/DP2 2-subunit DNA polymerase). In one embodiment, "Archaeal" DNA polymerase refers to thermostable Archaeal DNA polymerases (PCR-able) and include, but are not limited to, DNA polymerases isolated from *Pyrococcus* species (*furiosus*, species GB-D, *woesii*, *abyssi*, *horikoshii*), *Thermococcus* species (*kodakaraensis* KODI, *litoralis*, species 9 degrees North-7, species JDF-3, *gorgonarius*), *Pyrodicticum occultum*, and *Archaeoglobus fulgidus*. It is estimated that suitable archaea would exhibit maximal growth temperatures of >80-85° C. or optimal growth temperatures of >70-80° C. Appropriate PCR enzymes from the Archaeal pol I DNA polymerase group are commercially available, including Pfu (Stratagene), KOD (Toyobo), Pfx (Life Technologies, Inc.), Vent (New England Biolabs), Deep Vent (New England BioLabs), Tgo (Roche), and Pwo (Roche). Additional archaea related to those listed above are described in the following references: Archaea: A Laboratory Manual (Robb, F. T. and Place, A. R., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1995

As used herein, "mutant" polymerase refers to an Archaeal DNA polymerase, as defined herein, comprising one or more mutations that alter one or more activities of the DNA polymerase, for example, DNA polymerization, 3'-5' exonuclease activity or base analog detection activities. In one embodiment, the "mutant" polymerase of the invention refers to a DNA polymerase containing one or more mutations that reduce one or more base analog detection activities of the DNA polymerase. In a preferred embodiment, the "mutant" polymerase of the invention has a reduced uracil detection activity. In a preferred embodiment, the "mutant" polymerase of the invention has a reduced inosine detection activity. In another preferred embodiment, the "mutant" polymerase of the invention has a reduced uracil and inosine detection activity. A "mutant" polymerase as defined herein, includes a polymerase comprising one or more amino acid substitutions, one or more amino acid insertions, a truncation or an internal deletion.

A "mutant" polymerase as defined herein also includes a chimeric polymerase wherein any of the single, double or triple mutant Archaeal DNA polymerases described herein, any mutant Archaeal DNA polymerases comprising an insertion, described herein, or any of the truncated, or deleted mutant Archaeal DNA polymerases described herein, occur in combination with a polypeptide that increases processivity, thereby forming a chimera, as defined herein. A polypeptide

that increases processivity is described in U.S. patent application with Ser. No. 10/408,601, WO 01/92501 A1 and Pavlov et al., 2002, Proc. Natl. Acad. Sci. USA, 99:13510-13515, herein incorporated by reference in their entirety.

A “chimera” as defined herein, is a fusion of a first amino acid sequence (protein) comprising a wild type or mutant ARCHAEL DNA polymerase of the invention, joined to a second amino acid sequence defining a polypeptide that increases processivity, wherein the first and second amino acids are not found in the same relationship in nature. A “chimera” according to the invention contains two or more amino acid sequences (for example a sequence encoding a wild type or mutant ARCHAEL DNA polymerase and a polypeptide that increases processivity) from unrelated proteins, joined to form a new functional protein. A chimera of the invention may present a foreign polypeptide which is found (albeit in a different protein) in an organism which also expresses the first protein, or it may be an “interspecies”, “intergenic”, etc. fusion of protein structures expressed by different kinds of organisms. The invention encompasses chimeras wherein the polypeptide that increases processivity and/or efficiency is joined N-terminally or C-terminally to a wild-type Archaeal DNA polymerase or to any of the mutant Archaeal DNA polymerases described herein.

As used herein, “joined” refers to any method known in the art for functionally connecting polypeptide domains, including without limitation recombinant fusion with or without intervening domains, intein-mediated fusion, non-covalent association, and covalent bonding, including disulfide bonding, hydrogen bonding, electrostatic bonding, and conformational bonding.

As used herein, “mutation” refers to a change introduced into a wild type DNA sequence that changes the amino acid sequence encoded by the DNA, including, but not limited to, substitutions, insertions, deletions or truncations. The consequences of a mutation include, but are not limited to, the creation of a new character, property, function, or trait not found in the protein encoded by the parental DNA, including, but not limited to, N terminal truncation, C terminal truncation or chemical modification. A “mutation,” according to the present invention, may be created by genetic modification or chemical modification.

As used herein, “corresponding” refers to sequence similarity in a comparison of two or more nucleic acids or polypeptides, where functionally equivalent domains or sub-sequences are identified; such functionally equivalent domains or sub-sequences or amino acids within such a domain or sub-sequence are said to “correspond”. That is, two or more sequences are compared through a comparative alignment analysis in which an entire sequence is examined for regions of sequence that are similar or identical, and thus regions likely to be functionally equivalent to regions from the other sequence(s) are identified.

As used herein in reference to comparisons of an amino acid, amino acid sequence, or protein domain, the term “similar” refers to amino acids or domains that although not identical, represent “conservative” differences. By “conservative” is meant that the differing amino acid has like characteristics with the amino acid in the corresponding or reference sequence. Typical conservative substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. In calculating the degree (most often as a percentage) of similarity between two polypeptide sequences, one considers the number of positions at which identity or similarity is observed between corresponding amino acid residues in the two

polypeptide sequences in relation to the entire lengths of the two molecules being compared.

As used herein, the term “functionally equivalent” means that a given motif, region, or amino acid within a motif or region performs the same function with regard to the overall function of the enzyme as a motif, region or amino acid within a motif or region performs in another enzyme.

As used herein, “3' to 5' exonuclease deficient” or “3' to 5' exo-” refers to an enzyme that substantially lacks the ability to remove incorporated nucleotides from the 3' end of a DNA polymer. DNA polymerase exonuclease activities, such as the 3' to 5' exonuclease activity exemplified by members of the Family B polymerases, can be lost through mutation, yielding an exonuclease-deficient polymerase. As used herein, a DNA polymerase that is deficient in 3' to 5' exonuclease activity substantially lacks 3' to 5' exonuclease activity. “Substantially lacks” encompasses a complete lack of activity, for example, 0.03%, 0.05%, 0.1%, 1%, 5%, 10%, 20% or even up to 50% of the exonuclease activity relative to the parental enzyme. Methods used to generate and characterize 3'-5' exonuclease DNA polymerases including the D141A and E143A mutations as well as other mutations that reduce or eliminate 3'-5' exonuclease activity are disclosed in the pending U.S. patent application Ser. No. 09/698,341 (Sorge et al; filed Oct. 27, 2000). Additional mutations that reduce or eliminate 3' to 5' exonuclease activity are known in the art and contemplated herein.

As used herein, “base analogs” refer to bases that have undergone a chemical modification as a result of the elevated temperatures required for PCR reactions. In a preferred embodiment, “base analog” refers to uracil that is generated by deamination of cytosine. In another preferred embodiment, “base analog” refers to inosine that is generated by deamination of adenine.

As used herein, “reduced base analog detection” refers to a DNA polymerase with a reduced ability to recognize a base analog, for example, uracil or inosine, present in a DNA template. In this context, mutant DNA polymerase with “reduced” base analog detection activity is a DNA polymerase mutant having a base analog detection activity which is lower than that of the wild-type enzyme, i.e., having less than 10% (e.g., less than 8%, 6%, 4%, 2% or less than 1%) of the base analog detection activity of that of the wild-type enzyme. base analog detection activity may be determined according to the assays similar to those described for the detection of DNA polymerases having a reduced uracil detection as described in Greagg et al. (1999) Proc. Natl. Acad. Sci. 96, 9045-9050 and Example 3. Alternatively, “reduced” base analog detection refers to a mutant DNA polymerase with a reduced ability to recognize a base analog, the “reduced” recognition of a base analog being evident by an increase in the amount of >10 Kb PCR of at least 10%, preferably 50%, more preferably 90%, most preferably 99% or more, as compared to a wild type DNA polymerase without a reduced base analog detection activity. The amount of a >10 Kb PCR product is measured either by spectrophotometer-absorbance assays of gel eluted >10 Kb PCR DNA product or by fluorometric analysis of >10 Kb PCR products in an ethidium bromide stained agarose electrophoresis gel using, for example, a Molecular Dynamics (MD) FluorImager™ (Amersham Biosciences, catalogue #63-0007-79).

As used herein, “reduced uracil detection” refers to a DNA polymerase with a reduced ability to recognize a uracil base present in a DNA template. In this context, mutant DNA polymerase with “reduced” uracil detection activity is a DNA polymerase mutant having a uracil detection activity which is lower than that of the wild-type enzyme, i.e., having less than

10% (e.g., less than 8%, 6%, 4%, 2% or less than 1%) of the uracil detection activity of that of the wild-type enzyme. Uracil detection activity may be determined according to the assays described in Greagg et al. (1999) Proc. Natl. Acad. Sci. 96, 9045-9050 and as described herein below. Alternatively, “reduced” uracil detection refers to a mutant DNA polymerase with a reduced ability to recognize uracil, the “reduced” recognition of uracil being evident by an increase in the amount of >10 Kb PCR of at least 10%, preferably 50%, more preferably 90%, most preferably 99% or more, as compared to a wild type DNA polymerase without a reduced uracil detection activity. The amount of a >10 Kb PCR product is measured either by spectrophotometer-absorbance assays of gel eluted >10 Kb PCR DNA product or by fluorometric analysis of >10 Kb PCR products in an ethidium bromide stained agarose electrophoresis gel using, for example, a Molecular Dynamics (MD) FluorImager™ (Amersham Biosciences, catalogue #63-0007-79).

As used herein, the terms “reverse transcription activity” and “reverse transcriptase activity” are used interchangeably to refer to the ability of an enzyme (e.g., a reverse transcriptase or a DNA polymerase) to synthesize a DNA strand (i.e., cDNA) utilizing an RNA strand as a template. Methods for measuring RT activity are provided in the examples herein below and also are well known in the art. For example, the Quan-T-RT assay system is commercially available from Amersham (Arlington Heights, Ill.) and is described in Bosworth, et al., Nature 1989, 341:167-168.

As used herein, the term “increased reverse transcriptase activity” refers to the level of reverse transcriptase activity of a mutant enzyme (e.g., a DNA polymerase) as compared to its wild-type form. A mutant enzyme is said to have an “increased reverse transcriptase activity” if the level of its reverse transcriptase activity (as measured by methods described herein or known in the art) is at least 20% or more than its wild-type form, for example, at least 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% more or at least 2-fold, 3-fold, 4-fold, 5-fold, or 10-fold or more.

As used herein, “synthesis” refers to any in vitro method for making new strand of polynucleotide or elongating existing polynucleotide (i.e., DNA or RNA) in a template dependent manner. Synthesis, according to the invention, includes amplification, which increases the number of copies of a polynucleotide template sequence with the use of a polymerase. Polynucleotide synthesis (e.g., amplification) results in the incorporation of nucleotides into a polynucleotide (i.e., a primer), thereby forming a new polynucleotide molecule complementary to the polynucleotide template. The formed polynucleotide molecule and its template can be used as templates to synthesize additional polynucleotide molecules.

“DNA synthesis”, according to the invention, includes, but is not limited to, PCR, the labelling of polynucleotide (i.e., for probes and oligonucleotide primers), polynucleotide sequencing.

As used herein, “polymerase” refers to an enzyme that catalyzes the polymerization of nucleotide (i.e., the polymerase activity). Generally, the enzyme will initiate synthesis at the 3'-end of the primer annealed to a polynucleotide template sequence, and will proceed toward the 5' end of the template strand. “DNA polymerase” catalyzes the polymerization of deoxynucleotides. In a preferred embodiment, the “DNA polymerase” of the invention is an Archaeal DNA polymerase. A “DNA polymerase” useful according to the invention includes, but is not limited to those included in the section of the present specification entitled “Polymerases”.

As used herein, “polypeptide that increases processivity and/or efficiency” refers to a domain that is a protein or a

region of a protein or a protein complex, comprising a polypeptide sequence, or a plurality of peptide sequences wherein that region increases processivity, as defined herein, or increases salt resistance, as defined herein. A “polypeptide that increases processivity and/or efficiency useful according to the invention includes but is not limited to any of the domains included in Pavlov et al., supra or WO 01/92501, for example Sso7d, Sac7d, HMF-like proteins, PCNA homologs, and helix-hairpin-helix domains, for example derived from Topoisomerase V.

As used herein, “processivity” refers to the ability of a polynucleotide modifying enzyme, for example a polymerase, to remain attached to the template or substrate and perform multiple modification reactions. “Modification reactions” include but are not limited to polymerization, and exonucleolytic cleavage. “Processivity” also refers to the ability of a polynucleotide modifying enzyme, for example a polymerase, to modify relatively long (for example 0.5-1 kb, 1-5 kb or 5 kb or more) tracts of nucleotides. “Processivity” also refers to the ability of a polynucleotide modifying enzyme, for example a DNA polymerase, to perform a sequence of polymerization steps without intervening dissociation of the enzyme from the growing DNA chains. “Processivity” can depend on the nature of the polymerase, the sequence of a DNA template, and reaction conditions, for example, salt concentration, temperature or the presence of specific proteins.

As used herein, “increased processivity” refers to an increase of 5-10%, preferably 10-50%, more preferably 50-100% or more, as compared to a wild type or mutant ARCHAEAL DNA polymerase that lacks a polypeptide that increases processivity as defined herein. Methods for measuring processivity of a DNA polymerase are generally known in the art, e.g., as described in Sambrook et al. 1989, In Molecular Cloning, 2nd Edition, CSH Press, 7.79-7.83 and 13.8, and as described in U.S. patent application with Ser. No. 2002/0119467, hereby incorporated by reference. Processivity and increased processivity can be measured according to the methods defined herein and in Pavlov et al., supra and WO 01/92501 A1. Processivity can also be measured by any known method in the art, e.g., as described in U.S. Pat. No. 5,972,603, the entirety of which is incorporated herein by reference.

As used herein, the term “efficiency” of a DNA polymerase refers to a rate at which the DNA polymerase incorporates a nucleotide into a polynucleotide, or it may be defined as $N = N_0(1+E)^{CT}$ as described in “Amplification efficiency of thermostable DNA polymerases” Anal/Biochem. 321 (2003) 226-235 (incorporated herein by reference). Methods for measuring the rate of incorporation are described herein below and are generally known in the art, e.g., as described in Leung et al. (1989) Technique 1:11-15 and Caldwell et al. (1992) PCR Methods Applic. 2:28-33, hereby incorporated by reference.

The term “efficiency” may be also defined in terms of $N = N_0(1+E)^{CT}$. Methods for calculating efficiency this way are known in the art, e.g., as described in Arezi et al., 2003 Analytical Biochem. 321:226/235, hereby incorporated by reference. Theoretically, the amount of product doubles during each PCR cycle; in other words, $N = N_0 2^n$, where N is the number of amplified molecules, N_0 is the initial number of molecules, and n is the number of amplification cycles. Experimentally, amplification efficiency (E) is less than perfect, ranging from 0 to 1, and therefore the real PCR equation is $N = N_0(1+E)^n$. At threshold cycle, where the emission intensity of the amplification product measured by a real-time PCR instrument (such as the Mx4000 Multiplex Quantitative PCR

System; Stratagene, La Jolla, Calif.) is recorded as statistically significant above the background noise, the PCR equation transforms into $N = N_0(1+E)^{C_T}$. This equation can also be written as $\log N = \log N_0 + C_T \log(1+E)$, and therefore C_T is proportional to the negative of the log of the initial target copy number. thus, the plot of C_T versus the log of initial target copy number is a straight line, with a slope of $-[1/\log(1+E)]$ corresponding to amplification efficiency via the equation $E = 10^{(-1/\text{slope})} - 1$.

As used herein, "increased efficiency" refers to an increase of 5-10%, preferably 10-50%, more preferably 50-100% or more, as compared to a wild type archaeal DNA polymerase.

As used herein, "increased salt resistance" refers to a polymerase that exhibits >50% activity at a salt concentration that is known to be greater than the maximum salt concentration at which the wild-type polymerase is active. The maximum salt concentration differs for each polymerase and is known in the art, or can be experimentally determined according to methods in the art. For example, Pfu is inhibited at 30 mM (in PCR) so a Pfu enzyme with increased salt resistance would have significant activity (>50%) at salt concentrations above 30 mM. A polymerase with increased salt resistance that is a chimera comprising a polypeptide that increases salt resistance, as defined herein, is described in Pavlov et al. supra and WO 01/92501 A1.

As used herein, a DNA polymerase with a "reduced DNA polymerization activity" is a DNA polymerase mutant comprising a DNA polymerization activity which is lower than that of the wild-type enzyme, e.g., comprising less than 10% DNA (e.g., less than 8%, 6%, 4%, 2% or less than 1%) polymerization activity of that of the wild-type enzyme. Methods used to generate characterize Pfu DNA polymerases with reduced DNA polymerization activity are disclosed in the pending U.S. patent application Ser. No. 10/035,091 (Hogrefe, et al.; filed: Dec. 21, 2001); the pending U.S. patent application Ser. No. 10/079,241 (Hogrefe, et al.; filed Feb. 20, 2002); the pending U.S. patent application Ser. No. 10/208,508 (Hogrefe et al.; filed Jul. 30, 2002); and the pending U.S. patent application Ser. No. 10/227,110 (Hogrefe et al.; filed Aug. 23, 2002), the contents of which are hereby incorporated in their entirety.

As used herein, "thermostable" refers to an enzyme which is stable and active at temperatures as great as preferably between about 90-100° C. and more preferably between about 70-98° C. to heat as compared, for example, to a non-thermostable form of an enzyme with a similar activity. For example, a thermostable polynucleotide polymerase derived from thermophilic organisms such as *P. furiosus*, *M. jannaschii*, *A. fulgidus* or *P. horikoshii* are more stable and active at elevated temperatures as compared to a polynucleotide polymerase from *E. coli*. A representative thermostable polynucleotide polymerase isolated from *P. furiosus* (Pfu) is described in Lundberg et al., 1991, *Gene*, 108:1-6. Additional representative temperature stable polymerases include, e.g., polymerases extracted from the thermophilic bacteria *Thermus flavus*, *Thermus ruber*, *Thermus thermophilus*, *Bacillus stearothermophilus* (which has a somewhat lower temperature optimum than the others listed), *Thermus lacteus*, *Thermus rubens*, *Thermotoga maritima*, or from thermophilic archaea *Thermococcus litoralis*, and *Methanothermus fervidus*.

Temperature stable polymerases are preferred in a thermocycling process wherein double stranded polynucleotides are denatured by exposure to a high temperature (about 95° C.) during the PCR cycle.

As used herein, the term "template DNA molecule" refers to that strand of a polynucleotide from which a complemen-

tary polynucleotide strand is synthesized by a DNA polymerase, for example, in a primer extension reaction.

As used herein, the term "template dependent manner" is intended to refer to a process that involves the template dependent extension of a primer molecule (e.g., DNA synthesis by DNA polymerase). The term "template dependent manner" refers to polynucleotide synthesis of RNA or DNA wherein the sequence of the newly synthesised strand of polynucleotide is dictated by the well-known rules of complementary base pairing (see, for example, Watson, J. D. et al., In: *Molecular Biology of the Gene*, 4th Ed., W. A. Benjamin, Inc., Menlo Park, Calif. (1987)).

As used herein, an "amplified product" refers to the double strand polynucleotide population at the end of a PCR amplification reaction. The amplified product contains the original polynucleotide template and polynucleotide synthesized by DNA polymerase using the polynucleotide template during the PCR reaction.

As used herein, the term "abundance of polynucleotide" refers to the amount of a particular target polynucleotide sequence present in an amplification reaction, either before (e.g., the amount of the template polynucleotide), during (e.g., as in real-time PCR), or after the amplification (e.g., the amount of amplified product). The amount is generally measured as a relative amount in terms of concentration or copy number of the target sequence relative to the amount of a standard of known concentration or copy number. Alternatively, the amount in one unknown sample is measured relative to the amount in another unknown sample. As used herein, abundance of a polynucleotide is measured on the basis of the intensity of a detectable label, most often a fluorescent label. The methods of the invention permit one to extrapolate the relative amount of one or more target sequences in a polynucleotide sample from the amplification profile of that target sequence or sequences from that sample.

The term "fidelity" as used herein refers to the accuracy of DNA polymerization by template-dependent DNA polymerase. The fidelity of a DNA polymerase is measured by the error rate (the frequency of incorporating an inaccurate nucleotide, i.e., a nucleotide that is not incorporated at a template-dependent manner). The accuracy or fidelity of DNA polymerization is maintained by both the polymerase activity and the 3'-5' exonuclease activity of a DNA polymerase. The term "high fidelity" refers to an error rate of 5×10^{-6} per base pair or lower. The fidelity or error rate of a DNA polymerase may be measured using assays known to the art. For example, the error rates of DNA polymerase mutants can be tested using the lacI PCR fidelity assay described in Cline, J., Braman, J. C., and Hogrefe, H. H. (96) NAR 24:3546-3551. Briefly, a 1.9 kb fragment encoding the lacIOlacZ α target gene is amplified from pPRIAZ plasmid DNA using 2.5 U DNA polymerase (i.e. amount of enzyme necessary to incorporate 25 nmoles of total dNTPs in 30 min. at 72° C.) in the appropriate PCR buffer. The lacI-containing PCR products are then cloned into lambda GT 10 arms, and the percentage of lacI mutants (MF, mutation frequency) is determined in a color screening assay, as described (Lundberg, K. S., Shoemaker, D. D., Adams, M. W. W., Short, J. M., Sorge, J. A., and Mathur, E. J. (1991) *Gene* 180:1-8). Error rates are expressed as mutation frequency per bp per duplication (MF/bp/d), where bp is the number of detectable sites in the lacI gene sequence (349) and d is the number of effective target doublings. For each DNA polymerase mutant, at least two independent PCR amplifications are performed.

As used herein, "polynucleotide template" or "target polynucleotide template" or "template" refers to a polynucleotide containing an amplified region. The "amplified region," as

used herein, is a region of a polynucleotide that is to be either synthesized by polymerase chain reaction (PCR). For example, an amplified region of a polynucleotide template resides between two sequences to which two PCR primers are complementary to.

As used herein, the term "primer" refers to a single stranded DNA or RNA molecule that can hybridize to a polynucleotide template and prime enzymatic synthesis of a second polynucleotide strand. A primer useful according to the invention is between 10 to 100 nucleotides in length, preferably 17-50 nucleotides in length and more preferably 17-45 nucleotides in length.

"Complementary" refers to the broad concept of sequence complementarity between regions of two polynucleotide strands or between two nucleotides through base-pairing. It is known that an adenine nucleotide is capable of forming specific hydrogen bonds ("base pairing") with a nucleotide which is thymine or uracil. Similarly, it is known that a cytosine nucleotide is capable of base pairing with a guanine nucleotide.

As used herein, the term "homology" refers to the optimal alignment of sequences (either nucleotides or amino acids), which may be conducted by computerized implementations of algorithms. "Homology", with regard to polynucleotides, for example, may be determined by analysis with BLASTN version 2.0 using the default parameters. "Homology", with respect to polypeptides (i.e., amino acids), may be determined using a program, such as BLASTP version 2.2.2 with the default parameters, which aligns the polypeptides or fragments being compared and determines the extent of amino acid identity or similarity between them. It will be appreciated that amino acid "homology" includes conservative substitutions, i.e. those that substitute a given amino acid in a polypeptide by another amino acid of similar characteristics. Typically seen as conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Ala, Val, Leu and Ile with another aliphatic amino acid; replacement of a Ser with a Thr or vice versa; replacement of an acidic residue such as Asp or Glu with another acidic residue; replacement of a residue bearing an amide group, such as Asn or Gln, with another residue bearing an amide group; exchange of a basic residue such as Lys or Arg with another basic residue; and replacement of an aromatic residue such as Phe or Tyr with another aromatic residue.

The term "wild-type" refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source. In contrast, the term "modified" or "mutant" refers to a gene or gene product which displays altered characteristics when compared to the wild-type gene or gene product. For example, a mutant DNA polymerase in the present invention is a DNA polymerase which exhibits a reduced uracil detection activity.

As used herein, "additive" refers to a reagent which can increase the processivity, efficiency, or heat or salt stability, including but not limited to, Pfu dUTPase (PEF), PCNA, RPA, ssb, antibodies, DMSO, betaine, 3'-5' exonuclease (e.g., Pfu G387P), Ncp7, recA, T4gp32.

As used herein "FEN-1 nuclease" refers to thermostable FEN-1 endonucleases useful according to the invention and include, but are not limited to, FEN-1 endonuclease purified from the "hyperthermophiles", e.g., from *M. jannaschii*, *P. furiosus* and *P. woesei*. See U.S. Pat. No. 5,843,669, hereby incorporated by reference.

According to the methods of the present invention, the addition of FEN-1 in the amplification reaction dramatically increases the efficiency of PCR amplification. 400 ng to 4000 ng of FEN-1 may be used in each amplification reaction.

Preferably 400-1000 ng, more preferably, 400-600 ng of FEN-1 is used in the amplification reaction. In a preferred embodiment of the invention, 400 ng FEN-1 is used.

As used herein, a "PCR enhancing factor" or a "Polymerase Enhancing Factor" (PEF) refers to a complex or protein possessing polynucleotide polymerase enhancing activity including, but not limited to, PCNA, RFC, helicases etc (Hogrefe et al., 1997, Strategies 10:93-96; and U.S. Pat. No. 6,183,997, both of which are hereby incorporated by reference).

Amino acid residues identified herein are preferred in the natural L-configuration. In keeping with standard polypeptide nomenclature, J. Biol. Chem., 243:3557-3559, 1969, abbreviations for amino acid residues are as shown in the following Table I.

TABLE I

1-Letter	3-Letter	AMINO ACID
Y	Tyr	L-tyrosine
G	Gly	glycine
F	Phe	L-phenylalanine
M	Met	L-methionine
A	Ala	L-alanine
S	Ser	L-serine
I	Ile	L-isoleucine
L	Leu	L-leucine
T	Thr	L-threonine
V	Val	L-valine
P	Pro	L-proline
K	Lys	L-lysine
H	His	L-histidine
Q	Gln	L-glutamine
E	Glu	L-glutamic acid
W	Trp	L-tryptophan
R	Arg	L-arginine
D	Asp	L-aspartic acid
N	Asn	L-asparagine
C	Cys	L-cysteine

Misincorporation, base deamination and other base modifications greatly increase as a consequence of PCR reaction conditions, for example, elevated temperature. This results in the progressive accumulation of base analogs (for example uracil or inosine) in the PCR reaction that ultimately inhibit Archaeal proofreading DNA polymerases, such as Pfu, Vent and Deep Vent DNA polymerases, severely limiting their processivity and/or efficiency.

The present invention provides a remedy to the above problem of PCR reactions by disclosing compositions for Archaeal DNA polymerase mutants which increase PCR amplification processivity and/or efficiency and there uses thereof in PCR, including quantitative PCR and quantitative RT-PCR.

The mutant Archaeal DNA polymerases of the invention may provide for the use of fewer units of polymerase, may allow assays to be done using shorter extension times and/or may provide greater success in achieving higher yields and or longer products.

Archaeal DNA Polymerases

There are 2 different classes of DNA polymerases which have been identified in archaea: 1. Family B/pol I type (homologs of Pfu from *Pyrococcus furiosus*) and 2. pol II type (homologs of *P. furiosus* DP1/DP2 2-subunit polymerase). DNA polymerases from both classes have been shown to naturally lack an associated 5' to 3' exonuclease activity and to possess 3' to 5' exonuclease (proofreading) activity. Suitable DNA polymerases (pol I or pol II) can be derived from archaea with optimal growth temperatures that are similar to the desired assay temperatures.

15

Thermostable Archaeal DNA polymerases include, but are not limited to polymerases isolated from *Pyrococcus* species (*furiosus*, species GB-D, *woesii*, *abyssi*, *horikoshii*), *Thermococcus* species (*kodakaraensis* KOD 1, *litoralis*, species 9 degrees North-7, species JDF-3, *gorgonarius*), *Pyrodicticum occultum*, and *Archaeoglobus fulgidus*. It is estimated that suitable archaea would exhibit maximal growth temperatures of >80-85° C. or optimal growth temperatures of >70-80° C. Appropriate PCR enzymes from the Archaeal pol I DNA polymerase group are commercially available, including Pfu (Stratagene), KOD (Toyobo), Pfx (Life Technologies, Inc.), 9°N-7 (New England Biolabs, Inc), Vent (Tli) (New England Biolabs), Deep Vent (PGB-D) (New England Biolabs), Afu from *Archaeoglobus fulgidus* (e.g., Chalov et al., 2002, Dokl Biochem Biophys. 382:53-5), Mvo (Konisky et al., 1994, J. Bacteriol. 176: 6402-6403), D'Tok (Bergseid, M., Scott, B. R., Mathur, S., Nielson, K. B., Shoemaker, D., Mathur, E. J. 1992, Strategies 5, 50), Pis (Kahler et al., 2000, J. Bacteriol. 182 655-663), Csy (Schleperet al., 1998, J. Bacteriol. 180 (19), 5003-5009), Sac (Datukishvili et al., 1996, Gene 177 (1-2), 271-273), Soh (Iwai et al., 2000, DNA Res. 7 (4), 243-251), Sso (Pisani et al., 1992, Nucleic Acids Res. 20 (11), 2711-2716), Poc (Uemori et al., 1995, J. Bacteriol. 177 (8), 2164-2177), Ape (Kawarabayasi et al., 1999, DNA Res. 6 (2), 83-101), Tgo (Roche), and Pwo (Roche).

Additional Archaeal DNA polymerases related to those listed above are described in table 1 and in the following references: Archaea: A Laboratory Manual (Robb, F. T. and Place, A. R., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1995 and *Thermophilic Bacteria* (Kristjansson, J. K., ed.) CRC Press, Inc., Boca Raton, Fla., 1992.

The invention therefore provides for thermostable Archaeal DNA polymerases of either Family B/pol I type or pol II type with a reduced base analog detection activity.

TABLE II

Protein sequences for Archaeal DNA polymerases as represented by their accession numbers. Polynucleotide coding sequences can be found in references or nucleotide accession numbers identified in the Genbank database through the protein sequence accession numbers.	
Vent	<i>Thermococcus litoralis</i>
ACCESSION	AAA72101
PID	g348689
VERSION	AAA72101.1 GI: 348689
DBSOURCE	locus THCVDPF accession M74198.1
THEST	<i>THERMOCOCCUS</i> SP. (STRAIN TY)
ACCESSION	O33845
PID	g3913524
VERSION	O33845 GI: 3913524
DBSOURCE	swissprot: locus DPOL__THEST, accession O33845
Pab	<i>Pyrococcus abyssi</i>
ACCESSION	P77916
PID	g3913529
VERSION	P77916 GI: 3913529
DBSOURCE	swissprot: locus DPOL__PYRAB, accession P77916
PYRHO	<i>Pyrococcus horikoshii</i>
ACCESSION	O59610
PID	g3913526
VERSION	O59610 GI: 3913526
DBSOURCE	swissprot: locus DPOL__PYRHO, accession O59610
PYRSE	<i>PYROCOCCUS</i> SP. (STRAIN GE23)
ACCESSION	P77932
PID	g3913530
VERSION	P77932 GI: 3913530
DBSOURCE	swissprot: locus DPOL__PYRSE, accession P77932
DeepVent	<i>Pyrococcus</i> sp.
ACCESSION	AAA67131
PID	g436495
VERSION	AAA67131.1 GI: 436495

16

TABLE II-continued

Protein sequences for Archaeal DNA polymerases as represented by their accession numbers. Polynucleotide coding sequences can be found in references or nucleotide accession numbers identified in the Genbank database through the protein sequence accession numbers.	
DBSOURCE	locus PSU00707 accession U00707.1
Pfu	<i>Pyrococcus furiosus</i>
ACCESSION	P80061
PID	g399403
VERSION	P80061 GI: 399403
DBSOURCE	swissprot: locus DPOL__PYRFU, accession P80061
JDF-3	<i>Thermococcus</i> sp.
Unpublished	Baross gii2097756 pat US 5602011 12 Sequence 12 from patent U.S. Pat. No. 5602011
9degN	<i>THERMOCOCCUS</i> SP. (STRAIN 9°N-7).
ACCESSION	Q56366
PID	g3913540
VERSION	Q56366 GI: 3913540
DBSOURCE	swissprot: locus DPOL__THES9, accession Q56366
KOD	<i>Pyrococcus</i> sp.
ACCESSION	BAA06142
PID	g1620911
VERSION	BAA06142.1 GI:1620911
DBSOURCE	locus PYWKODPOL accession D29671.1
Tgo	<i>Thermococcus gorgonarius</i> .
ACCESSION	4699806
PID	g4699806
VERSION	GI:4699806
DBSOURCE	pdb: chain 65, release Feb 23, 1999
THEFM	<i>Thermococcus fumicolans</i>
ACCESSION	P74918
PID	g3913528
VERSION	P74918 GI:3913528
DBSOURCE	swissprot: locus DPOL__THEFM, accession P74918
METTH	<i>Methanobacterium thermoautotrophicum</i>
ACCESSION	O27276
PID	g3913522
VERSION	O27276 GI:3913522
DBSOURCE	swissprot: locus DPOL__METTH, accession O27276
Metja	<i>Methanococcus jannaschii</i>
ACCESSION	Q58295
PID	g3915679
VERSION	Q58295 GI:3915679
DBSOURCE	swissprot: locus DPOL__METJA, accession Q58295
POC	<i>Pyrodicticum occultum</i>
ACCESSION	B56277
PID	g1363344
VERSION	B56277 GI:1363344
DBSOURCE	pir: locus B56277
Apel	<i>Aeropyrum pernix</i>
ACCESSION	BAA81109
PID	g5105797
VERSION	BAA81109.1 GI:5105797
DBSOURCE	locus AP000063 accession AP000063.1
ARCFU	<i>Archaeoglobus fulgidus</i>
ACCESSION	O29753
PID	g3122019
VERSION	O29753 GI:3122019
DBSOURCE	swissprot: locus DPOL__ARCFU, accession O29753
<i>Desulfurococcus</i> sp. Tok.	
ACCESSION	6435708
PID	g6435708
VERSION	GT:6435708
9oN-7	
ACCESSION	Q56366
VERSION	Q56366 GI:3913540
Afu	
ACCESSION	O29753
VERSION	O29753 GI:3122019
Mvo	
ACCESSION	P52025
VERSION	P52025 GI:1706513
ACCESSION	AAF27815
VERSION	AAF27815.1 GI:6752664
Csy	
ACCESSION	AAC62712

TABLE II-continued

Protein sequences for Archaeal DNA polymerases as represented by their accession numbers. Polynucleotide coding sequences can be found in references or nucleotide accession numbers identified in the Genbank database through the protein sequence accession numbers.	
VERSION	AAC62712.1 GI:3599407
Sac	
ACCESSION	P95690
VERSION	P95690 GI:3913538
Soh	
ACCESSION	BAA23994
VERSION	BAA23994.1 GI:2696625
Sso	
ACCESSION	P26811
VERSION	P26811 GI:12643274

Mutant DNA Polymerases

3'-5' Exonuclease Deficient

In one embodiment, the mutant DNA polymerase is a mutant with deficient 3'-5' exonuclease activity.

DNA polymerases lacking 3'-5' exonuclease (proofreading) activity are preferred for applications requiring nucleotide analog incorporation (e.g., DNA sequencing) to prevent removal of nucleotide analogs after incorporation. The 3'-5' exonuclease activity associated with proofreading DNA polymerases can be reduced or abolished by mutagenesis. Sequence comparisons have identified three conserved motifs (exo I (DXE), II (NX₂₋₃(F/Y)D), III (YX₃D)) in the 3'-5' exonuclease domain of DNA polymerases (reviewed V. Derbyshire, J. K. Pinsonneault, and C. M. Joyce, *Methods Enzymol.* 262, 363 (1995)). For example, replacement of any of the conserved aspartic or glutamic acid residues with alanine has been shown to abolish the exonuclease activity of numerous DNA polymerases, including Archaeal DNA polymerases such as Vent (H. Kong, R. B. Kucera, and W. E. Jack, *J. Biol. Chem.* 268, 1965 (1993)) and Pfu (Stratagene, unpublished). It is understood, according to the present invention, that other amino acids within or outside the exonuclease motifs may also be mutated to render the DNA polymerase deficient in 3'-5' exonuclease activity (e.g., by affecting the tertiary structure of the exonuclease domain). Conservative substitutions lead to reduced exonuclease activity, as shown for mutants of the Archaeal 9° N-7 DNA polymerase (M. W. Southworth, H. Kong, R. B. Kucera, J. Ware, H. Jannasch, and F. B. Perler, *Proc. Natl. Acad. Sci.* 93, 5281 (1996)).

In one embodiment, a 3'-5' exonuclease deficient JDF-3, KOD, or Pfu DNA polymerase is produced.

In one embodiment of the invention, the mutant DNA polymerase contains a mutation at a position corresponding to D141 and/or E143 of JDF-3 DNA polymerase.

JDF-3 DNA polymerase mutants exhibiting substantially reduced 3'-5' exonuclease activity (e.g., with one or more mutations as D141A, D141N, D141S, D141T, D141E and E143A) were prepared by introducing amino acid substitutions at the conserved 141D or 143E residues in the exo I domain, as described in U.S. patent application with Ser. No. 10/223,650, hereby incorporated by reference.

It is appreciated that one skilled in the art would be able to make an Archaeal DNA polymerase with deficient 3'-5' exonuclease activity by comparing the sequence of the Archaeal DNA polymerase with the sequence of JDF-3 DNA polymerase and by mutating the amino acids within the corresponding conserved exo I, II, or III motifs. In addition, it is also appreciated that one skilled in the art would be able to make an Archaeal DNA polymerase with deficient 3'-5' exo-

nuclease activity by mutating one or more amino acid within the corresponding exo I, II, and III motifs.

Assays for DNA polymerase activity and 3'-5' exonuclease activity can be found in *DNA Replication 2nd Ed.*, Kornberg and Baker, supra; *Enzymes*, Dixon and Webb, Academic Press, San Diego, Calif. (1979), as well as other publications available to the person of ordinary skill in the art.

Suitable exonuclease activity assays include one described in Hogrefe et al (Hogrefe et al. 2001, *Methods in Enzymology*, 343:91-116, incorporated by reference). Another assay employs double-stranded λ DNA, which has been uniformly labeled with ³H S-adenosyl methionine (NEN #NET-155) and Sss I methylase (NEB), and then restriction digested with Pst I (Kong et al., 1993, *J. Biol. Chem.* 268:1965). Using double-stranded labeled DNA templates, one can determine specificity by measuring whether cpm's decrease (3'-5' exonuclease) with the addition of dNTPs (10-100 μ M). A typical exonuclease reaction cocktail consists of 1 $\times$ reaction buffer and 20 μ g/ml ³H-labeled digested double-stranded λ DNA (~10⁶ cpm's/ml), prepared as described (Kong et al., supra). Exonuclease activity can be measured in the appropriate PCR buffer or in a universal assay buffer such as 70 mM Tris HCl (pH 8.8), 2 mM MgCl₂, 0.1% Triton-X, and 100 μ g/ml BSA.

Percent exonuclease activity can be determined as: (corrected cpm's for mutants)/(corrected cpm's for wt DNA polymerase). To more precisely quantify % activity, cpm's released can be converted into units of exonuclease activity. One unit of exonuclease activity is defined as the amount of enzyme that catalyzes the acid-solubilization of 10 nmoles of total dNMPs in 30 minutes at a defined temperature. To determine units, background (average "minimum cpm's" value) is first subtracted from the average sample cpm's. Nmoles dNMPs released is calculated using the following equation:

$$\frac{(\text{corrected sample cpm's})}{\text{total cpm's}} \times \frac{(\text{ng DNA})}{\text{reaction}} \times \frac{(1 \text{ nmole dNMP})}{(330 \text{ ng dNMP})}$$

Units of exonuclease activity (in 30 minutes) can then be determined as:

$$\frac{(\text{nmoles dNMPs released per hr})}{2} \times \frac{(1 \text{ unit})}{(10 \text{ nmoles dNMPs released})}$$

Exonuclease specific activity (U/mg) can be extrapolated from the slope of the linear portion of units versus enzyme amount plots. Finally, % activity can be determined as:

$$\frac{\text{specific exonuclease activity} \\ (\text{U/mg}) \text{ of mutant DNA polymerase}}{\text{specific exonuclease activity (U/mg)} \\ \text{of wt DNA polymerase}}$$

In addition to the substrate described above, exonuclease activity can be also be quantified using [³H]-*E. coli* genomic DNA (NEN #NET561; 5.8 μ Ci/ μ g), a commercially-available substrate. A typical exonuclease reaction cocktail consists of 25 ng/ml ³H-labeled *E. coli* genomic DNA and 975 ng/ml cold *E. coli* genomic DNA in 1 $\times$ reaction buffer. Assays are performed as described above.

Reduced Uracil Base Detection

In one embodiment of the invention, the Archaeal polymerase is a mutant polymerase having reduced uracil base detection.

Examination of Archaeal DNA polymerases revealed the presence of a distinct "pocket" located on a surface-exposed face toward the outer edge of the polymerases (Fogg, et al., 2002, *Nature structural Biology*, 9:922-927, hereby incorporated by reference in its entirety). The pocket is formed entirely by residues from four conserved segments in the Archaeal DNA polymerase sequences. Corresponding to Pfu DNA polymerase sequence, the base of the pocket is formed by the main chain and side chains of amino acids Pro36, Tyr 37, and Ile 38, one face of the pocket is formed by amino acids 90-97, another face is formed by residues 111-116, and by Pro 115.

An wild type Archaeal DNA polymerase or an Archaeal DNA polymerase with deficient 3'-5' exonuclease activity may be mutated at or more amino acid positions corresponding to Pro36, Tyr 37, Ile 38, amino acids 90-97, residues 111-116, and Pro 115 in wild type Pfu DNA polymerase, e.g., as described in U.S. patent application with Ser. No. 10/408,601, filed Apr. 7, 2003, hereby incorporated by reference in its entirety.

In one embodiment of the invention, the mutant DNA polymerase is encoded by a polynucleotide sequence selected from SEQ ID Nos 17-24, wherein the codon encoding amino acid residue Valine at position 93 is replaced by the one of the following codons:

Codons encoding Arginine: AGA, AGG, CGA, CGC, CGG, CGT
Codons encoding Glutamic acid: GAA, GAG
Codons encoding Aspartic acid: GAT, GAC
Codons encoding Lysine: AAA, AAG
Codons encoding Glutamine: CAA, CAG
Codons encoding Asparagine AAC, AAU

In one embodiment, a mutant DNA polymerase has an amino acid sequence selected from the sequences of SEQ ID NOS: 27-34, wherein Valine at position 93 is replaced by one of Arginine, Glutamic acid, Aspartic acid, Lysine, Glutamine, and Asparagine.

Alternatively, the mutant DNA polymerase may be a Pfu DNA polymerase having a deletion of Valine at position 93 as shown in SEQ ID NO: 35, or alternatively, having a deletion of Aspartic acid at position 92, Valine at position 93, and Proline at position 94 as shown in SEQ ID NO: 36. Similarly, the mutant DNA polymerase may be a Pfu DNA polymerase having a deletion of the codon GTT encoding Valine at position 93 as shown in SEQ ID NO: 25, or alternatively having a deletion of the successive codons GAT, GTT, and CCC which encode residues Aspartic acid, Valine, and Proline at positions 92, 93, and 94 respectively as shown in SEQ ID NO: 26.

In one embodiment, a Pfu, KOD or JDF-3 DNA polymerase mutants exhibiting substantially reduced 3'-5' exonuclease activity (e.g., with one or more mutations as D141A, D141N, D141S, D141T, D141E and E143A) are mutated to further comprise one or more mutations at corresponding positions to Pro36, Tyr 37, Ile 38, amino acids 90-97, residues 111-116, and Pro 115 of wild type Pfu DNA polymerase.

The present invention encompass making an Archaeal DNA polymerase with reduced uracil base detection by comparing the sequence of the Archaeal DNA polymerase with the sequence of Pfu DNA polymerase and by mutating the amino acids within the corresponding conserved residues within the pocket forming amino acids. In addition, one skilled in the art would be able to make an Archaeal DNA

polymerase with reduced uracil base detection by mutating one or more amino acid within these amino acid positions. Increased Reverse Transcriptase Activity

Amino acid changes at the position corresponding to L408 of JDF-3 Family B DNA polymerase which lead to increased reverse transcriptase activity tend to introduce cyclic side chains, such as phenylalanine, tryptophan, histidine or tyrosine as described in U.S. patent application with Ser. No. 10/435,766, hereby incorporated by reference. While the amino acids with cyclic side chains are demonstrated herein to increase the reverse transcriptase activity of Archaeal Family B DNA polymerases, other amino acid changes at the LYP motif are contemplated to have effects on the reverse transcriptase activity. Thus, in order to modify the reverse transcriptase activity of another Archaeal Family B DNA polymerase, one would first look to modify the LYP motif of Region II, particularly the L or other corresponding amino acid of the LYP motif, first substituting cyclic side chains and assessing reverse transcriptase activity relative to wild-type as disclosed herein below in "Methods of Evaluating Mutants for Increased RT Activity." If necessary or if desired, one can subsequently modify the same position in the LYP motif with additional amino acids and similarly assess the effect on activity. Alternatively, or in addition, one can modify the other positions in the LYP motif and similarly assess the reverse transcriptase activity.

Methods for assaying reverse transcriptase (RT) activity based on the RNA-dependent synthesis of DNA have been well known in the art, e.g., as described in U.S. Pat. No. 3,755,086; Poiesz et al., (1980) *Proc. Natl. Acad. Sci. USA*, 77: 1415; Hoffman et al., (1985) *Virology* 147: 326; all hereby incorporated by reference.

Recently, highly sensitive PCR based assays have been developed that can detect RNA-dependent DNA polymerase in the equivalent of one to ten particles (Silver et al. (1993) *Nucleic Acids Res.* 21: 3593-4; U.S. Pat. No. 5,807,669). One such assay, designated as PBRT (PCR-based reverse transcriptase), has been used to detect RT activity in a variety of samples (Pyra et al. (1994) *Proc. Natl. Acad. Sci. USA* 51: 1544-8; Boni, et al. (1996) *J. Med. Virol.* 49: 23-28). This assay is 10^6 - 10^7 more sensitive than the conventional RT assay.

Other useful RT assays include, but are not limited to, one-step fluorescent probe product-enhanced reverse transcriptase assay described in Hepler, R. W., and Keller, P. M. (1998). *Biotechniques* 25(1), 98-106; an improved product enhanced reverse transcriptase assay described in Chang, A., Ostrove, J. M., and Bird, R. E. (1997) *J Virol Methods* 65(1), 45-54; an improved non-radioisotopic reverse transcriptase assay described in Nakano et al., (1994) *Kansenshogaku Zasshi* 68(7), 923-31; a highly sensitive qualitative and quantitative detection of reverse transcriptase activity as described in Yamamoto, S., Folks, T. M., and Heneine, W. (1996) *J Virol Methods* 61(1-2), 135-43, all references hereby incorporated by reference.

RT activity can be measured using radioactive or non-radioactive labels.

In one embodiment, 1 μ l of appropriately purified DNA polymerase mutant or diluted bacterial extract (i.e., heat-treated and clarified extract of bacterial cells expressing a cloned polymerase or mutated cloned polymerase) is added to 10 μ l of each nucleotide cocktail (200 μ M dATP, 200 μ M dGTP, 200 μ M dCTP and 5 μ Ci/ml α - 32 P dCTP and 200 μ M dTTP, a RNA template, 1 $\times$ appropriate buffer, followed by incubation at the optimal temperature for 30 minutes (e.g., 72 $^{\circ}$ C. for Pfu DNA polymerase), for example, as described in Hogrefe et al., 2001, *Methods in Enzymology*, 343:91-116.

Extension reactions are then quenched on ice, and 5 µl aliquots are spotted immediately onto DE81 ion-exchange filters (2.3 cm; Whatman #3658323). Unincorporated label is removed by 6 washes with 2×SCC (0.3M NaCl, 30 mM sodium citrate, pH 7.0), followed by a brief wash with 100% ethanol. Incorporated radioactivity is then measured by scintillation counting. Reactions that lack enzyme are also set up along with sample incubations to determine “total cpms” (omit filter wash steps) and “minimum cpms” (wash filters as above). Cpms bound is proportional to the amount of RT activity present per volume of bacterial extract or purified DNA polymerase.

In another embodiment, the RT activity is measured by incorporation of non-radioactive digoxigenin labeled dUTP into the synthesized DNA and detection and quantification of the incorporated label essentially according to the method described in Holtke, H.-J.; Sagner, G; Kessler, C. and Schmitz, G. (1992) *Biotechniques* 12, 104-113. The reaction is performed in a reaction mixture consists of the following components: 1 µg of polydA-(dT)₁₅, 33 µM of dTTP, 0.36 µM of labeled-dUTP, 200 mg/ml BSA, 10 mM Tris-HCl, pH 8.5, 20 mM KCl, 5 mM MgCl₂, 10 mM DTE and various amounts of DNA polymerase. The samples are incubated for 30 min. at 50° C., the reaction is stopped by addition of 2 µl 5 M EDTA, and the tubes placed on ice. After addition of 8 µl 5 M NaCl and 150 µl of Ethanol (precooled to -20° C.) the DNA is precipitated by incubation for 15 min on ice and pelleted by centrifugation for 10 min at 13000×rpm and 4° C. The pellet is washed with 100 µl of 70% Ethanol (precooled to -20° C.) and 0.2 M NaCl, centrifuged again and dried under vacuum.

The pellets are dissolved in 50 µl Tris-EDTA (10 mM/0.1 mM; pH 7.5). 5 µl of the sample are spotted into a well of a nylon membrane bottomed white microwave plate (Pall Filtrationstechnik GmbH, Dreieich, FRG, product no: SM045BWP). The DNA is fixed to the membrane by baking for 10 min. at 70° C. The DNA loaded wells are filled with 100 µl of 0.45 µm-filtrated 1% blocking solution (100 mM maleic acid, 150 mM NaCl, 1% (w/v) casein, pH 7.5). All following incubation steps are done at room temperature. After incubation for 2 min. the solution is sucked through the membrane with a suitable vacuum manifold at -0.4 bar. After repeating the washing step, the wells are filled with 100 µl of a 1:10,000-dilution of Anti-digoxigenin-AP, Fab fragments (Boehringer Mannheim, FRG, no: 1093274) diluted in the above blocking solution. After incubation for 2 min. and sucking this step is repeated once. The wells are washed twice under vacuum with 200 µl each time washing-buffer 1 (100 mM maleic-acid, 150 mM NaCl, 0.3%(v/v) TweenTM. 20, pH 7.5). After washing another two times under vacuum with 200 µl each time washing-buffer 2 (10 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl₂, pH 9.5) the wells are incubated for 5 min with 50 µl of CSPDTM (Boehringer Mannheim, no: 1655884), diluted 1:100 in washing-buffer 2, which serves as a chemiluminescent substrate for the alkaline phosphatase. The solution is sucked through the membrane and after 10 min incubation the RLU/s (Relative Light Unit per second) are detected in a Luminometer e.g. MicroLumat LB 96 P (EG&G Berthold, Wilbad, FRG). With a serial dilution of Taq DNA polymerase a reference curve is prepared from which the linear range serves as a standard for the activity determination of the DNA polymerase to be analyzed.

U.S. Pat. No. 6,100,039 (incorporated hereby by reference) describes another useful process for detecting reverse transcriptase activity using fluorescence polarization: the reverse transcriptase activity detection assays are performed using a BeaconTM 2000 Analyzer. The following reagents are purchased from commercial sources: fluorescein-labeled oligo

dA-F (Bio.Synthesis Corp., Lewisville, Tex.), AMV Reverse Transcriptase (Promega Corp., Madison, Wis.), and Polyadenylic Acid Poly A (Pharmacia Biotech, Milwaukee, Wis.). The assay requires a reverse transcriptase reaction step followed by a fluorescence polarization-based detection step. The reverse transcriptase reactions are completed using the directions accompanying the kit. In the reaction 20 ng of Oligo (dT) were annealed to 1 µg of Poly A at 70° C. for 5 minutes. The annealed reactions are added to an RT mix containing RT buffer and dTTP nucleotides with varying units of reverse transcriptase (30, 15, 7.5, 3.8, and 1.9 Units/Rxn). Reactions are incubated at 37° C. in a water bath. 5 µl aliquots are quenched at 5, 10, 15, 20, 25, 30, 45, and 60 minutes by adding the aliquots to a tube containing 20 µl of 125 mM NaOH. For the detection step, a 75 µl aliquot of oligo dA-F in 0.5 M Tris, pH 7.5, is added to each quenched reaction. The samples are incubated for 10 minutes at room temperature. Fluorescence polarization in each sample was measured using the BeaconTM 2000 Analyzer.

Additional Mutations

The mutant DNA polymerase of the present invention may contain additional mutations.

In one embodiment, the mutant DNA polymerase of the present invention contains a mutation which reduces its analog discrimination activity as described in U.S. application with Ser. No. 10/223,650, hereby incorporated by reference in its entirety.

In another embodiment, the mutant DNA polymerase of the present invention contains a mutation which reduces its polymerization activity as described in U.S. patent application with Ser. No. Ser. No. 10/227,110, hereby incorporated by reference.

In another embodiment, the mutant DNA polymerase of the present invention is a chimeric protein, e.g., as described in U.S. patent application with Ser. No. 10/324,846, hereby incorporated by reference in its entirety.

In another embodiment, the mutant DNA polymerase of the present invention also contains a mutation which increases the RT activity.

Preparing Mutant DNA Polymerase

Cloned wild-type DNA polymerases may be modified to generate forms exhibiting deficient 3'-5' exonuclease and/or reduced base analog detection activity (as well as other modified activities) by a number of methods. These include the methods described below and other methods known in the art. Any proofreading Archaeal DNA polymerase can be used to prepare for DNA polymerase with reduced base analog detection activity in the invention.

Genetic Modifications-Mutagenesis

Direct comparison of DNA polymerases from diverse organisms indicates that the domain structure of these enzymes is highly conserved and in many instances, it is possible to assign a particular function to a well-defined domain of the enzyme. The conserved exo motifs and the uracil pocket among the Archaeal DNA polymerases provide a useful model to direct genetic modifications for preparing DNA polymerase with desired activity.

The preferred method of preparing a DNA polymerase with desired activity, e.g., deficient 3'-5' exo activity and/or reduced base analog detection activity is by genetic modification (e.g., by modifying the DNA sequence of a wild-type DNA polymerase, or a mutant DNA polymerase). A number of methods are known in the art that permit the random as well as targeted mutation of DNA sequences (see for example, Ausubel et. al. *Short Protocols in Molecular Biology* (1995) 3rd Ed. John Wiley & Sons, Inc.). In addition, there are a number of commercially available kits for site-directed

mutagenesis, including both conventional and PCR-based methods. Examples include the EXSITE™ PCR-Based Site-directed Mutagenesis Kit available from Stratagene (Catalog No. 200502) and the QUIKCHANGE™ Site-directed mutagenesis Kit from Stratagene (Catalog No. 200518), and the CHAMELEON® double-stranded Site-directed mutagenesis kit, also from Stratagene (Catalog No. 200509).

In addition DNA polymerases with deficient 3'-5' exo activity and/or reduced base analog detection activity may be generated by insertional mutation or truncation (N-terminal, internal or C-terminal) according to methodology known to a person skilled in the art.

Older methods of site-directed mutagenesis known in the art rely on sub-cloning of the sequence to be mutated into a vector, such as an M13 bacteriophage vector, that allows the isolation of single-stranded DNA template. In these methods, one anneals a mutagenic primer (i.e., a primer capable of annealing to the site to be mutated but bearing one or mismatched nucleotides at the site to be mutated) to the single-stranded template and then polymerizes the complement of the template starting from the 3' end of the mutagenic primer. The resulting duplexes are then transformed into host bacteria and plaques are screened for the desired mutation.

More recently, site-directed mutagenesis has employed PCR methodologies, which have the advantage of not requiring a single-stranded template. In addition, methods have been developed that do not require sub-cloning. Several issues must be considered when PCR-based site-directed mutagenesis is performed. First, in these methods it is desirable to reduce the number of PCR cycles to prevent expansion of undesired mutations introduced by the polymerase. Second, a selection must be employed in order to reduce the number of non-mutated parental molecules persisting in the reaction. Third, an extended-length PCR method is preferred in order to allow the use of a single PCR primer set. And fourth, because of the non-template-dependent terminal extension activity of some thermostable polymerases it is often necessary to incorporate an end-polishing step into the procedure prior to blunt-end ligation of the PCR-generated mutant product.

The protocol described below accommodates these considerations through the following steps. First, the template concentration used is approximately 1000-fold higher than that used in conventional PCR reactions, allowing a reduction in the number of cycles from 25-30 down to 5-10 without dramatically reducing product yield. Second, the restriction endonuclease Dpn I (recognition target sequence: 5-Gm6ATC-3, where the A residue is methylated) is used to select against parental DNA, since most common strains of *E. coli* Dam methylate their DNA at the sequence 5-GATC-3. Third, Taq Extender is used in the PCR mix in order to increase the proportion of long (i.e., full plasmid length) PCR products. Finally, Pfu DNA polymerase is used to polish the ends of the PCR product prior to intramolecular ligation using T4 DNA ligase.

A non-limiting example for the isolation of mutant Archaeal DNA polymerases exhibiting reduced uracil detection activity is described in detail as follows:

Plasmid template DNA (approximately 0.5 pmole) is added to a PCR cocktail containing: 1× mutagenesis buffer (20 mM Tris HCl, pH 7.5; 8 mM MgCl₂; 40 µg/ml BSA); 12-20 pmole of each primer (one of skill in the art may design a mutagenic primer as necessary, giving consideration to those factors such as base composition, primer length and intended buffer salt concentrations that affect the annealing characteristics of oligonucleotide primers; one primer must contain the desired mutation, and one (the same or the other)

must contain a 5' phosphate to facilitate later ligation), 250 µM each dNTP, 2.5 U Taq DNA polymerase, and 2.5 U of Taq Extender (Available from Stratagene; See Nielson et al. (1994) Strategies 7: 27, and U.S. Pat. No. 5,556,772). Primers can be prepared using the triester method of Matteucci et al., 1981, J. Am. Chem. Soc. 103:3185-3191, incorporated herein by reference. Alternatively automated synthesis may be preferred, for example, on a Biosearch 8700 DNA Synthesizer using cyanoethyl phosphoramidite chemistry.

The PCR cycling is performed as follows: 1 cycle of 4 min at 94° C., 2 min at 50° C. and 2 min at 72° C; followed by 5-10 cycles of 1 min at 94° C, 2 min at 54° C. and The parental template DNA and the linear, PCR-generated DNA incorporating the mutagenic primer are treated with DpnI (10 U) and Pfu DNA polymerase (2.5 U). This results in the DpnI digestion of the in vivo methylated parental template and hybrid DNA and the removal, by Pfu DNA polymerase, of the non-template-directed Taq DNA polymerase-extended base(s) on the linear PCR product. The reaction is incubated at 37° C. for 30 min and then transferred to 72° C. for an additional 30 min. Mutagenesis buffer (115 µl of 1×) containing 0.5 mM ATP is added to the DpnI-digested, Pfu DNA polymerase-polished PCR products. The solution is mixed and 10 µl are removed to a new microfuge tube and T4 DNA ligase (2-4 U) is added. The ligation is incubated for greater than 60 min at 37° C. Finally, the treated solution is transformed into competent *E. coli* according to standard methods.

Methods of random mutagenesis, which will result in a panel of mutants bearing one or more randomly situated mutations, exist in the art. Such a panel of mutants may then be screened for those exhibiting reduced uracil detection activity relative to the wild-type polymerase (e.g., by measuring the incorporation of 10 nmoles of dNTPs into polymeric form in 30 minutes in the presence of 200 µM dUTP and at the optimal temperature for a given DNA polymerase). An example of a method for random mutagenesis is the so-called "error-prone PCR method". As the name implies, the method amplifies a given sequence under conditions in which the DNA polymerase does not support high fidelity incorporation. The conditions encouraging error-prone incorporation for different DNA polymerases vary, however one skilled in the art may determine such conditions for a given enzyme. A key variable for many DNA polymerases in the fidelity of amplification is, for example, the type and concentration of divalent metal ion in the buffer. The use of manganese ion and/or variation of the magnesium or manganese ion concentration may therefore be applied to influence the error rate of the polymerase.

Genes for desired mutant DNA polymerases generated by mutagenesis may be sequenced to identify the sites and number of mutations. For those mutants comprising more than one mutation, the effect of a given mutation may be evaluated by introduction of the identified mutation to the wild-type gene by site-directed mutagenesis in isolation from the other mutations borne by the particular mutant. Screening assays of the single mutant thus produced will then allow the determination of the effect of that mutation alone.

A person of average skill in the art having the benefit of this disclosure will recognize that polymerases with deficient 3'-5' exo activity and/or reduced uracil detection derived from JDF-3 or PFU or other exo+DNA polymerases including Vent DNA polymerase, JDF-3 DNA polymerase, Tgo DNA polymerase, and the like may be suitably used in the subject compositions.

In one embodiment, the invention provides DNA polymerase selected from Pfu, Tgo, JDF-3 and KOD comprising

one or more mutations at V93, and which demonstrate reduced uracil detection activity.

In another embodiment, the invention provides DNA polymerase selected from Pfu, Tgo, JDF-3 and KOD comprising one or more mutations at D141 and/or E143, which is deficient in 3'-5' exonuclease activity.

In another embodiment, the invention provides DNA polymerase selected from Pfu, Tgo, JDF-3 and KOD comprising one or more mutations at V93, and which demonstrate reduced uracil detection activity, and further comprising one or more mutations at D141 and/or E143, which is deficient in 3'-5' exonuclease activity.

In another embodiment, the invention provides DNA polymerase selected from Pfu, Tgo, JDF-3 and KOD comprising one or more mutations at V93, and which demonstrate reduced uracil detection activity, and further comprising one or more mutations at D141 and/or E143, which is deficient in 3'-5' exonuclease activity, as well as a mutation at L408, which has an increased reverse transcriptase activity.

The enzyme of the subject composition may comprise DNA polymerases that have not yet been isolated.

In preferred embodiments of the invention, the mutant Pfu DNA polymerase harbors an amino acid substitution at amino acid position, V93. In a preferred embodiment, the mutant Pfu DNA polymerase of the invention contains a Valine to Arginine, Valine to Glutamic acid, Valine to Lysine, Valine to Aspartic Acid, or Valine to Asparagine substitution at amino acid position 93.

The invention further provides for mutant Archaeal DNA polymerases with reduced base analog detection activity that contains a Valine to Arginine, Valine to Glutamic acid, Valine to Lysine, Valine to Aspartic Acid, Valine to Glutamine, or Valine to Asparagine substitution at amino acid position 93. In particular, FIG. 6 shows mutant Archaeal DNA polymerases of the invention with reduced base analog detection activity.

According to the invention, V93 mutant Pfu DNA polymerases with reduced uracil detection activity may contain one or more additional mutations that reduce or abolish one or more additional activities of V93 Pfu DNA polymerases, e.g., DNA polymerization activity or 3'-5' exonuclease activity. In one embodiment, the V93 mutant Pfu DNA polymerase according to the invention contains one or more mutations that renders the DNA polymerase 3'-5' exonuclease deficient. In another embodiment, the V93 mutant Pfu DNA polymerase according to the invention contains one or more mutations that the DNA polymerization activity of the V93 Pfu DNA polymerase.

In another embodiment, a mutant Archaeal dna polymerase is a chimera that further comprises a polypeptide that increases processivity and/or increases salt resistance. A polypeptide useful according to the invention and methods of preparing chimeras are described in WO 01/92501 A1 and Pavlov et al., 2002, Proc. Natl. Acad. Sci USA, 99:13510-13515. Both references are herein incorporated in their entirety.

The invention provides for V93R mutant Pfu DNA polymerases with reduced uracil detection activity containing one or more mutations that reduce DNA polymerization as disclosed in the pending U.S. patent application Ser. No. 10/035,091 (Hogrefe, et al.; filed: Dec. 21, 2001); the pending U.S. patent application Ser. No. 10/079,241 (Hogrefe, et al.; filed Feb. 20, 2002); the pending U.S. patent application Ser. No. 10/208,508 (Hogrefe et al.; filed Jul. 30, 2002); and the pending U.S. patent application Ser. No. 10/227,110 (Hogrefe et al.; filed Aug. 23, 2002), the contents of which are hereby incorporated in their entirety.

In a preferred embodiment, the invention provides for a V93R/G387P, V93E/G387P, V93D/G387P, V93K/G387P and V93N/G387P double mutant Pfu DNA polymerase with reduced DNA polymerization activity and reduced uracil detection activity.

The invention further provides for V93R, V93E, V93D, V93K and V93N mutant Pfu DNA polymerases with reduced uracil detection activity containing one or mutations that reduce or eliminate 3'-5' exonuclease activity as disclosed in the pending U.S. patent application Ser. No. 09/698,341 (Sorge et al; filed Oct. 27, 2000).

In a preferred embodiment, the invention provides for a V93R/D141A/E143A triple mutant Pfu DNA polymerase with reduced 3'-5' exonuclease activity and reduced uracil detection activity.

The invention further provides for combination of one or more mutations that may increase or eliminate base analog detection activity of an Archaeal DNA polymerase.

DNA polymerases containing additional mutations are generated by site directed mutagenesis using the Pfu DNA polymerase or Pfu V93R cDNA as a template DNA molecule, according to methods that are well known in the art and are described herein.

Methods used to generate Pfu DNA polymerases with reduced DNA polymerization activity are disclosed in the pending U.S. patent application Ser. No. 10/035,091 (Hogrefe, et al.; filed: Dec. 21, 2001); the pending U.S. patent application Ser. No. 10/079,241 (Hogrefe, et al.; filed Feb. 20, 2002); the pending U.S. patent application Ser. No. 10/208,508 (Hogrefe et al.; filed Jul. 30, 2002); and the pending U.S. patent application Ser. No. 10/227,110 (Hogrefe et al.; filed Aug. 23, 2002), the contents of which are hereby incorporated in their entirety.

Methods for generating 3'-5' exonuclease deficient Pfu are disclosed in U.S. Pat. No. 5,489,523, incorporated herein by reference.

Methods used to generate 3'-5' exonuclease deficient JDF-3 DNA polymerases including the D141A and E143A mutations are disclosed in the pending U.S. patent application Ser. No. 09/698,341 (Sorge et al; filed Oct. 27, 2000). A person skilled in the art in possession of the V93 Pfu DNA polymerase cDNA and the teachings of the pending U.S. patent application Ser. No. 09/698,341 (Sorge et al; filed Oct. 27, 2000) would have no difficulty introducing both the corresponding D141A and E143A mutations or other 3'-5' exonuclease mutations into the V93 Pfu DNA polymerase cDNA, as disclosed in the pending U.S. patent application Ser. No. 09/698,341, using established site directed mutagenesis methodology.

Such methods (e.g., for Pfu and JDF-3) can be readily used to generate other 3'-5' exonuclease deficient archaeal DNA polymerase. Sequence alignment techniques are known in the art and are taught herein. One skilled in the art would appreciate the teaching of the present invention and can identify amino acid sequences to mutate by aligning Pfu or JDF-3 sequence with another archaeal DNA polymerase.

Methods of preparing chimeras according to the invention are described in WO 01/92501 A1 and Pavlov et al., 2002, Proc. Natl. Acad. Sci USA, 99:13510-13515. Both references are herein incorporated in their entirety.

In one embodiment, the Pfu mutants are expressed and purified as described in U.S. Pat. No. 5,489,523, hereby incorporated by reference in its entirety.

Methods of Evaluating Mutants for Reduced Base Analog Detection Activity and 3'-5' Exonuclease Activity, etc.

Random or site-directed mutants generated as known in the art or as described herein and expressed in bacteria may be

screened for reduced uracil detection activity by several different assays. Embodiments for the expression of mutant and wild type enzymes is described herein. In one method, *exo*⁺ DNA polymerase proteins expressed in lytic lambda phage plaques generated by infection of host bacteria with expression vectors based on, for example, Lambda ZapII®, are transferred to a membrane support. The immobilized proteins are then assayed for polymerase activity on the membrane by immersing the membranes in a buffer containing a DNA template and the unconventional nucleotides to be monitored for incorporation.

Mutant polymerase libraries may be screened using a variation of the technique used by Sagner et al (Sagner, G., Ruger, R., and Kessler, C. (1991) *Gene* 97:119-123). For this approach, lambda phage clones are plated at a density of 10-20 plaques per square centimeter and replica plated. Proteins present in the plaques are transferred to filters and moistened with polymerase screening buffer (50 mM Tris (pH 8.0), 7 mM MgCl₂, 3 mM β-ME). The filters are kept between layers of plastic wrap and glass while the host cell proteins are heat-inactivated by incubation at 65° C. for 30 minutes. The heat-treated filters are then transferred to fresh plastic wrap and approximately 35 μl of polymerase assay cocktail are added for every square centimeter of filter. The assay cocktail consists of 1× cloned Pfu (cPfu) magnesium free buffer (1× buffer is 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH₄)₂SO₄, 100 μg/ml bovine serum albumin (BSA), and 0.1% Triton X-100; Pfu Magnesium-free buffer may be obtained from Stratagene (Catalog No. 200534)), 125 ng/ml activated calf thymus or salmon sperm DNA, 200 μM dATP, 200 μM dGTP, 200 μM dCTP and 5 μCi/ml α-³²P dCTP and 200 μM dUTP or 200 μM dTTP. The filters, in duplicate, are placed between plastic wrap and a glass plate and then incubated at 65° C. for one hour, and then at 70° C. for one hour and fifteen minutes. Filters are then washed three times in 2×SSC for five minutes per wash before rinsing twice in 100% ethanol and vacuum drying. Filters are then exposed to X-ray film (approximately 16 hours), and plaques that incorporate label in the presence of 200 μM dUTP or 200 μM dTTP are identified by aligning the filters with the original plate bearing the phage clones. Plaques identified in this way are re-plated at more dilute concentrations and assayed under similar conditions to allow the isolation of purified plaques.

In assays such as the one described above, the signal generated by the label is a direct measurement of the polymerization activity of the polymerase in the presence of 200 μM dUTP as compared to the polymerase activity of the same mutant polymerase in the presence of 200 μM dTTP. A plaque comprising a mutant DNA polymerase with reduced uracil detection activity as compared to that of the wild-type enzyme can then be identified and further tested in primer extension assays in which template dependent DNA synthesis is measured in the presence of 200 μM dUTP. For example, 1 μl of appropriately diluted bacterial extract (i.e., heat-treated and clarified extract of bacterial cells expressing a cloned polymerase or mutated cloned polymerase) is added to 10 μl of each nucleotide cocktail (200 μM dATP, 200 μM dGTP, 200 μM dCTP and 5 μCi/ml α-³²P dCTP, ³H-dCTP and 200 μM dUTP or 200 μM dTTP, activated calf thymus DNA, 1× appropriate buffer (see above)), followed by incubation at the optimal temperature for 30 minutes (e.g., 73° C. for Pfu DNA polymerase), for example, as described in Hogrefe et al., 2001, *Methods in Enzymology*, 343:91-116. Extension reactions are then quenched on ice, and 5 μl aliquots are spotted immediately onto DE81 ion-exchange filters (2.3 cm; Whatman #3658323). Unincorporated label is removed by 6 washes with 2×SSC (0.3M NaCl, 30 mM sodium citrate, pH

7.0), followed by a brief wash with 100% ethanol. Incorporated radioactivity is then measured by scintillation counting. Reactions that lack enzyme are also set up along with sample incubations to determine “total cpms” (omit filter wash steps) and “minimum cpms” (wash filters as above). Cpms bound is proportional to the amount of polymerase activity present per volume of bacterial extract. Mutants that can incorporate significant radioactivity in the presence of dUTP are selected for further analysis.

Mutant DNA polymerases with reduced uracil recognition can also be identified as those that can synthesize PCR products in the presence of 100% dUTP (See Example 3).

The “uracil detection” activity can also be determined using the long range primer extension assay on single uracil templates as described by Greagg et al., (1999) *Proc. Natl. Acad. Sci.* 96, 9045-9050. Briefly, the assay requires a 119-mer template that is generated by PCR amplification of a segment of pUC19 spanning the polylinker cloning site. PCR primer sequences are:

A, GACGTTGTAAACGACGGCCAGU; (SEQ ID NO: 3)

B, ACGTTGTAAACGACGGCCAGT; (SEQ ID NO: 4)
and

C, CAATTCACACAGGAAACAGCTATGACCATG. (SEQ ID NO: 5)

The 119-mer oligonucleotide incorporating either a U or T nucleotide 23 bases from the terminus of one strand, was synthesized by using Taq polymerase under standard PCR conditions, using primer C and either primer A or primer B. PCR products are then purified on agarose gels and extracted by using Qiagen columns.

For long range primer extension, primer C is annealed to one strand of the 119-bp PCR product by heating to 65° C. in reaction buffer and cooling to room temperature. The dNTPs, [α-³²P] dATP, and 5 units of DNA polymerase (Pfu, Taq and mutant Pfu DNA polymerase to be tested) are added in polymerase reaction buffer (as specified by the suppliers of each polymerase) to a final volume of 20 μl, and the reaction is allowed to proceed for 60 min at 55° C. Reaction products are subjected to electrophoresis in a denaturing acrylamide gel and scanned and recorded on a Fuji FLA-2000 phosphorimager. The ability of the DNA polymerases from the thermophilic archaea *Pyrococcus furiosus* (Pfu) and the test mutant Pfu DNA polymerase to extend a primer across a template containing a single deoxyuridine can then be determined and directly compared.

The 3' to 5' exonuclease activity of purified Archaeal DNA polymerase (e.g., Pfu, KOD, or JDF-3 DNA polymerase) may be assayed according to methods known in the art, e.g., as described herein above, and in U.S. Pat. No. 5,489,523, incorporated herein by reference.

For example, a sample containing 0.01 to 0.1 unit of DNA polymerase activity is admixed in a 25 μl exonuclease reaction admixture containing 40 mM Tris-Cl, pH 7.5, 10 mM MgCl₂, 2.5 μg of Taq I restriction endonuclease-digested Lambda DNA fragments filled in with ³H-dGTP and ³H-dCTP. The labelled DNA substrate was prepared by digesting 1 mg lambda gt10 with 1000 units Taq I at 68° C. for 3 hrs in 1× Universal Buffer (Stratagene), followed by filling in the 3' recessed ends with 25 μCi each of ³H-dGTP and ³H-dCTP using 50 units of Sequenase (USB; United States Biochemicals, Inc.); the labelled fragments were separated from unincorporated nucleotides by passage through a Nuc-Trap column (Stratagene) following the manufacturer's instructions. After a 30 min incubation of the endonuclease

reaction admixture at 72° C., the reaction was terminated by addition of 5 µl of 15 mg/ml BSA and 13 µl of 50% trichloroacetic acid, and incubated on ice for 30 min to precipitate the nucleic acids. The precipitated nucleic acids were then centrifuged at 9000×g for 5 min, and 25 µl of the resulting supernatant was removed for scintillation counting. All reactions were performed in triplicate. One unit of exonuclease activity catalyzes the acid solubilization of 10 nmole of total nucleotides in 30 min at 72° C.

The polymerization activity of any of the above enzymes can be defined by means well known in the art. One unit of DNA polymerization activity of conventional DNA polymerase, according to the subject invention, is defined as the amount of enzyme which catalyzes the incorporation of 10 nmoles of total deoxynucleotides (dNTPs) into polymeric form in 30 minutes at optimal temperature (e.g., 72° C. for Pfu DNA polymerase).

Expression of Wild-Type or Mutant Enzymes According to the Invention

Methods known in the art may be applied to express and isolate the mutated forms of DNA polymerase (i.e., the second enzyme) according to the invention. The methods described here can be also applied for the expression of wild-type enzymes useful (e.g., the first enzyme) in the invention. Many bacterial expression vectors contain sequence elements or combinations of sequence elements allowing high level inducible expression of the protein encoded by a foreign sequence. For example, as mentioned above, bacteria expressing an integrated inducible form of the T7 RNA polymerase gene may be transformed with an expression vector bearing a mutated DNA polymerase gene linked to the T7 promoter. Induction of the T7 RNA polymerase by addition of an appropriate inducer, for example, isopropyl-β-D-thiogalactopyranoside (IPTG) for a lac-inducible promoter, induces the high level expression of the mutated gene from the T7 promoter.

Appropriate host strains of bacteria may be selected from those available in the art by one of skill in the art. As a non-limiting example, *E. coli* strain BL-21 is commonly used for expression of exogenous proteins since it is protease deficient relative to other strains of *E. coli*. BL-21 strains bearing an inducible T7 RNA polymerase gene include WJ56 and ER2566 (Gardner & Jack, 1999, supra). For situations in which codon usage for the particular polymerase gene differs from that normally seen in *E. coli* genes, there are strains of BL-21 that are modified to carry tRNA genes encoding tRNAs with rarer anticodons (for example, argu, ileY, leuW, and proL tRNA genes), allowing high efficiency expression of cloned protein genes, for example, cloned Archaeal enzyme genes (several BL21 -CODON PLUS™ cell strains carrying rare-codon tRNAs are available from Stratagene, for example).

There are many methods known to those of skill in the art that are suitable for the purification of a modified DNA polymerase of the invention. For example, the method of Lawyer et al. (1993, *PCR Meth. & App.* 2: 275) is well suited for the isolation of DNA polymerases expressed in *E. coli*, as it was designed originally for the isolation of Taq polymerase. Alternatively, the method of Kong et al. (1993, *J. Biol. Chem.* 268: 1965, incorporated herein by reference) may be used, which employs a heat denaturation step to destroy host proteins, and two column purification steps (over DEAE-Sepharose and heparin-Sepharose columns) to isolate highly active and approximately 80% pure DNA polymerase. Further, DNA polymerase mutants may be isolated by an ammonium sulfate fractionation, followed by Q Sepharose and DNA cellulose

columns, or by adsorption of contaminants on a HiTrap Q column, followed by gradient elution from a HiTrap heparin column.

The invention further provides for mutant V93R, V93E, V93D, V93K or V93N Pfu DNA polymerases that contain one or more additional mutations with improved reverse transcriptase activity, as described in U.S. application with Ser. No. 10/435,766, hereby incorporated by reference. DNA Polymerase blend and PCR Additives

The invention further provides for compositions in which any of the Archaeal mutant DNA polymerases are mixed with either a second DNA polymerase (either wild type or another mutant DNA polymerase). For example, a mutant DNA polymerase with deficient 3'-5' exonuclease activity and reduced uracil detection activity (or additionally with increased reverse transcriptase activity) may be mixed with:

- a.) an Archaeal DNA polymerase with reduced polymerization activity
- b) a wild type DNA polymerase with no 3'-5' exonuclease activity, e.g., Taq polymerase
- c) a polymerase chimera (e.g., Pfu chimera as described in WO 01/92501 A1 or Pavlov et al. supra)
- d) a reverse transcriptase, such as HIV, HTLV-I, HTLV-II, FeLV, FIV, SIV, AMV, MMTV, and MoMuLV reverse transcriptases.

The present invention also provides a composition containing one mutant archaeal DNA polymerase with no 3'-5' exonuclease activity and another mutant archaeal DNA polymerase with 3'-5' exonuclease activity.

Preferably, both the mutant archaeal DNA polymerase with no 3'-5' exonuclease activity and the other mutant archaeal DNA polymerase with 3'-5' exonuclease activity contain a mutation at V93.

The present invention also provides compositions which contain the mutant DNA polymerase and an PCR additive, such as one or more selected from the group consisting of: Pfu dUTPase (PEF), PCNA, RPA, ssb, antibodies, DMSO, betaine, 3'-5' exonuclease (e.g., Pfu G387P), Ncp7, recA, and T4gp32, e.g., as described in U.S. patent application with Ser. No. 20020119467, hereby incorporated by reference in its entirety.

The addition of NCP7 to a reverse transcription reaction, significantly increases the processivity of the reverse transcriptase enzyme. Hence, it is expected that a number of other general RNA binding proteins will have the same effect. Non-limiting examples of such RNA binding proteins, include nucleocapsid proteins from other retroviruses (Ncp7 is derived from HIV-1), p50 (a protein which possesses strong, but non-specific, RNA-binding activity and is associated with cytoplasmic mRNA), the FRGY 2 protein from *Xenopus oocytes*, La antigen, and polypyrimidine tract binding protein (hnRNP I/PTB) (Ghetti et al., 1992 *Nucl. Acid. Res.* 20: 3671-3678; Dreyfuss et al., 1993, *Annu. Rev. Biochem.* 62: 289-321; Chang et al., 1994, *J. Virol.* 68:7008-7020; and Spirin, 1998, In Hershey et al., (Eds), *Translational Control*, Cold Spring Harbor Laboratory press, Cold Spring Harbor, N.Y. pp. 319-334).

Similarly, although the improvement in the processivity of a RNA-dependent polymerase has been demonstrated with reverse transcriptase, the present invention should not be so limited. A recent report has demonstrated that a single missense mutation with the catalytic fragment of Moloney murine leukemia virus (MMLV) RT (the parental RT from which superscript is derived) is sufficient to convert this enzyme from a RNA-dependent DNA polymerase to a RNA-dependent RNA polymerase (Giao et al., 1997, *Proc. Natl. Acad. Sci. USA* 94: 407-411). It is thus expected that general

RNA binding proteins will also stimulate the processivity of RNA-dependent RNA polymerases given that the inhibitory features of "difficult" RNA template will be present. Other examples of RNA-dependent RNA polymerases include the polymerases of all members of the picomavirus family which copy their mRNAs directly into ds RNA genome from a single stranded mRNA template.

In addition, it is expected that general DNA binding proteins will stimulate the processivity of DNA-dependent DNA polymerases and DNA-dependent RNA polymerase. While the methods of the instant invention have been demonstrated with rec A protein and single-strand DNA binding protein (SSB), other general DNA binding proteins could also be used as stimulators. A non-limiting example of a general DNA binding protein is the gene 32 product of T4 bacteriophage (T4gp32). Hence, it is expected that a number of other general DNA binding proteins will be able to stimulate, for example, T7DNA polymerase processivity during second strand synthesis when generating a cDNA library. Non-limiting examples of other general DNA binding proteins, include: ssCRE-BP/Pur. varies. (a protein isolated from rat lung); Hbsu (an essential nucleoid-associated protein from *Bacillus subtilis*); uvs. sup. y (a gene product of bacteriophage T4); replication protein A (a heterotrimeric ss DNA binding protein in eukaryotes); the BALF2 gene product of Epstein-Barr virus; the yeast RAD51 gene product; the SSB of *Bacillus subtilis* phage phi 29; and the SSB of adenovirus (Wei et al., 1998, *Ipn. J. Pharmacol.* 78: 418-42; Kohler et al., 1998, *Mol. Gen. Genet.* 260: 487-491; Sweezy et al., 1999, *Biochemistry* 38: 936-944; Brill et al., 1998, *Mol. Cel. Biol.* 18: 7225-7234; Tsurumi et al., 1998, *J. Gen. Virol.* 79: 1257-1264; Namsaraev et al., 1997, *Mol. Cell. Biol.* 17: 5359-5368; Soengas et al., 1997, *J. Biol. Chem.* 272: 303-310; and Kanellopoulos et al., 1995, *J. Struct. Biol.* 115: 113-116).

In addition non-limiting examples of DNA-dependent DNA polymerases which could benefit from the processivity enhancing methods and compositions of the present invention include *E. coli* DNA polymerase, the klenow fragment of *E. coli* DNA polymerase, Vent polymerase, Pfu polymerase, Bst DNA polymerase, and any other thermophilic DNA polymerase. Also, as pertaining to CDNA synthesis, *E. coli* DNA polymerase (see FIG. 1), T4 DNA polymerase, and thermophilic DNA polymerases have all been used to generate second strand product depending on the strategy being undertaken (In cDNA Library Protocols, 1997, Cowell et al., (eds). Humana Press, Totowa, N.J.).

In addition, a composition containing the mutant DNA polymerase of the present invention may also contain additives like antibodies for increased specificity (for hot start PCR, described in Borns et al. (2001) Strategies 14, pages 5-8 and also in manual accompanying commercially available kit, Stratagene Catalogue # 600320), DMSO for GC-rich PCR or single stranded DNA binding protein for higher specificity (commercially available, Stratagene Catalog # 600201), dUTP and/or uracil N-glycosylase.

Applications of the Subject Invention

In one aspect, the invention provides a method for DNA synthesis using the compositions of the subject invention. Typically, synthesis of a polynucleotide requires a synthesis primer, a synthesis template, polynucleotide precursors for incorporation into the newly synthesized polynucleotide, (e.g. dATP, dCTP, dGTP, dTTP), and the like. Detailed methods for carrying out polynucleotide synthesis are well known to the person of ordinary skill in the art and can be found, for example, in *Molecular Cloning second edition*, Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

A. Application in Amplification Reactions

"Polymerase chain reaction" or "PCR" refers to an in vitro method for amplifying a specific polynucleotide template sequence. The technique of PCR is described in numerous publications, including, PCR: A Practical Approach, M. J. McPherson, et al., IRL Press (1991), PCR Protocols: A Guide to Methods and Applications, by Innis, et al., Academic Press (1990), and PCR Technology: Principals and Applications for DNA Amplification, H. A. Erlich, Stockton Press (1989). PCR is also described in many U.S. Patents, including U.S. Pat. Nos. 4,683,195; 4,683,202; 4,800,159; 4,965,188; 4,889,818; 5,075,216; 5,079,352; 5,104,792; 5,023,171; 5,091,310; and 5,066,584, each of which is herein incorporated by reference.

For ease of understanding the advantages provided by the present invention, a summary of PCR is provided. The PCR reaction involves a repetitive series of temperature cycles and is typically performed in a volume of 50-100 μ l. The reaction mix comprises dNTPs (each of the four deoxynucleotides dATP, dCTP, dGTP, and dTTP), primers, buffers, DNA polymerase, and polynucleotide template. PCR requires two primers that hybridize with the double-stranded target polynucleotide sequence to be amplified. In PCR, this double-stranded target sequence is denatured and one primer is annealed to each strand of the denatured target. The primers anneal to the target polynucleotide at sites removed from one another and in orientations such that the extension product of one primer, when separated from its complement, can hybridize to the other primer. Once a given primer hybridizes to the target sequence, the primer is extended by the action of a DNA polymerase. The extension product is then denatured from the target sequence, and the process is repeated.

In successive cycles of this process, the extension products produced in earlier cycles serve as templates for DNA synthesis. Beginning in the second cycle, the product of amplification begins to accumulate at a logarithmic rate. The amplification product is a discrete double-stranded DNA molecule comprising: a first strand which contains the sequence of the first primer, eventually followed by the sequence complementary to the second primer, and a second strand which is complementary to the first strand.

Due to the enormous amplification possible with the PCR process, small levels of DNA carryover from samples with high DNA levels, positive control templates or from previous amplifications can result in PCR product, even in the absence of purposefully added template DNA. If possible, all reaction mixes are set up in an area separate from PCR product analysis and sample preparation. The use of dedicated or disposable vessels, solutions, and pipettes (preferably positive displacement pipettes) for RNA/DNA preparation, reaction mixing, and sample analysis will minimize cross contamination. See also Higuchi and Kwok, 1989, *Nature*, 339:237-238 and Kwok, and Orrego, in: Innis et al. eds., 1990, *PCR Protocols: A Guide to Methods and Applications*, Academic Press, Inc., San Diego, Calif., which are incorporated herein by reference.

The enzymes provided herein are also useful for dUTP/UNG cleanup methods that require PCR enzymes that incorporate dUTP (Longo et al., *Supra*).

In addition, Mutations that reduce uracil sensitivity are expected to improve the success rate of long-range amplification (higher yield, longer targets amplified). It is expected that mutations eliminating uracil detection will also increase the error rate of Archaeal DNA polymerases. If uracil stalling contributes to fidelity by preventing synthesis opposite promutagenic uracil (arising from cytosine deamination), then uracil insensitive mutants are likely to exhibit a higher

GC→TA transition mutation rate. It is therefore envisioned that optimal PCR performance and fidelity may be achieved by adding to uracil-insensitive Archaeal DNA polymerase mutants either thermostable exonucleases (e.g., polymerase reduced proofreading DNA polymerases, exonuclease III) or additional mutations that increase fidelity.

1. Thermostable Enzymes

For PCR amplifications, the enzymes used in the invention are preferably thermostable. As used herein, "thermostable" refers to an enzyme which is stable to heat, is heat resistant, and functions at high temperatures, e.g., 50 to 90° C. The thermostable enzyme according to the present invention must satisfy a single criterion to be effective for the amplification reaction, i.e., the enzyme must not become irreversibly denatured (inactivated) when subjected to the elevated temperatures for the time necessary to effect denaturation of double-stranded polynucleotides. By "irreversible denaturation" as used in this connection, is meant a process bringing a permanent and complete loss of enzymatic activity. The heating conditions necessary for denaturation will depend, e.g., on the buffer salt concentration and the length and nucleotide composition of the polynucleotides being denatured, but typically range from 85° C., for shorter polynucleotides, to 105° C. for a time depending mainly on the temperature and the polynucleotide length, typically from 0.25 minutes for shorter polynucleotides, to 4.0 minutes for longer pieces of DNA. Higher temperatures may be tolerated as the buffer salt concentration and/or GC composition of the polynucleotide is increased. Preferably, the enzyme will not become irreversibly denatured at 90 to 100° C. An enzyme that does not become irreversibly denatured, according to the invention, retains at least 10%, or at least 25%, or at least 50% or more function or activity during the amplification reaction.

2. PCR Reaction Mixture

In addition to the subject enzyme mixture, one of average skill in the art may also employ other PCR parameters to increase the fidelity of synthesis/amplification reaction. It has been reported PCR fidelity may be affected by factors such as changes in dNTP concentration, units of enzyme used per reaction, pH, and the ratio of Mg^{2+} to dNTPs present in the reaction (Mattila et al., 1991, supra).

Mg^{2+} concentration affects the annealing of the oligonucleotide primers to the template DNA by stabilizing the primer-template interaction, it also stabilizes the replication complex of polymerase with template-primer. It can therefore also increase non-specific annealing and produced undesirable PCR products (gives multiple bands in gel). When non-specific amplification occurs, Mg^{2+} may need to be lowered or EDTA can be added to chelate Mg^{2+} to increase the accuracy and specificity of the amplification.

Other divalent cations such as Mn^{2+} , or Co^{2+} can also affect DNA polymerization. Suitable cations for each DNA polymerase are known in the art (e.g., in *DNA Replication 2nd edition*, supra). Divalent cation is supplied in the form of a salt such $MgCl_2$, $Mg(OAc)_2$, $MgSO_4$, $MnCl_2$, $Mn(OAc)_2$, or $MnSO_4$. Usable cation concentrations in a Tris-HCl buffer are for $MnCl_2$ from 0.5 to 7 mM, preferably, between 0.5 and 2 mM, and for $MgCl_2$ from 0.5 to 10 mM. Usable cation concentrations in a Bicine/KOAc buffer are from 1 to 20 mM for $Mn(OAc)_2$, preferably between 2 and 5 mM.

Monovalent cation required by DNA polymerase may be supplied by the potassium, sodium, ammonium, or lithium salts of either chloride or acetate. For KCl, the concentration is between 1 and 200 mM, preferably the concentration is between 40 and 100 mM, although the optimum concentration may vary depending on the polymerase used in the reaction.

Deoxyribonucleotide triphosphates (dNTPs) are added as solutions of the salts of dATP, dCTP, dGTP, dUTP, and dTTP, such as disodium or lithium salts. In the present methods, a final concentration in the range of 1 μ M to 2 mM each is suitable, and 100-600 μ M is preferable, although the optimal concentration of the nucleotides may vary in the PCR reaction depending on the total dNTP and divalent metal ion concentration, and on the buffer, salts, particular primers, and template. For longer products, i.e., greater than 1500 bp, 500 μ M each dNTP may be preferred when using a Tris-HCl buffer.

dNTPs chelate divalent cations, therefore amount of divalent cations used may need to be changed according to the dNTP concentration in the reaction. Excessive amount of dNTPs (e.g., larger than 1.5 mM) can increase the error rate and possibly inhibit DNA polymerases. Lowering the dNTP (e.g., to 10-50 μ M) may therefore reduce error rate. PCR reaction for amplifying larger size template may need more dNTPs.

One suitable buffering agent is Tris-HCl, preferably pH 8.3, although the pH may be in the range 8.0-8.8. The Tris-HCl concentration is from 5-250 mM, although 10-100 mM is most preferred. A preferred buffering agent is Bicine-KOH, preferably pH 8.3, although pH may be in the range 7.8-8.7. Bicine acts both as a pH buffer and as a metal buffer. Tricine may also be used.

PCR is a very powerful tool for DNA amplification and therefore very little template DNA is needed. However, in some embodiments, to reduce the likelihood of error, a higher DNA concentration may be used, though too many templates may increase the amount of contaminants and reduce efficiency.

Usually, up to 3 μ M of primers may be used, but high primer to template ratio can result in non-specific amplification and primer-dimer formation. Therefore it is usually necessary to check primer sequences to avoid primer-dimer formation.

The invention provides for Pfu V93R, V93E, V93K, V93D, or V93N DNA polymerases with reduced uracil detection activity that enhance PCR of GC rich DNA templates by minimizing the effect of cytosine deamination in the template and by allowing the use of higher denaturation times and denaturation temperatures.

3. Cycling Parameters

Denaturation time may be increased if template GC content is high. Higher annealing temperature may be needed for primers with high GC content or longer primers. Gradient PCR is a useful way of determining the annealing temperature. Extension time should be extended for larger PCR product amplifications. However, extension time may need to be reduced whenever possible to limit damage to enzyme.

The number of cycle can be increased if the number of template DNA is very low, and decreased if high amount of template DNA is used.

4. PCR Enhancing Factors and Additives

PCR enhancing factors may also be used to improve efficiency of the amplification. As used herein, a "PCR enhancing factor" or a "Polymerase Enhancing Factor" (PEF) refers to a complex or protein possessing polynucleotide polymerase enhancing activity (Hogrefe et al., 1997, *Strategies* 10:93-96; and U.S. Pat. No. 6,183,997, both of which are hereby incorporated by references). For Pfu DNA polymerase, PEF comprises either P45 in native form (as a complex of P50 and P45) or as a recombinant protein. In the native complex of Pfu P50 and P45, only P45 exhibits PCR enhancing activity. The P50 protein is similar in structure to a bacterial flavoprotein. The P45 protein is similar in structure to dCTP deaminase and dUTPase, but it functions only as a

dUTPase converting dUTP to dUMP and pyrophosphate. PEF, according to the present invention, can also be selected from the group consisting of: an isolated or purified naturally occurring polymerase enhancing protein obtained from an archaeobacteria source (e.g., *Pyrococcus furiosus*); a wholly or partially synthetic protein having the same amino acid sequence as Pfu P45, or analogs thereof possessing polymerase enhancing activity; polymerase-enhancing mixtures of one or more of said naturally occurring or wholly or partially synthetic proteins; polymerase-enhancing protein complexes of one or more of said naturally occurring or wholly or partially synthetic proteins; or polymerase-enhancing partially purified cell extracts containing one or more of said naturally occurring proteins (U.S. Pat. No. 6,183,997, supra). The PCR enhancing activity of PEF is defined by means well known in the art. The unit definition for PEF is based on the dUTPase activity of PEF (P45), which is determined by monitoring the production of pyrophosphate (PPi) from dUTP. For example, PEF is incubated with dUTP (10 mM dUTP in 1× cloned Pfu PCR buffer) during which time PEF hydrolyzes dUTP to dUMP and PPi. The amount of PPi formed is quantitated using a coupled enzymatic assay system that is commercially available from Sigma (#P7275). One unit of activity is functionally defined as 4.0 nmole of PPi formed per hour (at 85° C.).

Other PCR additives may also affect the accuracy and specificity of PCR reaction. EDTA less than 0.5 mM may be present in the amplification reaction mix. Detergents such as Tween-20™ and Nonidet™ P-40 are present in the enzyme dilution buffers. A final concentration of non-ionic detergent approximately 0.1% or less is appropriate, however, 0.01-0.05% is preferred and will not interfere with polymerase activity. Similarly, glycerol is often present in enzyme preparations and is generally diluted to a concentration of 1-20% in the reaction mix. Glycerol (5-10%), formamide (1-5%) or DMSO (2-10%) can be added in PCR for template DNA with high GC content or long length (e.g., >1 kb). These additives change the T_m (melting temperature) of primer-template hybridization reaction and the thermostability of polymerase enzyme. BSA (up to 0.8 µg/µl) can improve efficiency of PCR reaction. Betaine (0.5-2M) is also useful for PCR over high GC content and long fragments of DNA. Tetramethylammonium chloride (TMAC, >50 mM), Tetraethylammonium chloride (TEAC), and Trimethylamine N-oxide (TMAO) may also be used. Test PCR reactions may be performed to determine optimum concentration of each additive mentioned above.

The invention provides for additive including, but not limited to antibodies (for hot start PCR) and ssb (higher specificity). The invention also contemplates mutant ARCHAEAL DNA polymerases in combination with accessory factors, for example as described in U.S. Pat. No. 6,333,158, and WO 01/09347 A2, hereby incorporated by reference in its entirety.

Various specific PCR amplification applications are available in the art (for reviews, see for example, Erlich, 1999, *Rev Immunogenet.*, 1:127-34; Prediger 2001, *Methods Mol. Biol.* 160:49-63; Jurecic et al., 2000, *Curr. Opin. Microbiol.* 3:316-21; Triglia, 2000, *Methods Mol. Biol.* 130:79-83; MacClelland et al., 1994, *PCR Methods Appl.* 4:S66-81; Abramson and Myers, 1993, *Current Opinion in Biotechnology* 4:41-47; each of which is incorporated herein by references).

The subject invention can be used in PCR applications including, but are not limited to, i) hot-start PCR which reduces non-specific amplification; ii) touch-down PCR which starts at high annealing temperature, then decreases annealing temperature in steps to reduce non-specific PCR product; iii) nested PCR which synthesizes more reliable

product using an outer set of primers and an inner set of primers; iv) inverse PCR for amplification of regions flanking a known sequence. In this method, DNA is digested, the desired fragment is circularized by ligation, then PCR using primer complementary to the known sequence extending outwards; v) AP-PCR (arbitrary primed)/RAPD (random amplified polymorphic DNA). These methods create genomic fingerprints from species with little-known target sequences by amplifying using arbitrary oligonucleotides; vi) RT-PCR which uses RNA-directed DNA polymerase (e.g., reverse transcriptase) to synthesize cDNAs which is then used for PCR. This method is extremely sensitive for detecting the expression of a specific sequence in a tissue or cells. It may also be use to quantify mRNA transcripts; vii) RACE (rapid amplification of cDNA ends). This is used where information about DNA/protein sequence is limited. The method amplifies 3' or 5' ends of cDNAs generating fragments of cDNA with only one specific primer each (plus one adaptor primer). Overlapping RACE products can then be combined to produce full length cDNA; viii) DD-PCR (differential display PCR) which is used to identify differentially expressed genes in different tissues. First step in DD-PCR involves RT-PCR, then amplification is performed using short, intentionally nonspecific primers; ix) Multiplex-PCR in which two or more unique targets of DNA sequences in the same specimen are amplified simultaneously. One DNA sequence can be use as control to verify the quality of PCR; x) Q/C-PCR (Quantitative comparative) which uses an internal control DNA sequence (but of different size) which compete with the target DNA (competitive PCR) for the same set of primers; xi) Recursive PCR which is used to synthesize genes. Oligonucleotides used in this method are complementary to stretches of a gene (>80 bases), alternately to the sense and to the anti-sense strands with ends overlapping (~20 bases); xii) Asymmetric PCR; xiii) In Situ PCR; xiv) Site-directed PCR Mutagenesis.

It should be understood that this invention is not limited to any particular amplification system. As other systems are developed, those systems may benefit by practice of this invention.

B. Application in Quantitative PCR and Quantitative RT-PCR

A typical PCR reaction includes multiple amplification steps, or cycles that selectively amplify a target nucleic acid species. A full description of the PCR process, and common variations thereof, such as quantitative PCR (QPCR), real-time QPCR, reverse transcription PCR (RT-PCR) and quantitative reverse transcription PCR (QRT-PCR) is beyond the scope of this disclosure and these methods are well-described in the art and have been broadly commercialized.

The present invention may be used to perform any of the above PCR methods known in the art (e.g., as reviewed in Joyce et al. (2002, *Methods Mol Biol.* 193:83-92), Klein (2002, *Trends Mol Med.* 8(6):257-60), Wittwer et al. (2001, *Methods.* 25(4):430-42), Freeman et al. (1999, *Biotechniques.* 26(1):112-22, 124-5), hereby incorporated by reference.

Reverse transcription of an RNA template into cDNA is an integral part of many techniques used in molecular biology. Accordingly, the reverse transcription procedures, compositions, and kits provided in the present invention find a wide variety of uses. For example, it is contemplated that the reverse transcription procedures and compositions of the present invention are utilized to produce cDNA inserts for cloning into cDNA library vectors (e.g., lambda gt10 [Huynh et al., In *DNA Cloning Techniques: A Practical Approach*, D. Glover, ed., IRL Press, Oxford, 49, 1985], lambda gt11 [Young and Davis, *Proc. Nat'l. Acad. Sci.*, 80:1194, 1983],

pBR322 [Watson, Gene 70:399-403, 1988], pUC19 [Yarnisch-Perron et al., Gene 33:103-119, 1985], and M13 [Messing et al., Nucl. Acids. Res. 9:309-321, 1981]). The present invention also finds use for identification of target RNAs in a sample via RT-PCR (e.g., U.S. Pat. No. 5,322,770, incorporated herein by reference). Additionally, the present invention finds use in providing cDNA templates for techniques such as differential display PCR (e.g., Liang and Pardee, Science 257(5072):967-71 (1992)). The DNA polymerase with increased RT activity, compositions or kits comprising such polymerase can be applied in any suitable applications, including, but not limited to the following examples.

1. Reverse Transcription

The present invention contemplates the use of thermostable DNA polymerase for reverse transcription reactions. Accordingly, in some embodiments of the present invention, thermostable DNA polymerases having increased RT activity are provided. In some embodiments, the thermostable DNA polymerase is selected from the DNA polymerases listed in Tables II-IV, for example, a Pfu or a JDF-3 DNA polymerase.

In some embodiments of the present invention, where a DNA polymerase with increased RT activity is utilized to reverse transcribe RNA, the reverse transcription reaction is conducted at about 50° C. to 80° C., preferably about 60° C. to 75° C. Optimal reaction temperature for each DNA polymerase is known in the art and may be relied upon as the optimal temperature for the mutant DNA polymerases of the present invention. Preferred conditions for reverse transcription are 1×MMLV RT buffer (50 mM Tris pH 8.3, 75 mM KCl, 10 mM DTT, 3 mM MgCl₂), containing 20% DMSO.

In still further embodiments, reverse transcription of an RNA molecule by a DNA polymerase with increased RT activity results in the production of a cDNA molecule that is substantially complementary to the RNA molecule. In other embodiments, the DNA polymerase with increased RT activity then catalyzes the synthesis of a second strand DNA complementary to the cDNA molecule to form a double stranded DNA molecule. In still further embodiments of the present invention, the DNA polymerase with increased RT activity catalyzes the amplification of the double stranded DNA molecule in a PCR as described below. In some embodiments, PCR is conducted in the same reaction mix as the reverse transcriptase reaction (i.e., a single tube reaction is performed). In other embodiments, PCR is performed in a separate reaction mix on an aliquot removed from the reverse transcription reaction (i.e., a two tube reaction is performed).

In another embodiment, the DNA polymerase mutants of the invention can be used for labeling cDNA for microarray analysis, e.g., with fluorescent labels such as Cy3, Cy5 or other labels. It is contemplated that DNA polymerase mutants as described herein would have the advantage of more efficient labeling or more uniform incorporation of labeled nucleotides relative to wild-type enzymes.

2. QPCR and RT-QPCR

The mutant DNA polymerase of the present invention is generally applicable to QPCR or RT-QPCR.

A quantitative reverse transcriptase polymerase chain reaction (RT-QPCR) method is provided for rapidly and accurately detecting low abundance RNA species in a population of RNA molecules (for example, and without limitation, total RNA or mRNA), including the steps of: a) incubating an RNA sample with a reverse transcriptase and a high concentration of a target sequence-specific reverse transcriptase primer under conditions suitable to generate cDNA; b) subsequently adding suitable polymerase chain reaction (PCR) reagents to the reverse transcriptase reaction, including a high concen-

tration of a PCR primer set specific to the cDNA and a thermostable DNA polymerase to the reverse transcriptase reaction, and c) cycling the PCR reaction for a desired number of cycles and under suitable conditions to generate PCR product ("amplicons") specific to the cDNA. By temporally separating the reverse transcriptase and the PCR reactions, and by using reverse transcriptase-optimized and PCR-optimized primers, excellent specificity is obtained. The reaction is conducted in a single tube (all tubes, containers, vials, cells and the like in which a reaction is performed may be referred to herein, from time to time, generically, as a "reaction vessel"), removing a source of contamination typically found in two-tube reactions. The high concentration primers permit very rapid QRT-PCR reactions, typically on the order of 20 minutes from the beginning of the reverse transcriptase reaction to the end of a 40 cycle PCR reaction. The realization of such a rapid QRT-PCR experiment is assisted by the availability of thermal cycling devices capable of generating a thermal ramp rate (ΔT) of at least about 5° C. per second.

The reaction c) may be performed in the same tube as the reverse transcriptase reaction by adding sufficient reagents to the reverse transcriptase (RT) reaction to create good, or even optimal conditions for the PCR reaction to proceed. A single tube may be loaded, prior to the running of the reverse transcriptase reaction, with: 1) the reverse transcriptase reaction mixture, and 2) the PCR reaction mixture to be mixed with the cDNA mixture after the reverse transcriptase reaction is completed. The reverse transcriptase reaction mixture and the PCR reaction mixture may be physically separated by a solid, or semi-solid (including amorphous, glassy substances and waxy) barrier of a composition that melts at a temperature greater than the incubation temperature of the reverse transcriptase reaction, but below the denaturing temperature of the PCR reaction. The barrier composition may be hydrophobic in nature and forms a second phase with the RT and PCR reaction mixtures when in liquid form. One example of such a barrier composition is wax beads, commonly used in PCR reactions, such as the AMPLIWAX PCR GEM products commercially available from Applied Biosystems of Foster City, Calif. and the STRATASPHERE Magnesium Wax Beads, commercially available from Stratagene of La Jolla, Calif.

In one type of two-step process, the first step involves synthesis of first strand cDNA with a reverse transcriptase, following by a second PCR step. In certain protocols, these steps are carried out in separate reaction tubes. In these two tube protocols, following reverse transcription of the initial RNA template in the first tube, an aliquot of the resultant product is then placed into the second PCR tube and subjected to PCR amplification.

In a second type of two-step process, both RT and PCR are carried out in the same tube using a compatible RT and PCR buffer. Typically, reverse transcription is carried out first, followed by addition of PCR reagents to the reaction tube and subsequent PCR.

Reverse transcription is commonly performed with viral reverse transcriptases isolated from Avian myeloblastosis virus (AMV-RT) or Moloney murine leukemia virus (MMLV-RT), which are active in the presence of magnesium ions.

The mutant DNA polymerase may be used in performing two-step RT-QPCR, in which RT is performed by a conventional reverse transcriptase and the quantitative PCR is performed by a mutant DNA polymerase of the present invention.

A variety of one-step RT-PCR protocols have been developed, see Blain & Goff, J. Biol. Chem. (1993) 5: 23585-23592; Blain & Goff, J. Virol. (1995) 69:4440-4452; Sellner

et al., *J. Virol. Method.* (1994) 49:47-58; PCR, *Essential Techniques* (ed. J. F. Burke, J. Wiley & Sons, New York) (1996) pp61-63; 80-81.

Some one-step systems are commercially available, for example, SuperScript One-Step RT-PCR System description on the world-wide web at lifetech.com/world_whatsnew/archive/nz_1_3.html; Access RT-PCR System and Access RT-PCR Introductory System described on the world wide web at promega.com/tbs/tb220/tb220.html; AdvanTaq & AdvanTaq Plus PCR kits and User Manual available at www.clontech.com, and ProSTAR™ HF single-tube RT-PCR kit (Stratagene, Catalog No. 600164, information available on the world wide web at stratagene.com).

Certain RT-PCR methods use an enzyme blend or enzymes with both reverse transcriptase and DNA polymerase or exonuclease activities, e.g., as described in U.S. Pat. Nos. 6,468,775; 6,399,320; 5,310,652; 6,300,073; patent application No. U.S. 2002/0119465A1; EP 1,132,470A1 and WO 00/71739A1, all of which are incorporated herein by reference.

The reverse transcription and PCR may also be performed in a single step reaction using a mutant DNA polymerase of the present invention which also contains an increased reverse transcriptase activity.

As used herein, "quantitative PCR (QPCR)" refers to a PCR amplification which is used to determine the abundance of polynucleotide as described herein above. To determine the abundance of a specific polynucleotide present in a PCR reaction, this method usually utilizes a labeling dye which fluoresces in proportion to the amount of target DNA species that is produced by the PCR reaction.

According to one embodiment of the present invention, the quantitative PCR methods may amplify, in the presence of Mg ions, a target nucleic acid by using dATP, dGTP, dCTP, dTTP or dUTP, a target nucleic acid (DNA or RNA), a mutant DNA polymerase of the invention, a primer, and a nucleic acid labeled with a fluorescent dye or an intercalator while repeatedly changing the temperature between low and high levels, and monitor increases in fluorescence emission from the fluorescent dye in real time in the course of the amplification.

In the case of a fluorescent probe, the reaction fluoresces in relative proportion to the quantity of DNA product produced.

TaqMan is a homogenous assay for detecting polynucleotides (U.S. Pat. No. 5,723,591). In this assay, two PCR primers flank a central probe oligonucleotide. The probe oligonucleotide contains two fluorescent moieties. During the polymerization step of the PCR process, the polymerase cleaves the probe oligonucleotide. The cleavage causes the two fluorescent moieties to become physically separated, which causes a change in the wavelength of the fluorescent emission. As more PCR product is created, the intensity of the novel wavelength increases. The TaqMan™ procedure (Applied Biosystems, CA) describes one such fluorescent methodology for performing Quantitative PCR. Briefly described, this system integrates the use of a detectable reporter construct, or probe, which comprises both a fluorescent label molecule and a quencher molecule. Ordinarily, the quencher nullifies the majority of fluorescence which may be emitted by the probe. During the amplification process, however, the quencher molecule is released from the probe allowing the fluorescent label to be detected. The quantity or intensity of fluorescence may then be correlated with the amount of product formed in the reaction. Using this information, calculations can be made to determine the initial quantity of template present. Quantitation in this manner is useful in applications including: determination of levels/concentrations of specific

DNA and RNA sequences in tissue samples, identification of viral loads, genotyping, and numerous other applications. For additional information regarding the fundamental concepts of quantitative PCR the reader is directed to *Allelic Discrimination by Nick-Translation PCR with Fluorogenic Probes*, L. G. Lee, C. R. Connell, and W. Bloch, *Nucleic Acids Research* 21:3761-3766, 1993 and *PCR Technology: Principles and Applications for DNA Amplification*. Karl Drlica, John Wiley and Sons, 1997.

Molecular beacons are an alternative to TaqMan (U.S. Pat. Nos. 6,277,607; 6,150,097; 6,037,130) for the detection of polynucleotides. Molecular beacons are oligonucleotide hairpins which undergo a conformational change upon binding to a perfectly matched template. The conformational change of the oligonucleotide increases the physical distance between a fluorophore moiety and a quencher moiety present on the oligonucleotide. This increase in physical distance causes the effect of the quencher to be diminished, thus increasing the signal derived from the fluorophore.

U.S. Pat. No. 6,174,670B1 discloses methods of monitoring hybridization during a polymerase chain reaction which are achieved with rapid thermal cycling and use of double stranded DNA dyes or specific hybridization probes in the presence of a fluorescence resonance energy transfer pair—fluorescein and Cy5.3 or Cy5.5. The method amplifies the target sequence by polymerase chain reaction in the presence of two nucleic acid probes that hybridize to adjacent regions of the target sequence, one of the probes being labeled with an acceptor fluorophore and the other probe labeled with a donor fluorophore of a fluorescence energy transfer pair such that upon hybridization of the two probes with the target sequence, the donor fluorophore interacts with the acceptor fluorophore to generate a detectable signal. The sample is then excited with light at a wavelength absorbed by the donor fluorophore and the fluorescent emission from the fluorescence energy transfer pair is detected for the determination of that target amount.

There are also several other fluorescent and enzymatic PCR technologies, such as *Scorpions™*, *Sunrise™* primers, and *DNAzymes*, for polynucleotide detection, where each polynucleotide to be detected requires a different oligonucleotide probe and two different fluorescent moieties.

In addition, QPCR may also be performed according to methods as described in U.S. Patent Application with Ser. No. 60/435,484, hereby incorporated by reference in its entirety.

In one embodiment, the mutant DNA polymerase is used in a method for detecting the amount of a target polynucleotide in an amplification reaction mixture, comprising: (a) providing a forward and a reverse primer which amplify the target polynucleotide in the amplification reaction mixture; (b) providing to the reaction mixture a target-hybridizing probe 1 comprising a target binding sequence (P1-DNA) which hybridizes to one strand of the target polynucleotide and a probe binding sequence (P1-P) which does not hybridize to the target polynucleotide, and a target-hybridizing probe 2 comprising a target binding sequence (P2-DNA) which hybridizes, in close proximity, to the same strand of the target polynucleotide and a probe binding sequence (P2-P) which does not hybridize to the target polynucleotide; (c) providing to the reaction mixture a non-target-hybridizing universal probe 3 labeled with label A and a non-target-hybridizing universal probe 4 labeled with label B, where the universal probe 3 hybridize to the P1-P sequence and the universal probe 4 hybridizes to the P2-P sequence, and where the label A interact with the label B to generate a signal; and (d) detecting the generated signal which is indicative as to the amount of the polynucleotide in the sample.

C. Application in Direct Cloning of PCR Amplified Product

It is understood that the amplified product produced using the subject enzyme can be cloned by any method known in the art. In one embodiment, the invention provides a composition which allows direct cloning of PCR amplified product.

The most common method for cloning PCR products involves incorporation of flanking restriction sites onto the ends of primer molecules. The PCR cycling is carried out and the amplified DNA is then purified, restricted with an appropriate endonuclease(s) and ligated to a compatible vector preparation.

A method for directly cloning PCR products eliminates the need for preparing primers having restriction recognition sequences and it would eliminate the need for a restriction step to prepare the PCR product for cloning. Additionally, such method would preferably allow cloning PCR products directly without an intervening purification step.

U.S. Pat. Nos. 5,827,657 and 5,487,993 (hereby incorporated by their entirety) disclose methods for direct cloning of PCR products using a DNA polymerase which takes advantage of the single 3'-deoxy-adenosine monophosphate (dAMP) residues attached to the 3' termini of PCR generated polynucleotides. Vectors are prepared with recognition sequences that afford single 3'-terminal deoxy-thymidine monophosphate (dTMP) residues upon reaction with a suitable restriction enzyme. Thus, PCR generated copies of genes can be directly cloned into the vectors without need for preparing primers having suitable restriction sites therein.

Taq DNA polymerase exhibits terminal transferase activity that adds a single dATP to the 3' ends of PCR products in the absence of template. This activity is the basis for the TA cloning method in which PCR products amplified with Taq are directly ligated into vectors containing single 3'dT overhangs. Archaeal DNA polymerase, on the other hand, lacks terminal transferase activity, and thus produces blunt-ended PCR products that are efficiently cloned into blunt-ended vectors.

In one embodiment, the invention provides for a PCR product, generated in the presence of a mutant DNA polymerase of the present invention, that is subsequently incubated with Taq DNA polymerase in the presence of dATP at 72° C. for 15-30 minutes. Addition of 3'-dAMP to the ends of the amplified DNA product then permits cloning into TA cloning vectors according to methods that are well known to a person skilled in the art.

D. Application in DNA Sequencing

The invention further provides for dideoxynucleotide DNA sequencing methods using thermostable DNA polymerases having a reduced base analog detection activity to catalyze the primer extension reactions. Methods for dideoxynucleotide DNA sequencing are well known in the art and are disclosed in U.S. Pat. Nos. 5,075,216, 4,795,699 and 5,885,813, the contents of which are hereby incorporated in their entirety.

E. Application in Mutagenesis

The mutant Archaeal DNA polymerases of the invention, preferably V93R Pfu DNA polymerase, also provide enhanced efficacy for PCR-based or linear amplification-based mutagenesis. The invention therefore provides for the use of the mutant Archaeal DNA polymerases with reduced base analog detection activity for site-directed mutagenesis and their incorporation into commercially available kits, for example, QuikChange Site-directed Mutagenesis, QuikChange Multi-Site-Directed Mutagenesis (Stratagene). Site-directed mutagenesis methods and reagents are disclosed in the pending U.S. patent application Ser. No. 10/198,449 (Hogrefe et al.; filed Jul. 18, 2002), the contents of which

are hereby incorporated in its entirety. The invention also encompasses Mutazyme (exo⁻ Pfu in combination with PEF, GeneMorph Kit). The GeneMorph kits are disclosed in the pending U.S. patent application Ser. No. 10/154,206 (filed May 23, 2002), the contents of which are hereby incorporated in its entirety.

All of the mutant Archaeal DNA polymerases contemplated herein are useful for PCR and RT-PCR.

Kits
The invention herein also contemplates a kit format which comprises a package unit having one or more containers of the subject composition and in some embodiments including containers of various reagents used for polynucleotide synthesis, including synthesis in PCR. The kit may also contain one or more of the following items: polynucleotide precursors, primers, buffers, instructions, and controls. Kits may include containers of reagents mixed together in suitable proportions for performing the methods in accordance with the invention. Reagent containers preferably contain reagents in unit quantities that obviate measuring steps when performing the subject methods.

The invention contemplates a kit comprising a combination of a mutant ARCHAEAL DNA polymerase of the invention, and another mutant or wild type DNA polymerase.

The invention contemplates a kit comprising a combination of a mutant Archaeal DNA polymerase of the invention, and a PCR additive.

EXAMPLES

Example 1

Construction of Tgo, Pfu, KOD or JDF-3 DNA Polymerase Mutants with Deficient 3'-5' Exonuclease Activity and Reduced Uracil Detection

In one embodiment of the invention, Tgo, Pfu, KOD or JDF-3 DNA polymerase mutants exhibiting substantially reduced 3'-5' exonuclease activity are prepared by introducing amino acid substitutions at the conserved 141D or 143E residues in the exo I domain. Using the CHAMELEON® Double-Stranded, Site-Directed Mutagenesis Kit (Stratagene), the following mutants are constructed: D141A, D141N, D141S, D141T, D141E and E143A for Tgo, Pfu, KOD or JDF-3 DNA polymerases.

To analyze Tgo, Pfu, KOD, JDF-3 mutant proteins, the DNA sequence encoding each of Tgo, Pfu, KOD, and JDF-3 DNA polymerases is PCR amplified using primers GGG AAA CAT ATG ATC CTT GAC GTT GAT TAC (SEQ ID NO: 109; where NdeI site in bold and start codon underlined) and GGG AAA GGA TCC TCA CTT CTT CTT CCC CTT C (SEQ ID NO: 110; where BamHI site shown in bold type). The PCR products are digested, purified, and ligated into a high expression level vector using standard methods. Plasmid clones are transformed into BL21(DE3). Recombinant bacterial clones are grown using standard procedures and polymerase mutants are expressed in the absence of induction. The exonuclease and polymerase activities of recombinant clones are assayed using bacterial lysates. Typically, crude extracts are heated at 70° C. for 15-30 minutes and then centrifuged to obtain a cleared lysate.

The combination exonuclease mutant D141A+E143A is also made as described above herein in the description.

The D141T, E143A, D141A or D141A+E143A double mutants which exhibits significantly reduced 3'-5' exo activity may be chosen for further mutagenesis. For experiment or

applications requiring maximal elimination of 3' to 5' exonuclease activity, the double mutant D141A+E143A is preferred.

Additional mutations are introduced into Tgo, Pfu, KOD or JDF-3 DNA polymerase exo-mutants that are likely to reduce uracil detection, while having minimal effects on polymerase or proofreading activity. With the QuikChange Multi kit, specific point mutations (e.g., V93E, H, K, R, and N) are introduced by incorporating one phosphorylated mutagenic primer or by selecting random mutants from a library of Tgo, Pfu, KOD or JDF-3 DNA V93 variants, created by incorporating a degenerate codon (V93G and L). Clones are sequenced to identify the incorporated mutations.

For example, Valine 93 in Tgo, Pfu, KOD or JDF-3 DNA DNA polymerase may be substituted with Glycine (G), asparagine (N), arginine [R], glutamic acid (E), histidine (H), and leucine (L) using the QuikChange primer sequences listed in FIG. 1.

Example 2

Preparation of Bacterial Extracts Containing Mutant Pfu, KOD or JDF-3 DNA Polymerases

Plasmid DNA is purified with the StrataPrep® Plasmid Miniprep Kit (Stratagene), and used to transform BL26-CodonPlus-RIL cells. Ampicillin resistant colonies are grown up in 1-5 liters of LB media containing Turbo Amp™ (100 µg/µl) and chloramphenicol (30 µg/µl) at 30° C. with moderate aeration. The cells are collected by centrifugation and stored at -80° C. until use.

Cell pellets (12-24 grams) are resuspended in 3 volumes of lysis buffer (buffer A: 50 mM Tris HCl (pH 8.2), 1 mM EDTA, and 10 mM βME). Lysozyme (1 mg/g cells) and PMSF (1 mM) were added and the cells were lysed for 1 hour at 4° C. The cell mixture is sonicated, and the debris removed by centrifugation at 15,000 rpm for 30 minutes (4° C.). Tween 20 and Igepal CA-630 are added to final concentrations of 0.1% and the supernatant is heated at 72° C. for 10 minutes. Heat denatured *E. coli* proteins are then removed by centrifugation at 15,000 rpm for 30 minutes (4° C.).

Example 3

Evaluate 3'-5' Exonuclease Activity and Assessment of dUTP Incorporation by PCR

There are several methods of measuring 3' to 5' exonuclease activity known in the art, including that of Kong et al. (Kong et al., 1993, J. Biol. Chem. 268: 1965) and that of Southworth et al. (Southworth et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93: 5281), the full contents of both of which are hereby incorporated by reference. For example, the exonuclease activity of wild type and active JDF-3 mutant polymerases as measured by the Kong et al. method were as follows: (other DNA polymerase mutants may be measured similarly)

Exo Activity (U/mg):

Wt	915
D141A	7
D141N	953
D141S	954
D141T	0.5

-continued

D141E	940
E143A	0.3

Partially-purified mutant preparations (heat-treated bacterial extracts) are assayed for dUTP incorporation during PCR. For example, a 2.3 kb fragment containing the Pfu pol gene was from plasmid DNA using PCR primers: (FPfuLIC) 5'-gACgACgACAAgATgATTTTAgATgTggAT-3' (SEQ ID NO:1) and (RPfuLIC) 5'-ggAACAAGACCCgTCTAg-ATTTTTTAATg-3' (SEQ ID NO: 2). Amplification reactions consisted of 1× cloned Pfu PCR buffer, 7 ng plasmid DNA, 100 ng of each primer, 2.5 U of Pfu mutant (or wild type Pfu), and 200 µM each dGTP, dCTP, and dATP. To assess relative dUTP incorporation, various amounts of dUTP (0-400 µM) and/or TTP (0-200 µM) were added to the PCR reaction cocktail. The amplification reactions were cycled as described in example 6. Other DNA polymerase mutants may be similarly tested.

Partially-purified preparations of the V93E and V93R mutants showed improved dUTP incorporation compared to wild type Pfu (FIG. 2a). Each mutant successfully amplified a 2.3 kb target in the presence of 200 µM dUTP (plus 200 µM each TTP, dATP, dCTP, dGTP). In contrast, extracts containing the Pfu V93N, V93G, V93H, and V93L mutants showed little-to-no amplification in the presence of 200 µM dUTP, similar to wild type Pfu (data not shown). Additional testing showed that the Pfu V93R mutant extract amplified the 2.3 kb target in the presence of 100% dUTP (0% TTP)(FIG. 2b).

KOD: Partially-purified preparations of KOD V93D, E, K, Q, and R showed reduced uracil sensitivity as evidenced by successful amplification of the 970 bp amplicon using dU-containing primers and TTP (FIG. 11). In contrast, wild type KOD and the KOD V93N mutant were unable to amplify using dU-primers and TTP. Only the KOD V93K and V93R mutants showed complete or nearly complete elimination of uracil sensitivity as shown by successful amplification in the presence of 100% dUTP (FIG. 11). In contrast, the KOD V93D, E, and Q substitutions only partially reduce uracil sensitivity since these mutants are unable to amplify in the presence of 100% dUTP.

The rationale for determining relative uracil sensitivity using PCR assays is as follows. Successful amplification with dU-primers indicates that reduction in uracil sensitivity is sufficient to allow the mutants to polymerize past the nine uracils in the PCR primers (to create the primer annealing sites). However, mutants that successfully amplify in the presence of 100% dUTP, must lack or almost completely lack uracil sensitivity, since they must polymerize past numerous uracils (~230 uracils per strand; 925 bp segment synthesized with 25% T content) in the template strand.

Tgo: Only the Tgo V93R mutant successfully amplified the 0.97 kb amplicon in the presence of 100% dUTP (FIG. 12), indicating that the arginine substitution was most effective in reducing uracil sensitivity.

JDF-3: Only the JDF-3 V93R and V93K mutants successfully amplified the 0.97 kb amplicon in the presence of 100% dUTP (FIG. 12), indicating that the arginine and lysine substitutions were the most effective in reducing uracil sensitivity. Product yields with 100% dUTP were noticeably lower than yields with 100% TTP suggesting that in JDF-3, the V93R mutation does not completely eliminate uracil sensitivity (FIG. 13). In contrast, Pfu V93R, Tgo V93R, and KOD V93R produce similar yields with TTP and dUTP, indicating that uracil sensitivity is almost completely eliminated.

Pfu deletions. We constructed deletions (92,92,94, 92-93, 93-94, 92-94) and insertions (1-3 glycines between D92 and V93) in Pfu centering around V93. Only the Pfu delta V93 and delta D92-V93-P94 mutants showed a reduction in uracil sensitivity (FIG. 14). Based on amplification of 0.6 kb, 2.6 kb, and 6 kb genomic amplicons, relative uracil sensitivity was determined as follows: (least sensitive/highest dTUP incorporation) Pfu V93R>Pfu delta 93>Pfu delta 92-94>wild type Pfu (most sensitive/no dUTP incorporation).

Example 4

Purification of DNA Polymerase Mutants

Bacterial expression of Pfu mutants. Pfu mutants (Tgo, or KOD or JDF-3 mutants) can be purified as described in U.S. Pat. No. 5,489,523 (purification of the *exo*⁻ Pfu D141A/E143A DNA polymerase mutant) or as follows. Clarified, heat-treated bacterial extracts were chromatographed on a Q-Sepharose™ Fast Flow column (~20 ml column), equilibrated in buffer B (buffer A plus 0.1% (v/v) Igepal CA-630, and 0.1% (v/v) Tween 20). Flow-through fractions were collected and then loaded directly onto a P11 Phosphocellulose column (~20 ml), equilibrated in buffer C (same as buffer B, except pH 7.5). The column was washed and then eluted with a 0-0.7M KCl gradient/Buffer C. Fractions containing Pfu DNA polymerase mutants (95 kD by SDS-PAGE) were dialyzed overnight against buffer D (50 mM Tris HCl (pH 7.5), 5 mM βME, 5% (v/v) glycerol, 0.2% (v/v) Igepal CA-630, 0.2% (v/v) Tween 20, and 0.5M NaCl) and then applied to a Hydroxyapatite column (~5 ml), equilibrated in buffer D. The column was washed and Pfu DNA polymerase mutants were eluted with buffer D2 containing 400 mM KPO₄, (pH 7.5), 5 mM βME, 5% (v/v) glycerol, 0.2% (v/v) Igepal CA-630, 0.2% (v/v) Tween 20, and 0.5 M NaCl. Purified proteins were spin concentrated using Centricon YM30 devices, and exchanged into Pfu final dialysis buffer (50 mM Tris-HCl (pH 8.2), 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 50% (v/v) glycerol, 0.1% (v/v) Igepal CA-630, and 0.1% (v/v) Tween 20).

Protein samples were evaluated for size, purity, and approximate concentration by SDS-PAGE using Tris-Glycine 4-20% acrylamide gradient gels. Gels were stained with silver stain or Sypro Orange (Molecular Probes). Protein concentration was determined relative to a BSA standard (Pierce) using the BCA assay (Pierce).

Results: Pfu *exo*-D141A/E143A mutants with additional V93E or V93R mutations were purified to 90% purity as determined by SDS-PAGE.

Example 5

Determining Mutant Polymerase Unit Concentration and Specific Activity

The unit concentration of purified Pfu mutant preparations was determined by PCR. In this assay, a 500 bp *lacZ* target is amplified from transgenic mouse genomic DNA using the forward primer: 5'-GACAGTCACTCCGCGCCG-3' (SEQ ID NO:15) and the reverse primer: 5'-CGACGACTCGTGAGCCCC-3' (SEQ ID NO: 16). Amplification reactions consisted of 1× cloned Pfu PCR buffer, 10 ng genomic DNA, 150 ng each primer, 200 μM each dNTP, and varying amounts of either wild type Pfu (1.25 U to 5 U) or Pfu mutant (0.625-12.5 U). Amplification was performed using a RoboCycler® temperature cycler (Stratagene) with the following program: (1 cycle) 95° C. for 2 minute; (30 cycles) 95° C. for 1 minute, 58° C. for 1 minute, 72° C. for 1.5 minutes; (1 cycle) 72° C. for 7 minutes. PCR products were examined on 1% agarose gels containing ethidium bromide.

Results: FIG. 3 contains a table listing the protein concentration, unit concentration, and specific activity of the purified Pfu V93R and V93E mutants.

The purified mutants were also re-assayed to assess dUTP incorporation during PCR, according to the method described in Example 3. FIG. 4 shows that the Pfu V93R mutant produces similar yields of the 500 bp amplicon in the presence of 100% TTP (lane 8), 50% TTP:50% dUTP (lane 5), and 100% dUTP (lane 7), while the Pfu V93E mutant produces high yields in the presence of 100% TTP (lane 1) and 50% TTP: 50% dUTP (lane 3) and lower yields in the presence of 100% dUTP (lane 4). In contrast, cloned Pfu can only amplify in the presence of 100% TTP (lane 12). These results indicate that the V93R and V93E mutations significantly improve dUTP incorporation compared to wild type Pfu, and that the V93R mutation appear to be superior to the V93E mutation with respect to reducing uracil detection.

Example 6

PCR Amplification with Purified DNA Polymerase Mutants

PCR reactions are conducted under standard conditions in cloned Pfu PCR buffer (10 mM KCl, 10 mM (NH₄)₂SO₄, 20 mM Tris HCl (pH 8.8), 2mM Mg SO₄, 0.1% Triton X-100, and 100 μg/ml BSA) with various amounts of cloned Pfu, PfuTurbo, or mutant Pfu DNA polymerase. For genomic targets 0.3-9 kb in length, PCR reactions contained 100 ng of human genomic DNA, 200 μM each dNTP, and 100 ng of each primer. For genomic targets >9 kb in length, PCR reactions contained 250 ng of human genomic DNA, 500 μM each dNTP, and 200 ng of each primer.

Table 3—Cycling Conditions:

TABLE 4

Amplicon	PCR primers	Cycling conditions
0.6 kb lambda	F: 5'-GGAATGAAGTTATCCCCGCTTCCCC (SEQ ID NO: 41) R: 5'-CCAGTTCATTGAGCGTATTTCAG-3' (SEQ ID NO: 42)	93° C. 1 min (1x) 93° C. 1 min, 60° C. 40 s, 72° C. 1 min (30x) 72° C. 10 min (1x)
0.97 lambda	FU: 5'-GGAAUGAAGUUAUCCCCGCUUCCCC- (SEQ ID NO: 75) RU: 5'-CCAGGUCUCCAGCGUGCCCA-3' (SEQ ID NO: 76) FT: 5'-GGAATGAAGTTATCCCCGCTTCCCC (SEQ ID NO: 77)	93° C. 1 min (1x) 93° C. 1 min, 60° C. 50 s, 72° C. 1 min (30x) 72° C. 10 min (1x)

TABLE 4-continued

Amplicon	PCR primers	Cycling conditions
	RT: 5'-CCAGGTCTCCAGCGTGCCCA-3' (SEQ ID NO: 78)	
2.6 kb Human genomic (α 1 anti-trypsin)	F: 5'GAG GAG AGC AGG AAA GGT GGA AC (SEQ ID NO: 79) R: 5'TGC AGA GCG ATT ATT CAG GAA TGC (SEQ ID NO: 80)	95° C. 2 min (1x) 95° C. 40 s, 58° C. 30 s, 72° C. 3 min (30x) 72° C. 7 min (1x)
6 kb Human genomic (α 1 anti-trypsin)	F: 5'GAG GAG AGC AGG AAA GGT GGA AC (SEQ ID NO: 81) R: 5'GAG CAA TGG TCA AAG TCA ACG TCA TCC ACA GC (SEQ ID NO: 82)	92° C. 2 min (1x) 92° C. 10 s, 58° C. 30 s, 68° C. 12 min (10x) 92° C. 10 s, 58° C. 30 s, 68° C. 12 min plus 10 s/cycle (20x) 68° C. 10 min (1x)

Pfu mutants are described here as examples, but the same protocol can be used for PCR by other DNA polymerase mutants (e.g., KOD and JDF-3). Comparisons were carried out to determine if mutations that improve dUTP incorporation, and hence reduce uracil detection, also improve PCR performance. In FIG. 5, a 12 kb target was amplified from human genomic DNA using 2 min per kb extension times. Under these conditions, 1 U, 2 U, and 4 U of the Pfu V93R mutant successfully amplified the target, while the same amount of cloned Pfu could not. In comparison, PfuTurbo successfully amplified the long target; however, PCR product yields were significantly lower than those produced with the V93R mutant (FIG. 5). Similar experiments employing 1 min per kb extension times showed that the 12 kb target could be amplified in high yield with 5 U and 10 U of Pfu V93R and amplified in low yield with 10 U of PfuTurbo (data not shown). In total, these results demonstrate that the V93R mutation dramatically improves the PCR performance of Pfu DNA polymerase.

Similar testing of the purified Pfu V93E mutant showed that although the V93E mutation improves dUTP incorporation (FIG. 2), this mutant is not robust enough to amplify the long 12 kb amplicon when assayed using enzyme amounts between 0.6 U and 10 U (data not shown). In comparison, the product was successfully amplified using 10 U of PfuTurbo (data not shown).

FIG. 8 shows the results of additional Pfu mutations on dUTP incorporation. Pfu V93K and V93R mutants show significantly improved dUTP incorporation compared to wild type Pfu. In contrast, the Pfu V93W, V93 V93W, V93Y and V93M mutants showed little to no improvement in dUTP incorporation (see FIG. 8A). In addition, both V93D and V93R mutants showed significantly improved dUTP incorporation, compared to wild type (FIG. 8B), while the V93N mutation showed a very small improvement in dUTP incorporation (FIG. 8C). The Pfu V93G mutation showed little to no improvement in dUTP incorporation.

Example 7

Construction of Pfu DNA Polymerase Deletion and Insertion Mutants

Mutants with altered polymerization activity may also be constructed using the exo- and/or V93 mutants obtained. For example, insertions and deletions were introduced in Pfu DNA polymerase in the region around V93 using the QuikChange Multi Site-Directed Mutagenesis Kit (Strat-

agene). FIG. 10 lists the primer sequences employed to generate useful mutations. Clones were sequenced to identify the incorporated mutations.

The following Pfu mutants were constructed: deletions of residues 93, 92, 94, 92-93, 93-94, and 92-94, and insertions of one, two, or three glycines between residues 92 and 93.

Example 8

Quantitative PCR Using Mutant DNA Polymerase of the Present Invention

PCR reactions may be set up as described above in Example 6. A Taqman probe (labeled) may be added as described by Applied Biosystems (CA). an oligonucleotide probe containing a reporter molecule-quencher molecule pair that specifically anneals to a region of a target polynucleotide “downstream”, i.e. in the direction of extension of primer binding sites. The reporter molecule and quencher molecule are positioned on the probe sufficiently close to each other such that whenever the reporter molecule is excited, the energy of the excited state nonradiatively transfers to the quencher molecule where it either dissipates nonradiatively or is emitted at a different emission frequency than that of the reporter molecule. During strand extension by a mutant DNA polymerase of the present invention, the probe anneals to the template where it is digested by the 5' to 3' exonuclease activity of the polymerase. As a result of the probe being digested, the reporter molecule is effectively separated from the quencher molecule such that the quencher molecule is no longer close enough to the reporter molecule to quench the reporter molecule's fluorescence. Thus, as more and more probes are digested during amplification, the number of reporter molecules in solution increases, thus resulting in an increasing number of unquenched reporter molecules which produce a stronger and stronger fluorescent signal. are labeled with a fluorophore and a quencher of that fluorophore, respectively. In the absence of target polynucleotide, the complementary sequences on either end of the molecule permit stem formation, bringing the labeled ends of the molecule together, so that fluorescence from the fluorophore is quenched. In the presence of the target polynucleotide, which bears sequence complementary to the loop and part of the stem structure of the beacon probe, the intermolecular hybridization of the probe to the target is energetically favored over intramolecular stem-loop formation, resulting in the separation of the fluorophore and the quencher, so that fluorescent signal is emitted upon excitation of the fluorophore. The more target present, the more probe hybridizes to it, and the more fluo-

rophore is freed from quenching, providing a read out of the amplification process in real time.

All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. While this invention has been particularly shown and

described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 110

<210> SEQ ID NO 1
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 1

gacgacgaca agatgatattt agatgtggat 30

<210> SEQ ID NO 2
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 2

ggaacaagac ccgtctagga ttttttaatg 30

<210> SEQ ID NO 3
 <211> LENGTH: 23
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (23)..(23)
 <223> OTHER INFORMATION: n = Uracil

<400> SEQUENCE: 3

gacgttgtaa aacgacggcc agn 23

<210> SEQ ID NO 4
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 4

acgttgtaaa acgacggcca gt 22

<210> SEQ ID NO 5
 <211> LENGTH: 31
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 5

caatttcaca caggaaacag ctatgaccat g 31

<210> SEQ ID NO 6
 <211> LENGTH: 37
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 6

gaacatcccc aagatgaacc cactattaga gaaaaag 37

<210> SEQ ID NO 7
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 7

ctttttctct aatagtgggt tcatcttggg gatgttc 37

<210> SEQ ID NO 8
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 8

gaacatcccc aagatagacc cactattaga gaaaaag 37

<210> SEQ ID NO 9
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 9

ctttttctct aatagtgggt ctatcttggg gatgttc 37

<210> SEQ ID NO 10
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 10

gaacatcccc aagataaccc cactattaga gaaaaag 37

<210> SEQ ID NO 11
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 11

ctttttctct aatagtgggg ttatcttggg gatgttc 37

<210> SEQ ID NO 12
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 12

gaacatcccc aagatcaccc cactattaga gaaaaag 37

-continued

```

<210> SEQ ID NO 13
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 13

ctttttctct aatagtgggg tgatcttggg gatgttc          37

<210> SEQ ID NO 14
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5' phosphate
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (16)..(17)
<223> OTHER INFORMATION: n= A, T, G or C

<400> SEQUENCE: 14

gaacatcccc aagatnnkcc cactattaga gaaaaag          37

<210> SEQ ID NO 15
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 15

gacagtcact ccggcccg          18

<210> SEQ ID NO 16
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 16

cgacgactcg tggagccc          18

<210> SEQ ID NO 17
<211> LENGTH: 2328
<212> TYPE: DNA
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 17

atgatttttag atgtggatta cataactgaa gaaggaaaac ctgttattag gctattcaaa          60
aaagagaacg gaaaatttaa gatagagcat gatagaactt ttagaccata catttacgct          120
cttctcaggg atgattcaaa gattgaagaa gttaagaaaa taacggggga aaggcatgga          180
aagattgtga gaattgttga ttagagagaag gttgagaaaa agtttctcgg caagcctatt          240
accgtgtgga aactttatatt ggaacatccc caagatgttc ccactattag agaaaaagtt          300
agagaacatc cagcagttgt ggacatcttc gaatacgata ttccatttgc aaagagatac          360
ctcatcgaca aaggcctaata accaatggag ggggaagaag agctaaagat tcttgccttc          420
gatatagaaa ccctctatca cgaaggagaa gagtttggaa aaggcccaat tataatgatt          480
agttatgcag atgaaaatga agcaaagtg attacttggg aaaacataga tcttcatac          540

```

-continued

gttgaggttg tatcaagcga gagagagatg ataaagagat ttctcaggat tatcagggag	600
aaggatcctg acattatagt tacttataat ggagactcat tcgcattccc atatttagcg	660
aaaagggcag aaaaacttgg gattaaatta accattggaa gagatggaag cgagcccaag	720
atgcagagaa taggcgatat gacggctgta gaagtcaagg gaagaatata ttctgacttg	780
tatcatgtaa taacaaggac aataaatctc ccaacatata cactagaggc tgtatatgaa	840
gcaatTTTTg gaaagccaaa ggagaaggta tacgccgacg agatagcaaa agcctgggaa	900
agtgagagaga accttgagag agttgccaaa tactcgatgg aagatgcaaa ggcaacttat	960
gaactcggga aagaattcct tccaatggaa attcagcttt caagattagt tggacaacct	1020
ttatgggatg tttcaaggtc aagcacaggg aaccttgtag agtggttctt acttaggaaa	1080
gcctacgaaa gaaacgaagt agctccaaac aagccaagtg aagaggagta tcaaagaagg	1140
ctcagggaga gctacacagg tggattcggt aaagagccag aaaaggggtt gtgggaaaac	1200
atagtatacc tagattttag agccctatat cctcggatta taattaccca caatgtttct	1260
cccgatactc taaatcttga gggatgcaag aactatgata tcgctcctca agtaggccac	1320
aagttctgca aggacatccc tggttttata ccaagtctct tgggacattt gttagaggaa	1380
agacaaaaga ttaagacaaa aatgaaggaa actcaagatc ctatagaaaa aatactcctt	1440
gactatagac aaaaagcgat aaaactctta gcaaatctt tctacggata ttatggctat	1500
gcaaaagcaa gatggtactg taaggagtgt gctgagagcg ttactgcctg gggaaagaaag	1560
tacatcgagt tagtatgaa ggagctcgaa gaaaagttag gatttaaagt cctctacatt	1620
gacactgatg gtctctatgc aactatocca ggaggagaaa gtgaggaaat aaagaaaaag	1680
gctctagaat ttgtaaaata cataaattca aagctccctg gactgctaga gcttgaatat	1740
gaagggtttt ataagagggg attctctggt acgaagaaga ggtatgcagt aatagatgaa	1800
gaaggaaaag tcattactcg tggtttagag atagtttaga gagattggag tgaattgca	1860
aaagaaactc aagctagagt ttggagaca atactaaaac acggagatgt tgaagaagct	1920
gtgagaatag taaaagaagt aatacaaaag cttgccatt atgaaattcc accagagaag	1980
ctcgcaatat atgagcagat aacaagacca ttacatgagt ataaggcgat aggtcctcac	2040
gtagctgttg caaagaaact agctgctaaa ggagttaaaa taaagccagg aatggtaatt	2100
ggatacatag tacttagagg cgatggtcca attagcaata gggcaattct agctgaggaa	2160
tacgatccca aaaagcacaa gtatgacgca gaattattaca tggagaacca ggttcttcca	2220
gcggtactta ggatattgga gggatttga tacagaaagg aagacctcag ataccaaag	2280
acaagacaag tcggcctaac ttctgggtt aacattaata aatcctag	2328

<210> SEQ ID NO 18

<211> LENGTH: 2325

<212> TYPE: DNA

<213> ORGANISM: Pyrococcus sp.

<400> SEQUENCE: 18

atgatcctcg acactgacta cataaccgag gatggaaagc ctgtcataag aattttcaag	60
aaggaaaaac gcgagtttaa gattgagtac gaccggactt ttgaacceta cttctacgcc	120
ctcctgaagg acgattctgc cattgaggaa gtcaagaaga taaccgcga gaggcacggg	180
acggttgtaa cggttaagcg ggttgaaaag gttcagaaga agttcctcgg gagaccagtt	240
gaggtctgga aactctactt tactcatcgg caggacgtcc cagcgataag ggacaagata	300
cgagagcatc cagcagttat tgacatctac gactacgaca tacccttcgc caagcgctac	360

-continued

ctcatagaca agggattagt gccaatggaa ggcgacgagg agctgaaaat gctcgccctc	420
gacattgaaa ctctctacca tgagggcgag gagttcgccg aggggccaat ccttatgata	480
agctacgcgc acgaggaagg ggccagggtg ataacttgga agaactgga tctccctac	540
gttgacgtcg tctcgacgga gaggagatg ataaagcgct tcctccgtgt tgtgaaggag	600
aaagaccgag acgttctcat aacctacaac ggcgacaact tgcacttcgc ctatctgaaa	660
aagcgctgtg aaaagctcgg aataaacttc gccctcggaa gggatggaag cgagccgaag	720
attcagagga tgggcgacag gtttgccgtc gaagtgaagg gacggataca cttcgatctc	780
tatcctgtga taagacggac gataaacctg cccacataca cgcttgaggc cgtttatgaa	840
gccgtcttcg gtcacgccga ggagaagggt tacgctgagg aaataaccac agcctgggaa	900
accggcgaga accttgagag agtcgcccgc tactcgatgg aagatgcgaa ggtcacatac	960
gagcttgagg aggagttcct tcgcatggag gccagcttt ctgccttaat cgccagctc	1020
ctctgggacg tctcccgctc cagcactggc aacctcgttg agtggttcct cctcaggaag	1080
gcctatgaga ggaatgagct ggcccgaac aagcccgatg aaaaggagct ggccagaaga	1140
cggcagagct atgaaggagg ctatgtaaaa gagcccgaga gagggttggt ggagaacata	1200
gtgtacctag atttttagatc cctgtacccc tcaatcatca tcaaccacaa cgtctcgccg	1260
gatacgctca acagagaagg atgcaaggaa tatgacgttg cccacacagt cgccaccgc	1320
ttctgcaagg acttcccagg atttatcccg agcctgcttg gagacctcct agaggagagg	1380
cagaagataa agaagaagat gaaggccacg attgacccga tcgagaggaa gctcctcgat	1440
tacaggcaga gggccatcaa gatcctggca aacagctact acggttacta cggtatgca	1500
agggcgcgct ggtactgcaa ggagtgtgca gagagcgtaa cggcctgggg aagggagtac	1560
ataacgatga ccatcaagga gatagaggaa aagtacggct ttaaggtaat ctacagcgac	1620
accgacggat tttttgccac aatacctgga gccgatgctg aaacgtcaa aaagaaggct	1680
atggagttcc tcaagtatat caacgcaaaa cttccgggcg cgcttgagct cgagtacgag	1740
ggcttctaca aacgcggctt cttcgtcacg aagaagaagt atgcggtgat agacgaggaa	1800
ggcaagataa caacgcgcgg acttgagatt gtgaggcgtg actggagcga gatagcgaaa	1860
gagacgcagg cgagggttct tgaagcttg ctaaaggacg gtgacgtcga gaaggccgtg	1920
aggatagtca aagaagttac cgaaaagctg agcaagtacg aggttcgcc ggagaagctg	1980
gtgatccacg agcagataac gagggattha aaggactaca aggcaaccgg tccccacgtt	2040
gccgttgcca agaggttggc cgcgagagga gtcaaaatac gccctggaac ggtgataagc	2100
tacatcgctc tcaagggtc tgggaggata ggcgacaggc cgataccgtt cgacgagttc	2160
gacccgacga agcacaagta cgacgccgag tactacattg agaaccaggt tctccagcc	2220
gttgagagaa ttctgagagc cttcggttac cgcaaggaa acctcgcta ccagaagacg	2280
agacaggttg gtttgagtgc ttggctgaag ccgaaggga cttga	2325

<210> SEQ ID NO 19

<211> LENGTH: 2325

<212> TYPE: DNA

<213> ORGANISM: Thermococcus litoralis

<400> SEQUENCE: 19

atgatactgg acactgatta cataacaaaa gatggcaagc ctataatccg aatttttaag	60
aaagagaacg gggagtttaa aatagaactt gacctcatt ttcagcccta tatatatgct	120
cttctcaaag atgactccgc tattgaggag ataaaggcaa taaaggcgga gagacatgga	180

-continued

aaaactgtga gagtgctcga tgcagtga aa gtcaggaaaa aatTTTTTggg aagggaaagt	240
gaagtctgga agctcatttt cgagcatccc caagacgttc cagctatgcg gggcaaaata	300
agggaaacatc cagctgtggt tgacatttac gaatatgaca taccctttgc caagcgttat	360
ctcatagaca agggcttgat tcccatggag ggagacgagg agcttaagct ccttgccctt	420
gatattgaaa cgTTTTatca tgaggagat gaatttggaa agggcgagat aataatgatt	480
agttatgccg atgaagaaga gggcagagta atcacatgga aaaatatcga ttgccgtat	540
gtcagatgtg tgtccaatga aagagaaatg ataagcggt ttgttcaagt tgttaaagaa	600
aaagaccccg atgtgataat aacttacaat ggggacaatt ttgatttgcc gtatctcata	660
aaacgggcag aaaagctggg agttcggctt gtcttaggaa gggacaaaga acatcccgaa	720
cccaagattc agaggatggg tgatagtttt gctgtggaaa tcaagggtag aatccacttt	780
gatcttttcc cagttgtgcg aaggacgata aacctcccaa cgtatacgct tgaggcagtt	840
tatgaagcag ttttaggaaa aacccaaagc aaattaggag cagaggaaat tgcgctata	900
tgggaaacag aagaagcat gaaaaaacta gcccagtaact caatggaaga tgctagggca	960
acgtatgagc tcgggaagga attcttcccc atggaagctg agctggcaaa gctgataggt	1020
caaagtgtat gggacgtctc gagatcaagc accggcaacc tcgtggagtg gtatctttta	1080
aggggtgcat acgcgaggaa tgaacttgca ccgaacaaac ctgatgagga agagtataaa	1140
cggcgcttaa gaacaactta cctgggagga tatgtaaaag agccagaaaa aggtttgttg	1200
gaaaaatatca tttatttggg ttcccgagc ctgtaccctt caataatagt tactcacaac	1260
gtatccccag atacccttga aaaagagggc tgtaagaatt acgatgttg tccgatagta	1320
ggatataggt tctgaagga ctttccgggc tttattccct ccatactcgg ggacttaatt	1380
gcaatgaggc aagatataaa gaagaaaatg aaatccacaa ttgaccgat cgaaaagaaa	1440
atgctcgatt ataggcaaa ggctattaaa ttgcttgcaa acagctatta cggctatatg	1500
gggtatccta aggcaagatg gtactcgaag gaatgtgctg aaagcgttac cgcgtgggg	1560
agacactaca tagagatgac gataagagaa atagaggaaa agttcggctt taaggttctt	1620
tatgcggaca ctgacggctt ttatgccaca ataccgggg aaaagcctga actcattaaa	1680
aagaaagcca aggaattcct aaactacata aactccaaac ttccaggctt gcttgagctt	1740
gagtatgagg gcttttactt gagaggatc tttgttaca aaaagcgcta tgcagtcata	1800
gatgaagagg gcaggataac aacaaggggc ttggaagtag taaggagaga ttggagttag	1860
atagctaagg agactcaggc aaaggtttta gaggtatata ttaaaggagg aagtgttgaa	1920
aaagctgtag aagttgttag agatgttgta gagaaaatag caaaatacag ggttccactt	1980
gaaaagcttg ttatccatga gcagattacc agggatttaa aggactacaa agccattggc	2040
cctcatgtcg cgatagcaaa aagacttgcc gcaagaggga taaaagtga accgggcaca	2100
ataataagct atatcgttct caaagggagc ggaaagataa gcgatagggt aattttactt	2160
acagaatacg atcctagaaa acacaagtac gatccggact actacataga aaaccaagtt	2220
ttgccggcag tacttaggat actcgaagcg tttggataga gaaaggagga ttaaggtat	2280
caaagctcaa aacaacccgg cttagatgca tggctcaaga ggtag	2325

<210> SEQ ID NO 20

<211> LENGTH: 2328

<212> TYPE: DNA

<213> ORGANISM: *Pyrococcus* sp.

<400> SEQUENCE: 20

-continued

atgatacttg acgctgacta catcaccgag gatgggaagc cgattataag gattttcaag	60
aaagaaaacg gcgagtttaa ggttgagtag gacagaaact ttagacctta catttacgct	120
ctcctcaaag atgactcgca gattgatgag gttaggaaga taaccgccga gaggcacggg	180
aagatagtag gaattataga tgccgaaaag gtaaggaaga agttcctggg gaggccgatt	240
gaggtagtga ggctgtactt tgaacacctt caggacgttc ccgcaataag ggataagata	300
agagagcatt ccgcagttat tgacatcttt gactacgaca ttccgttcgc gaagaggtac	360
ctaatagaca aaggcctaatt tccaatggaa ggcatgaag agctcaagtt gctcgcat	420
gacatagaaa ccctctatca cgaaggggag gagttcgcga aggggcccata tataatgata	480
agctatgctg atgaggaaga agccaaagtc ataactggga aaaagatcga tctcccgtag	540
gtcagagtag tttccagcga gagggagatg ataaagcggg ttctcaaggt gataagggag	600
aaagatcccg atgttataat tacctacaac ggcatgattt tcgaccttcc ctatctagtt	660
aagagggccg aaaagctcgg gataaagcta ccctggggaa gggacggtag tgagccaaag	720
atgcagagggc ttggggatgat gacagcgggt gagataaagg gaagataca ctttgacctc	780
taccacgtga ttaggagaac gataaacctc ccaacataca ccctcgaggg agtttatgag	840
gcaatcttcg gaaagccaaa ggagaaagtt tacgctcacg agatagctga ggccgggag	900
actggaaagg gactggagag agttgcaaag tattcaatgg aggatgcaa ggtaacgtac	960
gagctcggta gggagtcttt cccaatggag gccagcttt caaggttagt cggccagccc	1020
ctgtgggatg tttctaggtc ttcaactggc aacttggtgg agtggtacct cctcaggaag	1080
gcctacgaga ggaatgaatt ggctccaaac aagccggatg agagggagta cgagagaagg	1140
ctaagggaga gctacgtcg gggatagctt aaggagccgg agaaagggct ctgggagggg	1200
ttagtctccc tagatttcag gagcctgtac ccctcgataa taatcaccca taacgtctca	1260
ccggatagcg tgaacaggga aggggttagg gaatacgtat tcgcccaga ggttgggcac	1320
aagttctgca aggacttccc ggggtttatc cccagcctgc tcaagaggtt attggatgaa	1380
aggcaagaaa taaaaggaa gatgaaagct tctaaagacc caatcgagaa gaagatgctt	1440
gattacagggc aacgggcaat caaaatcctg gcaaacagct attatgggta ttatgggtac	1500
gcaaaagccc gttggtactg taaggagtgc gcagagagcg ttacggcctg ggggagggaa	1560
tatatagagt tcgtaaggaa ggaactggag gaaaagtctg ggttcaaagt cttatacata	1620
gacacagatg gactctacgc cacaattcct ggggcaaac ccgaggagat aaagaagaaa	1680
gccctagagt tcgtagatta tataaacgcc aagctcccag ggctgttgga gcttgagtac	1740
gagggcttct acgtgagagg gttcttcgtg acgaagaaga agtatgcgtt gatagatgag	1800
gaaggggaaga taatcactag ggggcttgaa atagtcagga gggactggag cgaaatagcc	1860
aaagaaaccc aagcaaaagt cctagaggct atcctaagc atggcaacgt tgaggaggca	1920
gtaaagatag ttaaggaggt aactgaaaag ctgagcaagt acgaaatacc tccagaaaag	1980
ctagttattt acgagcagat cagcaggccc cttcacgagt acaaggctat aggtccgcac	2040
gttgccgtgg caaaaagggt agccgctaga ggagtaaagg tgaggcctgg catggtgata	2100
gggtacatag tgctgagggg agacgggcca ataagcaaga gggctatcct tgcagaggag	2160
ttcgatctca ggaagcataa gtatgacgt gattattaca tagaaaatca ggttttacct	2220
gccgttctta gaatattaga ggcctttggg tacaggaaaag aagacctcag gtggcagaag	2280
actaaacaga caggctctac ggcatggctt aacatcaaga agaagtaa	2320

-continued

<210> SEQ ID NO 21
 <211> LENGTH: 2331
 <212> TYPE: DNA
 <213> ORGANISM: Thermococcus sp.

<400> SEQUENCE: 21

```

atgataccttg acgttgatta catcaccgag aatggaaagc ccgtcatcag ggtcttcaag    60
aaggagaacg gcgagttagc gattgaatac gaccgcgagt tcgagcccta cttctacgcg    120
ctcctcaggg acgactctgc catcgaagaa atcaaaaaga taaccgcgga gaggcacggc    180
agggctcgtta aggttaacgc cgcggagaag gtgaagaaaa agttctctcg caggctctgtg    240
gaggctctggg tctctactt caccgacccg caggacgttc cggcaatccg cgacaaaata    300
aggaagcacc ccgcggtcat cgacatctac gactacgaca tacccttcgc caagcgctac    360
ctcatagaca agggcctaata cccgatggaa ggtgaggaag agcttaact catgtccttc    420
gacatcgaga cgctctacca cgaggagaa gagtttgaa ccgggccgat tctgatgata    480
agctacccg atgaaagcga ggcgcgcgtg ataacctgga agaagatcga ccttccttac    540
gttgagggtg tctccaccga gaaggagatg attaagcgtc tcttgagggt cgttaaggag    600
aaggaccgcg acgtgctgat aacatacaac ggcgacaact tcgacttcgc ctacctgaaa    660
aagcgctgtg agaagcttg cgtgagcttt accctcggga gggacgggag cgagccgaag    720
atacagcgca tgggggacag gtttcgggc gaggtgaagg gcagggtaca cttcgacctt    780
tatccagtca taaggcgcac cataaacctc ccgacctaca cccttgaggc tgtatacgag    840
gcggttttcg gcaagcccaa ggagaaggtc tacgccgagg agatagccac cgctgggag    900
accggcgagg ggettgagag ggtcgcgcgc tactcgatgg aggacgcgag ggttacctac    960
gagcttgga cggagttctt cccgatggag gccagcttt ccaggctcat cggccaaggc    1020
ctctgggacg ttcccgctc cagcaccggc aacctcgtcg agtggttcct cctaaggaag    1080
gcctacgaga ggaacgaact cgctcccaac aagcccgacg agagggagct ggcgaggaga    1140
agggggggct acgcgggtg ctacgtcaag gagccggagc ggggactgtg ggacaatatc    1200
gtgtatctag accttcctag tctctacctc tcaatcataa tcaccacaa cgtctcgcca    1260
gatacgtca accgcgagg gtgtaggagc tacgacgttg ccccgagggt cggtcacaag    1320
ttctgcaagg acttccccg cttcattccg agcctgctcg gaaacctgct ggaggaaagg    1380
cagaagataa agaggaagat gaaggcaact ctgacccgc tggagaagaa tctctcgat    1440
tacaggcaac gcgccatcaa gattctcgcc aacagctact acggctacta cggctatgcc    1500
agggcaagat ggtactgcag ggagtgcgcc gagagcgtta cggcatgggg aaggagtagc    1560
atcgaaatgg tcatcagaga gcttgaggaa aagttcgggt ttaaagtcct ctatgcagac    1620
acagacgggc tccatgccac cattctgga gcggacgctg aaacagtcaa gaaaaaggca    1680
atggagttct taaactatat caatcccaaa ctgcccggcc ttctcgaact cgaatacgag    1740
ggcttctacg tcaggggctt cttcgtcacg aagaaaaagt acgcggtcat cgacgaggag    1800
ggcaagataa ccacgcgcgg gcttgagata gtcaggcgcg actggagcga gatagcgaag    1860
gagacgcagg cgaggggttt ggaggcgata ctcaggcacg gtgacgttga agaggccgtc    1920
agaattgtca gggaagtac cgaaaagctg agcaagtacg aggttcgcc ggagaagctg    1980
gttatccacg agcagataac gcgcgagctc aaggactaca aggccaccg cccgcacgta    2040
gccatagcga agcgtttggc cgccagaggt gttaaaatcc ggcccgaac tgtgataagc    2100
tacatcgctc tgaagggtc cggaaggata ggcgacaggc cgattccctt cgacgagttc    2160
gacccgacga agcacaagta cgatgcggac tactacatcg agaaccaggt tctgccggca    2220

```

-continued

```
gttgagagaa tcttcagggc cttcggttac cgcaaggaag acctgcgcta ccagaagacg 2280
aggcagggtcg ggcttggcgc gtggctgaag ccgaagggga agaagaagtg a 2331
```

<210> SEQ ID NO 22

<211> LENGTH: 2322

<212> TYPE: DNA

<213> ORGANISM: Thermococcus gorgonaius

<400> SEQUENCE: 22

```
atgatcctcg atacagacta cataactgag gatggaaagc cgtcatcag gatcttcaag 60
aaggagaacg gcgagttcaa aatagactac gacagaaact ttgagccata catctacgcg 120
ctcttgaagg acgactctgc gattgaggac gtcaagaaga taactgccga gaggcacggc 180
actaccgtta gggttgtcag ggccgagaaa gtgaagaaga agttcctagg caggccgata 240
gagggtctgga agctctactt cactcaccoc caggacgttc ccgcaatcag ggacaagata 300
aaggagcatc ctgcggttgt ggacatctac gagtacgaca tccccttcgc gaagcgctac 360
ctcatagaca aaggcttaat cccgatggag ggcgacgagg aacttaagat gctcgccttc 420
gacatcgaga cgctctatca cgagggcgag gagttcgccg aagggcctat cctgatgata 480
agctacgcgc acgaggaagg ggcgcgcgtt attacctgga agaatatcga ccttccttat 540
gtcgcgctcg ttccaccga gaaggagatg ataaagcgtt tcttcaaggt cgtcaaggaa 600
aaggatcccg acgtcctcat aacctacaac ggcgacaact tcgacttcgc ctacctcaag 660
aagcgctccg agaagctcgg agtcaagttc atcctcggaa gggaaggagg cgagccgaaa 720
atccagcgca tgggcgatcg ctttgcggtg gaggtcaagg gaaggattca cttcgacctc 780
taccocgtca ttaggagaac gattaacctc cccacttaca cccttgaggc agtatatgaa 840
gccatctttg gacagccgaa ggagaaggtc tacgtgagg agatagcgca ggccctggaa 900
acgggcgagg gattagaaag ggtggccgc tactcgatgg aggcgcgaaa ggtaacctat 960
gaactcgaa aagagttctt ccctatggaa gccagctct cgcgcctcgt aggccagagc 1020
ctctgggatg tatctcgctc gagtaccgga aacctcgctc agtggttttt gctgaggaag 1080
gcctacgaga ggaatgaact tgcacaaaac aagccggacg agaggagct ggcaagaaga 1140
agggagagct acgcgggtgg atacgtcaag gagccgaaa ggggactgtg ggagaacatc 1200
gtgtatcttg acttccgctc cctgtatcct tcgataataa taccataa cgtctccct 1260
gatacactca acagggaggg ttgtgaggag tacgacgtgg ctctcaggt aggccataag 1320
ttctgcaagg acttccccgg cttcatccca agcctcctcg gagacctctt ggaggagaga 1380
cagaaggtaa agaagaagat gaaggccact atagacccaa tcgagaagaa actcctcgat 1440
tacaggcaac gagcaatcaa aatccttgct aatagcttct acggttacta cggctatgca 1500
aaggcccgct ggtactgcaa ggagtgcgcc gagagcgtta ccgcttgggg caggcagtac 1560
atcgagacca cgataaggga aatagaggag aaatttggtt ttaaagtcct ctacgcggac 1620
acagatggat ttttcgcaac aatacctgga gcggacgccg aaaccgtcaa aaagaaggca 1680
aaggagttcc tggactacat caacgcaaaa ctgcccggcc tgctcgaact cgaatacgag 1740
ggcttctaca agcgcggctt cttcgtgacg aagaagaagt acgcggttat agacgaggag 1800
gacaagataa cgacgcgcgg gcttgaataa gttaggcgtg actggagcga gatagcgaag 1860
gagacgcagg cgagggttct tgaggcgata ctaaagcacg gtgacgttga agaagcggtg 1920
aggattgtca aagaggttac ggagaagctg agcaagtacg aggttcacc ggagaagctg 1980
gtcatctacg agcagataac ccgcgacctg aaggactaca aggccaccgg gccgcatgtg 2040
```

-continued

```

gctgttgcaa aacgcctcgc cgcaaggggg ataaaaatcc ggcccggaac ggtcataagc 2100
tacatcgtgc tcaaaggctc gggaaggatt ggggacaggg ctataccctt tgacgaattt 2160
gacccggcaa agcacaagta cgatgcagaa tactacatcg agaaccaggt tcttcagct 2220
gtggagagga ttctgagggc ctttggttac cgtaaagaag atttaagga tcagaaaacg 2280
cggcaggttg gcttgggggc gtggctaaaa cctaagacat ga 2322

```

```

<210> SEQ ID NO 23
<211> LENGTH: 2328
<212> TYPE: DNA
<213> ORGANISM: Pyrococcus furiosus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1161)..(1161)
<223> OTHER INFORMATION: n = A, T, G or C

```

```

<400> SEQUENCE: 23

```

```

atgatttttag atgtggatta cataactgaa gaaggaaaac ctgttattag gctattcaaa 60
aaagagaacg gaaaatttaa gatagagcat gatagaactt ttagaccata catttacgct 120
cttctcaggg atgattcaaa gattgaagaa gttaagaaaa taacggggga aaggcatgga 180
aagattgtga gaattgttga ttagagagaag gttgagaaaa agtttctcgg caagcctatt 240
accgtgtgga aactttattt ggaacatccc caagatgttc ccaactattag agaaaaagtt 300
agagaacatc cagcagttgt ggacatcttc gaatacgata ttccatttgc aaagagatac 360
ctcatcgaca aaggcctaata accaatggag ggggaagaag agctaaagat tcttgccttc 420
gatatagaaa cctctatca cgaaggagaa gagtttgga aaggcccaat tataatgatt 480
agttagcgag atgaaaatga agcaaagggt attacttga aaaacataga tcttcatac 540
gttgagggtg tatcaagcga gagagagatg ataagagat ttctcaggat tatcagggag 600
aaggatcctg acattatagt tacttataat ggagactcat tcgcattccc atatttagcg 660
aaaagggcag aaaaacttgg gattaaatta accattgga gagatggaag cgagcccaag 720
atgcagagaa taggcgatat gacggctgta gaagtcaagg gaagaatata ttctgacttg 780
tatcatgtaa taacaaggac aataaatctc ccaacatata cactagaggc tgtatatgaa 840
gcaatttttg gaaagccaaa ggagaaggta tacgccgacg agatagcaaa agcctgggaa 900
agtggagaga accttgagag agttgccaaa tactcgatgg aagatgcaaa ggcaacttat 960
gaactcggga aagaattcct tccaatggaa attcagcttt caagattagt tggacaacct 1020
ttatgggatg tttcaaggtc aagcacaggg aaccttgtag agtggttctt acttaggaaa 1080
gcctacgaaa gaaacgaagt agctccaaac aagccaagt aagaggagta tcaagaagg 1140
ctcagggaga gctacacacc nggattcgtt aaagagccag aaaaggggtt gtgggaaaac 1200
atagtatacc tagatttttag agccctatat cctcogatta taattaccca caatgtttct 1260
cccgatactc taaatcttga gggatgcaag aactatgata tcgctcctca agtaggccac 1320
aagttctgca aggacatccc tggttttata ccaagtctct tgggacattt gttagaggaa 1380
agacaaaaga ttaagacaaa aatgaaggaa actcaagatc ctatagaaaa aatactcctt 1440
gactatagac aaaaagcgat aaaactctta gcaaatctt tctacggata ttatggctat 1500
gcaaaagcaa gatggtagtg taaggagtgt gctgagagcg ttactgcctg ggaagaaaag 1560
tacatcgagt tagtatggaa ggagctcgaa gaaaagtttg gatttaaagt cctctacatt 1620
gacactgatg gtctctatgc aactatccca ggaggagaaa gtgaggaaat aaagaaaaag 1680
gctctagaat ttgtaaaata cataaattca aagctccctg gactgctaga gcttgaatat 1740

```

-continued

```

gaagggtttt ataagagggg attcttcgtt acgaagaaga ggtatgcagt aatagatgaa 1800
gaaggaaaag tcattactcg tggtttagag atagttagga gagattggag tgaattgca 1860
aaagaaactc aagctagagt ttggagaca atactaaaac acggagatgt tgaagaagct 1920
gtgagaatag taaaagaagt aatacaaaaag cttgccatt atgaaattcc accagagaag 1980
ctcgcaatat atgagcagat aacaagacca ttacatgagt ataaggcagt aggtcctcac 2040
gtagctgttg caaagaaact agctgctaaa ggagttaaaa taaagccagg aatggtaatt 2100
ggatacatag tacttagagg cgatgggtcca attagcaata gggcaattct agctgaggaa 2160
tacgatccca aaaagcaca gtatgacgca gaatattaca tggagaacca ggttcttcca 2220
gcggtactta ggatattgga gggatttga tacagaaagg aagacctcag ataccaaag 2280
acaagacaag tcggcctaac ttctggctt aacattaata aatcctag 2328

```

```

<210> SEQ ID NO 24
<211> LENGTH: 2328
<212> TYPE: DNA
<213> ORGANISM: Pyrococcus furiosus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (423)..(423)
<223> OTHER INFORMATION: n= A, T, G or C
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (429)..(429)
<223> OTHER INFORMATION: n= A, T, G or C

```

```

<400> SEQUENCE: 24

```

```

atgatttttag atgtggatta cataactgaa gaaggaaaac ctgttattag gctattcaaa 60
aaagagaacg gaaaatttaa gatagagcat gatagaactt ttagaccata catttacgct 120
cttctcaggg atgattcaaa gattgaagaa gttaagaaaa taacggggga aaggcatgga 180
aagattgtga gaattgttga tgtagagaag gttgagaaaa agtttctcgg caagcctatt 240
accgtgtgga aactttattt ggaacatccc caagatgttc ccactattag agaaaaagtt 300
agagaacatc cagcagttgt ggacatcttc gaatacgata ttccatttgc aaagagatac 360
ctcatcgaca aaggcctaata accaatggag ggggaagaag agctaaagat tcttgccctc 420
gcnatagcna ccctctatca cgaaggagaa gagtttggaa aaggcccaat tataatgatt 480
agttatgcag atgaaaatga agcaaaggty attacttga aaaacataga tcttcatac 540
gttgaggttg tatcaagcga gagagagatg ataaagagat ttctcaggat tatcagggag 600
aaggatcctg acattatagt tacttataat ggagactcat tcgcattccc atatttagcg 660
aaaagggcag aaaaacttgg gattaaatta accattggaa gagatggaag cgagcccaag 720
atgcagagaa taggcgatat gacggctgta gaagtcaagg gaagaataga tttcgacttg 780
tatcatgtaa taacaaggac aataaatcto ccaacatata cactagaggc tgtatatgaa 840
gcaatttttg gaaagccaaa ggagaaggta tacgccgacg agatagcaaa agcctgggaa 900
agtggagaga accttgagag agttgccaaa tactcgatgg aagatgcaaa ggcaacttat 960
gaactcggga aagaattcct tccaatggaa attcagcttt caagattagt tggacaacct 1020
ttatgggatg tttcaaggtc aagcacaggg aacctttag agtggttctt acttaggaaa 1080
gcctacgaaa gaaacgaagt agctccaaac aagccaagt aagaggagta tcaaagaagg 1140
ctcagggaga gctacacagg tggattcggt aaagagccag aaaaggggtt gtgggaaaac 1200
atagtatacc tagattttag agccctatat ccctcgatta taattacce caatgtttct 1260
cccgatactc taaatcttga gggatgcaag aactatgata tcgctcctca agtaggccac 1320

```

-continued

```

aagttctgca aggacatccc tggttttata ccaagtctct tgggacattt gtttagaggaa 1380
agacaaaaga ttaagacaaa aatgaaggaa actcaagatc ctatagaaaa aatactcctt 1440
gactatagac aaaaagcgat aaaactctta gcaaattctt tctacggata ttatggctat 1500
gcaaaagcaa gatggtactg taaggagtggt gctgagagcg ttactgcctg gggaagaaaag 1560
tacatcgagt tagtatggaa ggagctcgaa gaaaagtttg gatttaaagt cctctacatt 1620
gacactgatg gtctctatgc aactatccca ggaggagaaa gtgaggaaat aaagaaaaag 1680
gctctagaat ttgtaaaata cataaattca aagctccctg gactgctaga gcttgaatat 1740
gaagggtttt ataagagggg attcttcgtt acgaagaaga ggtatgcagt aatagatgaa 1800
gaaggaagaa tcattactcg tggtttagag atagtttaga gagattggag tgaattgca 1860
aaagaaactc aagctagagt ttggagaca atactaaaac acggagatgt tgaagaagct 1920
gtgagaatag taaaagaagt aatacaaaaag cttgccaatt atgaaattcc accagagaag 1980
ctcgcaatat atgagcagat aacaagacca ttacatgagt ataaggcgat aggtcctcac 2040
gtagctgttg caaagaaact agctgctaaa ggagttaaaa taaagccagg aatggtaatt 2100
ggatacatag tacttagagg cgatggtcca attagcaata gggcaattct agctgaggaa 2160
tacgatccca aaaagcaca gtatgacgca gaatattaca tggagaacca ggttcttcca 2220
gcggtactta ggatattgga gggatttgga tacagaaagg aagacctcag atacaaaag 2280
acaagacaag tcggcctaac ttctgggctt aacattaaaa aatcctag 2328

```

<210> SEQ ID NO 25

<211> LENGTH: 2325

<212> TYPE: DNA

<213> ORGANISM: *Pyrococcus furiosus*

<400> SEQUENCE: 25

```

atgatttttag atgtggatta cataactgaa gaaggaaaac ctgttattag gctattcaaa 60
aaagagaacg gaaaatttaa gatagagcat gatagaactt ttagaccata catttacgct 120
cttctcaggg atgattcaaa gattgaagaa gtttaagaaa taacggggga aaggcatgga 180
aagattgtga gaattgttga tgtagagaag gttgagaaaa agtttctcgg caagcctatt 240
accgtgtgga aactttattt ggaacatccc caagatccca ctattagaga aaaagttaga 300
gaacatccag cagttgtgga catcttcgaa tacgatattc catttgcaa gagatactc 360
atcgacaaag gcctaatacc aatggagggg gaagaagagc taaagattct tgcttcgat 420
atagaaacc tctatcacga aggagaagag ttggaaaaag gcccaattat aatgattagt 480
tatgcagatg aaaatgaagc aaaggtgatt acttgaaaa acatagatct tccatacgtt 540
gaggttgtat caagcgagag agagatgata aagagatttc tcaggattat cagggagaag 600
gatcctgaca ttatagttac ttataatgga gactcattcg cattccata tttagcgaaa 660
agggcagaaa aacttgggat taaattaacc attggaagag atggaagcga gcccaagatg 720
cagagaatag gcgatatgac ggctgtagaa gtcaaggga gaatacattt cgacttgat 780
catgtaataa caaggacaat aaatctccca acatacacac tagaggctgt atatgaagca 840
atttttggaa agccaaagga gaaggtatac gccacgaga tagcaaaagc ctgggaaagt 900
ggagagaacc ttgagagagt tgccaaatac tcgatggaag atgcaaaggc aacttatgaa 960
ctcgggaaag aattccttcc aatggaaatt cagctttcaa gattagttgg acaaccttta 1020
tgggatgttt caaggtcaag cacagggaac cttgtagagt ggttcttact taggaaagcc 1080
tacgaagaa acgaagtagc tccaacaag ccaagtgaag aggagtatca aagaaggctc 1140

```


-continued

```

agggagagct acacaggtgg attcgttaaa gagccagaaa aggggtttgtg ggaaaacata 1200
gtatacctag atttttagagc cctatatccc tcgattataa ttaccacaaa tgtttctccc 1260
gatactctaa atcttgaggg atgcaagaac tatgatatcg ctctcaagt aggccacaag 1320
ttctgcaagg acatccctgg ttttatacca agtctcttgg gacatttgtt agaggaaaga 1380
caaaagatta agacaaaaat gaaggaaact caagatccta tagaaaaaat actccttgac 1440
tatagacaaa aagcgataaa actccttagca aattctttct acggatatta tggctatgca 1500
aaagcaagat ggtactgtaa ggagtgtgct gagagcgta ctgcctgggg aagaaaagtac 1560
atcgagttag tatggaagga gctcgaagaa aagtttggt ttaaagtcct ctacattgac 1620
actgatggtc tctatgcaac tatcccagga ggagaaagt aggaaataa gaaaaaggct 1680
ctagaatttg taaaatacat aaattcaaag ctccctggac tgctagagct tgaatatgaa 1740
gggttttata agaggggatt ctctgttacg aagaagaggt atgcagtaat agatgaagaa 1800
ggaaaagtca ttactcgtgg tttagagata gttaggagag attggagtga aattgcaaaa 1860
gaaactcaag cttaggtttt ggagacaata ctaaacacg gagatgttga agaagctgtg 1920
agaatagtaa aagaagtaat acaaaagctt gccattatg aaattccacc agagaagctc 1980
gcaatatatg agcagataac aagaccatta catgagtata aggcgatagg tcctcacgta 2040
gctgttgcaa agaaactagc tgctaagga gttaaaataa agccaggaat ggtaattgga 2100
tacatagtac ttagaggcga tggccaatt agcaatagg caattctagc tgaggaatac 2160
gatcccaaaa agcacaagta tgacgcagaa tattacatgg agaaccaggt tcttcacgag 2220
gtacttagga tattggaggg atttgatagc agaaaggaag acctcagata ccaaagaca 2280
agacaagtcg gcctaacttc ctggcttaac attaaaaaat cctag 2325

```

<210> SEQ ID NO 26

<211> LENGTH: 2319

<212> TYPE: DNA

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 26

```

atgatttttag atgtggatta cataactgaa gaaggaaaac ctgttattag gctattcaaa 60
aaagagaacg gaaaatttaa gatagagcat gatagaactt ttagaccata catttacgct 120
cttctcaggg atgattcaaa gattgaagaa gttaagaaaa taacggggga aaggcatgga 180
aagatttgta gaattgttga ttagagagaag gttgagaaaa agtttctcgg caagcctatt 240
accgtgtgga aactttattt ggaacatccc caaactatta gagaaaaagt tagagaacat 300
ccagcagttg tggacatctt cgaatacgat attccatttg caaagagata cctcatcgac 360
aaaggcctaa taccaatgga gggggaagaa gagctaaaga ttcttgcctt cgatatagaa 420
accctctatc acgaaggaga agagtgttga aaaggcccaa ttataatgat tagttatgca 480
gatgaaaatg aagcaaaggt gattacttgg aaaaacatag atcttcata cgttgagggt 540
gtatcaagcg agagagagat gataaagaga tttctcagga ttatcagga gaagatcct 600
gacattatag ttacttataa tggagactca ttcgcattcc catatttagc gaaaagggca 660
gaaaaacttg ggattaaatt aaccattgga agagatggaa gcgagcccaa gatgcagaga 720
ataggcgata tgacggctgt agaagtcaag ggaagaatac atttcgactt gtatcatgta 780
ataacaagga caataaatct cccaacatac aactagagg ctgtatatga agcaattttt 840
ggaaagccaa aggagaaggt atacgccgac gagatagcaa aagcctggga aagtggagag 900
aaccttgaga gagttgccaa atactcgatg gaagatgcaa aggcaactta tgaactcggg 960

```

-continued

```

aaagaattcc ttccaatgga aattcagctt tcaagattag ttggacaacc tttatgggat 1020
gtttcaaggt caagcacagg gaaccttgta gagtggttct tacttaggaa agcctacgaa 1080
agaaaacgaag tagctccaaa caagccaagt gaagaggagt atcaaagaag gctcagggag 1140
agctacacag gtggattcgt taaagagcca gaaaaggggt tgtgggaaaa catagtatac 1200
ctagatttta gagccctata tcctcgatt ataattaccc acaatgttc tcccgatact 1260
ctaaatcttg aggatgcaa gaactatgat atcgctcctc aagtaggcca caagttctgc 1320
aaggacatcc ctggttttat accaagtctc ttgggacatt tgtagagga aagacaaaag 1380
attaagacaa aaatgaagga aactcaagat cctatagaaa aaatactcct tgactataga 1440
caaaaagcga taaaactctt agcaaattct ttctacggat attatggcta tgcaaaagca 1500
agatgggtact gtaaggagtg tgctgagagc gttactgcct ggggaagaaa gtacatcgag 1560
ttagtatgga aggagctcga agaaaagttt ggatttaaag tcctctacat tgacactgat 1620
ggctctctatg caactatccc aggaggagaa agtgaggaaa taaagaaaaa ggctctagaa 1680
tttgtaaaat acataaaattc aaagctccct ggactgctag agcttgaata tgaagggttt 1740
tataagaggg gattcttcgt tacgaagaag aggtatgcag taatagatga agaaggaaaa 1800
gtcattactc gtggtttaga gatagttagg agagattgga gtgaaattgc aaaagaaact 1860
caagctagag ttttgagac aatactaaaa cacggagatg ttgaagaagc tgtgagaata 1920
gtaaaagaag taatacaaaa gcttgccaat tatgaaattc caccagagaa gctcgcaata 1980
tatgagcaga taacaagacc attacatgag tataaggcga taggtcctca cgtagctgtt 2040
gcaaagaaac tagctgctaa aggagttaaa ataaagccag gaatggtaat tggatacata 2100
gtacttagag gcgatgggcc aattagcaat agggcaattc tagctgagga atacgatccc 2160
aaaaagcaca agtatgacgc agaattattc atggagaacc aggttcttcc agcgggtactt 2220
aggatattgg agggatttgg atacagaaag gaagacctca gataccaaaa gacaagacaa 2280
gtcggcctaa cttcttggt taacattaaa aaatcctag 2319

```

<210> SEQ ID NO 27

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: *Pyrococcus furiosus*

<400> SEQUENCE: 27

```

Met Ile Leu Asp Val Asp Tyr Ile Thr Glu Gly Lys Pro Val Ile
 1             5             10            15

Arg Leu Phe Lys Lys Glu Asn Gly Lys Phe Lys Ile Glu His Asp Arg
 20            25            30

Thr Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Lys Ile
 35            40            45

Glu Glu Val Lys Lys Ile Thr Gly Glu Arg His Gly Lys Ile Val Arg
 50            55            60

Ile Val Asp Val Glu Lys Val Glu Lys Lys Phe Leu Gly Lys Pro Ile
 65            70            75            80

Thr Val Trp Lys Leu Tyr Leu Glu His Pro Gln Asp Val Pro Thr Ile
 85            90            95

Arg Glu Lys Val Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr
100           105           110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115           120           125

Met Glu Gly Glu Glu Glu Leu Lys Ile Leu Ala Phe Asp Ile Glu Thr

```

130					135					140					
Leu	Tyr	His	Glu	Gly	Glu	Glu	Phe	Gly	Lys	Gly	Pro	Ile	Ile	Met	Ile
145					150					155					160
Ser	Tyr	Ala	Asp	Glu	Asn	Glu	Ala	Lys	Val	Ile	Thr	Trp	Lys	Asn	Ile
				165					170					175	
Asp	Leu	Pro	Tyr	Val	Glu	Val	Val	Ser	Ser	Glu	Arg	Glu	Met	Ile	Lys
				180				185					190		
Arg	Phe	Leu	Arg	Ile	Ile	Arg	Glu	Lys	Asp	Pro	Asp	Ile	Ile	Val	Thr
		195					200					205			
Tyr	Asn	Gly	Asp	Ser	Phe	Asp	Phe	Pro	Tyr	Leu	Ala	Lys	Arg	Ala	Glu
	210					215					220				
Lys	Leu	Gly	Ile	Lys	Leu	Thr	Ile	Gly	Arg	Asp	Gly	Ser	Glu	Pro	Lys
225					230					235					240
Met	Gln	Arg	Ile	Gly	Asp	Met	Thr	Ala	Val	Glu	Val	Lys	Gly	Arg	Ile
				245					250					255	
His	Phe	Asp	Leu	Tyr	His	Val	Ile	Thr	Arg	Thr	Ile	Asn	Leu	Pro	Thr
			260					265					270		
Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Ile	Phe	Gly	Lys	Pro	Lys	Glu
		275					280					285			
Lys	Val	Tyr	Ala	Asp	Glu	Ile	Ala	Lys	Ala	Trp	Glu	Ser	Gly	Glu	Asn
	290					295					300				
Leu	Glu	Arg	Val	Ala	Lys	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Ala	Thr	Tyr
305					310					315					320
Glu	Leu	Gly	Lys	Glu	Phe	Leu	Pro	Met	Glu	Ile	Gln	Leu	Ser	Arg	Leu
				325					330					335	
Val	Gly	Gln	Pro	Leu	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu
			340					345					350		
Val	Glu	Trp	Phe	Leu	Leu	Arg	Lys	Ala	Tyr	Glu	Arg	Asn	Glu	Val	Ala
		355					360					365			
Pro	Asn	Lys	Pro	Ser	Glu	Glu	Glu	Tyr	Gln	Arg	Arg	Leu	Arg	Glu	Ser
	370				375						380				
Tyr	Thr	Gly	Gly	Phe	Val	Lys	Glu	Pro	Glu	Lys	Gly	Leu	Trp	Glu	Asn
385					390					395					400
Ile	Val	Tyr	Leu	Asp	Phe	Arg	Ala	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr
			405						410					415	
His	Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Leu	Glu	Gly	Cys	Lys	Asn	Tyr
			420					425					430		
Asp	Ile	Ala	Pro	Gln	Val	Gly	His	Lys	Phe	Cys	Lys	Asp	Ile	Pro	Gly
	435						440					445			
Phe	Ile	Pro	Ser	Leu	Leu	Gly	His	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Ile
	450					455					460				
Lys	Thr	Lys	Met	Lys	Glu	Thr	Gln	Asp	Pro	Ile	Glu	Lys	Ile	Leu	Leu
465					470					475					480
Asp	Tyr	Arg	Gln	Lys	Ala	Ile	Lys	Leu	Leu	Ala	Asn	Ser	Phe	Tyr	Gly
				485					490					49	

-continued

Ala Leu Glu Phe Val Lys Tyr Ile Asn Ser Lys Leu Pro Gly Leu Leu
565 570 575

Glu Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys
580 585 590

Lys Arg Tyr Ala Val Ile Asp Glu Glu Gly Lys Val Ile Thr Arg Gly
595 600 605

Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
610 615 620

Ala Arg Val Leu Glu Thr Ile Leu Lys His Gly Asp Val Glu Glu Ala
625 630 635 640

Val Arg Ile Val Lys Glu Val Ile Gln Lys Leu Ala Asn Tyr Glu Ile
645 650 655

Pro Pro Glu Lys Leu Ala Ile Tyr Glu Gln Ile Thr Arg Pro Leu His
660 665 670

Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Lys Leu Ala
675 680 685

Ala Lys Gly Val Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Ile Val
690 695 700

Leu Arg Gly Asp Gly Pro Ile Ser Asn Arg Ala Ile Leu Ala Glu Glu
705 710 715 720

Tyr Asp Pro Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
725 730 735

Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Gly Phe Gly Tyr Arg
740 745 750

Lys Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Thr Ser
755 760 765

Trp Leu Asn Ile Lys Lys Ser
770 775

<210> SEQ ID NO 28

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus sp.

<400> SEQUENCE: 28

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg
20 25 30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Gln Ile
35 40 45

Asp Glu Val Arg Lys Ile Thr Ala Glu Arg His Gly Lys Ile Val Arg
50 55 60

Ile Ile Asp Ala Glu Lys Val Arg Lys Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Arg Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Lys Ile Arg Glu His Ser Ala Val Ile Asp Ile Phe Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Asp Glu Glu Leu Lys Leu Leu Ala Phe Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Ala Lys Gly Pro Ile Ile Met Ile
145 150 155 160

Ser	Tyr	Ala	Asp	Glu	Glu	Ala	Lys	Val	Ile	Thr	Trp	Lys	Lys	Ile	
				165								175			
Asp	Leu	Pro	Tyr	Val	Glu	Val	Val	Ser	Ser	Glu	Arg	Glu	Met	Ile	Lys
				180						185		190			
Arg	Phe	Leu	Lys	Val	Ile	Arg	Glu	Lys	Asp	Pro	Asp	Val	Ile	Ile	Thr
				195						200		205			
Tyr	Asn	Gly	Asp	Ser	Phe	Asp	Leu	Pro	Tyr	Leu	Val	Lys	Arg	Ala	Glu
				210						215		220			
Lys	Leu	Gly	Ile	Lys	Leu	Pro	Leu	Gly	Arg	Asp	Gly	Ser	Glu	Pro	Lys
				225						230		235			
Met	Gln	Arg	Leu	Gly	Asp	Met	Thr	Ala	Val	Glu	Ile	Lys	Gly	Arg	Ile
				245						250		255			
His	Phe	Asp	Leu	Tyr	His	Val	Ile	Arg	Arg	Thr	Ile	Asn	Leu	Pro	Thr
				260						265		270			
Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Ile	Phe	Gly	Lys	Pro	Lys	Glu
				275						280		285			
Lys	Val	Tyr	Ala	His	Glu	Ile	Ala	Glu	Ala	Trp	Glu	Thr	Gly	Lys	Gly
				290						295		300			
Leu	Glu	Arg	Val	Ala	Lys	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Val	Thr	Tyr
				305						310		315			
Glu	Leu	Gly	Arg	Glu	Phe	Phe	Pro	Met	Glu	Ala	Gln	Leu	Ser	Arg	Leu
				325						330		335			
Val	Gly	Gln	Pro	Leu	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu
				340						345		350			
Val	Glu	Trp	Tyr	Leu	Leu	Arg	Lys	Ala	Tyr	Glu	Arg	Asn	Glu	Leu	Ala
				355						360		365			
Pro	Asn	Lys	Pro	Asp	Glu	Arg	Glu	Tyr	Glu	Arg	Arg	Leu	Arg	Glu	Ser
				370						375		380			
Tyr	Ala	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Lys	Gly	Leu	Trp	Glu	Gly
				385						390		395			
Leu	Val	Ser	Leu	Asp	Phe	Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr
				405						410		415			
His	Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Arg	Glu	Gly	Cys	Arg	Glu	Tyr
				420						425		430			
Asp	Val	Ala	Pro	Glu	Val	Gly	His	Lys	Phe	Cys	Lys	Asp	Phe	Pro	Gly
				435						440		445			
Phe	Ile	Pro	Ser	Leu	Leu	Lys	Arg	Leu	Leu	Asp	Glu	Arg	Gln	Glu	Ile
				450						455		460			
Lys	Arg	Lys	Met	Lys	Ala	Ser	Lys	Asp	Pro	Ile	Glu	Lys	Lys	Met	Leu
				465						470		475			
Asp	Tyr	Arg	Gln	Arg	Ala	Ile	Lys	Ile	Leu	Ala	Asn	Ser	Tyr	Tyr	Gly
				485						490		495			
Tyr	Tyr	Gly	Tyr	Ala	Lys	Ala	Arg	Trp	Tyr	Cys	Lys	Glu	Cys	Ala	Glu
				500						505		510			
Ser	Val	Thr	Ala	Trp	Gly	Arg	Glu	Tyr	Ile	Glu	Phe	Val	Arg	Lys	Glu
				515						520		525			
Leu	Glu	Glu	Lys	Phe	Gly	Phe	Lys	Val	Leu	Tyr	Ile	Asp	Thr	Asp	Gly
				530						535		540			
Leu	Tyr	Ala	Thr	Ile	Pro	Gly	Ala	Lys	Pro	Glu	Glu	Ile	Lys	Lys	Lys
				545						550		555			
Ala	Leu	Glu	Phe	Val	Asp	Tyr	Ile	Asn	Ala	Lys	Leu	Pro	Gly	Leu	Leu
				565						570		575			
Glu	Leu	Glu	Tyr	Glu	Gly	Phe	Tyr	Val	Arg	Gly	Phe				

-continued

Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Ile Thr Arg Gly
 595 600 605
 Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
 610 615 620
 Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
 625 630 635 640
 Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Ile
 645 650 655
 Pro Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu His
 660 665 670
 Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
 675 680 685
 Ala Arg Gly Val Lys Val Arg Pro Gly Met Val Ile Gly Tyr Ile Val
 690 695 700
 Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Leu Ala Glu Glu
 705 710 715 720
 Phe Asp Leu Arg Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
 725 730 735
 Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly Tyr Arg
 740 745 750
 Lys Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Thr Gly Leu Thr Ala
 755 760 765
 Trp Leu Asn Ile Lys Lys Lys
 770 775

<210> SEQ ID NO 29
 <211> LENGTH: 773
 <212> TYPE: PRT
 <213> ORGANISM: thermococcus gorgonarius

<400> SEQUENCE: 29

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile
 1 5 10 15
 Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Asp Tyr Asp Arg
 20 25 30
 Asn Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45
 Glu Asp Val Lys Lys Ile Thr Ala Glu Arg His Gly Thr Thr Val Arg
 50 55 60
 Val Val Arg Ala Glu Lys Val Lys Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80
 Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
 85 90 95
 Arg Asp Lys Ile Lys Glu His Pro Ala Val Val Asp Ile Tyr Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125
 Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Ile
 165 170 175
 Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
 180 185 190

-continued

Arg Phe Leu Lys Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Ser Glu
 210 215 220
 Lys Leu Gly Val Lys Phe Ile Leu Gly Arg Glu Gly Ser Glu Pro Lys
 225 230 235 240
 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Gln Pro Lys Glu
 275 280 285
 Lys Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Thr Gly Glu Gly
 290 295 300
 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Val Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Arg Glu Ser Tyr
 370 375 380
 Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415
 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Glu Glu Tyr Asp
 420 425 430
 Val Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe
 435 440 445
 Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Val Lys
 450 455 460
 Lys Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Lys Lys Leu Leu Asp
 465 470 475 480
 Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly Tyr
 485 490 495
 Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
 500 505 510
 Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Thr Thr Ile Arg Glu Ile
 515 520 525
 Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
 530 535 540
 Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
 545 550 555 560
 Lys Glu Phe Leu Asp Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu Glu
 565 570 575
 Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys
 580 585 590
 Lys Tyr Ala Val Ile Asp Glu Glu Asp Lys Ile Thr Thr Arg Gly Leu
 595 600 605
 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala

-continued

610	615	620
Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val		
625	630	635 640
Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro		
	645	650 655
Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Asp Leu Lys Asp		
	660	665 670
Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala		
	675	680 685
Arg Gly Ile Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu		
	690	695 700
Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe		
	710	715 720
Asp Pro Ala Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln		
	725	730 735
Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys		
	740	745 750
Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp		
	755	760 765
Leu Lys Pro Lys Thr		
	770	

<210> SEQ ID NO 30
 <211> LENGTH: 774
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus sp.

<400> SEQUENCE: 30

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile		
1	5	10 15
Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg		
	20	25 30
Thr Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile		
	35	40 45
Glu Glu Val Lys Lys Ile Thr Ala Glu Arg His Gly Thr Val Val Thr		
	50	55 60
Val Lys Arg Val Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Val		
	65	70 75 80
Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile		
	85	90 95
Arg Asp Lys Ile Arg Glu His Gly Ala Val Ile Asp Ile Tyr Glu Tyr		
	100	105 110
Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Val Pro		
	115	120 125
Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Gln Thr		
	130	135 140
Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile		
	145	150 155 160
Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Val		
	165	170 175
Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Arg Glu Met Ile Lys		
	180	185 190
Arg Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr		
	195	200 205
Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu		

-continued

210	215	220
Lys Leu Gly Ile Asn Phe Ala	Leu Gly Arg Asp Gly Ser Glu Pro Lys	
225	230	235 240
Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile		
	245	250 255
His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr		
	260	265 270
Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Gln Pro Lys Glu		
	275	280 285
Lys Val Tyr Ala Glu Glu Ile Thr Pro Ala Trp Glu Thr Gly Glu Asn		
	290	295 300
Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr		
	305	310 315 320
Glu Leu Gly Lys Glu Phe Leu Pro Met Glu Ala Gln Leu Ser Arg Leu		
	325	330 335
Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu		
	340	345 350
Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala		
	355	360 365
Pro Asn Lys Pro Asp Glu Lys Glu Leu Ala Arg Arg Arg Gln Ser Tyr		
	370	375 380
Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Asn Ile		
	385	390 395 400
Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His		
	405	410 415
Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp		
	420	425 430
Val Ala Pro Gln Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly Phe		
	435	440 445
Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Ile Lys		
	450	455 460
Lys Lys Met Lys Ala Thr Ile Asp Pro Ile Glu Arg Lys Leu Leu Asp		
	465	470 475 480
Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr		
	485	490 495
Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser		
	500	505 510
Val Thr Ala Trp Gly Arg Glu Tyr Ile Thr Met Thr Ile Lys Glu Ile		
	515	520 525
Glu Glu Lys Tyr Gly Phe Lys Val Ile Tyr Ser Asp Thr Asp Gly Phe		
	530	535 540
Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala		
	545	550 555 560
Met Glu Phe Leu Asn Tyr Ile Asn Ala Lys Leu Pro Gly Ala Leu Glu		
	565	570 575
Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys		
	580	585 590
Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu		
	595	600 605
Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala		
	610	615 620
Arg Val Leu Glu Ala Leu Leu Lys Asp Gly Asp Val Glu Lys Ala Val		
	625	630 635 640

-continued

Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
645 650 655

Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Asp Leu Lys Asp
660 665 670

Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
675 680 685

Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
690 695 700

Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
705 710 715 720

Asp Pro Thr Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Ser Ala Trp
755 760 765

Leu Lys Pro Lys Gly Thr
770

<210> SEQ ID NO 31
<211> LENGTH: 774
<212> TYPE: PRT
<213> ORGANISM: thermococcus litoralis

<400> SEQUENCE: 31

Met Ile Leu Asp Thr Asp Tyr Ile Thr Lys Asp Gly Lys Pro Ile Ile
1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Leu Asp Pro
20 25 30

His Phe Gln Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35 40 45

Glu Glu Ile Lys Ala Ile Lys Gly Glu Arg His Gly Lys Thr Val Arg
50 55 60

Val Leu Asp Ala Val Lys Val Arg Lys Lys Phe Leu Gly Arg Glu Val
65 70 75 80

Glu Val Trp Lys Leu Ile Phe Glu His Pro Gln Asp Val Pro Ala Met
85 90 95

Arg Gly Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Tyr Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Asp Glu Glu Leu Lys Leu Leu Ala Phe Asp Ile Glu Thr
130 135 140

Phe Tyr His Glu Gly Asp Glu Phe Gly Lys Gly Glu Ile Ile Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Glu Glu Ala Arg Val Ile Thr Trp Lys Asn Ile
165 170 175

Asp Leu Pro Tyr Val Asp Val Val Ser Asn Glu Arg Glu Met Ile Lys
180 185 190

Arg Phe Val Gln Val Val Lys Glu Lys Asp Pro Asp Val Ile Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Leu Pro Tyr Leu Ile Lys Arg Ala Glu
210 215 220

Lys Leu Gly Val Arg Leu Val Leu Gly Arg Asp Lys Glu His Pro Glu
225 230 235 240

Pro	Lys	Ile	Gln	Arg	Met	Gly	Asp	Ser	Phe	Ala	Val	Glu	Ile	Lys	Gly	
				245					250					255		
Arg	Ile	His	Phe	Asp	Leu	Phe	Pro	Val	Val	Arg	Arg	Thr	Ile	Asn	Leu	
				260					265					270		
Pro	Thr	Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Val	Leu	Gly	Lys	Thr	
				275					280					285		
Lys	Ser	Lys	Leu	Gly	Ala	Glu	Glu	Ile	Ala	Ala	Ile	Trp	Glu	Thr	Glu	
				290					295					300		
Glu	Ser	Met	Lys	Lys	Leu	Ala	Gln	Tyr	Ser	Met	Glu	Asp	Ala	Arg	Ala	
				305					310					315		
Thr	Tyr	Glu	Leu	Gly	Lys	Glu	Phe	Phe	Pro	Met	Glu	Ala	Glu	Leu	Ala	
				325					330					335		
Lys	Leu	Ile	Gly	Gln	Ser	Val	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	
				340					345					350		
Asn	Leu	Val	Glu	Trp	Tyr	Leu	Leu	Arg	Val	Ala	Tyr	Ala	Arg	Asn	Glu	
				355					360					365		
Leu	Ala	Pro	Asn	Lys	Pro	Asp	Glu	Glu	Glu	Tyr	Lys	Arg	Arg	Leu	Arg	
				370					375					380		
Thr	Thr	Tyr	Leu	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Lys	Gly	Leu	Trp	
				385					390					395		
Glu	Asn	Ile	Ile	Tyr	Leu	Asp	Phe	Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	
				405					410					415		
Val	Thr	His	Asn	Val	Ser	Pro	Asp	Thr	Leu	Glu	Lys	Glu	Gly	Cys	Lys	
				420					425					430		
Asn	Tyr	Asp	Val	Ala	Pro	Ile	Val	Gly	Tyr	Arg	Phe	Cys	Lys	Asp	Phe	
				435					440					445		
Pro	Gly	Phe	Ile	Pro	Ser	Ile	Leu	Gly	Asp	Leu	Ile	Ala	Met	Arg	Gln	
				450					455					460		
Asp	Ile	Lys	Lys	Lys	Met	Lys	Ser	Thr	Ile	Asp	Pro	Ile	Glu	Lys	Lys	
				465					470					475		
Met	Leu	Asp	Tyr	Arg	Gln	Arg	Ala	Ile	Lys	Leu	Leu	Ala	Asn	Ser	Tyr	
				485					490					495		
Tyr	Gly	Tyr	Met	Gly	Tyr	Pro	Lys	Ala	Arg	Trp	Tyr	Ser	Lys	Glu	Cys	
				500					505					510		
Ala	Glu	Ser	Val	Thr	Ala	Trp	Gly	Arg	His	Tyr	Ile	Glu	Met	Thr	Ile	
				515					520					525		
Arg	Glu	Ile	Glu	Glu	Lys	Phe	Gly	Phe	Lys	Val	Leu	Tyr	Ala	Asp	Thr	
				530					535					540		
Asp	Gly	Phe	Tyr	Ala	Thr	Ile	Pro	Gly	Glu	Lys	Pro	Glu	Leu	Ile	Lys	
				545					550					555		
Lys	Lys	Ala	Lys	Glu	Phe	Leu	Asn	Tyr	Ile	Asn	Ser	Lys	Leu	Pro	Gly	
				565					570					575		
Leu	Leu	Glu	Leu	Glu	Tyr	Glu	Gly	Phe	Tyr	Leu	Arg	Gly	Phe	Phe	Val	
				580					585					590		
Thr	Lys	Lys	Arg	Tyr	Ala	Val	Ile	Asp	Glu	Glu	Gly	Arg	Ile	Thr	Thr	
				595					600					605		
Arg	Gly	Leu	Glu	Val	Val	Arg	Arg	Asp	Trp	Ser	Glu	Ile	Ala	Lys	Glu	
				610					615					620		
Thr	Gln	Ala	Lys	Val	Leu	Glu	Ala	Ile	Leu	Lys	Glu	Gly	Ser	Val	Glu	
				625					630					635		
Lys	Ala	Val	Glu	Val	Val	Arg	Asp	Val	Val	Glu	Lys	Ile	Ala	Lys	T	

-continued

Leu Lys Asp Tyr Lys Ala Ile Gly Pro His Val Ala Ile Ala Lys Arg
 675 680 685
 Leu Ala Ala Arg Gly Ile Lys Val Lys Pro Gly Thr Ile Ile Ser Tyr
 690 695 700
 Ile Val Leu Lys Gly Ser Gly Lys Ile Ser Asp Arg Val Ile Leu Leu
 705 710 715 720
 Thr Glu Tyr Asp Pro Arg Lys His Lys Tyr Asp Pro Asp Tyr Tyr Ile
 725 730 735
 Glu Asn Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly
 740 745 750
 Tyr Arg Lys Glu Asp Leu Arg Tyr Gln Ser Ser Lys Gln Thr Gly Leu
 755 760 765
 Asp Ala Trp Leu Lys Arg
 770

<210> SEQ ID NO 32
 <211> LENGTH: 776
 <212> TYPE: PRT
 <213> ORGANISM: Thermococcus sp.

<400> SEQUENCE: 32

Met Ile Leu Asp Val Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Ile
 1 5 10 15
 Arg Val Phe Lys Lys Glu Asn Gly Glu Phe Arg Ile Glu Tyr Asp Arg
 20 25 30
 Glu Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Arg Asp Asp Ser Ala Ile
 35 40 45
 Glu Glu Ile Lys Lys Ile Thr Ala Glu Arg His Gly Arg Val Val Lys
 50 55 60
 Val Lys Arg Ala Glu Lys Val Lys Lys Lys Phe Leu Gly Arg Ser Val
 65 70 75 80
 Glu Val Trp Val Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
 85 90 95
 Arg Asp Lys Ile Arg Lys His Pro Ala Val Ile Asp Ile Tyr Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
 115 120 125
 Met Glu Gly Glu Glu Glu Leu Lys Leu Met Ser Phe Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Ser Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
 165 170 175
 Asp Leu Pro Tyr Val Glu Val Val Ser Thr Glu Lys Glu Met Ile Lys
 180 185 190
 Arg Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
 210 215 220
 Lys Leu Gly Val Ser Phe Thr Leu Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240
 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Val
 245 250 255
 His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270

-continued

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Lys Pro Lys Glu
 275 280 285
 Lys Val Tyr Ala Glu Glu Ile Ala Thr Ala Trp Glu Thr Gly Glu Gly
 290 295 300
 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Arg Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Ile Gly Gln Gly Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Arg Gly Gly Tyr
 370 375 380
 Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415
 Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Arg Ser Tyr Asp
 420 425 430
 Val Ala Pro Glu Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe
 435 440 445
 Ile Pro Ser Leu Leu Gly Asn Leu Leu Glu Glu Arg Gln Lys Ile Lys
 450 455 460
 Arg Lys Met Lys Ala Thr Leu Asp Pro Leu Glu Lys Asn Leu Leu Asp
 465 470 475 480
 Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr
 485 490 495
 Tyr Gly Tyr Ala Arg Ala Arg Trp Tyr Cys Arg Glu Cys Ala Glu Ser
 500 505 510
 Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Met Val Ile Arg Glu Leu
 515 520 525
 Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Leu
 530 535 540
 His Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
 545 550 555 560
 Met Glu Phe Leu Asn Tyr Ile Asn Pro Lys Leu Pro Gly Leu Leu Glu
 565 570 575
 Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys Lys
 580 585 590
 Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
 595 600 605
 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
 610 615 620
 Arg Val Leu Glu Ala Ile Leu Arg His Gly Asp Val Glu Glu Ala Val
 625 630 635 640
 Arg Ile Val Arg Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
 645 650 655
 Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Glu Leu Lys Asp
 660 665 670
 Tyr Lys Ala Thr Gly Pro His Val Ala Ile Ala Lys Arg Leu Ala Ala
 675 680 685
 Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu

-continued

690	695	700
Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe		
705	710	715 720
Asp Pro Thr Lys His Lys Tyr Asp Ala Asp Tyr Tyr Ile Glu Asn Gln		
	725	730 735
Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys		
	740	745 750
Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp		
	755	760 765
Leu Lys Pro Lys Gly Lys Lys Lys		
770	775	

<210> SEQ ID NO 33

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 33

Met Ile Leu Asp Val Asp Tyr Ile Thr Glu Glu Gly Lys Pro Val Ile		
1	5	10 15
Arg Leu Phe Lys Lys Glu Asn Gly Lys Phe Lys Ile Glu His Asp Arg		
	20	25 30
Thr Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Lys Ile		
	35	40 45
Glu Glu Val Lys Lys Ile Thr Gly Glu Arg His Gly Lys Ile Val Arg		
	50	55 60
Ile Val Asp Val Glu Lys Val Glu Lys Lys Phe Leu Gly Lys Pro Ile		
65	70	75 80
Thr Val Trp Lys Leu Tyr Leu Glu His Pro Gln Asp Val Pro Thr Ile		
	85	90 95
Arg Glu Lys Val Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr		
	100	105 110
Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro		
	115	120 125
Met Glu Gly Glu Glu Glu Leu Lys Ile Leu Ala Phe Asp Ile Glu Thr		
	130	135 140
Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile		
145	150	155 160
Ser Tyr Ala Asp Glu Asn Glu Ala Lys Val Ile Thr Trp Lys Asn Ile		
	165	170 175
Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys		
	180	185 190
Arg Phe Leu Arg Ile Ile Arg Glu Lys Asp Pro Asp Ile Ile Val Thr		
	195	200 205
Tyr Asn Gly Asp Ser Phe Asp Phe Pro Tyr Leu Ala Lys Arg Ala Glu		
	210	215 220
Lys Leu Gly Ile Lys Leu Thr Ile Gly Arg Asp Gly Ser Glu Pro Lys		
225	230	235 240
Met Gln Arg Ile Gly Asp Met Thr Ala Val Glu Val Lys Gly Arg Ile		
	245	250 255
His Phe Asp Leu Tyr His Val Ile Thr Arg Thr Ile Asn Leu Pro Thr		
	260	265 270
Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu		
	275	280 285
Lys Val Tyr Ala Asp Glu Ile Ala Lys Ala Trp Glu Ser Gly Glu Asn		

-continued

290	295	300
Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Ala Thr Tyr 305 310 315 320		
Glu Leu Gly Lys Glu Phe Leu Pro Met Glu Ile Gln Leu Ser Arg Leu 325 330 335		
Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu 340 345 350		
Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Val Ala 355 360 365		
Pro Asn Lys Pro Ser Glu Glu Glu Tyr Gln Arg Arg Leu Arg Glu Ser 370 375 380		
Tyr Thr Pro Gly Phe Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Asn 385 390 395 400		
Ile Val Tyr Leu Asp Phe Arg Ala Leu Tyr Pro Ser Ile Ile Ile Thr 405 410 415		
His Asn Val Ser Pro Asp Thr Leu Asn Leu Glu Gly Cys Lys Asn Tyr 420 425 430		
Asp Ile Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Ile Pro Gly 435 440 445		
Phe Ile Pro Ser Leu Leu Gly His Leu Leu Glu Glu Arg Gln Lys Ile 450 455 460		
Lys Thr Lys Met Lys Glu Thr Gln Asp Pro Ile Glu Lys Ile Leu Leu 465 470 475 480		
Asp Tyr Arg Gln Lys Ala Ile Lys Leu Leu Ala Asn Ser Phe Tyr Gly 485 490 495		
Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu 500 505 510		
Ser Val Thr Ala Trp Gly Arg Lys Tyr Ile Glu Leu Val Trp Lys Glu 515 520 525		
Leu Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly 530 535 540		
Leu Tyr Ala Thr Ile Pro Gly Gly Glu Ser Glu Glu Ile Lys Lys Lys 545 550 555 560		
Ala Leu Glu Phe Val Lys Tyr Ile Asn Ser Lys Leu Pro Gly Leu Leu 565 570 575		
Glu Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys 580 585 590		
Lys Arg Tyr Ala Val Ile Asp Glu Glu Gly Lys Val Ile Thr Arg Gly 595 600 605		
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln 610 615 620		
Ala Arg Val Leu Glu Thr Ile Leu Lys His Gly Asp Val Glu Glu Ala 625 630 635 640		
Val Arg Ile Val Lys Glu Val Ile Gln Lys Leu Ala Asn Tyr Glu Ile 645 650 655		
Pro Pro Glu Lys Leu Ala Ile Tyr Glu Gln Ile Thr Arg Pro Leu His 660 665 670		
Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Lys Leu Ala 675 680 685		
Ala Lys Gly Val Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Ile Val 690 695 700		
Leu Arg Gly Asp Gly Pro Ile Ser Asn Arg Ala Ile Leu Ala Glu Glu 705 710 715 720		

-continued

Tyr Asp Pro Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
725 730 735

Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Gly Phe Gly Tyr Arg
740 745 750

Lys Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Thr Ser
755 760 765

Trp Leu Asn Ile Lys Lys Ser
770 775

<210> SEQ ID NO 34
<211> LENGTH: 775
<212> TYPE: PRT
<213> ORGANISM: *Pyrococcus furiosus*

<400> SEQUENCE: 34

Met Ile Leu Asp Val Asp Tyr Ile Thr Glu Glu Gly Lys Pro Val Ile
1 5 10 15

Arg Leu Phe Lys Lys Glu Asn Gly Lys Phe Lys Ile Glu His Asp Arg
20 25 30

Thr Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Lys Ile
35 40 45

Glu Glu Val Lys Lys Ile Thr Gly Glu Arg His Gly Lys Ile Val Arg
50 55 60

Ile Val Asp Val Glu Lys Val Glu Lys Lys Phe Leu Gly Lys Pro Ile
65 70 75 80

Thr Val Trp Lys Leu Tyr Leu Glu His Pro Gln Asp Val Pro Thr Ile
85 90 95

Arg Glu Lys Val Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Glu Glu Glu Leu Lys Ile Leu Ala Phe Ala Ile Ala Thr
130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Asn Glu Ala Lys Val Ile Thr Trp Lys Asn Ile
165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys
180 185 190

Arg Phe Leu Arg Ile Ile Arg Glu Lys Asp Pro Asp Ile Ile Val Thr
195 200 205

Tyr Asn Gly Asp Ser Phe Asp Phe Pro Tyr Leu Ala Lys Arg Ala Glu
210 215 220

Lys Leu Gly Ile Lys Leu Thr Ile Gly Arg Asp Gly Ser Glu Pro Lys
225 230 235 240

Met Gln Arg Ile Gly Asp Met Thr Ala Val Glu Val Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Tyr His Val Ile Thr Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu
275 280 285

Lys Val Tyr Ala Asp Glu Ile Ala Lys Ala Trp Glu Ser Gly Glu Asn
290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Ala Thr Tyr
305 310 315 320

-continued

Glu	Leu	Gly	Lys	Glu	Phe	Leu	Pro	Met	Glu	Ile	Gln	Leu	Ser	Arg	Leu		
				325					330					335			
Val	Gly	Gln	Pro	Leu	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu		
			340					345					350				
Val	Glu	Trp	Phe	Leu	Leu	Arg	Lys	Ala	Tyr	Glu	Arg	Asn	Glu	Val	Ala		
		355					360					365					
Pro	Asn	Lys	Pro	Ser	Glu	Glu	Glu	Tyr	Gln	Arg	Arg	Leu	Arg	Glu	Ser		
	370				375					380							
Tyr	Thr	Gly	Gly	Phe	Val	Lys	Glu	Pro	Glu	Lys	Gly	Leu	Trp	Glu	Asn		
385				390					395						400		
Ile	Val	Tyr	Leu	Asp	Phe	Arg	Ala	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr		
			405						410					415			
His	Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Leu	Glu	Gly	Cys	Lys	Asn	Tyr		
		420						425					430				
Asp	Ile	Ala	Pro	Gln	Val	Gly	His	Lys	Phe	Cys	Lys	Asp	Ile	Pro	Gly		
	435						440					445					
Phe	Ile	Pro	Ser	Leu	Leu	Gly	His	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Ile		
	450					455					460						
Lys	Thr	Lys	Met	Lys	Glu	Thr	Gln	Asp	Pro	Ile	Glu	Lys	Ile	Leu	Leu		
465				470					475						480		
Asp	Tyr	Arg	Gln	Lys	Ala	Ile	Lys	Leu	Leu	Ala	Asn	Ser	Phe	Tyr	Gly		
			485					490						495			
Tyr	Tyr	Gly	Tyr	Ala	Lys	Ala	Arg	Trp	Tyr	Cys	Lys	Glu	Cys	Ala	Glu		
		500					505						510				
Ser	Val	Thr	Ala	Trp	Gly	Arg	Lys	Tyr	Ile	Glu	Leu	Val	Trp	Lys	Glu		
	515					520						525					
Leu	Glu	Glu	Lys	Phe	Gly	Phe	Lys	Val	Leu	Tyr	Ile	Asp	Thr	Asp	Gly		
	530				535						540						
Leu	Tyr	Ala	Thr	Ile	Pro	Gly	Gly	Glu	Ser	Glu	Glu	Ile	Lys	Lys	Lys		
545				550					555						560		
Ala	Leu	Glu	Phe	Val	Lys	Tyr	Ile	Asn	Ser	Lys	Leu	Pro	Gly	Leu	Leu		
			565					570						575			
Glu	Leu	Glu	Tyr	Glu	Gly	Phe	Tyr	Lys	Arg	Gly	Phe	Phe	Val	Thr	Lys		
		580						585					590				
Lys	Arg	Tyr	Ala	Val	Ile	Asp	Glu	Glu	Gly	Lys	Val	Ile	Thr	Arg	Gly		
		595				600						605					
Leu	Glu	Ile	Val	Arg	Arg	Asp	Trp	Ser	Glu	Ile	Ala	Lys	Glu	Thr	Gln		
	610				615						620						
Ala	Arg	Val	Leu	Glu	Thr	Ile	Leu	Lys	His	Gly	Asp	Val	Glu	Glu	Ala		
625			630					635						640			
Val	Arg	Ile	Val	Lys	Glu	Val	Ile	Gln	Lys	Leu	Ala	Asn	Tyr	Glu	Ile		
		645						650						655			
Pro	Pro	Glu	Lys	Leu	Ala	Ile	Tyr	Glu	Gln	Ile	Thr	Arg	Pro	Leu	His		
		660					665						670				
Glu	Tyr	Lys	Ala	Ile	Gly	Pro	His	Val	Ala	Val	Ala	Lys	Lys	Leu	Ala		
	675					680						685					
Ala	Lys	Gly	Val	Lys	Ile	Lys	Pro	Gly	Met	Val	Ile	Gly	Tyr	Ile	Val		
	690				695						700						
Leu	Arg	Gly	Asp	Gly	Pro	Ile	Ser	Asn	Arg	Ala	Ile	Leu	Ala	Glu	Glu		
705				710					715					720			
Tyr	Asp	Pro	Lys	Lys	His	Lys	Tyr	Asp	Ala	Glu	Tyr	Tyr	Ile	Glu	Asn		
			725					730						735			
Gln	Val	Leu	Pro	Ala	Val	Leu	Arg	Ile	Leu	Glu	Gly	Phe	Gly	Tyr	Arg		
		740					745						750				

-continued

Lys Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Thr Ser
 755 760 765

Trp Leu Asn Ile Lys Lys Ser
 770 775

<210> SEQ ID NO 35

<211> LENGTH: 774

<212> TYPE: PRT

<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 35

Met Ile Leu Asp Val Asp Tyr Ile Thr Glu Glu Gly Lys Pro Val Ile
 1 5 10 15

Arg Leu Phe Lys Lys Glu Asn Gly Lys Phe Lys Ile Glu His Asp Arg
 20 25 30

Thr Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Lys Ile
 35 40 45

Glu Glu Val Lys Lys Ile Thr Gly Glu Arg His Gly Lys Ile Val Arg
 50 55 60

Ile Val Asp Val Glu Lys Val Glu Lys Lys Phe Leu Gly Lys Pro Ile
 65 70 75 80

Thr Val Trp Lys Leu Tyr Leu Glu His Pro Gln Asp Pro Thr Ile Arg
 85 90 95

Glu Lys Val Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr Asp
 100 105 110

Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro Met
 115 120 125

Glu Gly Glu Glu Leu Lys Ile Leu Ala Phe Asp Ile Glu Thr Leu
 130 135 140

Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile Ser
 145 150 155 160

Tyr Ala Asp Glu Asn Glu Ala Lys Val Ile Thr Trp Lys Asn Ile Asp
 165 170 175

Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys Arg
 180 185 190

Phe Leu Arg Ile Ile Arg Glu Lys Asp Pro Asp Ile Ile Val Thr Tyr
 195 200 205

Asn Gly Asp Ser Phe Asp Phe Pro Tyr Leu Ala Lys Arg Ala Glu Lys
 210 215 220

Leu Gly Ile Lys Leu Thr Ile Gly Arg Asp Gly Ser Glu Pro Lys Met
 225 230 235 240

Gln Arg Ile Gly Asp Met Thr Ala Val Glu Val Lys Gly Arg Ile His
 245 250 255

Phe Asp Leu Tyr His Val Ile Thr Arg Thr Ile Asn Leu Pro Thr Tyr
 260 265 270

Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu Lys
 275 280 285

Val Tyr Ala Asp Glu Ile Ala Lys Ala Trp Glu Ser Gly Glu Asn Leu
 290 295 300

Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Ala Thr Tyr Glu
 305 310 315 320

Leu Gly Lys Glu Phe Leu Pro Met Glu Ile Gln Leu Ser Arg Leu Val
 325 330 335

Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu Val
 340 345 350

-continued

Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Val Ala Pro
 355 360 365
 Asn Lys Pro Ser Glu Glu Glu Tyr Gln Arg Arg Leu Arg Glu Ser Tyr
 370 375 380
 Thr Gly Gly Phe Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Phe Arg Ala Leu Tyr Pro Ser Ile Ile Ile Thr His
 405 410 415
 Asn Val Ser Pro Asp Thr Leu Asn Leu Glu Gly Cys Lys Asn Tyr Asp
 420 425 430
 Ile Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Ile Pro Gly Phe
 435 440 445
 Ile Pro Ser Leu Leu Gly His Leu Leu Glu Glu Arg Gln Lys Ile Lys
 450 455 460
 Thr Lys Met Lys Glu Thr Gln Asp Pro Ile Glu Lys Ile Leu Leu Asp
 465 470 475 480
 Tyr Arg Gln Lys Ala Ile Lys Leu Leu Ala Asn Ser Phe Tyr Gly Tyr
 485 490 495
 Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
 500 505 510
 Val Thr Ala Trp Gly Arg Lys Tyr Ile Glu Leu Val Trp Lys Glu Leu
 515 520 525
 Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
 530 535 540
 Tyr Ala Thr Ile Pro Gly Gly Glu Ser Glu Glu Ile Lys Lys Lys Ala
 545 550 555 560
 Leu Glu Phe Val Lys Tyr Ile Asn Ser Lys Leu Pro Gly Leu Leu Glu
 565 570 575
 Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys
 580 585 590
 Arg Tyr Ala Val Ile Asp Glu Glu Gly Lys Val Ile Thr Arg Gly Leu
 595 600 605
 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
 610 615 620
 Arg Val Leu Glu Thr Ile Leu Lys His Gly Asp Val Glu Glu Ala Val
 625 630 635 640
 Arg Ile Val Lys Glu Val Ile Gln Lys Leu Ala Asn Tyr Glu Ile Pro
 645 650 655
 Pro Glu Lys Leu Ala Ile Tyr Glu Gln Ile Thr Arg Pro Leu His Glu
 660 665 670
 Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Lys Leu Ala Ala
 675 680 685
 Lys Gly Val Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Ile Val Leu
 690 695 700
 Arg Gly Asp Gly Pro Ile Ser Asn Arg Ala Ile Leu Ala Glu Glu Tyr
 705 710 715 720
 Asp Pro Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
 725 730 735
 Val Leu Pro Ala Val Leu Arg Ile Leu Glu Gly Phe Gly Tyr Arg Lys
 740 745 750
 Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Thr Ser Trp
 755 760 765
 Leu Asn Ile Lys Lys Ser

-continued

770

```

<210> SEQ ID NO 36
<211> LENGTH: 772
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 36

Met Ile Leu Asp Val Asp Tyr Ile Thr Glu Glu Gly Lys Pro Val Ile
 1             5             10            15

Arg Leu Phe Lys Lys Glu Asn Gly Lys Phe Lys Ile Glu His Asp Arg
      20            25            30

Thr Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Lys Ile
      35            40            45

Glu Glu Val Lys Lys Ile Thr Gly Glu Arg His Gly Lys Ile Val Arg
      50            55            60

Ile Val Asp Val Glu Lys Val Glu Lys Lys Phe Leu Gly Lys Pro Ile
      65            70            75            80

Thr Val Trp Lys Leu Tyr Leu Glu His Pro Gln Thr Ile Arg Glu Lys
      85            90            95

Val Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr Asp Ile Pro
      100           105           110

Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro Met Glu Gly
      115           120           125

Glu Glu Glu Leu Lys Ile Leu Ala Phe Asp Ile Glu Thr Leu Tyr His
      130           135           140

Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile Ser Tyr Ala
      145           150           155           160

Asp Glu Asn Glu Ala Lys Val Ile Thr Trp Lys Asn Ile Asp Leu Pro
      165           170           175

Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys Arg Phe Leu
      180           185           190

Arg Ile Ile Arg Glu Lys Asp Pro Asp Ile Ile Val Thr Tyr Asn Gly
      195           200           205

Asp Ser Phe Asp Phe Pro Tyr Leu Ala Lys Arg Ala Glu Lys Leu Gly
      210           215           220

Ile Lys Leu Thr Ile Gly Arg Asp Gly Ser Glu Pro Lys Met Gln Arg
      225           230           235           240

Ile Gly Asp Met Thr Ala Val Glu Val Lys Gly Arg Ile His Phe Asp
      245           250           255

Leu Tyr His Val Ile Thr Arg Thr Ile Asn Leu Pro Thr Tyr Thr Leu
      260           265           270

Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu Lys Val Tyr
      275           280           285

Ala Asp Glu Ile Ala Lys Ala Trp Glu Ser Gly Glu Asn Leu Glu Arg
      290           295           300

Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Ala Thr Tyr Glu Leu Gly
      305           310           315           320

Lys Glu Phe Leu Pro Met Glu Ile Gln Leu Ser Arg Leu Val Gly Gln
      325           330           335

Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu Val Glu Trp
      340           345           350

Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Val Ala Pro Asn Lys
      355           360           365

Pro Ser Glu Glu Glu Tyr Gln Arg Arg Leu Arg Glu Ser Tyr Thr Gly

```

-continued

370	375	380
Gly Phe Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Asn Ile Val Tyr 385 390 395 400		
Leu Asp Phe Arg Ala Leu Tyr Pro Ser Ile Ile Ile Thr His Asn Val 405 410 415		
Ser Pro Asp Thr Leu Asn Leu Glu Gly Cys Lys Asn Tyr Asp Ile Ala 420 425 430		
Pro Gln Val Gly His Lys Phe Cys Lys Asp Ile Pro Gly Phe Ile Pro 435 440 445		
Ser Leu Leu Gly His Leu Leu Glu Glu Arg Gln Lys Ile Lys Thr Lys 450 455 460		
Met Lys Glu Thr Gln Asp Pro Ile Glu Lys Ile Leu Leu Asp Tyr Arg 465 470 475 480		
Gln Lys Ala Ile Lys Leu Leu Ala Asn Ser Phe Tyr Gly Tyr Tyr Gly 485 490 495		
Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser Val Thr 500 505 510		
Ala Trp Gly Arg Lys Tyr Ile Glu Leu Val Trp Lys Glu Leu Glu Glu 515 520 525		
Lys Phe Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu Tyr Ala 530 535 540		
Thr Ile Pro Gly Gly Glu Ser Glu Glu Ile Lys Lys Lys Ala Leu Glu 545 550 555 560		
Phe Val Lys Tyr Ile Asn Ser Lys Leu Pro Gly Leu Leu Glu Leu Glu 565 570 575		
Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys Arg Tyr 580 585 590		
Ala Val Ile Asp Glu Glu Gly Lys Val Ile Thr Arg Gly Leu Glu Ile 595 600 605		
Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala Arg Val 610 615 620		
Leu Glu Thr Ile Leu Lys His Gly Asp Val Glu Glu Ala Val Arg Ile 625 630 635 640		
Val Lys Glu Val Ile Gln Lys Leu Ala Asn Tyr Glu Ile Pro Pro Glu 645 650 655		
Lys Leu Ala Ile Tyr Glu Gln Ile Thr Arg Pro Leu His Glu Tyr Lys 660 665 670		
Ala Ile Gly Pro His Val Ala Val Ala Lys Lys Leu Ala Ala Lys Gly 675 680 685		
Val Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Ile Val Leu Arg Gly 690 695 700		
Asp Gly Pro Ile Ser Asn Arg Ala Ile Leu Ala Glu Glu Tyr Asp Pro 705 710 715 720		
Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln Val Leu 725 730 735		
Pro Ala Val Leu Arg Ile Leu Glu Gly Phe Gly Tyr Arg Lys Glu Asp 740 745 750		
Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Thr Ser Trp Leu Asn 755 760 765		
Ile Lys Lys Ser 770		

<210> SEQ ID NO 37

<211> LENGTH: 2322

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Thermococcus gorgonarius
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(2322)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (277)..(279)
<223> OTHER INFORMATION: Tgo93 (R): nnn = AGA, AGG, CGA, CGC, CGG, CGT;
    Tgo 93 (E): nnn = GAA, GAG; Tgo93 (D): nnn = GAT, GAC (D) ;Tgo93
    (K): nnn = AAA, AAG (K) ; Tgo93 (Q): nnn = CAA, CAG (Q) ; Tgo93
    (N): nnn = AAC, AAU (N)

<400> SEQUENCE: 37

atg atc ctc gat aca gac tac ata act gag gat gga aag ccc gtc atc      48
Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile
1           5           10          15

agg atc ttc aag aag gag aac ggc gag ttc aaa ata gac tac gac aga      96
Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Asp Tyr Asp Arg
20          25          30

aac ttt gag cca tac atc tac gcg ctc ttg aag gac gac tct gcg att      144
Asn Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35          40          45

gag gac gtc aag aag ata act gcc gag agg cac ggc act acc gtt agg      192
Glu Asp Val Lys Lys Ile Thr Ala Glu Arg His Gly Thr Thr Val Arg
50          55          60

gtt gtc agg gcc gag aaa gtg aag aag aag ttc cta ggc agg ccg ata      240
Val Val Arg Ala Glu Lys Val Lys Lys Lys Phe Leu Gly Arg Pro Ile
65          70          75          80

gag gtc tgg aag ctc tac ttc act cac ccc cag gac nnn ccc gca atc      288
Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Xaa Pro Ala Ile
85          90          95

agg gac aag ata aag gag cat cct gcc gtt gtg gac atc tac gag tac      336
Arg Asp Lys Ile Lys Glu His Pro Ala Val Val Asp Ile Tyr Glu Tyr
100         105         110

gac atc ccc ttc gcg aag cgc tac ctc ata gac aaa ggc tta atc ccg      384
Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115         120         125

atg gag ggc gac gag gaa ctt aag atg ctc gcc ttc gac atc gag acg      432
Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
130         135         140

ctc tat cac gag ggc gag gag ttc gcc gaa ggg cct atc ctg atg ata      480
Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile
145         150         155         160

agc tac gcc gac gag gaa ggg gcg cgc gtt att acc tgg aag aat atc      528
Ser Tyr Ala Asp Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Ile
165         170         175

gac ctt ccc tat gtc gac gtc gtt tcc acc gag aag gag atg ata aag      576
Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
180         185         190

cgc ttc ctc aag gtc gtc aag gaa aag gat ccc gac gtc ctc ata acc      624
Arg Phe Leu Lys Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
195         200         205

tac aac ggc gac aac ttc gac ttc gcc tac ctc aag aag cgc tcc gag      672
Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Ser Glu
210         215         220

aag ctc gga gtc aag ttc atc ctc gga agg gaa ggg agc gag ccg aaa      720
Lys Leu Gly Val Lys Phe Ile Leu Gly Arg Glu Gly Ser Glu Pro Lys
225         230         235         240

atc cag cgc atg ggc gat cgc ttt gcg gtg gag gtc aag gga agg att      768
Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
245         250         255

cac ttc gac ctc tac ccc gtc att agg aga acg att aac ctc ccc act      816

```

-continued

His	Phe	Asp	Leu	Tyr	Pro	Val	Ile	Arg	Arg	Thr	Ile	Asn	Leu	Pro	Thr	
		260						265				270				
tac	acc	ctt	gag	gca	gta	tat	gaa	gcc	atc	ttt	gga	cag	ccg	aag	gag	864
Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Ile	Phe	Gly	Gln	Pro	Lys	Glu	
		275					280				285					
aag	gtc	tac	gct	gag	gag	ata	gcg	cag	gcc	tgg	gaa	acg	ggc	gag	gga	912
Lys	Val	Tyr	Ala	Glu	Glu	Ile	Ala	Gln	Ala	Trp	Glu	Thr	Gly	Glu	Gly	
	290				295					300						
tta	gaa	agg	gtg	gcc	cgc	tac	tcg	atg	gag	gac	gca	aag	gta	acc	tat	960
Leu	Glu	Arg	Val	Ala	Arg	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Val	Thr	Tyr	
305			310						315					320		
gaa	ctc	gga	aaa	gag	ttc	ttc	cct	atg	gaa	gcc	cag	ctc	tcg	cgc	ctc	1008
Glu	Leu	Gly	Lys	Glu	Phe	Phe	Pro	Met	Glu	Ala	Gln	Leu	Ser	Arg	Leu	
		325						330					335			
gta	ggc	cag	agc	ctc	tgg	gat	gta	tct	cgc	tcg	agt	acc	gga	aac	ctc	1056
Val	Gly	Gln	Ser	Leu	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu	
	340				345							350				
gtc	gag	tgg	ttt	ttg	ctg	agg	aag	gcc	tac	gag	agg	aat	gaa	ctt	gca	1104
Val	Glu	Trp	Phe	Leu	Leu	Arg	Lys	Ala	Tyr	Glu	Arg	Asn	Glu	Leu	Ala	
	355				360					365						
cca	aac	aag	cgc	gac	gag	agg	gag	ctg	gca	aga	aga	agg	gag	agc	tac	1152
Pro	Asn	Lys	Pro	Asp	Glu	Arg	Glu	Leu	Ala	Arg	Arg	Arg	Glu	Ser	Tyr	
	370				375					380						
gcg	ggt	gga	tac	gtc	aag	gag	ccc	gaa	agg	gga	ctg	tgg	gag	aac	atc	1200
Ala	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Arg	Gly	Leu	Trp	Glu	Asn	Ile	
385			390					395						400		
gtg	tat	ctg	gac	ttc	cgc	tcc	ctg	tat	cct	tcg	ata	ata	atc	acc	cat	1248
Val	Tyr	Leu	Asp	Phe	Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr	His	
	405							410					415			
aac	gtc	tcc	cct	gat	aca	ctc	aac	agg	gag	ggt	tgt	gag	gag	tac	gac	1296
Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Arg	Glu	Gly	Cys	Glu	Glu	Tyr	Asp	
	420							425				430				
gtg	gct	cct	cag	gta	ggc	cat	aag	ttc	tgc	aag	gac	ttc	ccc	ggc	ttc	1344
Val	Ala	Pro	Gln	Val	Gly	His	Lys	Phe	Cys	Lys	Asp	Phe	Pro	Gly	Phe	
	435				440							445				
atc	cca	agc	ctc	ctc	gga	gac	ctc	ttg	gag	gag	aga	cag	aag	gta	aag	1392
Ile	Pro	Ser	Leu	Leu	Gly	Asp	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Val	Lys	
	450				455						460					
aag	aag	atg	aag	gcc	act	ata	gac	cca	atc	gag	aag	aaa	ctc	ctc	gat	1440
Lys	Lys	Met	Lys	Ala	Thr	Ile	Asp	Pro	Ile	Glu	Lys	Lys	Leu	Leu	Asp	
465			470					475						480		
tac	agg	caa	cga	gca	atc	aaa	atc	ctt	gct	aat	agc	ttc	tac	ggt	tac	1488
Tyr	Arg	Gln	Arg	Ala	Ile	Lys	Ile	Leu	Ala	Asn	Ser	Phe	Tyr	Gly	Tyr	
	485							490					495			
tac	ggc	tat	gca	aag	gcc	cgc	tgg	tac	tgc	aag	gag	tgc	gcc	gag	agc	1536
Tyr	Gly	Tyr	Ala	Lys	Ala	Arg	Trp	Tyr	Cys	Lys	Glu	Cys	Ala	Glu	Ser	
	500						505					510				
gtt	acc	gct	tgg	ggc	agg	cag	tac	atc	gag	acc	acg	ata	agg	gaa	ata	1584
Val	Thr	Ala	Trp	Gly	Arg	Gln	Tyr	Ile	Glu	Thr	Thr	Ile	Arg	Glu	Ile	
	515					520						525				
gag	gag	aaa	ttt	ggc	ttt	aaa	gtc	ctc	tac	gcg	gac	aca	gat	gga	ttt	1632
Glu	Glu	Lys	Phe	Gly	Phe	Lys	Val	Leu	Tyr	Ala	Asp	Thr	Asp	Gly	Phe	
	530				535						540					
ttc	gca	aca	ata	cct	gga	gcg	gac	gcc	gaa	acc	gtc	aaa	aag	aag	gca	1680
Phe	Ala	Thr	Ile	Pro	Gly	Ala	Asp	Ala	Glu	Thr	Val	Lys	Lys	Lys	Ala	
545			550					555						560		
aag	gag	ttc	ctg	gac	tac	atc	aac	gcc	aaa	ctg	ccc	ggc	ctg	ctc	gaa	1728
Lys	Glu	Phe	Leu	Asp	Tyr	Ile	Asn	Ala	Lys	Leu	Pro	Gly	Leu	Leu	Glu	
	565					570						575				
ctc	gaa	tac	gag	ggc	ttc	tac	aag	cgc	ggc	ttc	ttc	gtg	acg	aag	aag	1776

-continued

Leu	Glu	Tyr	Glu	Gly	Phe	Tyr	Lys	Arg	Gly	Phe	Phe	Val	Thr	Lys	Lys		
			580					585					590				
aag	tac	gcg	gtt	ata	gac	gag	gag	gac	aag	ata	acg	acg	cgc	ggg	ctt	1824	
Lys	Tyr	Ala	Val	Ile	Asp	Glu	Glu	Asp	Lys	Ile	Thr	Thr	Arg	Gly	Leu		
		595				600					605						
gaa	ata	gtt	agg	cgt	gac	tgg	agc	gag	ata	gcg	aag	gag	acg	cag	gcg	1872	
Glu	Ile	Val	Arg	Arg	Asp	Trp	Ser	Glu	Ile	Ala	Lys	Glu	Thr	Gln	Ala		
	610					615				620							
agg	gtt	ctt	gag	gcg	ata	cta	aag	cac	ggg	gac	gtt	gaa	gaa	gcg	gta	1920	
Arg	Val	Leu	Glu	Ala	Ile	Leu	Lys	His	Gly	Asp	Val	Glu	Glu	Ala	Val		
	625			630					635					640			
agg	att	gtc	aaa	gag	gtt	acg	gag	aag	ctg	agc	aag	tac	gag	gtt	cca	1968	
Arg	Ile	Val	Lys	Glu	Val	Thr	Glu	Lys	Leu	Ser	Lys	Tyr	Glu	Val	Pro		
		645						650					655				
ccg	gag	aag	ctg	gtc	atc	tac	gag	cag	ata	acc	cgc	gac	ctg	aag	gac	2016	
Pro	Glu	Lys	Leu	Val	Ile	Tyr	Glu	Gln	Ile	Thr	Arg	Asp	Leu	Lys	Asp		
		660						665					670				
tac	aag	gcc	acc	ggg	cgg	cat	gtg	gct	gtt	gca	aaa	cgc	ctc	gcc	gca	2064	
Tyr	Lys	Ala	Thr	Gly	Pro	His	Val	Ala	Val	Ala	Lys	Arg	Leu	Ala	Ala		
	675					680						685					
agg	ggg	ata	aaa	atc	cgg	ccc	gga	acg	gtc	ata	agc	tac	atc	gtg	ctc	2112	
Arg	Gly	Ile	Lys	Ile	Arg	Pro	Gly	Thr	Val	Ile	Ser	Tyr	Ile	Val	Leu		
	690					695				700							
aaa	ggc	tcg	gga	agg	att	ggg	gac	agg	gct	ata	ccc	ttt	gac	gaa	ttt	2160	
Lys	Gly	Ser	Gly	Arg	Ile	Gly	Asp	Arg	Ala	Ile	Pro	Phe	Asp	Glu	Phe		
	705			710					715					720			
gac	ccg	gca	aag	cac	aag	tac	gat	gca	gaa	tac	tac	atc	gag	aac	cag	2208	
Asp	Pro	Ala	Lys	His	Lys	Tyr	Asp	Ala	Glu	Tyr	Tyr	Ile	Glu	Asn	Gln		
		725						730					735				
gtt	ctt	cca	gct	gtg	gag	agg	att	ctg	agg	gcc	ttt	ggg	tac	cgt	aaa	2256	
Val	Leu	Pro	Ala	Val	Glu	Arg	Ile	Leu	Arg	Ala	Phe	Gly	Tyr	Arg	Lys		
		740						745					750				
gaa	gat	tta	agg	tat	cag	aaa	acg	cgg	cag	gtt	ggc	ttg	ggg	gcg	tgg	2304	
Glu	Asp	Leu	Arg	Tyr	Gln	Lys	Thr	Arg	Gln	Val	Gly	Leu	Gly	Ala	Trp		
		755				760						765					
cta	aaa	cct	aag	aca	tga											2322	
Leu	Lys	Pro	Lys	Thr													
		770															

<210> SEQ ID NO 38

<211> LENGTH: 773

<212> TYPE: PRT

<213> ORGANISM: Thermococcus gorgonarius

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (93)..(93)

<223> OTHER INFORMATION: The 'Xaa' at location 93 stands for Lys, Asn, Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro, Leu, Tyr, Trp, Cys, or Phe.

<400> SEQUENCE: 38

Met	Ile	Leu	Asp	Thr	Asp	Tyr	Ile	Thr	Glu	Asp	Gly	Lys	Pro	Val	Ile
1				5					10					15	

Arg	Ile	Phe	Lys	Lys	Glu	Asn	Gly	Glu	Phe	Lys	Ile	Asp	Tyr	Asp	Arg
		20					25					30			

Asn	Phe	Glu	Pro	Tyr	Ile	Tyr	Ala	Leu	Leu	Lys	Asp	Asp	Ser	Ala	Ile
	35						40					45			

Glu	Asp	Val	Lys	Lys	Ile	Thr	Ala	Glu	Arg	His	Gly	Thr	Thr	Val	Arg
	50					55				60					

Val	Val	Arg	Ala	Glu	Lys	Val	Lys	Lys	Lys	Phe	Leu	Gly	Arg	Pro	Ile
	65				70				75					80	

Glu	Val	Trp	Lys	Leu	Tyr	Phe	Thr	His	Pro	Gln	Asp	Xaa	Pro	Ala	Ile	
				85					90					95		
Arg	Asp	Lys	Ile	Lys	Glu	His	Pro	Ala	Val	Val	Asp	Ile	Tyr	Glu	Tyr	
				100					105					110		
Asp	Ile	Pro	Phe	Ala	Lys	Arg	Tyr	Leu	Ile	Asp	Lys	Gly	Leu	Ile	Pro	
				115					120					125		
Met	Glu	Gly	Asp	Glu	Glu	Leu	Lys	Met	Leu	Ala	Phe	Asp	Ile	Glu	Thr	
				130					135					140		
Leu	Tyr	His	Glu	Gly	Glu	Glu	Phe	Ala	Glu	Gly	Pro	Ile	Leu	Met	Ile	
				145					150					155		
Ser	Tyr	Ala	Asp	Glu	Gly	Ala	Arg	Val	Ile	Thr	Trp	Lys	Asn	Ile		
				165					170					175		
Asp	Leu	Pro	Tyr	Val	Asp	Val	Val	Ser	Thr	Glu	Lys	Glu	Met	Ile	Lys	
				180					185					190		
Arg	Phe	Leu	Lys	Val	Val	Lys	Glu	Lys	Asp	Pro	Asp	Val	Leu	Ile	Thr	
				195					200					205		
Tyr	Asn	Gly	Asp	Asn	Phe	Asp	Phe	Ala	Tyr	Leu	Lys	Lys	Arg	Ser	Glu	
				210					215					220		
Lys	Leu	Gly	Val	Lys	Phe	Ile	Leu	Gly	Arg	Glu	Gly	Ser	Glu	Pro	Lys	
				225					230					235		
Ile	Gln	Arg	Met	Gly	Asp	Arg	Phe	Ala	Val	Glu	Val	Lys	Gly	Arg	Ile	
				245					250					255		
His	Phe	Asp	Leu	Tyr	Pro	Val	Ile	Arg	Arg	Thr	Ile	Asn	Leu	Pro	Thr	
				260					265					270		
Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Ile	Phe	Gly	Gln	Pro	Lys	Glu	
				275					280					285		
Lys	Val	Tyr	Ala	Glu	Glu	Ile	Ala	Gln	Ala	Trp	Glu	Thr	Gly	Glu	Gly	
				290					295					300		
Leu	Glu	Arg	Val	Ala	Arg	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Val	Thr	Tyr	
				305					310					315		
Glu	Leu	Gly	Lys	Glu	Phe	Phe	Pro	Met	Glu	Ala	Gln	Leu	Ser	Arg	Leu	
				325					330					335		
Val	Gly	Gln	Ser	Leu	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu	
				340					345					350		
Val	Glu	Trp	Phe	Leu	Leu	Arg	Lys	Ala	Tyr	Glu	Arg	Asn	Glu	Leu	Ala	
				355					360					365		
Pro	Asn	Lys	Pro	Asp	Glu	Arg	Glu	Leu	Ala	Arg	Arg	Arg	Glu	Ser	Tyr	
				370					375					380		
Ala	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Arg	Gly	Leu	Trp	Glu	Asn	Ile	
				385					390					395		
Val	Tyr	Leu	Asp	Phe	Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr	His	
				405					410					415		
Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Arg	Glu	Gly	Cys	Glu	Glu	Tyr	Asp	
				420					425					430		
Val	Ala	Pro	Gln	Val	Gly	His	Lys	Phe	Cys	Lys	Asp	Phe	Pro	Gly	Phe	
				435					440					445		
Ile	Pro	Ser	Leu	Leu	Gly	Asp	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Val	Lys	
				450					455					460		
Lys	Lys	Met	Lys	Ala	Thr	Ile	Asp	Pro	Ile	Glu	Lys	Lys	Leu	Leu	Asp	
				465					470					475		
Tyr	Arg	Gln	Arg	Ala	Ile	Lys	Ile	Leu	Ala	Asn	Ser	Phe	Tyr	Gly	T	

-continued

Val Thr Ala Trp Gly Arg Gln Tyr Ile Glu Thr Thr Ile Arg Glu Ile
 515 520 525
 Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe
 530 535 540
 Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
 545 550 555 560
 Lys Glu Phe Leu Asp Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu Glu
 565 570 575
 Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys Lys
 580 585 590
 Lys Tyr Ala Val Ile Asp Glu Glu Asp Lys Ile Thr Thr Arg Gly Leu
 595 600 605
 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
 610 615 620
 Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val
 625 630 635 640
 Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
 645 650 655
 Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Asp Leu Lys Asp
 660 665 670
 Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
 675 680 685
 Arg Gly Ile Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
 690 695 700
 Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe
 705 710 715 720
 Asp Pro Ala Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
 725 730 735
 Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys
 740 745 750
 Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp
 755 760 765
 Leu Lys Pro Lys Thr
 770

<210> SEQ ID NO 39
 <211> LENGTH: 775
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus furiosus

<400> SEQUENCE: 39

Met Ile Leu Asp Val Asp Tyr Ile Thr Glu Glu Gly Lys Pro Val Ile
 1 5 10 15
 Arg Leu Phe Lys Lys Glu Asn Gly Lys Phe Lys Ile Glu His Asp Arg
 20 25 30
 Thr Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Lys Ile
 35 40 45
 Glu Glu Val Lys Lys Ile Thr Gly Glu Arg His Gly Lys Ile Val Arg
 50 55 60
 Ile Val Asp Val Glu Lys Val Glu Lys Lys Phe Leu Gly Lys Pro Ile
 65 70 75 80
 Thr Val Trp Lys Leu Tyr Leu Glu His Pro Gln Asp Val Pro Thr Ile
 85 90 95
 Arg Glu Lys Val Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr
 100 105 110

Asp	Ile	Pro	Phe	Ala	Lys	Arg	Tyr	Leu	Ile	Asp	Lys	Gly	Leu	Ile	Pro
Met	Glu	Gly	Glu	Glu	Glu	Leu	Lys	Ile	Leu	Ala	Phe	Asp	Ile	Glu	Thr
Leu	Tyr	His	Glu	Gly	Glu	Glu	Phe	Gly	Lys	Gly	Pro	Ile	Ile	Met	Ile
Ser	Tyr	Ala	Asp	Glu	Asn	Glu	Ala	Lys	Val	Ile	Thr	Trp	Lys	Asn	Ile
Asp	Leu	Pro	Tyr	Val	Glu	Val	Val	Ser	Ser	Glu	Arg	Glu	Met	Ile	Lys
Arg	Phe	Leu	Arg	Ile	Ile	Arg	Glu	Lys	Asp	Pro	Asp	Ile	Ile	Val	Thr
Tyr	Asn	Gly	Asp	Ser	Phe	Asp	Phe	Pro	Tyr	Leu	Ala	Lys	Arg	Ala	Glu
Lys	Leu	Gly	Ile	Lys	Leu	Thr	Ile	Gly	Arg	Asp	Gly	Ser	Glu	Pro	Lys
Met	Gln	Arg	Ile	Gly	Asp	Met	Thr	Ala	Val	Glu	Val	Lys	Gly	Arg	Ile
His	Phe	Asp	Leu	Tyr	His	Val	Ile	Thr	Arg	Thr	Ile	Asn	Leu	Pro	Thr
Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Ile	Phe	Gly	Lys	Pro	Lys	Glu
Lys	Val	Tyr	Ala	Asp	Glu	Ile	Ala	Lys	Ala	Trp	Glu	Ser	Gly	Glu	Asn
Leu	Glu	Arg	Val	Ala	Lys	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Ala	Thr	Tyr
Glu	Leu	Gly	Lys	Glu	Phe	Leu	Pro	Met	Glu	Ile	Gln	Leu	Ser	Arg	Leu
Val	Gly	Gln	Pro	Leu	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu
Val	Glu	Trp	Phe	Leu	Leu	Arg	Lys	Ala	Tyr	Glu	Arg	Asn	Glu	Val	Ala
Pro	Asn	Lys	Pro	Ser	Glu	Glu	Glu	Tyr	Gln	Arg	Arg	Leu	Arg	Glu	Ser
Tyr	Thr	Gly	Gly	Phe	Val	Lys	Glu	Pro	Glu	Lys	Gly	Leu	Trp	Glu	Asn
Ile	Val	Tyr	Leu	Asp	Phe	Arg	Ala	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr
His	Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Leu	Glu	Gly	Cys	Lys	Asn	Tyr
Asp	Ile	Ala	Pro	Gln	Val	Gly	His	Lys	Phe	Cys	Lys	Asp	Ile	Pro	Gly
Phe	Ile	Pro	Ser	Leu	Leu	Gly	His	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Ile
Lys	Thr	Lys	Met	Lys	Glu	Thr	Gln	Asp	Pro	Ile	Glu	Lys	Ile	Leu	Leu
Asp	Tyr	Arg	Gln	Lys	Ala	Ile	Lys	Leu	Leu	Ala	Asn	Ser	Phe	Tyr	Gly
Tyr	Tyr	Gly	Tyr	Ala	Lys	Ala	Arg	Trp	Tyr	Cys	Lys	Glu	Cys	Ala	Glu
Ser	Val	Thr	Ala	Trp	Gly	Arg	Lys	Tyr	Ile	Glu	Leu	Val	Trp	Lys	Glu
Leu	Glu	Glu	Lys	Phe	Gly	Phe	Lys	Val	Leu	Tyr	Ile	Asp	Thr	Asp	Gly

-continued

530	535	540
Leu Tyr Ala Thr Ile Pro Gly Gly Glu Ser Glu Glu Ile Lys Lys Lys		
545	550	555 560
Ala Leu Glu Phe Val Lys Tyr Ile Asn Ser Lys Leu Pro Gly Leu Leu		
	565	570 575
Glu Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys		
	580	585 590
Lys Arg Tyr Ala Val Ile Asp Glu Glu Gly Lys Val Ile Thr Arg Gly		
	595	600 605
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln		
	610	615 620
Ala Arg Val Leu Glu Thr Ile Leu Lys His Gly Asp Val Glu Glu Ala		
	625	630 635 640
Val Arg Ile Val Lys Glu Val Ile Gln Lys Leu Ala Asn Tyr Glu Ile		
	645	650 655
Pro Pro Glu Lys Leu Ala Ile Tyr Glu Gln Ile Thr Arg Pro Leu His		
	660	665 670
Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Lys Leu Ala		
	675	680 685
Ala Lys Gly Val Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Ile Val		
	690	695 700
Leu Arg Gly Asp Gly Pro Ile Ser Asn Arg Ala Ile Leu Ala Glu Glu		
	705	710 715 720
Tyr Asp Pro Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn		
	725	730 735
Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Gly Phe Gly Tyr Arg		
	740	745 750
Lys Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Thr Ser		
	755	760 765
Trp Leu Asn Ile Lys Lys Ser		
	770	775

<210> SEQ ID NO 40
 <211> LENGTH: 3499
 <212> TYPE: DNA
 <213> ORGANISM: Pyrococcus furiosus
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (2788)..(2789)
 <223> OTHER INFORMATION: n= A, T, G or C
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (3287)..(3289)
 <223> OTHER INFORMATION: n= A, T, G or C
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (3290)..(3292)
 <223> OTHER INFORMATION: n= A, T, G or C
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (3473)..(3473)
 <223> OTHER INFORMATION: n= A, T, G or C
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (3478)..(3478)
 <223> OTHER INFORMATION: n= A, T, G or C

<400> SEQUENCE: 40

ccctggctect gggccacat atatgttctt actcgcttt atgaagaatc cccagtcgc	60
tctaacctgg gttatagtga caaatcttc tccaccaccg cccaagaagg ttatttctat	120
caactctaca cctcccctat ttctctctt atgagatttt taagtatagt tatagagaag	180

-continued

gttttatact ccaaactgag ttagtagata tgtggggagc ataatgattt tagatgtgga	240
ttacataact gaagaaggaa aacctgttat taggctattc aaaaagaga acggaattt	300
taagatagag catgatagaa ctttttagacc atacatttac gctcttctca gggatgattc	360
aaagattgaa gaagttaaga aaataacggg ggaaagcat ggaaagattg tgagaattgt	420
tgatgtagag aagggtgaga aaaagtcttct cggcaagcct attaccgtgt ggaaacttta	480
tttggaacat cccaagatg ttccactat tagagaaaaa gttagagaac atccagcagt	540
tgtggacatc ttccaatcg atattccatt tgcaagaga tacctcatcg acaaaggcct	600
aataccaatg gagggggaag aagagctaaa gattcttgcc ttcgatatag aaacctcta	660
tcacgaagga gaagagtgtt gaaaaggccc aattataatg attagttagt cagatgaaaa	720
tgaagcaaag gtgattactt ggaaaaacat agatcttcca tacgttgagg ttgtatcaag	780
cgagagagag atgataaaga gatttctcag gattatcagg gagaaggatc ctgacattat	840
agttacttat aatggagact cattcgactt cccatattta gcgaaaaggg cagaaaaact	900
tgggattaaa ttaaccattg gaagagatgg aagcgagccc aagatgcaga gaataggcga	960
tatgacggct gtgaagatca agggaagaat acatttcgac ttgtatcatg taataacaag	1020
gacaataaat ctccaacat acacactaga ggctgtatat gaagcaattt ttggaaagcc	1080
aaaggagaag gtatacgccg acgagatagc aaaagcctgg gaaagtggag agaacctga	1140
gagagtggcc aaatactcga tggaagatgc aaaggcaact tatgaactcg ggaaagaatt	1200
ccttccaatg gaaattcagc ttccaagatt agttggacaa cctttatggg atgtttcaag	1260
gtcaagcaca gggaaccttg tagagtgggt cttacttagg aaagcctacg aaagaaacga	1320
agtagctcca aacaagccaa gtgaagagga gtatcaaaga aggctcaggg agagctacac	1380
agggtggattc gttaaagagc cagaaaaggg gttgtgggaa aacatagtat acctagattt	1440
tagagcccta tatccctcga ttataattac ccacaatgtt tctcccata ctctaaatct	1500
tgagggatgc aagaactatg atatcgctcc tcaagtaggc cacaagttct gcaaggacat	1560
ccctggtttt ataccaagtc tcttgggaca tttgttagag gaaagacaaa agattaagac	1620
aaaaatgaag gaaactcaag atcctataga aaaaactctc cttgactata gacaaaaagc	1680
gataaaactc tttagcaaat ctttctacgg atattatggc tatgcaaaag caagatggta	1740
ctgtaaggag tgtgctgaga gcgttactgc ctggggaaga aagtacatcg agttagtatg	1800
gaaggagctc gaagaaaagt ttggatttaa agtcctctac attgacactg atggctctta	1860
tgcaactatc ccaggaggag aaagtgagga aataaagaaa aaggctctag aatttgtaaa	1920
atacataaat tcaaagctcc ctggactgct agagcttgaa tatgaagggt ttataagag	1980
gggattcttc gttacgaaga agaggatgac agtaatagat gaagaaggaa aagtcattac	2040
tcgtggttta gagatagtta ggagagattg gagtgaattt gcaaaagaaa ctcaagctag	2100
agttttggag acaatactaa aacacggaga tgttgaagaa gctgtgagaa tagtaaaaga	2160
agtaatacaa aagcttgcca attatgaaat tccaccagag aagctcgcaa tatatgagca	2220
gataacaaga ccattacatg agtataaggc gataggtcct cacgtagctg ttgcaagaa	2280
actagctgct aaaggagtta aaataaagcc aggaatggta attggatata tagtacttag	2340
aggcgatggt ccaattagca atagggcaat tctagctgag gaatacgate ccaaaaagca	2400
caagtatgac gcagaatatt acattgagaa ccagggttctt ccagcggtag ttaggatatt	2460
ggagggatth ggatacagaa aggaagacct cagataccaa aagacaagac aagtcggcct	2520
aacttctctg cttaacatta aaaaatccta gaaaagcagat agatatcaac ttttattctt	2580

-continued

tctaacccttt ttctatgaaa gaagaactga gcaggaatta ccagttcttc cgttatttta	2640
tgggtaatta aaaacccatg ctcttgggag aatcttcgaa taaaatccct aacttcaggc	2700
tttgctaagt gaatagaata aacaacatca ctcaactcaa acgccttcgt tagaaatggt	2760
ctatctgcat gcttctctgg ctcggaanng gaggattcat aacaacagta tcaacattct	2820
cagagaattg agaaacatca gaaactttga cttctacaac atttctaact ttgcaactct	2880
tcaagatttt ctaaaaagaat tttaacggcc tcctcgtcaa ttctgacgac gtagatcttt	2940
tttgctccaa gcagagccgc tccaatggat aacacccctg ttcccgcacc caagtcgct	3000
acaatttttt ccttgatatct cctaattgat aagcaagcca aaggagagta gatgctacct	3060
ttccgggagt ttgtattgc tctagccaag gtttgggatt ttgaaatcct ttaactctgg	3120
aaagtataat ttcaagctcc ttcttcttca tgacagatga aaaattgttt tgtctctttt	3180
taacttttac agaaataact gtctcaaatt atgacaactc ttgacatttt tacttcatta	3240
ccagggtaat gtttttaagt atgaaatttt tctttcatag aggaggnnnn nngtcctctc	3300
ctcgatttcc ttgggtgtgc tccatatgat aagcttccaa agtgggtgtt cagactttta	3360
gacactcaaa taccagacga caatggtgtg ctcaactcaag ccccatatgg gttgagaaaa	3420
gtagaagcgg cactactcag atgcttcccc aggaatgagg ttgttgtagc tontcccnga	3480
aagattgaga tgttcttgg	3499

<210> SEQ ID NO 41
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 41

ggaatgaagt tatccccgct tcccc	25
-----------------------------	----

<210> SEQ ID NO 42
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 42

ccagttcatt cagcgtattc ag	22
--------------------------	----

<210> SEQ ID NO 43
 <211> LENGTH: 31
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 43

gaacatcccc aagataaacc cactattaga g	31
------------------------------------	----

<210> SEQ ID NO 44
 <211> LENGTH: 31
 <212> TYPE: DNA
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 44

ctctaatagt gggtttatct tggggatgtt c	31
------------------------------------	----

-continued

<210> SEQ ID NO 45
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5' phosphate

<400> SEQUENCE: 45

gaacatcccc aagatgcacc cactattaga gaaaaag 37

<210> SEQ ID NO 46
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 46

gaacatcccc aagatgaccc cactattaga gaaaaag 37

<210> SEQ ID NO 47
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 47

gaacatcccc aagattgccc ccactattag agaaaaag 38

<210> SEQ ID NO 48
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 48

gaacatcccc aagatatacc cactattaga gaaaaag 37

<210> SEQ ID NO 49
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 49

gaacatcccc aagatatgcc cactattaga gaaaaag 37

-continued

<210> SEQ ID NO 50
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 50

gaacatcccc aagatttccc cactattaga gaaaaaag 37

<210> SEQ ID NO 51
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 51

gaacatcccc aagatcctccc cactattaga gaaaaaag 37

<210> SEQ ID NO 52
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 52

gaacatcccc aagatagccc cactattaga gaaaaaag 37

<210> SEQ ID NO 53
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 53

gaacatcccc aagatacacc cactattaga gaaaaaag 37

<210> SEQ ID NO 54
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 54

gaacatcccc aagattaccc cactattaga gaaaaaag 37

-continued

<210> SEQ ID NO 55
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(1)
<223> OTHER INFORMATION: 5'-phosphate

<400> SEQUENCE: 55

gaacatcccc aagattggcc cactattaga gaaaaag 37

<210> SEQ ID NO 56
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 56

ctcatccgca ggaccagcca gcgataagg acaag 35

<210> SEQ ID NO 57
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 57

ctcatccgca ggaccgtcca gcgataagg acaag 35

<210> SEQ ID NO 58
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 58

ctcatccgca ggacaaacca gcgataagg acaag 35

<210> SEQ ID NO 59
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 59

ctcatccgca ggacaatcca gcgataagg acaag 35

<210> SEQ ID NO 60
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 60

ctcatccgca ggacgagcca gcgataagg acaag 35

<210> SEQ ID NO 61
<211> LENGTH: 35

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 61

ctcatccgca ggacgatcca gcgataaggg acaag 35

<210> SEQ ID NO 62
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 62

cacccccagg accaaccgc aatcaggga aagg 34

<210> SEQ ID NO 63
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 63

cacccccagg acagaccgc aatcaggga aagg 34

<210> SEQ ID NO 64
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 64

cacccccagg acaatccgc aatcaggga aagg 34

<210> SEQ ID NO 65
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 65

cacccccagg acaaaccgc aatcaggga aagg 34

<210> SEQ ID NO 66
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 66

cacccccagg acgaaccgc aatcaggga aagg 34

<210> SEQ ID NO 67
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 67

cacccccagg acgaccgc aatcaggga aagg 34

-continued

<210> SEQ ID NO 68
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 68

acgcacccgc aggaccaacc ggcaatccgc gac 33

<210> SEQ ID NO 69
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 69

acgcacccgc aggaccgtcc ggcaatccgc gac 33

<210> SEQ ID NO 70
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 70

acgcacccgc aggacgagcc ggcaatccgc gac 33

<210> SEQ ID NO 71
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 71

acgcacccgc aggacgatcc ggcaatccgc gac 33

<210> SEQ ID NO 72
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 72

acgcacccgc aggacaaaacc ggcaatccgc gac 33

<210> SEQ ID NO 73
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 73

gaacatcccc aagatcccac tattagag 28

<210> SEQ ID NO 74
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

-continued

<400> SEQUENCE: 74

gaacatcccc aaactattag ag

22

<210> SEQ ID NO 75

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (5)..(5)

<223> OTHER INFORMATION: n = U

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (10)..(10)

<223> OTHER INFORMATION: n = U

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (11)..(11)

<223> OTHER INFORMATION: n = U

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (13)..(13)

<223> OTHER INFORMATION: n = U

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (20)..(21)

<223> OTHER INFORMATION: n = U

<400> SEQUENCE: 75

ggaangaagn nancccgcn ncccc

25

<210> SEQ ID NO 76

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (6)..(6)

<223> OTHER INFORMATION: n = U

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (8)..(8)

<223> OTHER INFORMATION: n = U

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (15)..(15)

<223> OTHER INFORMATION: n = U

<400> SEQUENCE: 76

ccaggncncc agcgngccca

20

<210> SEQ ID NO 77

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 77

ggaatgaagt tatccccgct tcccc

25

<210> SEQ ID NO 78

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

-continued

```

<400> SEQUENCE: 78
ccaggtctcc agcgtgccca                                20

<210> SEQ ID NO 79
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 79
gaggagagca ggaaaggtgg aac                            23

<210> SEQ ID NO 80
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 80
tgcagagcga ttattcagga atgc                            24

<210> SEQ ID NO 81
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 81
gaggagagca ggaaaggtgg aac                            23

<210> SEQ ID NO 82
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 82
gagcaatggt caaagtcaac gtcattcaca gc                 32

<210> SEQ ID NO 83
<211> LENGTH: 774
<212> TYPE: PRT
<213> ORGANISM: Thermococcus litoralis

<400> SEQUENCE: 83
Met Ile Leu Asp Thr Asp Tyr Ile Thr Lys Asp Gly Lys Pro Ile Ile
1           5           10           15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Leu Asp Pro
20          25          30

His Phe Gln Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35          40          45

Glu Glu Ile Lys Ala Ile Lys Gly Glu Arg His Gly Lys Thr Val Arg
50          55          60

Val Leu Asp Ala Val Lys Val Arg Lys Lys Phe Leu Gly Arg Glu Val
65          70          75          80

Glu Val Trp Lys Leu Ile Phe Glu His Pro Gln Asp Val Pro Ala Met
85          90          95

Arg Gly Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Tyr Glu Tyr

```

-continued

100							105					110				
Asp	Ile	Pro	Phe	Ala	Lys	Arg	Tyr	Leu	Ile	Asp	Lys	Gly	Leu	Ile	Pro	
115							120					125				
Met	Glu	Gly	Asp	Glu	Glu	Leu	Lys	Leu	Leu	Ala	Phe	Asp	Ile	Glu	Thr	
130							135					140				
Phe	Tyr	His	Glu	Gly	Asp	Glu	Phe	Gly	Lys	Gly	Glu	Ile	Ile	Met	Ile	
145							150					155				
Ser	Tyr	Ala	Asp	Glu	Glu	Glu	Ala	Arg	Val	Ile	Thr	Trp	Lys	Asn	Ile	
165							170					175				
Asp	Leu	Pro	Tyr	Val	Asp	Val	Val	Ser	Asn	Glu	Arg	Glu	Met	Ile	Lys	
180							185					190				
Arg	Phe	Val	Gln	Val	Val	Lys	Glu	Lys	Asp	Pro	Asp	Val	Ile	Ile	Thr	
195							200					205				
Tyr	Asn	Gly	Asp	Asn	Phe	Asp	Leu	Pro	Tyr	Leu	Ile	Lys	Arg	Ala	Glu	
210							215					220				
Lys	Leu	Gly	Val	Arg	Leu	Val	Leu	Gly	Arg	Asp	Lys	Glu	His	Pro	Glu	
225							230					235				
Pro	Lys	Ile	Gln	Arg	Met	Gly	Asp	Ser	Phe	Ala	Val	Glu	Ile	Lys	Gly	
245							250					255				
Arg	Ile	His	Phe	Asp	Leu	Phe	Pro	Val	Val	Arg	Arg	Thr	Ile	Asn	Leu	
260							265					270				
Pro	Thr	Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Val	Leu	Gly	Lys	Thr	
275							280					285				
Lys	Ser	Lys	Leu	Gly	Ala	Glu	Glu	Ile	Ala	Ala	Ile	Trp	Glu	Thr	Glu	
290							295					300				
Glu	Ser	Met	Lys	Lys	Leu	Ala	Gln	Tyr	Ser	Met	Glu	Asp	Ala	Arg	Ala	
305							310					315				
Thr	Tyr	Glu	Leu	Gly	Lys	Glu	Phe	Phe	Pro	Met	Glu	Ala	Glu	Leu	Ala	
325							330					335				
Lys	Leu	Ile	Gly	Gln	Ser	Val	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	
340							345					350				
Asn	Leu	Val	Glu	Trp	Tyr	Leu	Leu	Arg	Val	Ala	Tyr	Ala	Arg	Asn	Glu	
355							360					365				
Leu	Ala	Pro	Asn	Lys	Pro	Asp	Glu	Glu	Glu	Tyr	Lys	Arg	Arg	Leu	Arg	
370							375					380				
Thr	Thr	Tyr	Leu	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Lys	Gly	Leu	Trp	
385							390					395				
Glu	Asn	Ile	Ile	Tyr	Leu	Asp	Phe	Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	
405							410					415				
Val	Thr	His	Asn	Val	Ser	Pro	Asp	Thr	Leu	Glu	Lys	Glu	Gly	Cys	Lys	
420							425					430				
Asn	Tyr	Asp	Val	Ala	Pro	Ile	Val	Gly	Tyr	Arg	Phe	Cys	Lys	Asp	Phe	
435							440					445				
Pro	Gly	Phe	Ile	Pro	Ser	Ile	Leu	Gly	Asp	Leu	Ile	Ala	Met	Arg	Gln	
450							455					460				
Asp	Ile	Lys	Lys	Lys	Met	Lys	Ser	Thr	Ile	Asp	Pro	Ile	Glu	Lys	Lys	
465							470					475				
Met	Leu	Asp	Tyr	Arg	Gln	Arg	Ala	Ile	Lys	Leu	Leu	Ala	Asn	Ser	Tyr	
485							490					495				
Tyr	Gly	Tyr	Met	Gly	Tyr	Pro	Lys	Ala	Arg	Trp	Tyr	Ser	Lys	Glu	Cys	
500							505					510				
Ala	Glu	Ser	Val	Thr	Ala	Trp	Gly	Arg	His	Tyr	Ile	Glu	Met	Thr	Ile	
515							520					525				

-continued

Arg Glu Ile Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr
 530 535 540
 Asp Gly Phe Tyr Ala Thr Ile Pro Gly Glu Lys Pro Glu Leu Ile Lys
 545 550 555 560
 Lys Lys Ala Lys Glu Phe Leu Asn Tyr Ile Asn Ser Lys Leu Pro Gly
 565 570 575
 Leu Leu Glu Leu Glu Tyr Glu Gly Phe Tyr Leu Arg Gly Phe Phe Val
 580 585 590
 Thr Lys Lys Arg Tyr Ala Val Ile Asp Glu Glu Gly Arg Ile Thr Thr
 595 600 605
 Arg Gly Leu Glu Val Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu
 610 615 620
 Thr Gln Ala Lys Val Leu Glu Ala Ile Leu Lys Glu Gly Ser Val Glu
 625 630 635 640
 Lys Ala Val Glu Val Val Arg Asp Val Val Glu Lys Ile Ala Lys Tyr
 645 650 655
 Arg Val Pro Leu Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Asp
 660 665 670
 Leu Lys Asp Tyr Lys Ala Ile Gly Pro His Val Ala Ile Ala Lys Arg
 675 680 685
 Leu Ala Ala Arg Gly Ile Lys Val Lys Pro Gly Thr Ile Ile Ser Tyr
 690 695 700
 Ile Val Leu Lys Gly Ser Gly Lys Ile Ser Asp Arg Val Ile Leu Leu
 705 710 715 720
 Thr Glu Tyr Asp Pro Arg Lys His Lys Tyr Asp Pro Asp Tyr Tyr Ile
 725 730 735
 Glu Asn Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly
 740 745 750
 Tyr Arg Lys Glu Asp Leu Arg Tyr Gln Ser Ser Lys Gln Thr Gly Leu
 755 760 765
 Asp Ala Trp Leu Lys Arg
 770

<210> SEQ ID NO 84
 <211> LENGTH: 1829
 <212> TYPE: PRT
 <213> ORGANISM: Thermococcus sp.
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (1118)..(1118)
 <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (1123)..(1123)
 <223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 84

Met Ile Leu Asp Thr Asp Tyr Ile Thr Lys Asp Gly Lys Pro Ile Ile
 1 5 10 15
 Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Leu Asp Pro
 20 25 30
 His Phe Gln Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45
 Asp Glu Ile Lys Ala Ile Lys Gly Glu Arg His Gly Lys Ile Val Arg
 50 55 60
 Val Val Asp Ala Val Lys Val Lys Lys Lys Phe Leu Gly Arg Asp Val
 65 70 75 80
 Glu Val Trp Lys Leu Ile Phe Glu His Pro Gln Asp Val Pro Ala Leu

-continued

85							90					95				
Arg	Gly	Lys	Ile	Arg	Glu	His	Pro	Ala	Val	Ile	Asp	Ile	Tyr	Glu	Tyr	
			100				105						110			
Asp	Ile	Pro	Phe	Ala	Lys	Arg	Tyr	Leu	Ile	Asp	Lys	Gly	Leu	Ile	Pro	
			115				120						125			
Met	Glu	Gly	Asp	Glu	Glu	Leu	Lys	Leu	Met	Ala	Phe	Asp	Ile	Glu	Thr	
			130				135						140			
Phe	Tyr	His	Glu	Gly	Asp	Glu	Phe	Gly	Lys	Gly	Glu	Ile	Ile	Met	Ile	
			145	150						155			160			
Ser	Tyr	Ala	Asp	Glu	Glu	Glu	Ala	Arg	Val	Ile	Thr	Trp	Lys	Asn	Ile	
			165						170			175				
Asp	Leu	Pro	Tyr	Val	Asp	Val	Val	Ser	Asn	Glu	Arg	Glu	Met	Ile	Lys	
			180						185			190				
Arg	Phe	Val	Gln	Ile	Val	Arg	Glu	Lys	Asp	Pro	Asp	Val	Leu	Ile	Thr	
			195			200						205				
Tyr	Asn	Gly	Asp	Asn	Phe	Asp	Leu	Pro	Tyr	Leu	Ile	Lys	Arg	Ala	Glu	
						215						220				
Lys	Leu	Gly	Val	Thr	Leu	Leu	Leu	Gly	Arg	Asp	Lys	Glu	His	Pro	Glu	
			225			230			235			240				
Pro	Lys	Ile	His	Arg	Met	Gly	Asp	Ser	Phe	Ala	Val	Glu	Ile	Lys	Gly	
			245						250			255				
Arg	Ile	His	Phe	Asp	Leu	Phe	Pro	Val	Val	Arg	Arg	Thr	Ile	Asn	Leu	
			260			265						270				
Pro	Thr	Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Val	Leu	Gly	Lys	Thr	
			275			280						285				
Lys	Ser	Lys	Leu	Gly	Ala	Glu	Glu	Ile	Ala	Ala	Ile	Trp	Glu	Thr	Glu	
			290			295			300							
Glu	Ser	Met	Lys	Lys	Leu	Ala	Gln	Tyr	Ser	Met	Glu	Asp	Ala	Arg	Ala	
			305			310			315			320				
Thr	Tyr	Glu	Leu	Gly	Lys	Glu	Phe	Phe	Pro	Met	Glu	Ala	Glu	Leu	Ala	
			325						330			335				
Lys	Leu	Ile	Gly	Gln	Ser	Val	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	
			340			345						350				
Asn	Leu	Val	Glu	Trp	Tyr	Leu	Leu	Arg	Val	Ala	Tyr	Glu	Arg	Asn	Glu	
			355			360						365				
Leu	Ala	Pro	Asn	Lys	Pro	Asp	Glu	Glu	Glu	Tyr	Arg	Arg	Arg	Leu	Arg	
			370			375			380							
Thr	Thr	Tyr	Leu	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Arg	Gly	Leu	Trp	
			385			390			395			400				
Glu	Asn	Ile	Ala	Tyr	Leu	Asp	Phe	Arg	Cys	His	Pro	Ala	Asp	Thr	Lys	
			405						410			415				
Val	Ile	Val	Lys	Gly	Lys	Gly	Ile	Val	Asn	Ile	Ser	Asp	Val	Lys	Glu	
			420			425						430				
Gly	Asp	Tyr	Ile	Leu	Gly	Ile	Asp	Gly	Trp	Gln	Arg	Val	Lys	Lys	Val	
			435			440						445				
Trp	Lys	Tyr	His	Tyr	Glu	Gly	Lys	Leu	Ile	Asn	Ile	Asn	Gly	Leu	Lys	
			450			455			460							
Cys	Thr	Pro	Asn	His	Lys	Val	Pro	Val	Val	Thr	Glu	Asn	Asp	Arg	Gln	
			465			470			475			480				
Thr	Arg	Ile	Arg	Asp	Ser	Leu	Ala	Lys	Ser	Phe	Leu	Ser	Gly	Lys	Val	
			485						490			495				
Lys	Gly	Lys	Ile	Ile	Thr	Thr	Lys	Leu	Phe	Glu	Lys	Ile	Ala	Glu	Phe	
			500			505						510				

-continued

Glu	Lys	Asn	Lys	Pro	Ser	Glu	Glu	Glu	Ile	Leu	Lys	Gly	Glu	Leu	Ser
	515						520					525			
Gly	Ile	Ile	Leu	Ala	Glu	Gly	Thr	Leu	Leu	Arg	Lys	Asp	Ile	Glu	Tyr
	530					535					540				
Phe	Asp	Ser	Ser	Arg	Gly	Lys	Lys	Arg	Ile	Ser	His	Gln	Tyr	Arg	Val
	545				550					555					560
Glu	Ile	Thr	Ile	Gly	Glu	Asn	Glu	Lys	Glu	Leu	Leu	Glu	Arg	Ile	Leu
				565					570						575
Tyr	Ile	Phe	Asp	Lys	Leu	Phe	Gly	Ile	Arg	Pro	Ser	Val	Lys	Lys	Lys
			580					585					590		
Gly	Asp	Thr	Asn	Ala	Leu	Lys	Ile	Thr	Thr	Ala	Lys	Lys	Ala	Val	Tyr
			595					600					605		
Leu	Gln	Ile	Glu	Glu	Leu	Leu	Lys	Asn	Ile	Glu	Ser	Leu	Tyr	Ala	Pro
	610						615				620				
Ala	Val	Leu	Arg	Gly	Phe	Phe	Glu	Arg	Asp	Ala	Thr	Val	Asn	Lys	Ile
	625				630					635					640
Arg	Ser	Thr	Ile	Val	Val	Thr	Gln	Gly	Thr	Asn	Asn	Lys	Trp	Lys	Ile
				645					650						655
Asp	Ile	Val	Ala	Lys	Leu	Leu	Asp	Ser	Leu	Gly	Ile	Pro	Tyr	Ser	Arg
			660					665					670		
Tyr	Glu	Tyr	Lys	Tyr	Ile	Glu	Asn	Gly	Lys	Glu	Leu	Thr	Lys	His	Ile
		675					680						685		
Leu	Glu	Ile	Thr	Gly	Arg	Asp	Gly	Leu	Ile	Leu	Phe	Gln	Thr	Leu	Val
	690					695					700				
Gly	Phe	Ile	Ser	Ser	Glu	Lys	Asn	Glu	Ala	Leu	Glu	Lys	Ala	Ile	Glu
	705					710				715					720
Val	Arg	Glu	Met	Asn	Arg	Leu	Lys	Asn	Asn	Ser	Phe	Tyr	Asn	Leu	Ser
				725					730					735	
Thr	Phe	Glu	Val	Ser	Ser	Glu	Tyr	Tyr	Lys	Gly	Glu	Val	Tyr	Asp	Leu
			740					745					750		
Thr	Leu	Glu	Gly	Asn	Pro	Tyr	Tyr	Phe	Ala	Asn	Gly	Ile	Leu	Thr	His
		755					760						765		
Asn	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Val	Thr	His	Asn	Val	Ser	Pro	Asp
		770				775						780			
Thr	Leu	Glu	Arg	Glu	Gly	Cys	Lys	Asn	Tyr	Asp	Val	Ala	Pro	Ile	Val
		785				790				795					800
Gly	Tyr	Lys	Phe	Cys	Lys	Asp	Phe	Pro	Gly	Phe	Ile	Pro	Ser	Ile	Leu
			805						810					815	
Gly	Glu	Leu	Ile	Thr	Met	Arg	Gln	Glu	Ile	Lys	Lys	Lys	Met	Lys	Ala
			820					825					830		
Thr	Ile	Asp	Pro	Ile	Glu	Lys	Lys	Met	Leu	Asp	Tyr	Arg	Gln	Arg	Ala
		835					840						845		
Val	Lys	Leu	Leu	Ala	Asn	Ser	Ile	Leu	Pro	Asn	Glu	Trp	Leu	Pro	Ile
		850				855					860				
Ile	Glu	Asn	Gly	Glu	Val	Lys	Phe	Val	Lys	Ile	Gly	Glu	Phe	Ile	Asp
		865				870				875					880
Arg	Tyr	Met	Glu	Glu	Gln	Lys	Asp	Lys	Val	Arg	Thr	Val	Asp	Asn	Thr
			885						890					895	
Glu	Val	Leu	Glu	Val	Asp	Asn	Ile	Phe	Ala	Phe	Ser	Leu	Asn	Lys	Glu
			900					905					910		
Ser	Lys	Lys	Ser	Glu	Ile	Lys	Lys	Val	Lys	Ala	Leu	Ile	Arg	His	Lys
		915					920						925		
Tyr	Lys	Gly	Glu	Ala	Tyr	Glu	Val	Glu	Leu	Asn	Ser	Gly	Arg	Lys	Ile
		930					935						940		

-continued

His Ile Thr Arg Gly His Ser Leu Phe Thr Ile Arg Asn Gly Lys Ile
 945 950 955 960
 Lys Glu Ile Trp Gly Glu Val Lys Val Gly Asp Leu Ile Ile Val
 965 970 975
 Pro Lys Lys Val Lys Leu Asn Glu Lys Glu Ala Val Ile Asn Ile Pro
 980 985 990
 Glu Leu Ile Ser Lys Leu Pro Asp Glu Asp Thr Ala Asp Val Val Met
 995 1000 1005
 Thr Thr Pro Val Lys Gly Arg Lys Asn Phe Phe Lys Gly Met Leu
 1010 1015 1020
 Arg Thr Leu Lys Trp Ile Phe Gly Glu Glu Ser Lys Arg Ile Arg
 1025 1030 1035
 Thr Phe Asn Arg Tyr Leu Phe His Leu Glu Glu Leu Gly Phe Val
 1040 1045 1050
 Lys Leu Leu Pro Arg Gly Tyr Glu Val Thr Asp Trp Glu Gly Leu
 1055 1060 1065
 Lys Arg Tyr Arg Gln Leu Tyr Glu Lys Leu Val Lys Asn Leu Arg
 1070 1075 1080
 Tyr Asn Gly Asn Lys Arg Glu Tyr Leu Val Arg Phe Asn Asp Ile
 1085 1090 1095
 Lys Asp Ser Val Ser Cys Phe Pro Arg Lys Glu Leu Glu Glu Trp
 1100 1105 1110
 Lys Ile Gly Thr Xaa Lys Gly Phe Arg Xaa Lys Cys Ile Leu Lys
 1115 1120 1125
 Val Asp Glu Asp Phe Gly Lys Phe Leu Gly Tyr Tyr Val Ser Glu
 1130 1135 1140
 Gly Tyr Ala Gly Ala Gln Lys Asn Lys Thr Gly Gly Met Ser Tyr
 1145 1150 1155
 Ser Val Lys Leu Tyr Asn Glu Asn Pro Asn Val Leu Lys Asp Met
 1160 1165 1170
 Lys Asn Ile Ala Glu Lys Phe Phe Gly Lys Val Arg Val Gly Lys
 1175 1180 1185
 Asn Cys Val Asp Ile Pro Lys Lys Met Ala Tyr Leu Leu Ala Lys
 1190 1195 1200
 Ser Leu Cys Gly Val Thr Ala Glu Asn Lys Arg Ile Pro Ser Ile
 1205 1210 1215
 Ile Phe Asp Ser Ser Glu Pro Val Arg Trp Ala Phe Leu Arg Ala
 1220 1225 1230
 Tyr Phe Val Gly Asp Gly Asp Ile His Pro Ser Lys Arg Leu Arg
 1235 1240 1245
 Leu Ser Thr Lys Ser Glu Leu Leu Ala Asn Gln Leu Val Phe Leu
 1250 1255 1260
 Leu Asn Ser Leu Gly Val Ser Ser Ile Lys Ile Gly Phe Asp Ser
 1265 1270 1275
 Gly Val Tyr Arg Val Tyr Ile Asn Glu Asp Leu Pro Phe Leu Gln
 1280 1285 1290
 Thr Ser Arg Gln Lys Asn Thr Tyr Tyr Pro Asn Leu Ile Pro Lys
 1295 1300 1305
 Glu Val Leu Glu Glu Ile Phe Gly Arg Lys Phe Gln Lys Asn Ile
 1310 1315 1320
 Thr Phe Glu Lys Phe Lys Glu Leu Ala Asp Ser Gly Lys Leu Asp
 1325 1330 1335
 Lys Arg Lys Val Lys Leu Leu Asp Phe Leu Leu Asn Gly Asp Ile

-continued

1340	1345	1350
Val Leu Asp Arg Val Lys Asn	Val Glu Lys Arg Glu	Tyr Glu Gly
1355	1360	1365
Tyr Val Tyr Asp Leu Ser Val	Glu Asp Asn Glu Asn	Phe Leu Val
1370	1375	1380
Gly Phe Gly Leu Leu Tyr Ala	His Asn Ser Tyr Tyr	Gly Tyr Met
1385	1390	1395
Gly Tyr Pro Lys Ala Arg Trp	Tyr Ser Lys Glu Cys	Ala Glu Ser
1400	1405	1410
Val Thr Ala Trp Gly Arg His	Tyr Ile Glu Met Thr	Ile Lys Glu
1415	1420	1425
Ile Glu Glu Lys Phe Gly Phe	Lys Val Leu Tyr Ala	Asp Ser Val
1430	1435	1440
Thr Gly Asp Thr Glu Ile Ile	Val Lys Arg Asn Gly	Arg Ile Glu
1445	1450	1455
Phe Val Pro Ile Glu Lys Leu	Phe Glu Arg Val Asp	Tyr Arg Ile
1460	1465	1470
Gly Glu Lys Glu Tyr Cys Ile	Leu Glu Asp Val Glu	Ala Leu Thr
1475	1480	1485
Leu Asp Asn Arg Gly Lys Leu	Ile Trp Lys Lys Val	Pro Tyr Val
1490	1495	1500
Met Arg His Arg Ala Lys Lys	Lys Val Tyr Arg Ile	Trp Ile Thr
1505	1510	1515
Asn Ser Trp Tyr Ile Asp Val	Thr Glu Asp His Ser	Leu Ile Val
1520	1525	1530
Ala Glu Asp Gly Leu Lys Glu	Ala Arg Pro Met Glu	Ile Glu Gly
1535	1540	1545
Lys Ser Leu Ile Ala Thr Lys	Asp Asp Leu Ser Gly	Val Glu Tyr
1550	1555	1560
Ile Lys Pro His Ala Ile Glu	Glu Ile Ser Tyr Asn	Gly Tyr Val
1565	1570	1575
Tyr Asp Ile Glu Val Glu Gly	Thr His Arg Phe Phe	Ala Asn Gly
1580	1585	1590
Ile Leu Val His Asn Thr Asp	Gly Phe Tyr Ala Thr	Ile Pro Gly
1595	1600	1605
Glu Lys Pro Glu Thr Ile Lys	Lys Lys Ala Lys Glu	Phe Leu Lys
1610	1615	1620
Tyr Ile Asn Ser Lys Leu Pro	Gly Leu Leu Glu Leu	Glu Tyr Glu
1625	1630	1635
Gly Phe Tyr Leu Arg Gly Phe	Phe Val Ala Lys Lys	Arg Tyr Ala
1640	1645	1650
Val Ile Asp Glu Glu Gly Arg	Ile Thr Thr Arg Gly	Leu Glu Val
1655	1660	1665
Val Arg Arg Asp Trp Ser Glu	Ile Ala Lys Glu Thr	Gln Ala Lys
1670	1675	1680
Val Leu Glu Ala Ile Leu Lys	Glu Asp Ser Val Glu	Lys Ala Val
1685	1690	1695
Glu Ile Val Lys Asp Val Val	Glu Glu Ile Ala Lys	Tyr Gln Val
1700	1705	1710
Pro Leu Glu Lys Leu Val Ile	His Glu Gln Ile Thr	Lys Asp Leu
1715	1720	1725
Ser Glu Tyr Lys Ala Ile Gly	Pro His Val Ala Ile	Ala Lys Arg
1730	1735	1740

-continued

Leu Ala Ala Lys Gly Ile Lys Val Arg Pro Gly Thr Ile Ile Ser
 1745 1750 1755
 Tyr Ile Val Leu Arg Gly Ser Gly Lys Ile Ser Asp Arg Val Ile
 1760 1765 1770
 Leu Leu Ser Glu Tyr Asp Pro Lys Lys His Lys Tyr Asp Pro Asp
 1775 1780 1785
 Tyr Tyr Ile Glu Asn Gln Val Leu Pro Ala Val Leu Arg Ile Leu
 1790 1795 1800
 Glu Ala Phe Gly Tyr Arg Lys Glu Asp Leu Lys Tyr Gln Ser Ser
 1805 1810 1815
 Lys Gln Val Gly Leu Asp Ala Trp Leu Lys Lys
 1820 1825

<210> SEQ ID NO 85

<211> LENGTH: 771

<212> TYPE: PRT

<213> ORGANISM: *Pyrococcus abyssi*

<400> SEQUENCE: 85

Met Ile Ile Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
 1 5 10 15
 Arg Ile Phe Lys Lys Glu Lys Gly Glu Phe Lys Val Glu Tyr Asp Arg
 20 25 30
 Thr Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45
 Asp Glu Val Lys Lys Ile Thr Ala Glu Arg His Gly Lys Ile Val Arg
 50 55 60
 Ile Thr Glu Val Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80
 Glu Val Trp Lys Leu Tyr Leu Glu His Pro Gln Asp Val Pro Ala Ile
 85 90 95
 Arg Glu Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Thr Pro
 115 120 125
 Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Ser Ile
 165 170 175
 Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys
 180 185 190
 Arg Leu Val Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220
 Lys Leu Gly Ile Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
 225 230 235 240
 Met Gln Arg Met Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Ser Lys Glu
 275 280 285

-continued

Lys	Val	Tyr	Ala	His	Glu	Ile	Ala	Glu	Ala	Trp	Glu	Thr	Gly	Lys	Gly
290						295					300				
Leu	Glu	Arg	Val	Ala	Lys	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Val	Thr	Phe
305					310					315					320
Glu	Leu	Gly	Lys	Glu	Phe	Phe	Pro	Met	Glu	Ala	Gln	Leu	Ala	Arg	Leu
				325					330					335	
Val	Gly	Gln	Pro	Val	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu
			340					345					350		
Val	Glu	Trp	Phe	Leu	Leu	Arg	Lys	Ala	Tyr	Glu	Arg	Asn	Glu	Leu	Ala
			355				360					365			
Pro	Asn	Lys	Pro	Asp	Glu	Arg	Glu	Tyr	Glu	Arg	Arg	Leu	Arg	Glu	Ser
	370					375					380				
Tyr	Glu	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Lys	Gly	Leu	Trp	Glu	Gly
385					390					395					400
Ile	Val	Ser	Leu	Asp	Phe	Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr
				405					410						415
His	Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Arg	Glu	Asn	Cys	Lys	Glu	Tyr
			420					425					430		
Asp	Val	Ala	Pro	Gln	Val	Gly	His	Arg	Phe	Cys	Lys	Asp	Phe	Pro	Gly
		435					440					445			
Phe	Ile	Pro	Ser	Leu	Leu	Gly	Asn	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Ile
	450					455					460				
Lys	Lys	Arg	Met	Lys	Glu	Ser	Lys	Asp	Pro	Val	Glu	Lys	Lys	Leu	Leu
465				470					475						480
Asp	Tyr	Arg	Gln	Arg	Ala	Ile	Lys	Ile	Leu	Ala	Asn	Ser	Tyr	Tyr	Gly
			485						490					495	
Tyr	Tyr	Gly	Tyr	Ala	Lys	Ala	Arg	Trp	Tyr	Cys	Lys	Glu	Cys	Ala	Glu
			500					505					510		
Ser	Val	Thr	Ala	Trp	Gly	Arg	Gln	Tyr	Ile	Asp	Leu	Val	Arg	Arg	Glu
		515					520					525			
Leu	Glu	Ser	Arg	Gly	Phe	Lys	Val	Leu	Tyr	Ile	Asp	Thr	Asp	Gly	Leu
	530					535					540				
Tyr	Ala	Thr	Ile	Pro	Gly	Ala	Lys	His	Glu	Glu	Ile	Lys	Glu	Lys	Ala
545					550					555					560
Leu	Lys	Phe	Val	Glu	Tyr	Ile	Asn	Ser	Lys	Leu	Pro	Gly	Leu	Leu	Glu
			565						570				575		
Leu	Glu	Tyr	Glu	Gly	Phe	Tyr	Ala	Arg	Gly	Phe	Phe	Val	Thr	Lys	Lys
			580					585					590		
Lys	Tyr	Ala	Leu	Ile	Asp	Glu	Glu	Gly	Lys	Ile	Val	Thr	Arg	Gly	Leu
		595				600						605			
Glu	Ile	Val	Arg	Arg	Asp	Trp	Ser	Glu	Ile	Ala	Lys	Glu	Thr	Gln	Ala
	610				615					620					
Lys	Val	Leu	Glu	Ala	Ile	Leu	Lys	His	Gly	Asn	Val	Asp	Glu	Ala	Val
625				630						635					640
Lys	Ile	Val	Lys	Glu	Val	Thr	Glu	Lys	Leu	Ser	Lys	Tyr	Glu	Ile	Pro
			645						650				655		
Pro	Glu	Lys	Leu	Val	Ile	Tyr	Glu	Gln	Ile	Thr	Arg	Pro	Leu	Ser	Glu
			660				665					670			
Tyr	Lys	Ala	Ile	Gly	Pro	His	Val	Ala	Val	Ala	Lys	Arg	Leu	Ala	Ala
		675					680					685			
Lys	Gly	Val	Lys	Val	Lys	Pro	Gly	Met	Val	Ile	Gly	Tyr	Ile	Val	Leu
	690					695					700				
Arg	Gly	Asp	Gly	Pro	Ile	Ser	Lys	Arg	Ala	Ile	Ala	Ile	Glu	Glu	Phe
705					710					715					720

-continued

Asp Pro Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Lys Tyr Gln Lys Thr Lys Gln Val Gly Leu Gly Ala Trp
755 760 765

Leu Lys Phe
770

<210> SEQ ID NO 86
<211> LENGTH: 1235
<212> TYPE: PRT
<213> ORGANISM: *Pyrococcus horikoshii*

<400> SEQUENCE: 86

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg
20 25 30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Ala Ile
35 40 45

Asp Glu Ile Lys Lys Ile Thr Ala Gln Arg His Gly Lys Val Val Arg
50 55 60

Ile Val Glu Thr Glu Lys Ile Gln Arg Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Lys Leu Tyr Leu Glu His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Thr Pro
115 120 125

Met Glu Gly Asn Glu Lys Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Val Ile Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Lys Ile
165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys
180 185 190

Arg Leu Ile Arg Val Ile Lys Glu Lys Asp Pro Asp Val Ile Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
210 215 220

Lys Leu Gly Ile Lys Leu Leu Leu Gly Arg Asp Asn Ser Glu Pro Lys
225 230 235 240

Met Gln Lys Met Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu
275 280 285

Lys Val Tyr Ala Asp Glu Ile Ala Lys Ala Trp Glu Thr Gly Glu Gly
290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305 310 315 320

-continued

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335
 Val Gly Gln Pro Val Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Lys Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380
 Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Gly
 385 390 395 400
 Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415
 His Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Glu Glu Tyr
 420 425 430
 Asp Val Ala Pro Lys Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
 435 440 445
 Phe Ile Pro Ser Leu Leu Gly Gln Leu Leu Glu Glu Arg Gln Lys Ile
 450 455 460
 Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Lys Lys Leu Leu
 465 470 475 480
 Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Ile Leu Pro
 485 490 495
 Asp Glu Trp Leu Pro Ile Val Glu Asn Glu Lys Val Arg Phe Val Lys
 500 505 510
 Ile Gly Asp Phe Ile Asp Arg Glu Ile Glu Glu Asn Ala Glu Arg Val
 515 520 525
 Lys Arg Asp Gly Glu Thr Glu Ile Leu Glu Val Lys Asp Leu Lys Ala
 530 535 540
 Leu Ser Phe Asn Arg Glu Thr Lys Lys Ser Glu Leu Lys Lys Val Lys
 545 550 555 560
 Ala Leu Ile Arg His Arg Tyr Ser Gly Lys Val Tyr Ser Ile Lys Leu
 565 570 575
 Lys Ser Gly Arg Arg Ile Lys Ile Thr Ser Gly His Ser Leu Phe Ser
 580 585 590
 Val Lys Asn Gly Lys Leu Val Lys Val Arg Gly Asp Glu Leu Lys Pro
 595 600 605
 Gly Asp Leu Val Val Val Pro Gly Arg Leu Lys Leu Pro Glu Ser Lys
 610 615 620
 Gln Val Leu Asn Leu Val Glu Leu Leu Leu Lys Leu Pro Glu Glu Glu
 625 630 635 640
 Thr Ser Asn Ile Val Met Met Ile Pro Val Lys Gly Arg Lys Asn Phe
 645 650 655
 Phe Lys Gly Met Leu Lys Thr Leu Tyr Trp Ile Phe Gly Glu Gly Glu
 660 665 670
 Arg Pro Arg Thr Ala Gly Arg Tyr Leu Lys His Leu Glu Arg Leu Gly
 675 680 685
 Tyr Val Lys Leu Lys Arg Arg Gly Cys Glu Val Leu Asp Trp Glu Ser
 690 695 700
 Leu Lys Arg Tyr Arg Lys Leu Tyr Glu Thr Leu Ile Lys Asn Leu Lys
 705 710 715 720
 Tyr Asn Gly Asn Ser Arg Ala Tyr Met Val Glu Phe Asn Ser Leu Arg
 725 730 735
 Asp Val Val Ser Leu Met Pro Ile Glu Glu Leu Lys Glu Trp Ile Ile

-continued

740						745						750					
Gly	Glu	Pro	Arg	Gly	Pro	Lys	Ile	Gly	Thr	Phe	Ile	Asp	Val	Asp	Asp		
755						760						765					
Ser	Phe	Ala	Lys	Leu	Leu	Gly	Tyr	Tyr	Ile	Ser	Ser	Gly	Asp	Val	Glu		
770						775						780					
Lys	Asp	Arg	Val	Lys	Phe	His	Ser	Lys	Asp	Gln	Asn	Val	Leu	Glu	Asp		
785						790						795					
Ile	Ala	Lys	Leu	Ala	Glu	Lys	Leu	Phe	Gly	Lys	Val	Arg	Arg	Gly	Arg		
805						810						815					
Gly	Tyr	Ile	Glu	Val	Ser	Gly	Lys	Ile	Ser	His	Ala	Ile	Phe	Arg	Val		
820						825						830					
Leu	Ala	Glu	Gly	Lys	Arg	Ile	Pro	Glu	Phe	Ile	Phe	Thr	Ser	Pro	Met		
835						840						845					
Asp	Ile	Lys	Val	Ala	Phe	Leu	Lys	Gly	Leu	Asn	Gly	Asn	Ala	Glu	Glu		
850						855						860					
Leu	Thr	Phe	Ser	Thr	Lys	Ser	Glu	Leu	Leu	Val	Asn	Gln	Leu	Ile	Leu		
865						870						875					
Leu	Leu	Asn	Ser	Ile	Gly	Val	Ser	Asp	Ile	Lys	Ile	Glu	His	Glu	Lys		
885						890						895					
Gly	Val	Tyr	Arg	Val	Tyr	Ile	Asn	Lys	Lys	Glu	Ser	Ser	Asn	Gly	Asp		
900						905						910					
Ile	Val	Leu	Asp	Ser	Val	Glu	Ser	Ile	Glu	Val	Glu	Lys	Tyr	Glu	Gly		
915						920						925					
Tyr	Val	Tyr	Asp	Leu	Ser	Val	Glu	Asp	Asn	Glu	Asn	Phe	Leu	Val	Gly		
930						935						940					
Phe	Gly	Leu	Leu	Tyr	Ala	His	Asn	Ser	Tyr	Tyr	Gly	Tyr	Tyr	Gly	Tyr		
945						950						955					
Ala	Lys	Ala	Arg	Trp	Tyr	Cys	Lys	Glu	Cys	Ala	Glu	Ser	Val	Thr	Ala		
965						970						975					
Trp	Gly	Arg	Gln	Tyr	Ile	Asp	Leu	Val	Arg	Arg	Glu	Leu	Glu	Ala	Arg		
980						985						990					
Gly	Phe	Lys	Val	Leu	Tyr	Ile	Asp	Thr	Asp	Gly	Leu	Tyr	Ala	Thr	Ile		
995						1000						1005					
Pro	Gly	Val	Lys	Asp	Trp	Glu	Glu	Val	Lys	Arg	Arg	Ala	Leu	Glu			
1010						1015						1020					
Phe	Val	Asp	Tyr	Ile	Asn	Ser	Lys	Leu	Pro	Gly	Val	Leu	Glu	Leu			
1025						1030						1035					
Glu	Tyr	Glu	Gly	Phe	Tyr	Ala	Arg	Gly	Phe	Phe	Val	Thr	Lys	Lys			
1040						1045						1050					
Lys	Tyr	Ala	Leu	Ile	Asp	Glu	Glu	Gly	Lys	Ile	Val	Thr	Arg	Gly			
1055						1060						1065					
Leu	Glu	Ile	Val	Arg	Arg	Asp	Trp	Ser	Glu	Ile	Ala	Lys	Glu	Thr			
1070						1075						1080					
Gln	Ala	Arg	Val	Leu	Glu	Ala	Ile	Leu	Lys	His	Gly	Asn	Val	Glu			
1085						1090						1095					
Glu	Ala	Val	Lys	Ile	Val	Lys	Asp	Val	Thr	Glu	Lys	Leu	Thr	Asn			
1100						1105						1110					
Tyr	Glu	Val	Pro	Pro	Glu	Lys	Leu	Val	Ile	Tyr	Glu	Gln	Ile	Thr			
1115						1120						1125					
Arg	Pro	Ile	Asn	Glu	Tyr	Lys	Ala	Ile	Gly	Pro	His	Val	Ala	Val			
1130						1135						1140					
Ala	Lys	Arg	Leu	Met	Ala	Arg	Gly	Ile	Lys	Val	Lys	Pro	Gly	Met			
1145						1150						1155					

-continued

Val Ile Gly Tyr Ile Val Leu Arg Gly Asp Gly Pro Ile Ser Lys
 1160 1165 1170

Arg Ala Ile Ser Ile Glu Glu Phe Asp Pro Arg Lys His Lys Tyr
 1175 1180 1185

Asp Ala Glu Tyr Tyr Ile Glu Asn Gln Val Leu Pro Ala Val Glu
 1190 1195 1200

Arg Ile Leu Lys Ala Phe Gly Tyr Lys Arg Glu Asp Leu Arg Trp
 1205 1210 1215

Gln Lys Thr Lys Gln Val Gly Leu Gly Ala Trp Ile Lys Val Lys
 1220 1225 1230

Lys Ser
 1235

<210> SEQ ID NO 87
 <211> LENGTH: 771
 <212> TYPE: PRT
 <213> ORGANISM: Pyrococcus sp.

<400> SEQUENCE: 87

Met Ile Ile Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
 1 5 10 15

Arg Ile Phe Lys Lys Glu Lys Gly Glu Phe Lys Val Glu Tyr Asp Arg
 20 25 30

Thr Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45

Asp Glu Val Lys Lys Ile Thr Ala Glu Arg His Gly Lys Ile Val Arg
 50 55 60

Ile Thr Glu Val Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Ile
 65 70 75 80

Glu Val Trp Lys Leu Tyr Leu Glu His Pro Gln Asp Val Pro Ala Ile
 85 90 95

Arg Glu Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr
 100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Thr Pro
 115 120 125

Met Glu Gly Asn Glu Glu Leu Thr Phe Leu Ala Val Asp Ile Glu Thr
 130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile
 145 150 155 160

Ser Tyr Ala Asp Glu Glu Gly Ala Lys Val Ile Thr Trp Lys Ser Ile
 165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys
 180 185 190

Arg Leu Val Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
 195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Leu Lys Arg Ala Glu
 210 215 220

Lys Leu Gly Ile Lys Leu Pro Leu Gly Arg Asp Asn Ser Glu Pro Lys
 225 230 235 240

Met Gln Arg Met Gly Asp Ser Leu Ala Val Glu Ile Lys Gly Arg Ile
 245 250 255

His Phe Asp Leu Phe Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Ser Lys Glu
 275 280 285

-continued

Lys Val Tyr Ala His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
 290 295 300
 Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Phe
 305 310 315 320
 Glu Leu Gly Lys Glu Phe Phe Pro Met Glu Ala Gln Leu Ala Arg Leu
 325 330 335
 Val Gly Gln Pro Val Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380
 Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Gly
 385 390 395 400
 Ile Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415
 His Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Asn Cys Lys Glu Tyr
 420 425 430
 Asp Val Ala Pro Gln Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly
 435 440 445
 Phe Ile Pro Ser Leu Leu Gly Asn Leu Leu Glu Glu Arg Gln Lys Ile
 450 455 460
 Lys Lys Arg Met Lys Glu Ser Lys Asp Pro Val Glu Lys Lys Leu Leu
 465 470 475 480
 Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly
 485 490 495
 Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
 500 505 510
 Ser Val Thr Ala Trp Gly Arg Gln Tyr Ile Asp Leu Val Arg Arg Glu
 515 520 525
 Leu Glu Ser Ser Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Leu
 530 535 540
 Tyr Ala Thr Ile Pro Gly Ala Lys Pro Asn Glu Ile Lys Glu Lys Ala
 545 550 555 560
 Leu Lys Phe Val Glu Tyr Ile Asn Ser Lys Leu Pro Gly Leu Leu Glu
 565 570 575
 Leu Glu Tyr Glu Gly Phe Tyr Ala Arg Gly Phe Phe Val Thr Lys Lys
 580 585 590
 Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Val Thr Arg Gly Leu
 595 600 605
 Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
 610 615 620
 Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Asp Glu Ala Val
 625 630 635 640
 Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Ile Pro
 645 650 655
 Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu Ser Glu
 660 665 670
 Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
 675 680 685
 Lys Gly Val Lys Val Lys Pro Gly Met Val Ile Gly Tyr Ile Val Leu
 690 695 700
 Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Ala Ile Glu Glu Phe
 705 710 715 720

-continued

Asp Pro Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
725 730 735

Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Lys Gln Val Gly Leu Gly Ala Trp
755 760 765

Leu Lys Phe
770

<210> SEQ ID NO 88
<211> LENGTH: 775
<212> TYPE: PRT
<213> ORGANISM: Pyrococcus sp.

<400> SEQUENCE: 88

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Ile Ile
1 5 10 15

Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Val Glu Tyr Asp Arg
20 25 30

Asn Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Gln Ile
35 40 45

Asp Glu Val Arg Lys Ile Thr Ala Glu Arg His Gly Lys Ile Val Arg
50 55 60

Ile Ile Asp Ala Glu Lys Val Arg Lys Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Arg Leu Tyr Phe Glu His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Lys Ile Arg Glu His Ser Ala Val Ile Asp Ile Phe Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Asp Glu Glu Leu Lys Leu Leu Ala Phe Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Ala Lys Gly Pro Ile Ile Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Glu Glu Ala Lys Val Ile Thr Trp Lys Lys Ile
165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys
180 185 190

Arg Phe Leu Lys Val Ile Arg Glu Lys Asp Pro Asp Val Ile Ile Thr
195 200 205

Tyr Asn Gly Asp Ser Phe Asp Leu Pro Tyr Leu Val Lys Arg Ala Glu
210 215 220

Lys Leu Gly Ile Lys Leu Pro Leu Gly Arg Asp Gly Ser Glu Pro Lys
225 230 235 240

Met Gln Arg Leu Gly Asp Met Thr Ala Val Glu Ile Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Tyr His Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu
275 280 285

Lys Val Tyr Ala His Glu Ile Ala Glu Ala Trp Glu Thr Gly Lys Gly
290 295 300

Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305 310 315 320

-continued

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Arg Glu Tyr Glu Arg Arg Leu Arg Glu Ser
 370 375 380
 Tyr Ala Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Gly
 385 390 395 400
 Leu Val Ser Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr
 405 410 415
 His Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Arg Glu Tyr
 420 425 430
 Asp Val Ala Pro Glu Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly
 435 440 445
 Phe Ile Pro Ser Leu Leu Lys Arg Leu Leu Asp Glu Arg Gln Glu Ile
 450 455 460
 Lys Arg Lys Met Lys Ala Ser Lys Asp Pro Ile Glu Lys Lys Met Leu
 465 470 475 480
 Asp Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly
 485 490 495
 Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu
 500 505 510
 Ser Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Phe Val Arg Lys Glu
 515 520 525
 Leu Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly
 530 535 540
 Leu Tyr Ala Thr Ile Pro Gly Ala Lys Pro Glu Glu Ile Lys Lys Lys
 545 550 555 560
 Ala Leu Glu Phe Val Asp Tyr Ile Asn Ala Lys Leu Pro Gly Leu Leu
 565 570 575
 Glu Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys
 580 585 590
 Lys Lys Tyr Ala Leu Ile Asp Glu Glu Gly Lys Ile Ile Thr Arg Gly
 595 600 605
 Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln
 610 615 620
 Ala Lys Val Leu Glu Ala Ile Leu Lys His Gly Asn Val Glu Glu Ala
 625 630 635 640
 Val Lys Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Ile
 645 650 655
 Pro Pro Glu Lys Leu Val Ile Tyr Glu Gln Ile Thr Arg Pro Leu His
 660 665 670
 Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Arg Leu Ala
 675 680 685
 Ala Arg Gly Val Lys Val Arg Pro Gly Met Val Ile Gly Tyr Ile Val
 690 695 700
 Leu Arg Gly Asp Gly Pro Ile Ser Lys Arg Ala Ile Leu Ala Glu Glu
 705 710 715 720
 Phe Asp Leu Arg Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn
 725 730 735
 Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Ala Phe Gly Tyr Arg

-continued

740	745	750
Lys Glu Asp Leu Arg Trp Gln Lys Thr Lys Gln Thr Gly Leu Thr Ala		
755	760	765
Trp Leu Asn Ile Lys Lys Lys		
770	775	

<210> SEQ ID NO 89
 <211> LENGTH: 775
 <212> TYPE: PRT
 <213> ORGANISM: *Pyrococcus furiosus*
 <400> SEQUENCE: 89

Met Ile Leu Asp Val Asp Tyr Ile Thr Glu Glu Gly Lys Pro Val Ile		
1	5	10 15
Arg Leu Phe Lys Lys Glu Asn Gly Lys Phe Lys Ile Glu His Asp Arg		
20	25	30
Thr Phe Arg Pro Tyr Ile Tyr Ala Leu Leu Arg Asp Asp Ser Lys Ile		
35	40	45
Glu Glu Val Lys Lys Ile Thr Gly Glu Arg His Gly Lys Ile Val Arg		
50	55	60
Ile Val Asp Val Glu Lys Val Glu Lys Lys Phe Leu Gly Lys Pro Ile		
65	70	75 80
Thr Val Trp Lys Leu Tyr Leu Glu His Pro Gln Asp Val Pro Thr Ile		
85	90	95
Arg Glu Lys Val Arg Glu His Pro Ala Val Val Asp Ile Phe Glu Tyr		
100	105	110
Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro		
115	120	125
Met Glu Gly Glu Glu Glu Leu Lys Ile Leu Ala Phe Asp Ile Glu Thr		
130	135	140
Leu Tyr His Glu Gly Glu Glu Phe Gly Lys Gly Pro Ile Ile Met Ile		
145	150	155 160
Ser Tyr Ala Asp Glu Asn Glu Ala Lys Val Ile Thr Trp Lys Asn Ile		
165	170	175
Asp Leu Pro Tyr Val Glu Val Val Ser Ser Glu Arg Glu Met Ile Lys		
180	185	190
Arg Phe Leu Arg Ile Ile Arg Glu Lys Asp Pro Asp Ile Ile Val Thr		
195	200	205
Tyr Asn Gly Asp Ser Phe Asp Phe Pro Tyr Leu Ala Lys Arg Ala Glu		
210	215	220
Lys Leu Gly Ile Lys Leu Thr Ile Gly Arg Asp Gly Ser Glu Pro Lys		
225	230	235 240
Met Gln Arg Ile Gly Asp Met Thr Ala Val Glu Val Lys Gly Arg Ile		
245	250	255
His Phe Asp Leu Tyr His Val Ile Thr Arg Thr Ile Asn Leu Pro Thr		
260	265	270
Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Lys Pro Lys Glu		
275	280	285
Lys Val Tyr Ala Asp Glu Ile Ala Lys Ala Trp Glu Ser Gly Glu Asn		
290	295	300
Leu Glu Arg Val Ala Lys Tyr Ser Met Glu Asp Ala Lys Ala Thr Tyr		
305	310	315 320
Glu Leu Gly Lys Glu Phe Leu Pro Met Glu Ile Gln Leu Ser Arg Leu		
325	330	335
Val Gly Gln Pro Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu		

-continued

340	345	350
Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Val Ala 355 360 365		
Pro Asn Lys Pro Ser Glu Glu Glu Tyr Gln Arg Arg Leu Arg Glu Ser 370 375 380		
Tyr Thr Gly Gly Phe Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Asn 385 390 395 400		
Ile Val Tyr Leu Asp Phe Arg Ala Leu Tyr Pro Ser Ile Ile Ile Thr 405 410 415		
His Asn Val Ser Pro Asp Thr Leu Asn Leu Glu Gly Cys Lys Asn Tyr 420 425 430		
Asp Ile Ala Pro Gln Val Gly His Lys Phe Cys Lys Asp Ile Pro Gly 435 440 445		
Phe Ile Pro Ser Leu Leu Gly His Leu Leu Glu Glu Arg Gln Lys Ile 450 455 460		
Lys Thr Lys Met Lys Glu Thr Gln Asp Pro Ile Glu Lys Ile Leu Leu 465 470 475 480		
Asp Tyr Arg Gln Lys Ala Ile Lys Leu Leu Ala Asn Ser Phe Tyr Gly 485 490 495		
Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu 500 505 510		
Ser Val Thr Ala Trp Gly Arg Lys Tyr Ile Glu Leu Val Trp Lys Glu 515 520 525		
Leu Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly 530 535 540		
Leu Tyr Ala Thr Ile Pro Gly Gly Glu Ser Glu Glu Ile Lys Lys Lys 545 550 555 560		
Ala Leu Glu Phe Val Lys Tyr Ile Asn Ser Lys Leu Pro Gly Leu Leu 565 570 575		
Glu Leu Glu Tyr Glu Gly Phe Tyr Lys Arg Gly Phe Phe Val Thr Lys 580 585 590		
Lys Arg Tyr Ala Val Ile Asp Glu Glu Gly Lys Val Ile Thr Arg Gly 595 600 605		
Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln 610 615 620		
Ala Arg Val Leu Glu Thr Ile Leu Lys His Gly Asp Val Glu Glu Ala 625 630 635 640		
Val Arg Ile Val Lys Glu Val Ile Gln Lys Leu Ala Asn Tyr Glu Ile 645 650 655		
Pro Pro Glu Lys Leu Ala Ile Tyr Glu Gln Ile Thr Arg Pro Leu His 660 665 670		
Glu Tyr Lys Ala Ile Gly Pro His Val Ala Val Ala Lys Lys Leu Ala 675 680 685		
Ala Lys Gly Val Lys Ile Lys Pro Gly Met Val Ile Gly Tyr Ile Val 690 695 700		
Leu Arg Gly Asp Gly Pro Ile Ser Asn Arg Ala Ile Leu Ala Glu Glu 705 710 715 720		
Tyr Asp Pro Lys Lys His Lys Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn 725 730 735		
Gln Val Leu Pro Ala Val Leu Arg Ile Leu Glu Gly Phe Gly Tyr Arg 740 745 750		
Lys Glu Asp Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Thr Ser 755 760 765		

-continued

Trp Leu Asn Ile Lys Lys Ser
770 775

<210> SEQ ID NO 90
 <211> LENGTH: 776
 <212> TYPE: PRT
 <213> ORGANISM: Thermococcus sp. JDF-3

<400> SEQUENCE: 90

Met Ile Leu Asp Val Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Ile
1 5 10 15

Arg Val Phe Lys Lys Glu Asn Gly Glu Phe Arg Ile Glu Tyr Asp Arg
20 25 30

Glu Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Arg Asp Asp Ser Ala Ile
35 40 45

Glu Glu Ile Lys Lys Ile Thr Ala Glu Arg His Gly Arg Val Val Lys
50 55 60

Val Lys Arg Ala Glu Lys Val Lys Lys Lys Phe Leu Gly Arg Ser Val
65 70 75 80

Glu Val Trp Val Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Lys Ile Arg Lys His Pro Ala Val Ile Asp Ile Tyr Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Glu Glu Glu Leu Lys Leu Met Ser Phe Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
145 150 155 160

Ser Tyr Ala Asp Glu Ser Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
165 170 175

Asp Leu Pro Tyr Val Glu Val Val Ser Thr Glu Lys Glu Met Ile Lys
180 185 190

Arg Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
210 215 220

Lys Leu Gly Val Ser Phe Thr Leu Gly Arg Asp Gly Ser Glu Pro Lys
225 230 235 240

Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Val
245 250 255

His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Lys Pro Lys Glu
275 280 285

Lys Val Tyr Ala Glu Glu Ile Ala Thr Ala Trp Glu Thr Gly Glu Gly
290 295 300

Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Arg Val Thr Tyr
305 310 315 320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
325 330 335

Ile Gly Gln Gly Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340 345 350

Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
355 360 365

Pro	Asn	Lys	Pro	Asp		Glu	Arg	Glu	Leu	Ala	Arg	Arg	Arg	Gly	Gly	Tyr	
370						375					380						
Ala	Gly	Gly	Tyr	Val		Lys	Glu	Pro	Glu	Arg	Gly	Leu	Trp	Asp	Asn	Ile	
385						390					395						
Val	Tyr	Leu	Asp	Phe		Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr	His	
405						410					415						
Asn	Val	Ser	Pro	Asp		Thr	Leu	Asn	Arg	Glu	Gly	Cys	Arg	Ser	Tyr	Asp	
420						425					430						
Val	Ala	Pro	Glu	Val		Gly	His	Lys	Phe	Cys	Lys	Asp	Phe	Pro	Gly	Phe	
435						440					445						
Ile	Pro	Ser	Leu	Leu		Gly	Asn	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Ile	Lys	
450						455					460						
Arg	Lys	Met	Lys	Ala		Thr	Leu	Asp	Pro	Leu	Glu	Lys	Asn	Leu	Leu	Asp	
465						470					475						
Tyr	Arg	Gln	Arg	Ala		Ile	Lys	Ile	Leu	Ala	Asn	Ser	Tyr	Tyr	Gly	Tyr	
485						490					495						
Tyr	Gly	Tyr	Ala	Arg		Ala	Arg	Trp	Tyr	Cys	Arg	Glu	Cys	Ala	Glu	Ser	
500						505					510						
Val	Thr	Ala	Trp	Gly		Arg	Glu	Tyr	Ile	Glu	Met	Val	Ile	Arg	Glu	Leu	
515						520					525						
Glu	Glu	Lys	Phe	Gly		Phe	Lys	Val	Leu	Tyr	Ala	Asp	Thr	Asp	Gly	Leu	
530						535					540						
His	Ala	Thr	Ile	Pro		Gly	Ala	Asp	Ala	Glu	Thr	Val	Lys	Lys	Lys	Ala	
545						550					555						
Met	Glu	Phe	Leu	Asn		Tyr	Ile	Asn	Pro	Lys	Leu	Pro	Gly	Leu	Leu	Glu	
565						570					575						
Leu	Glu	Tyr	Glu	Gly		Phe	Tyr	Val	Arg	Gly	Phe	Phe	Val	Thr	Lys	Lys	
580						585					590						
Lys	Tyr	Ala	Val	Ile		Asp	Glu	Glu	Gly	Lys	Ile	Thr	Thr	Arg	Gly	Leu	
595						600					605						
Glu	Ile	Val	Arg	Arg		Asp	Trp	Ser	Glu	Ile	Ala	Lys	Glu	Thr	Gln	Ala	
610						615					620						
Arg	Val	Leu	Glu	Ala		Ile	Leu	Arg	His	Gly	Asp	Val	Glu	Glu	Ala	Val	
625						630					635						
Arg	Ile	Val	Arg	Glu		Val	Thr	Glu	Lys	Leu	Ser	Lys	Tyr	Glu	Val	Pro	
645						650					655						
Pro	Glu	Lys	Leu	Val		Ile	His	Glu	Gln	Ile	Thr	Arg	Glu	Leu	Lys	Asp	
660						665					670						
Tyr	Lys	Ala	Thr	Gly		Pro	His	Val	Ala	Ile	Ala	Lys	Arg	Leu	Ala	Ala	
675						680					685						
Arg	Gly	Val	Lys	Ile		Arg	Pro	Gly	Thr	Val	Ile	Ser	Tyr	Ile	Val	Leu	
690						695					700						
Lys	Gly	Ser	Gly	Arg		Ile	Gly	Asp	Arg	Ala	Ile	Pro	Phe	Asp	Glu	Phe	
705						710					715						
Asp	Pro	Thr	Lys	His		Lys	Tyr	Asp	Ala	Asp	Tyr	Tyr	Ile	Glu	Asn	Gln	
725						730					735						
Val	Leu	Pro	Ala	Val		Glu	Arg	Ile	Leu	Arg	Ala	Phe	Gly	Tyr	Arg	Lys	
740						745					750						
Glu	Asp	Leu	Arg	Tyr		Gln	Lys	Thr	Arg	Gln	Val	Gly	Leu	Gly	Ala	Trp	
755						760					765						
Leu	Lys	Pro	Lys	Gly		Lys	Lys	Lys									
770						775											

-continued

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Thermococcus sp.

<400> SEQUENCE: 91

```

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Ile
 1           5           10           15

Arg Val Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
 20           25           30

Thr Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35           40           45

Glu Asp Val Lys Lys Val Thr Ala Lys Arg His Gly Thr Val Val Lys
 50           55           60

Val Lys Arg Ala Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Ile
 65           70           75           80

Glu Val Trp Lys Leu Tyr Phe Asn His Pro Gln Asp Val Pro Ala Ile
 85           90           95

Arg Asp Arg Ile Arg Ala His Pro Ala Val Val Asp Ile Tyr Glu Tyr
100          105          110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115          120          125

Met Glu Gly Asp Glu Glu Leu Thr Met Leu Ala Phe Asp Ile Glu Thr
130          135          140

Leu Tyr His Glu Gly Glu Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
145          150          155          160

Ser Tyr Ala Asp Gly Ser Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
165          170          175

Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
180          185          190

Arg Phe Leu Arg Val Val Arg Glu Lys Asp Pro Asp Val Leu Ile Thr
195          200          205

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
210          215          220

Glu Leu Gly Ile Lys Phe Thr Leu Gly Arg Asp Gly Ser Glu Pro Lys
225          230          235          240

Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
245          250          255

His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260          265          270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Lys Pro Lys Glu
275          280          285

Lys Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Ser Gly Glu Gly
290          295          300

Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305          310          315          320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
325          330          335

Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
340          345          350

Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Lys Arg Asn Glu Leu Ala
355          360          365

Pro Asn Lys Pro Asp Glu Arg Glu Leu Ala Arg Arg Arg Gly Gly Tyr
370          375          380

Ala Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Asp Asn Ile
385          390          395          400

```

-continued

```

Val Tyr Leu Asp Phe Arg Ser Leu Tyr Pro Ser Ile Ile Ile Thr His
      405                      410                      415
Asn Val Ser Pro Asp Thr Leu Asn Arg Glu Gly Cys Lys Glu Tyr Asp
      420                      425                      430
Val Ala Pro Glu Val Gly His Lys Phe Cys Lys Asp Phe Pro Gly Phe
      435                      440                      445
Ile Pro Ser Leu Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Ile Lys
      450                      455                      460
Arg Lys Met Lys Ala Thr Val Asp Pro Leu Glu Lys Lys Leu Leu Asp
      465                      470                      475                      480
Tyr Arg Gln Arg Ala Ile Lys Ile Leu Ala Asn Ser Phe Tyr Gly Tyr
      485                      490                      495
Tyr Gly Tyr Ala Lys Ala Arg Trp Tyr Cys Lys Glu Cys Ala Glu Ser
      500                      505                      510
Val Thr Ala Trp Gly Arg Glu Tyr Ile Glu Met Val Ile Arg Glu Leu
      515                      520                      525
Glu Glu Lys Phe Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Leu
      530                      535                      540
His Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys Ala
      545                      550                      555                      560
Lys Glu Phe Leu Lys Tyr Ile Asn Pro Lys Leu Pro Gly Leu Leu Glu
      565                      570                      575
Leu Glu Tyr Glu Gly Phe Tyr Val Arg Gly Phe Phe Val Thr Lys Lys
      580                      585                      590
Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr Thr Arg Gly Leu
      595                      600                      605
Glu Ile Val Arg Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala
      610                      615                      620
Arg Val Leu Glu Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val
      625                      630                      635                      640
Arg Ile Val Lys Glu Val Thr Glu Lys Leu Ser Lys Tyr Glu Val Pro
      645                      650                      655
Pro Glu Lys Leu Val Ile His Glu Gln Ile Thr Arg Asp Leu Arg Asp
      660                      665                      670
Tyr Lys Ala Thr Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala
      675                      680                      685
Arg Gly Val Lys Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu
      690                      695                      700
Lys Gly Ser Gly Arg Ile Gly Asp Arg Ala Ile Pro Ala Asp Glu Phe
      705                      710                      715                      720
Asp Pro Thr Lys His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln
      725                      730                      735
Val Leu Pro Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Arg Lys
      740                      745                      750
Glu Asp Leu Arg Tyr Gln Lys Thr Lys Gln Val Gly Leu Gly Ala Trp
      755                      760                      765
Leu Lys Val Lys Gly Lys Lys
      770                      775

```

<210> SEQ ID NO 92

<211> LENGTH: 1671

<212> TYPE: PRT

<213> ORGANISM: *Pyrococcus* sp.

<400> SEQUENCE: 92

-continued

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile
 1 5 10 15
 Arg Ile Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
 20 25 30
 Thr Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
 35 40 45
 Glu Glu Val Lys Lys Ile Thr Ala Glu Arg His Gly Thr Val Val Thr
 50 55 60
 Val Lys Arg Val Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Val
 65 70 75 80
 Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
 85 90 95
 Arg Asp Lys Ile Arg Glu His Pro Ala Val Ile Asp Ile Tyr Glu Tyr
 100 105 110
 Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Val Pro
 115 120 125
 Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
 130 135 140
 Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile
 145 150 155 160
 Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Val
 165 170 175
 Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Arg Glu Met Ile Lys
 180 185 190
 Arg Phe Leu Arg Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
 195 200 205
 Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
 210 215 220
 Lys Leu Gly Ile Asn Phe Ala Leu Gly Arg Asp Gly Ser Glu Pro Lys
 225 230 235 240
 Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
 245 250 255
 His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
 260 265 270
 Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Gln Pro Lys Glu
 275 280 285
 Lys Val Tyr Ala Glu Glu Ile Thr Thr Ala Trp Glu Thr Gly Glu Asn
 290 295 300
 Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
 305 310 315 320
 Glu Leu Gly Lys Glu Phe Leu Pro Met Glu Ala Gln Leu Ser Arg Leu
 325 330 335
 Ile Gly Gln Ser Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
 340 345 350
 Val Glu Trp Phe Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
 355 360 365
 Pro Asn Lys Pro Asp Glu Lys Glu Leu Ala Arg Arg Arg Gln Ser Tyr
 370 375 380
 Glu Gly Gly Tyr Val Lys Glu Pro Glu Arg Gly Leu Trp Glu Asn Ile
 385 390 395 400
 Val Tyr Leu Asp Phe Arg Cys His Pro Ala Asp Thr Lys Val Val Val
 405 410 415
 Lys Gly Lys Gly Ile Ile Asn Ile Ser Glu Val Gln Glu Gly Asp Tyr

-continued

420	425	430
Val Leu Gly Ile Asp Gly Trp	Gln Arg Val Arg Lys	Val Trp Glu Tyr
435	440	445
Asp Tyr Lys Gly Glu Leu Val	Asn Ile Asn Gly Leu Lys	Cys Thr Pro
450	455	460
Asn His Lys Leu Pro Val Val	Thr Lys Asn Glu Arg Gln	Thr Arg Ile
465	470	475
Arg Asp Ser Leu Ala Lys Ser	Phe Leu Thr Lys Lys Val	Lys Gly Lys
485	490	495
Ile Ile Thr Thr Pro Leu Phe	Tyr Glu Ile Gly Arg Ala	Thr Ser Glu
500	505	510
Asn Ile Pro Glu Glu Glu Val	Leu Lys Gly Glu Leu Ala	Gly Ile Leu
515	520	525
Leu Ala Glu Gly Thr Leu Leu	Arg Lys Asp Val Glu Tyr	Phe Asp Ser
530	535	540
Ser Arg Lys Lys Arg Arg Ile	Ser His Gln Tyr Arg Val	Glu Ile Thr
545	550	555
Ile Gly Lys Asp Glu Glu Glu	Phe Arg Asp Arg Ile Thr	Tyr Ile Phe
565	570	575
Glu Arg Leu Phe Gly Ile Thr	Pro Ser Ile Ser Glu Lys	Lys Gly Thr
580	585	590
Asn Ala Val Thr Leu Lys Val	Ala Lys Lys Asn Val Tyr	Leu Lys Val
595	600	605
Lys Glu Ile Met Asp Asn Ile	Glu Ser Leu His Ala Pro	Ser Val Leu
610	615	620
Arg Gly Phe Phe Glu Gly Asp	Gly Ser Val Asn Arg Val	Arg Arg Ser
625	630	635
Ile Val Ala Thr Gln Gly Thr	Lys Asn Glu Trp Lys Ile	Lys Leu Val
645	650	655
Ser Lys Leu Leu Ser Gln Leu	Gly Ile Pro His Gln Thr	Tyr Thr Tyr
660	665	670
Gln Tyr Gln Glu Asn Gly Lys	Asp Arg Ser Arg Tyr Ile	Leu Glu Ile
675	680	685
Thr Gly Lys Asp Gly Leu Ile	Leu Phe Gln Thr Leu Ile	Gly Phe Ile
690	695	700
Ser Glu Arg Lys Asn Ala Leu	Leu Asn Lys Ala Ile Ser	Gln Arg Glu
705	710	715
Met Asn Asn Leu Glu Asn Asn	Gly Phe Tyr Arg Leu Ser	Glu Phe Asn
725	730	735
Val Ser Thr Glu Tyr Tyr Glu	Gly Lys Val Tyr Asp Leu	Thr Leu Glu
740	745	750
Gly Thr Pro Tyr Tyr Phe Ala	Asn Gly Ile Leu Thr His	Asn Ser Leu
755	760	765
Tyr Pro Ser Ile Ile Ile Thr	His Asn Val Ser Pro Asp	Thr Leu Asn
770	775	780
Arg Glu Gly Cys Lys Glu Tyr	Asp Val Ala Pro Gln Val	Gly His Arg
785	790	795
Phe Cys Lys Asp Phe Pro Gly	Phe Ile Pro Ser Leu Leu	Gly Asp Leu
805	810	815
Leu Glu Glu Arg Gln Lys Ile	Lys Lys Lys Met Lys Ala	Thr Ile Asp
820	825	830
Pro Ile Glu Arg Lys Leu Leu	Asp Tyr Arg Gln Arg Ala	Ile Lys Ile
835	840	845

-continued

Leu Ala Asn Ser Ile Leu Pro Glu Glu Trp Leu Pro Val Leu Glu Glu
 850 855 860
 Gly Glu Val His Phe Val Arg Ile Gly Glu Leu Ile Asp Arg Met Met
 865 870 875 880
 Glu Glu Asn Ala Gly Lys Val Lys Arg Glu Gly Glu Thr Glu Val Leu
 885 890 895
 Glu Val Ser Gly Leu Glu Val Pro Ser Phe Asn Arg Arg Thr Asn Lys
 900 905 910
 Ala Glu Leu Lys Arg Val Lys Ala Leu Ile Arg His Asp Tyr Ser Gly
 915 920 925
 Lys Val Tyr Thr Ile Arg Leu Lys Ser Gly Arg Arg Ile Lys Ile Thr
 930 935 940
 Ser Gly His Ser Leu Phe Ser Val Arg Asn Gly Glu Leu Val Glu Val
 945 950 955 960
 Thr Gly Asp Glu Leu Lys Pro Gly Asp Leu Val Ala Val Pro Arg Arg
 965 970 975
 Leu Glu Leu Pro Glu Arg Asn His Val Leu Asn Leu Val Glu Leu Leu
 980 985 990
 Leu Gly Thr Pro Glu Glu Glu Thr Leu Asp Ile Val Met Thr Ile Pro
 995 1000 1005
 Val Lys Gly Lys Lys Asn Phe Phe Lys Gly Met Leu Arg Thr Leu
 1010 1015 1020
 Arg Trp Ile Phe Gly Glu Glu Lys Arg Pro Arg Thr Ala Arg Arg
 1025 1030 1035
 Tyr Leu Arg His Leu Glu Asp Leu Gly Tyr Val Arg Leu Lys Lys
 1040 1045 1050
 Ile Gly Tyr Glu Val Leu Asp Trp Asp Ser Leu Lys Asn Tyr Arg
 1055 1060 1065
 Arg Leu Tyr Glu Ala Leu Val Glu Asn Val Arg Tyr Asn Gly Asn
 1070 1075 1080
 Lys Arg Glu Tyr Leu Val Glu Phe Asn Ser Ile Arg Asp Ala Val
 1085 1090 1095
 Gly Ile Met Pro Leu Lys Glu Leu Lys Glu Trp Lys Ile Gly Thr
 1100 1105 1110
 Leu Asn Gly Phe Arg Met Arg Lys Leu Ile Glu Val Asp Glu Ser
 1115 1120 1125
 Leu Ala Lys Leu Leu Gly Tyr Tyr Val Ser Glu Gly Tyr Ala Arg
 1130 1135 1140
 Lys Gln Arg Asn Pro Lys Asn Gly Trp Ser Tyr Ser Val Lys Leu
 1145 1150 1155
 Tyr Asn Glu Asp Pro Glu Val Leu Asp Asp Met Glu Arg Leu Ala
 1160 1165 1170
 Ser Arg Phe Phe Gly Lys Val Arg Arg Gly Arg Asn Tyr Val Glu
 1175 1180 1185
 Ile Pro Lys Lys Ile Gly Tyr Leu Leu Phe Glu Asn Met Cys Gly
 1190 1195 1200
 Val Leu Ala Glu Asn Lys Arg Ile Pro Glu Phe Val Phe Thr Ser
 1205 1210 1215
 Pro Lys Gly Val Arg Leu Ala Phe Leu Glu Gly Tyr Phe Ile Gly
 1220 1225 1230
 Asp Gly Asp Val His Pro Asn Lys Arg Leu Arg Leu Ser Thr Lys
 1235 1240 1245
 Ser Glu Leu Leu Ala Asn Gln Leu Val Leu Leu Leu Asn Ser Val
 1250 1255 1260

-continued

Gly Val Ser Ala Val Lys Leu	Gly His Asp Ser Gly Val Tyr Arg
1265	1270 1275
Val Tyr Ile Asn Glu Glu Leu	Pro Phe Val Lys Leu Asp Lys Lys
1280	1285 1290
Lys Asn Ala Tyr Tyr Ser His	Val Ile Pro Lys Glu Val Leu Ser
1295	1300 1305
Glu Val Phe Gly Lys Val Phe	Gln Lys Asn Val Ser Pro Gln Thr
1310	1315 1320
Phe Arg Lys Met Val Glu Asp	Gly Arg Leu Asp Pro Glu Lys Ala
1325	1330 1335
Gln Arg Leu Ser Trp Leu Ile	Glu Gly Asp Val Val Leu Asp Arg
1340	1345 1350
Val Glu Ser Val Asp Val Glu	Asp Tyr Asp Gly Tyr Val Tyr Asp
1355	1360 1365
Leu Ser Val Glu Asp Asn Glu	Asn Phe Leu Val Gly Phe Gly Leu
1370	1375 1380
Val Tyr Ala His Asn Ser Tyr	Tyr Gly Tyr Tyr Gly Tyr Ala Arg
1385	1390 1395
Ala Arg Trp Tyr Cys Lys Glu	Cys Ala Glu Ser Val Thr Ala Trp
1400	1405 1410
Gly Arg Glu Tyr Ile Thr Met	Thr Ile Lys Glu Ile Glu Glu Lys
1415	1420 1425
Tyr Gly Phe Lys Val Ile Tyr	Ser Asp Thr Asp Gly Phe Phe Ala
1430	1435 1440
Thr Ile Pro Gly Ala Asp Ala	Glu Thr Val Lys Lys Lys Ala Met
1445	1450 1455
Glu Phe Leu Lys Tyr Ile Asn	Ala Lys Leu Pro Gly Ala Leu Glu
1460	1465 1470
Leu Glu Tyr Glu Gly Phe Tyr	Lys Arg Gly Phe Phe Val Thr Lys
1475	1480 1485
Lys Lys Tyr Ala Val Ile Asp	Glu Glu Gly Lys Ile Thr Thr Arg
1490	1495 1500
Gly Leu Glu Ile Val Arg Arg	Asp Trp Ser Glu Ile Ala Lys Glu
1505	1510 1515
Thr Gln Ala Arg Val Leu Glu	Ala Leu Leu Lys Asp Gly Asp Val
1520	1525 1530
Glu Lys Ala Val Arg Ile Val	Lys Glu Val Thr Glu Lys Leu Ser
1535	1540 1545
Lys Tyr Glu Val Pro Pro Glu	Lys Leu Val Ile His Glu Gln Ile
1550	1555 1560
Thr Arg Asp Leu Lys Asp Tyr	Lys Ala Thr Gly Pro His Val Ala
1565	1570 1575
Val Ala Lys Arg Leu Ala Ala	Arg Gly Val Lys Ile Arg Pro Gly
1580	1585 1590
Thr Val Ile Ser Tyr Ile Val	Leu Lys Gly Ser Gly Arg Ile Gly
1595	1600 1605
Asp Arg Ala Ile Pro Phe Asp	Glu Phe Asp Pro Thr Lys His Lys
1610	1615 1620
Tyr Asp Ala Glu Tyr Tyr Ile	Glu Asn Gln Val Leu Pro Ala Val
1625	1630 1635
Glu Arg Ile Leu Arg Ala Phe	Gly Tyr Arg Lys Glu Asp Leu Arg
1640	1645 1650
Tyr Gln Lys Thr Arg Gln Val	Gly Leu Ser Ala Trp Leu Lys Pro

-continued

1655	1660	1665
------	------	------

Lys Gly Thr
1670

<210> SEQ ID NO 93
 <211> LENGTH: 773
 <212> TYPE: PRT
 <213> ORGANISM: Thermococcus sp.

<400> SEQUENCE: 93

Met	Ile	Leu	Asp	Thr	Asp	Tyr	Ile	Thr	Glu	Asp	Gly	Lys	Pro	Val	Ile
1				5					10					15	
Arg	Ile	Phe	Lys	Lys	Glu	Asn	Gly	Glu	Phe	Lys	Ile	Asp	Tyr	Asp	Arg
			20				25						30		
Asn	Phe	Glu	Pro	Tyr	Ile	Tyr	Ala	Leu	Leu	Lys	Asp	Asp	Ser	Ala	Ile
			35				40					45			
Glu	Asp	Val	Lys	Lys	Ile	Thr	Ala	Glu	Arg	His	Gly	Thr	Thr	Val	Arg
			50			55					60				
Val	Val	Arg	Ala	Glu	Lys	Val	Lys	Lys	Lys	Phe	Leu	Gly	Arg	Pro	Ile
65				70						75				80	
Glu	Val	Trp	Lys	Leu	Tyr	Phe	Thr	His	Pro	Gln	Asp	Val	Pro	Ala	Ile
			85						90					95	
Arg	Asp	Lys	Ile	Lys	Glu	His	Pro	Ala	Val	Val	Asp	Ile	Tyr	Glu	Tyr
			100				105						110		
Asp	Ile	Pro	Phe	Ala	Lys	Arg	Tyr	Leu	Ile	Asp	Lys	Gly	Leu	Ile	Pro
			115				120					125			
Met	Glu	Gly	Asp	Glu	Glu	Leu	Lys	Met	Leu	Ala	Phe	Asp	Ile	Glu	Thr
			130			135					140				
Leu	Tyr	His	Glu	Gly	Glu	Glu	Phe	Ala	Glu	Gly	Pro	Ile	Leu	Met	Ile
145					150					155				160	
Ser	Tyr	Ala	Asp	Glu	Glu	Gly	Ala	Arg	Val	Ile	Thr	Trp	Lys	Asn	Ile
			165						170					175	
Asp	Leu	Pro	Tyr	Val	Asp	Val	Val	Ser	Thr	Glu	Lys	Glu	Met	Ile	Lys
			180					185					190		
Arg	Phe	Leu	Lys	Val	Val	Lys	Glu	Lys	Asp	Pro	Asp	Val	Leu	Ile	Thr
			195				200					205			
Tyr	Asn	Gly	Asp	Asn	Phe	Asp	Phe	Ala	Tyr	Leu	Lys	Lys	Arg	Ser	Glu
			210			215					220				
Lys	Leu	Gly	Val	Lys	Phe	Ile	Leu	Gly	Arg	Glu	Gly	Ser	Glu	Pro	Lys
225				230						235				240	
Ile	Gln	Arg	Met	Gly	Asp	Arg	Phe	Ala	Val	Glu	Val	Lys	Gly	Arg	Ile
			245						250					255	
His	Phe	Asp	Leu	Tyr	Pro	Val	Ile	Arg	Arg	Thr	Ile	Asn	Leu	Pro	Thr
			260					265					270		
Tyr	Thr	Leu	Glu	Ala	Val	Tyr	Glu	Ala	Ile	Phe	Gly	Gln	Pro	Lys	Glu
			275				280					285			
Lys	Val	Tyr	Ala	Glu	Glu	Ile	Ala	Gln	Ala	Trp	Glu	Thr	Gly	Glu	Gly
			290			295					300				
Leu	Glu	Arg	Val	Ala	Arg	Tyr	Ser	Met	Glu	Asp	Ala	Lys	Val	Thr	Tyr
305				310						315				320	
Glu	Leu	Gly	Lys	Glu	Phe	Phe	Pro	Met	Glu	Ala	Gln	Leu	Ser	Arg	Leu
			325						330					335	
Val	Gly	Gln	Ser	Leu	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu
			340					345					350		
Val	Glu	Trp	Phe	Leu	Leu	Arg	Lys	Ala	Tyr	Glu	Arg	Asn	Glu	Leu	Ala

355					360					365						
Pro	Asn	Lys	Pro	Asp	Glu	Arg	Glu	Leu	Ala	Arg	Arg	Arg	Glu	Ser	Tyr	
370					375					380						
Ala	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Arg	Gly	Leu	Trp	Glu	Asn	Ile	
385					390					395					400	
Val	Tyr	Leu	Asp	Phe	Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr	His	
405					410					415						
Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Arg	Glu	Gly	Cys	Glu	Glu	Tyr	Asp	
420					425					430						
Val	Ala	Pro	Gln	Val	Gly	His	Lys	Phe	Cys	Lys	Asp	Phe	Pro	Gly	Phe	
435					440					445						
Ile	Pro	Ser	Leu	Leu	Gly	Asp	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Val	Lys	
450					455					460						
Lys	Lys	Met	Lys	Ala	Thr	Ile	Asp	Pro	Ile	Glu	Lys	Lys	Leu	Leu	Asp	
465					470					475					480	
Tyr	Arg	Gln	Arg	Ala	Ile	Lys	Ile	Leu	Ala	Asn	Ser	Phe	Tyr	Gly	Tyr	
485					490					495						
Tyr	Gly	Tyr	Ala	Lys	Ala	Arg	Trp	Tyr	Cys	Lys	Glu	Cys	Ala	Glu	Ser	
500					505					510						
Val	Thr	Ala	Trp	Gly	Arg	Gln	Tyr	Ile	Glu	Thr	Thr	Ile	Arg	Glu	Ile	
515					520					525						
Glu	Glu	Lys	Phe	Gly	Phe	Lys	Val	Leu	Tyr	Ala	Asp	Thr	Asp	Gly	Phe	
530					535					540						
Phe	Ala	Thr	Ile	Pro	Gly	Ala	Asp	Ala	Glu	Thr	Val	Lys	Lys	Lys	Ala	
545					550					555					560	
Lys	Glu	Phe	Leu	Asp	Tyr	Ile	Asn	Ala	Lys	Leu	Pro	Gly	Leu	Leu	Glu	
565					570					575						
Leu	Glu	Tyr	Glu	Gly	Phe	Tyr	Lys	Arg	Gly	Phe	Phe	Val	Thr	Lys	Lys	
580					585					590						
Lys	Tyr	Ala	Val	Ile	Asp	Glu	Glu	Asp	Lys	Ile	Thr	Thr	Arg	Gly	Leu	
595					600					605						
Glu	Ile	Val	Arg	Arg	Asp	Trp	Ser	Glu	Ile	Ala	Lys	Glu	Thr	Gln	Ala	
610					615					620						
Arg	Val	Leu	Glu	Ala	Ile	Leu	Lys	His	Gly	Asp	Val	Glu	Glu	Ala	Val	
625					630					635					640	
Arg	Ile	Val	Lys	Glu	Val	Thr	Glu	Lys	Leu	Ser	Lys	Tyr	Glu	Val	Pro	
645					650					655						
Pro	Glu	Lys	Leu	Val	Ile	Tyr	Glu	Gln	Ile	Thr	Arg	Asp	Leu	Lys	Asp	
660					665					670						
Tyr	Lys	Ala	Thr	Gly	Pro	His	Val	Ala	Val	Ala	Lys	Arg	Leu	Ala	Ala	
675					680					685						
Arg	Gly	Ile	Lys	Ile	Arg	Pro	Gly	Thr	Val	Ile	Ser	Tyr	Ile	Val	Leu	
690					695					700						
Lys	Gly	Ser	Gly	Arg	Ile	Gly	Asp	Arg	Ala	Ile	Pro	Phe	Asp	Glu	Phe	
705					710					715					720	
Asp	Pro	Ala	Lys	His	Lys	Tyr	Asp	Ala	Glu	Tyr	Tyr	Ile	Glu	Asn	Gln	
725					730					735						
Val	Leu	Pro	Ala	Val	Glu	Arg	Ile	Leu	Arg	Ala	Phe	Gly	Tyr	Arg	Lys	
740					745					750						
Glu	Asp	Leu	Arg	Tyr	Gln	Lys	Thr	Arg	Gln	Val	Gly	Leu	Gly	Ala	Trp	
755					760					765						
Leu	Lys	Pro	Lys	Thr												
770																

-continued

```

<210> SEQ ID NO 94
<211> LENGTH: 1523
<212> TYPE: PRT
<213> ORGANISM: Thermococcus fumicolans

<400> SEQUENCE: 94

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asp Gly Arg Pro Val Ile
 1             5             10             15

Arg Val Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
          20             25             30

Asp Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
          35             40             45

Glu Asp Val Lys Lys Ile Thr Ala Ser Arg His Gly Thr Thr Val Arg
          50             55             60

Val Val Arg Ala Gly Lys Val Lys Lys Lys Phe Leu Gly Arg Pro Ile
          65             70             75             80

Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile
          85             90             95

Arg Asp Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Tyr Glu Tyr
          100            105            110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
          115            120            125

Met Glu Gly Asp Glu Glu Leu Lys Met Leu Ala Phe Asp Ile Glu Thr
          130            135            140

Leu Tyr His Glu Gly Glu Glu Phe Ala Glu Gly Pro Ile Leu Met Ile
          145            150            155            160

Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Lys Ile
          165            170            175

Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
          180            185            190

Arg Phe Leu Lys Val Val Lys Glu Lys Asp Pro Asp Val Leu Ile Thr
          195            200            205

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Ser Glu
          210            215            220

Lys Leu Gly Val Lys Phe Ile Leu Gly Arg Asp Gly Ser Glu Pro Lys
          225            230            235            240

Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
          245            250            255

His Phe Asp Leu Tyr Pro Val Ile Arg His Thr Ile Asn Leu Pro Thr
          260            265            270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Ile Phe Gly Gln Pro Lys Glu
          275            280            285

Lys Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Thr Gly Glu Gly
          290            295            300

Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
          305            310            315            320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
          325            330            335

Val Gly Gln Ser Phe Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu
          340            345            350

Val Glu Trp Tyr Leu Leu Arg Lys Ala Tyr Glu Arg Asn Glu Leu Ala
          355            360            365

Pro Asn Lys Pro Ser Gly Arg Glu Leu Glu Arg Arg Gly Gly Tyr
          370            375            380

```

-continued

Ala	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Arg	Gly	Leu	Trp	Glu	Asn	Ile	
385					390					395					400	
Ala	Tyr	Leu	Asp	Phe	Arg	Cys	His	Pro	Ala	Asp	Thr	Lys	Val	Ile	Val	
			405						410					415		
Lys	Gly	Lys	Gly	Val	Val	Asn	Ile	Ser	Glu	Val	Arg	Glu	Gly	Asp	Tyr	
			420					425						430		
Val	Leu	Gly	Ile	Asp	Gly	Trp	Gln	Lys	Val	Gln	Arg	Val	Trp	Glu	Tyr	
			435				440						445			
Asp	Tyr	Glu	Gly	Glu	Leu	Val	Asn	Ile	Asn	Gly	Leu	Lys	Cys	Thr	Pro	
	450					455						460				
Asn	His	Lys	Leu	Pro	Val	Val	Arg	Arg	Thr	Glu	Arg	Gln	Thr	Ala	Ile	
	465				470					475					480	
Arg	Asp	Ser	Leu	Ala	Lys	Ser	Phe	Leu	Thr	Lys	Lys	Val	Lys	Gly	Lys	
			485						490						495	
Leu	Ile	Thr	Thr	Pro	Leu	Phe	Glu	Lys	Ile	Gly	Lys	Ile	Glu	Arg	Glu	
			500					505					510			
Asp	Val	Pro	Glu	Glu	Glu	Ile	Leu	Lys	Gly	Glu	Leu	Ala	Gly	Ile	Ile	
		515						520					525			
Leu	Ala	Glu	Gly	Thr	Leu	Leu	Arg	Lys	Asp	Val	Glu	Tyr	Phe	Asp	Ser	
	530						535				540					
Ser	Arg	Gly	Lys	Lys	Arg	Val	Ser	His	Gln	Tyr	Arg	Val	Glu	Ile	Thr	
	545				550					555					560	
Val	Gly	Ala	Gln	Glu	Glu	Asp	Phe	Gln	Arg	Arg	Ile	Val	Tyr	Ile	Phe	
			565						570						575	
Glu	Arg	Leu	Phe	Gly	Val	Thr	Pro	Ser	Val	Tyr	Arg	Lys	Lys	Asn	Thr	
		580						585						590		
Asn	Ala	Ile	Thr	Phe	Lys	Val	Ala	Lys	Lys	Glu	Val	Tyr	Leu	Arg	Val	
		595					600						605			
Arg	Glu	Ile	Met	Asp	Gly	Ile	Glu	Asn	Leu	His	Ala	Pro	Ser	Val	Leu	
	610						615					620				
Arg	Gly	Phe	Phe	Glu	Gly	Asp	Gly	Ser	Val	Asn	Lys	Val	Arg	Lys	Thr	
	625				630					635					640	
Val	Val	Val	Asn	Gln	Gly	Thr	Asn	Asn	Glu	Trp	Lys	Ile	Glu	Val	Val	
			645						650						655	
Ser	Lys	Leu	Leu	Asn	Lys	Leu	Gly	Ile	Pro	His	Arg	Arg	Tyr	Thr	Tyr	
		660						665						670		
Asp	Tyr	Thr	Glu	Arg	Glu	Lys	Thr	Met	Thr	Thr	His	Ile	Leu	Glu	Ile	
		675					680						685			
Ala	Gly	Arg	Asp	Gly	Leu	Ile	Leu	Phe	Gln	Thr	Ile	Val	Gly	Phe	Ile	
	690						695					700				
Ser	Thr	Glu	Lys	Asn	Met	Ala	Leu	Glu	Glu	Ala	Ile	Arg	Asn	Arg	Glu	
	705				710					715					720	
Val	Asn	Arg	Leu	Glu	Asn	Asn	Ala	Phe	Tyr	Thr	Leu	Ala	Asp	Phe	Thr	
			725						730						735	
Ala	Lys	Thr	Glu	Tyr	Tyr	Lys	Gly	Lys	Val	Tyr	Asp	Leu	Thr	Leu	Glu	
		740						745						750		
Gly	Thr	Pro	Tyr	Tyr	Phe	Ala	Asn	Gly	Ile	Leu	Thr	His	Asn	Ser	Leu	
		755					760						765			
Tyr	Pro	Ser	Ile	Ile	Ile	Ser	His	Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	
	770						775					780				
Arg	Glu	Gly	Cys	Gly	Glu	Tyr	Asp	Glu	Ala	Pro	Gln	Val	Gly	His	Arg	
	785					790				795					800	
Phe	Cys	Lys	Asp	Phe	Pro	Gly	Phe	Ile	Pro	Ser	Leu	Leu	Gly	Asp	Leu	
			805						810						815	

-continued

Leu Asp Glu Arg Gln Lys Val Lys Lys His Met Lys Ala Thr Val Asp
 820 825 830
 Pro Ile Glu Lys Lys Leu Leu Asp Tyr Arg Gln Arg Ala Ile Lys Ile
 835 840 845
 Leu Ala Asn Ser Phe Tyr Gly Tyr Tyr Gly Tyr Ala Lys Ala Arg Trp
 850 855 860
 Tyr Cys Lys Glu Cys Ala Glu Ser Val Thr Ala Trp Gly Arg Gln Tyr
 865 870 875 880
 Ile Glu Thr Thr Met Arg Glu Ile Glu Glu Lys Phe Gly Phe Lys Val
 885 890 895
 Leu Tyr Ala Asp Ser Val Thr Gly Asp Thr Glu Val Thr Ile Arg Arg
 900 905 910
 Asn Gly Arg Ile Glu Phe Val Pro Ile Glu Lys Leu Phe Glu Arg Val
 915 920 925
 Asp His Arg Val Gly Glu Lys Glu Tyr Cys Val Leu Gly Gly Val Glu
 930 935 940
 Ala Leu Thr Leu Asp Asn Arg Gly Arg Leu Val Trp Lys Lys Val Pro
 945 950 955 960
 Tyr Val Met Arg His Lys Thr Asp Lys Arg Ile Tyr Arg Val Trp Phe
 965 970 975
 Thr Asn Ser Trp Tyr Leu Asp Val Thr Glu Asp His Ser Leu Ile Gly
 980 985 990
 Tyr Leu Asn Thr Ser Lys Val Lys Pro Gly Lys Pro Leu Lys Glu Arg
 995 1000 1005
 Leu Val Glu Val Lys Pro Glu Glu Leu Gly Gly Lys Val Lys Ser
 1010 1015 1020
 Leu Ile Thr Pro Asn Arg Pro Ile Ala Arg Thr Ile Lys Ala Asn
 1025 1030 1035
 Pro Ile Ala Val Lys Leu Trp Glu Leu Ile Gly Leu Leu Val Gly
 1040 1045 1050
 Asp Gly Asn Trp Gly Gly Gln Ser Asn Trp Ala Lys Tyr Tyr Val
 1055 1060 1065
 Gly Leu Ser Cys Gly Leu Asp Lys Ala Glu Ile Glu Arg Lys Val
 1070 1075 1080
 Leu Asn Pro Leu Arg Glu Ala Ser Val Ile Ser Asn Tyr Tyr Asp
 1085 1090 1095
 Lys Ser Lys Lys Gly Asp Val Ser Ile Leu Ser Lys Trp Leu Ala
 1100 1105 1110
 Gly Phe Met Val Lys Tyr Phe Lys Asp Glu Asn Gly Asn Lys Ala
 1115 1120 1125
 Ile Pro Ser Phe Met Phe Asn Leu Pro Arg Glu Tyr Ile Glu Ala
 1130 1135 1140
 Phe Leu Arg Gly Leu Phe Ser Ala Asp Gly Thr Val Ser Leu Arg
 1145 1150 1155
 Arg Gly Ile Pro Glu Ile Arg Leu Thr Ser Val Asn Arg Glu Leu
 1160 1165 1170
 Ser Asp Ala Val Arg Lys Leu Leu Trp Leu Val Gly Val Ser Asn
 1175 1180 1185
 Ser Leu Phe Thr Glu Thr Lys Pro Asn Arg Tyr Leu Glu Lys Glu
 1190 1195 1200
 Ser Gly Thr His Ser Ile His Val Arg Ile Lys Asn Lys His Arg
 1205 1210 1215
 Phe Ala Asp Arg Ile Gly Phe Leu Ile Asp Arg Lys Ser Thr Lys

-continued

1220	1225	1230
Leu Ser Glu Asn Leu Gly Gly His Thr Asn Lys Lys Arg Ala Tyr		
1235	1240	1245
Lys Tyr Asp Phe Asp Leu Val Tyr Pro Arg Lys Ile Glu Glu Ile		
1250	1255	1260
Thr Tyr Asp Gly Tyr Val Tyr Asp Ile Glu Val Glu Gly Thr His		
1265	1270	1275
Arg Phe Phe Ala Asn Gly Ile Leu Val His Asn Thr Asp Gly Phe		
1280	1285	1290
Phe Ala Thr Ile Pro Gly Ala Asp Ala Glu Thr Val Lys Lys Lys		
1295	1300	1305
Ala Arg Glu Phe Leu Asn Tyr Ile Asn Pro Lys Leu Pro Gly Leu		
1310	1315	1320
Leu Glu Leu Glu Tyr Glu Gly Phe Tyr Arg Arg Gly Phe Phe Val		
1325	1330	1335
Thr Lys Lys Lys Tyr Ala Val Ile Asp Glu Glu Gly Lys Ile Thr		
1340	1345	1350
Thr Arg Gly Leu Glu Ile Val Arg Arg Asp Trp Ser Glu Val Ala		
1355	1360	1365
Lys Glu Thr Gln Ala Arg Val Leu Glu Ala Ile Leu Arg His Gly		
1370	1375	1380
Asp Val Glu Glu Ala Val Arg Ile Val Lys Glu Val Thr Glu Lys		
1385	1390	1395
Leu Ser Lys Tyr Glu Val Pro Pro Glu Lys Leu Val Ile His Glu		
1400	1405	1410
Gln Ile Thr Arg Glu Leu Lys Asp Tyr Lys Ala Thr Gly Pro His		
1415	1420	1425
Val Ala Ile Ala Lys Arg Leu Ala Ala Arg Gly Ile Lys Val Arg		
1430	1435	1440
Pro Gly Thr Val Ile Ser Tyr Ile Val Leu Lys Gly Ser Gly Arg		
1445	1450	1455
Ile Gly Asp Arg Thr Ile Pro Phe Asp Glu Phe Asp Pro Thr Lys		
1460	1465	1470
His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln Val Leu Pro		
1475	1480	1485
Ala Val Glu Arg Ile Leu Lys Ala Phe Gly Tyr Lys Lys Glu Asp		
1490	1495	1500
Leu Arg Tyr Gln Lys Thr Arg Gln Val Gly Leu Gly Ala Trp Leu		
1505	1510	1515
Lys Met Gly Lys Lys		
1520		
<210> SEQ ID NO 95		
<211> LENGTH: 586		
<212> TYPE: PRT		
<213> ORGANISM: Methanobacterium thermoautotrophicum		
<400> SEQUENCE: 95		
Met Glu Asp Tyr Arg Met Val Leu Leu Asp Ile Asp Tyr Val Thr Val		
1	5	10
Asp Glu Val Pro Val Ile Arg Leu Phe Gly Lys Asp Lys Ser Gly Gly		
20	25	30
Asn Glu Pro Ile Ile Ala His Asp Arg Ser Phe Arg Pro Tyr Ile Tyr		
35	40	45
Ala Ile Pro Thr Asp Leu Asp Glu Cys Leu Arg Glu Leu Glu Glu Leu		

50					55					60					
Glu 65	Leu	Glu	Lys	Leu	Glu 70	Val	Lys	Glu	Met	Arg 75	Asp	Leu	Gly	Arg	Pro 80
Thr	Glu	Val	Ile 85	Arg	Ile	Glu	Phe	Arg	His 90	Pro	Gln	Asp	Val	Pro 95	Lys
Ile	Arg	Asp	Arg 100	Ile	Arg	Asp	Leu	Glu 105	Ser	Val	Arg	Asp	Ile 110	Arg	Glu
His	Asp	Ile 115	Pro	Phe	Tyr	Arg	Arg 120	Tyr	Leu	Ile	Asp	Lys 125	Ser	Ile	Val
Pro	Met	Glu 130	Glu	Leu	Glu	Phe 135	Gln	Gly	Val	Glu	Val 140	Asp	Ser	Ala	Pro
Ser	Val	Thr 145	Thr	Asp	Val 150	Arg	Thr	Val	Glu	Val 155	Thr	Gly	Arg	Val	Gln 160
Ser	Thr	Gly	Ser 165	Gly	Ala	His	Gly	Leu 170	Asp	Ile	Leu	Ser	Phe	Asp 175	Ile
Glu	Val	Arg 180	Asn	Pro	His	Gly	Met 185	Pro	Asp	Pro	Glu	Lys	Asp 190	Glu	Ile
Val	Met	Ile 195	Gly	Val	Ala	Gly 200	Asn	Met	Gly	Tyr	Glu	Ser 205	Val	Ile	Ser
Thr	Ala	Gly 210	Asp	His	Leu	Asp 215	Phe	Val	Glu	Val 220	Val	Glu	Asp	Glu	Arg
Glu 225	Leu	Leu	Glu	Arg	Phe 230	Ala	Glu	Ile	Val	Ile 235	Asp	Lys	Lys	Pro	Asp 240
Ile	Leu	Val	Gly 245	Tyr	Asn	Ser	Asp	Asn	Phe 250	Asp	Phe	Pro	Tyr	Ile 255	Thr
Arg	Arg	Ala 260	Ala	Ile	Leu	Gly	Ala 265	Glu	Leu	Asp	Leu	Gly	Trp 270	Asp	Gly
Ser	Lys	Ile 275	Arg	Thr	Met	Arg 280	Arg	Gly	Phe	Ala	Asn	Ala 285	Thr	Ala	Ile
Lys	Gly	Thr 290	Val	His	Val 295	Asp	Leu	Tyr	Pro	Val 300	Met	Arg	Arg	Tyr	Met
Asn 305	Leu	Asp	Arg	Tyr 310	Thr	Leu	Glu	Arg	Val 315	Tyr	Gln	Glu	Leu	Phe	Gly 320
Glu	Glu	Lys 325	Ile	Asp	Leu	Pro	Gly	Asp 330	Arg	Leu	Trp	Glu	Tyr	Trp 335	Asp
Arg	Asp	Glu 340	Leu	Arg	Asp	Glu	Leu 345	Phe	Arg	Tyr	Ser	Leu	Asp 350	Asp	Val
Val	Ala	Thr 355	His	Arg	Ile	Ala 360	Glu	Lys	Ile	Leu	Pro	Leu 365	Asn	Leu	Glu
Leu	Thr	Arg 370	Leu	Val	Gly 375	Gln	Pro	Leu	Phe	Asp 380	Ile	Ser	Arg	Met	Ala
Thr 385	Gly	Gln	Gln	Ala 390	Glu	Trp	Phe	Leu	Val	Arg 395	Lys	Ala	Tyr	Gln	Tyr 400
Gly	Glu	Leu	Val 405	Pro	Asn	Lys	Pro	Ser	Gln 410	Ser	Asp	Phe	Ser	Ser	Arg
Arg	Gly	Arg 420	Arg	Ala	Val	Gly	Gly 425	Tyr	Val	Lys	Glu	Pro	Glu 430	Lys	Gly
Leu	His	Glu 435	Asn	Ile	Val	Gln	Phe 440	Asp	Phe	Arg	Ser	Leu 445	Tyr	Pro	Ser
Ile	Ile	Ile 450	Ser	Lys	Asn 455	Ile	Ser	Pro	Asp	Thr	Leu	Thr	Asp	Asp	Glu
Glu 465	Ser	Glu	Cys	Tyr 470	Val	Ala	Pro	Glu	Tyr	Gly 475	Tyr	Arg	Phe	Arg	Lys 480

-continued

Ser Pro Arg Gly Phe Val Pro Ser Val Ile Gly Glu Ile Leu Ser Glu
485 490 495

Arg Val Arg Ile Lys Glu Glu Met Lys Gly Ser Asp Asp Pro Met Glu
500 505 510

Arg Lys Ile Leu Asn Val Gln Gln Glu Ala Leu Lys Arg Leu Ala Asn
515 520 525

Thr Met Tyr Gly Val Tyr Gly Tyr Ser Arg Phe Arg Trp Tyr Ser Met
530 535 540

Glu Cys Ala Glu Ala Ile Thr Ala Trp Gly Arg Asp Tyr Ile Lys Lys
545 550 555 560

Thr Ile Lys Thr Ala Glu Glu Phe Gly Phe His Thr Val Tyr Ala Asp
565 570 575

Thr Asp Gly Phe Tyr Ala Thr Tyr Arg Gly
580 585

<210> SEQ ID NO 96
<211> LENGTH: 1634
<212> TYPE: PRT
<213> ORGANISM: Methanococcus jannaschii

<400> SEQUENCE: 96

Met Gly Met Ser Met Gly Lys Ile Lys Ile Asp Ala Leu Ile Asp Asn
1 5 10 15

Thr Tyr Lys Thr Ile Glu Asp Lys Ala Val Ile Tyr Leu Tyr Leu Ile
20 25 30

Asn Ser Ile Leu Lys Asp Arg Asp Phe Lys Pro Tyr Phe Tyr Val Glu
35 40 45

Leu His Lys Glu Lys Val Glu Asn Glu Asp Ile Glu Lys Ile Lys Glu
50 55 60

Phe Leu Leu Lys Asn Asp Leu Leu Lys Phe Val Glu Asn Ile Glu Val
65 70 75 80

Val Lys Lys Ile Ile Leu Arg Lys Glu Lys Glu Val Ile Lys Ile Ile
85 90 95

Ala Thr His Pro Gln Lys Val Pro Lys Leu Arg Lys Ile Lys Glu Cys
100 105 110

Glu Ile Val Lys Glu Ile Tyr Glu His Asp Ile Pro Phe Ala Lys Arg
115 120 125

Tyr Leu Ile Asp Asn Glu Ile Ile Pro Met Thr Tyr Trp Asp Phe Glu
130 135 140

Asn Lys Lys Pro Val Ser Ile Glu Ile Pro Lys Leu Lys Ser Val Ala
145 150 155 160

Phe Asp Met Glu Val Tyr Asn Arg Asp Thr Glu Pro Asn Pro Glu Arg
165 170 175

Asp Pro Ile Leu Met Ala Ser Phe Trp Asp Glu Asn Gly Gly Lys Val
180 185 190

Ile Thr Tyr Lys Glu Phe Asn His Pro Asn Ile Glu Val Val Lys Asn
195 200 205

Glu Lys Glu Leu Ile Lys Lys Ile Ile Glu Thr Leu Lys Glu Tyr Asp
210 215 220

Val Ile Tyr Thr Tyr Asn Gly Asp Asn Phe Asp Phe Pro Tyr Leu Lys
225 230 235 240

Ala Arg Ala Lys Ile Tyr Gly Ile Asp Ile Asn Leu Gly Lys Asp Gly
245 250 255

Glu Glu Leu Lys Ile Lys Arg Gly Gly Met Glu Tyr Arg Ser Tyr Ile
260 265 270

-continued

Pro Gly Arg Val His Ile Asp Leu Tyr Pro Ile Ser Arg Arg Leu Leu	
275	280 285
Lys Leu Thr Lys Tyr Thr Leu Glu Asp Val Val Tyr Asn Leu Phe Gly	
290	295 300
Ile Glu Lys Leu Lys Ile Pro His Thr Lys Ile Val Asp Tyr Trp Ala	
305	310 315 320
Asn Asn Asp Lys Thr Leu Ile Glu Tyr Ser Leu Gln Asp Ala Lys Tyr	
325	330 335
Thr Tyr Lys Ile Gly Lys Tyr Phe Phe Pro Leu Glu Val Met Phe Ser	
340	345 350
Arg Ile Val Asn Gln Thr Pro Phe Glu Ile Thr Arg Met Ser Ser Gly	
355	360 365
Gln Met Val Glu Tyr Leu Leu Met Lys Arg Ala Phe Lys Glu Asn Met	
370	375 380
Ile Val Pro Asn Lys Pro Asp Glu Glu Glu Tyr Arg Arg Arg Val Leu	
385	390 395 400
Thr Thr Tyr Glu Gly Gly Tyr Val Lys Glu Pro Glu Lys Gly Met Phe	
405	410 415
Glu Asp Ile Ile Ser Met Asp Phe Arg Cys His Pro Lys Gly Thr Lys	
420	425 430
Val Val Val Lys Gly Lys Gly Ile Val Asn Ile Glu Asp Val Lys Glu	
435	440 445
Gly Asn Tyr Val Leu Gly Ile Asp Gly Trp Gln Lys Val Lys Lys Val	
450	455 460
Trp Lys Tyr Glu Tyr Glu Gly Glu Leu Ile Asn Val Asn Gly Leu Lys	
465	470 475 480
Cys Thr Pro Asn His Lys Ile Pro Leu Arg Tyr Lys Ile Lys His Lys	
485	490 495
Lys Ile Asn Lys Asn Asp Tyr Leu Val Arg Asp Ile Tyr Ala Lys Ser	
500	505 510
Leu Leu Thr Lys Phe Lys Gly Glu Gly Lys Leu Ile Leu Cys Lys Asp	
515	520 525
Phe Glu Thr Ile Gly Asn Tyr Glu Lys Tyr Ile Asn Asp Met Asp Glu	
530	535 540
Asp Phe Ile Leu Lys Ser Glu Leu Ile Gly Ile Leu Leu Ala Glu Gly	
545	550 555 560
His Leu Leu Arg Arg Asp Ile Glu Tyr Phe Asp Ser Ser Arg Gly Lys	
565	570 575
Lys Arg Ile Ser His Gln Tyr Arg Val Glu Ile Thr Val Asn Glu Asp	
580	585 590
Glu Lys Asp Phe Ile Glu Lys Ile Lys Tyr Ile Phe Lys Lys Leu Phe	
595	600 605
Asn Tyr Glu Leu Tyr Val Arg Arg Lys Lys Gly Thr Lys Ala Ile Thr	
610	615 620
Leu Gly Cys Ala Lys Lys Asp Ile Tyr Leu Lys Ile Glu Glu Ile Leu	
625	630 635 640
Lys Asn Lys Glu Lys Tyr Leu Pro Asn Ala Ile Leu Arg Gly Phe Phe	
645	650 655
Glu Gly Asp Gly Tyr Val Asn Thr Val Arg Arg Ala Val Val Val Asn	
660	665 670
Gln Gly Thr Asn Asn Tyr Asp Lys Ile Lys Phe Ile Ala Ser Leu Leu	
675	680 685
Asp Arg Leu Gly Ile Lys Tyr Ser Phe Tyr Thr Tyr Ser Tyr Glu Glu	
690	695 700

-continued

Arg Gly Lys Lys Leu Lys Arg Tyr Val Ile Glu Ile Phe Ser Lys Gly
 705 710 715 720
 Asp Leu Ile Lys Phe Ser Ile Leu Ile Ser Phe Ile Ser Arg Arg Lys
 725 730 735
 Asn Asn Leu Leu Asn Glu Ile Ile Arg Gln Lys Thr Leu Tyr Lys Ile
 740 745 750
 Gly Asp Tyr Gly Phe Tyr Asp Leu Asp Asp Val Cys Val Ser Leu Glu
 755 760 765
 Ser Tyr Lys Gly Glu Val Tyr Asp Leu Thr Leu Glu Gly Arg Pro Tyr
 770 775 780
 Tyr Phe Ala Asn Gly Ile Leu Thr His Asn Ser Leu Tyr Pro Ser Ile
 785 790 795 800
 Ile Ile Ser Tyr Asn Ile Ser Pro Asp Thr Leu Asp Cys Glu Cys Cys
 805 810 815
 Lys Asp Val Ser Glu Lys Ile Leu Gly His Trp Phe Cys Lys Lys Lys
 820 825 830
 Glu Gly Leu Ile Pro Lys Thr Leu Arg Asn Leu Ile Glu Arg Arg Ile
 835 840 845
 Asn Ile Lys Arg Arg Met Lys Lys Met Ala Glu Ile Gly Glu Ile Asn
 850 855 860
 Glu Glu Tyr Asn Leu Leu Asp Tyr Glu Gln Lys Ser Leu Lys Ile Leu
 865 870 875 880
 Ala Asn Ser Ile Leu Pro Asp Glu Tyr Leu Thr Ile Ile Glu Glu Asp
 885 890 895
 Gly Ile Lys Val Val Lys Ile Gly Glu Tyr Ile Asp Asp Leu Met Arg
 900 905 910
 Lys His Lys Asp Lys Ile Lys Phe Ser Gly Ile Ser Glu Ile Leu Glu
 915 920 925
 Thr Lys Asn Leu Lys Thr Phe Ser Phe Asp Lys Ile Thr Lys Lys Cys
 930 935 940
 Glu Ile Lys Lys Val Lys Ala Leu Ile Arg His Pro Tyr Phe Gly Lys
 945 950 955 960
 Ala Tyr Lys Ile Lys Leu Arg Ser Gly Arg Thr Ile Lys Val Thr Arg
 965 970 975
 Gly His Ser Leu Phe Lys Tyr Glu Asn Gly Lys Ile Val Glu Val Lys
 980 985 990
 Gly Asp Asp Val Arg Phe Gly Asp Leu Ile Val Val Pro Lys Lys Leu
 995 1000 1005
 Thr Cys Val Asp Lys Glu Val Val Ile Asn Ile Pro Lys Arg Leu
 1010 1015 1020
 Ile Asn Ala Asp Glu Glu Glu Ile Lys Asp Leu Val Ile Thr Lys
 1025 1030 1035
 His Lys Asp Lys Ala Phe Phe Val Lys Leu Lys Lys Thr Leu Glu
 1040 1045 1050
 Asp Ile Glu Asn Asn Lys Leu Lys Val Ile Phe Asp Asp Cys Ile
 1055 1060 1065
 Leu Tyr Leu Lys Glu Leu Gly Leu Ile Asp Tyr Asn Ile Ile Lys
 1070 1075 1080
 Lys Ile Asn Lys Val Asp Ile Lys Ile Leu Asp Glu Glu Lys Phe
 1085 1090 1095
 Lys Ala Tyr Lys Lys Tyr Phe Asp Thr Val Ile Glu His Gly Asn
 1100 1105 1110
 Phe Lys Lys Gly Arg Cys Asn Ile Gln Tyr Ile Lys Ile Lys Asp

-continued

1115	1120	1125
Tyr Ile Ala Asn Ile Pro Asp Lys Glu Phe Glu Asp Cys Glu Ile 1130 1135 1140		
Gly Ala Tyr Ser Gly Lys Ile Asn Ala Leu Leu Lys Leu Asp Glu 1145 1150 1155		
Lys Leu Ala Lys Phe Leu Gly Phe Phe Val Thr Arg Gly Arg Leu 1160 1165 1170		
Lys Lys Gln Lys Leu Lys Gly Glu Thr Val Tyr Glu Ile Ser Val 1175 1180 1185		
Tyr Lys Ser Leu Pro Glu Tyr Gln Lys Glu Ile Ala Glu Thr Phe 1190 1195 1200		
Lys Glu Val Phe Gly Ala Gly Ser Met Val Lys Asp Lys Val Thr 1205 1210 1215		
Met Asp Asn Lys Ile Val Tyr Leu Val Leu Lys Tyr Ile Phe Lys 1220 1225 1230		
Cys Gly Asp Lys Asp Lys Lys His Ile Pro Glu Glu Leu Phe Leu 1235 1240 1245		
Ala Ser Glu Ser Val Ile Lys Ser Phe Leu Asp Gly Phe Leu Lys 1250 1255 1260		
Ala Lys Lys Asn Ser His Lys Gly Thr Ser Thr Phe Met Ala Lys 1265 1270 1275		
Asp Glu Lys Tyr Leu Asn Gln Leu Met Ile Leu Phe Asn Leu Val 1280 1285 1290		
Gly Ile Pro Thr Arg Phe Thr Pro Val Lys Asn Lys Gly Tyr Lys 1295 1300 1305		
Leu Thr Leu Asn Pro Lys Tyr Gly Thr Val Lys Asp Leu Met Leu 1310 1315 1320		
Asp Glu Val Lys Glu Ile Glu Ala Phe Glu Tyr Ser Gly Tyr Val 1325 1330 1335		
Tyr Asp Leu Ser Val Glu Asp Asn Glu Asn Phe Leu Val Asn Asn 1340 1345 1350		
Ile Tyr Ala His Asn Ser Val Tyr Gly Tyr Leu Ala Phe Pro Arg 1355 1360 1365		
Ala Arg Phe Tyr Ser Arg Glu Cys Ala Glu Ile Val Thr Tyr Leu 1370 1375 1380		
Gly Arg Lys Tyr Ile Leu Glu Thr Val Lys Glu Ala Glu Lys Phe 1385 1390 1395		
Gly Phe Lys Val Leu Tyr Ile Asp Thr Asp Gly Phe Tyr Ala Ile 1400 1405 1410		
Trp Lys Glu Lys Ile Ser Lys Glu Glu Leu Ile Lys Lys Ala Met 1415 1420 1425		
Glu Phe Val Glu Tyr Ile Asn Ser Lys Leu Pro Gly Thr Met Glu 1430 1435 1440		
Leu Glu Phe Glu Gly Tyr Phe Lys Arg Gly Ile Phe Val Thr Lys 1445 1450 1455		
Lys Arg Tyr Ala Leu Ile Asp Glu Asn Gly Arg Val Thr Val Lys 1460 1465 1470		
Gly Leu Glu Phe Val Arg Arg Asp Trp Ser Asn Ile Ala Lys Ile 1475 1480 1485		
Thr Gln Arg Arg Val Leu Glu Ala Leu Leu Val Glu Gly Ser Ile 1490 1495 1500		
Glu Lys Ala Lys Lys Ile Ile Gln Asp Val Ile Lys Asp Leu Arg 1505 1510 1515		

-continued

Glu Lys Lys Ile Lys Lys Glu Asp Leu Ile Ile Tyr Thr Gln Leu
 1520 1525 1530
 Thr Lys Asp Pro Lys Glu Tyr Lys Thr Thr Ala Pro His Val Glu
 1535 1540 1545
 Ile Ala Lys Lys Leu Met Arg Glu Gly Lys Arg Ile Lys Val Gly
 1550 1555 1560
 Asp Ile Ile Gly Tyr Ile Ile Val Lys Gly Thr Lys Ser Ile Ser
 1565 1570 1575
 Glu Arg Ala Lys Leu Pro Glu Glu Val Asp Ile Asp Asp Ile Asp
 1580 1585 1590
 Val Asn Tyr Tyr Ile Asp Asn Gln Ile Leu Pro Pro Val Leu Arg
 1595 1600 1605
 Ile Met Glu Ala Val Gly Val Ser Lys Asn Glu Leu Lys Lys Glu
 1610 1615 1620
 Gly Ala Gln Leu Thr Leu Asp Lys Phe Phe Lys
 1625 1630

<210> SEQ ID NO 97

<211> LENGTH: 803

<212> TYPE: PRT

<213> ORGANISM: Pyrodictium occultum

<400> SEQUENCE: 97

Met Thr Glu Thr Ile Glu Phe Val Leu Leu Asp Ser Ser Tyr Glu Ile
 1 5 10 15
 Leu Gly Lys Glu Pro Val Val Ile Leu Trp Gly Ile Thr Leu Asp Gly
 20 25 30
 Lys Arg Val Val Leu Leu Asp His Arg Phe Arg Pro Tyr Phe Tyr Ala
 35 40 45
 Leu Ile Ala Arg Gly Tyr Glu Asp Met Val Glu Glu Ile Ala Ala Ser
 50 55 60
 Ile Arg Arg Leu Ser Val Val Lys Ser Pro Ile Ile Asp Ala Lys Pro
 65 70 75 80
 Leu Asp Lys Arg Tyr Phe Gly Arg Pro Arg Lys Ala Val Lys Ile Thr
 85 90 95
 Thr Met Ile Pro Glu Ser Val Arg His Tyr Arg Glu Ala Val Lys Lys
 100 105 110
 Ile Glu Gly Val Glu Asp Ser Leu Glu Ala Asp Ile Arg Phe Ala Met
 115 120 125
 Arg Tyr Leu Ile Asp Lys Arg Leu Tyr Pro Phe Thr Val Tyr Arg Ile
 130 135 140
 Pro Val Glu Asp Ala Gly Arg Asn Pro Gly Phe Arg Val Asp Arg Val
 145 150 155 160
 Tyr Lys Val Ala Gly Asp Pro Glu Pro Leu Ala Asp Ile Thr Arg Ile
 165 170 175
 Asp Leu Pro Pro Met Arg Leu Val Ala Phe Asp Ile Glu Val Tyr Ser
 180 185 190
 Arg Arg Gly Ser Pro Asn Pro Ala Arg Asp Pro Val Ile Ile Val Ser
 195 200 205
 Leu Arg Asp Ser Glu Gly Lys Glu Arg Leu Ile Glu Ala Glu Gly His
 210 215 220
 Asp Asp Arg Arg Val Leu Arg Glu Phe Val Glu Tyr Val Arg Ala Phe
 225 230 235 240
 Asp Pro Asp Ile Ile Val Gly Tyr Asn Ser Asn His Phe Asp Trp Pro
 245 250 255

Tyr	Leu	Met	Glu	Arg	Ala	Arg	Arg	Leu	Gly	Ile	Lys	Leu	Asp	Val	Thr
			260					265						270	
Arg	Arg	Val	Gly	Ala	Glu	Pro	Thr	Thr	Ser	Val	Tyr	Gly	His	Val	Ser
		275					280					285			
Val	Gln	Gly	Arg	Leu	Asn	Val	Asp	Leu	Tyr	Asp	Tyr	Ala	Glu	Glu	Met
		290				295					300				
Pro	Glu	Ile	Lys	Met	Lys	Thr	Leu	Glu	Glu	Val	Ala	Glu	Tyr	Leu	Gly
305					310					315					320
Val	Met	Lys	Lys	Ser	Glu	Arg	Val	Ile	Ile	Glu	Trp	Trp	Arg	Ile	Pro
				325				330						335	
Glu	Tyr	Trp	Asp	Asp	Glu	Lys	Lys	Arg	Gln	Leu	Leu	Glu	Arg	Tyr	Ala
			340					345					350		
Leu	Asp	Asp	Val	Arg	Ala	Thr	Tyr	Gly	Leu	Ala	Glu	Lys	Met	Leu	Pro
		355					360					365			
Phe	Ala	Ile	Gln	Leu	Ser	Thr	Val	Thr	Gly	Val	Pro	Leu	Asp	Gln	Val
		370				375					380				
Gly	Ala	Met	Gly	Val	Gly	Phe	Arg	Leu	Glu	Trp	Tyr	Leu	Met	Arg	Ala
385					390					395					400
Ala	Tyr	Asp	Met	Asn	Glu	Leu	Val	Pro	Asn	Arg	Val	Glu	Arg	Arg	Gly
				405					410					415	
Glu	Ser	Tyr	Lys	Gly	Ala	Val	Val	Leu	Lys	Pro	Leu	Lys	Gly	Val	His
			420					425					430		
Glu	Asn	Val	Val	Val	Leu	Asp	Phe	Ser	Ser	Met	Tyr	Pro	Ser	Ile	Met
		435					440					445			
Ile	Lys	Tyr	Asn	Val	Gly	Pro	Asp	Thr	Ile	Val	Asp	Asp	Pro	Ser	Glu
	450					455					460				
Cys	Pro	Lys	Tyr	Gly	Gly	Cys	Tyr	Val	Ala	Pro	Glu	Val	Gly	His	Arg
465					470					475					480
Phe	Arg	Arg	Ser	Pro	Pro	Gly	Phe	Phe	Lys	Thr	Val	Leu	Glu	Asn	Leu
				485					490					495	
Leu	Lys	Leu	Arg	Arg	Gln	Val	Lys	Glu	Lys	Met	Lys	Glu	Phe	Pro	Pro
			500					505					510		
Asp	Ser	Pro	Glu	Tyr	Arg	Leu	Tyr	Asp	Glu	Arg	Gln	Lys	Ala	Leu	Lys
		515					520					525			
Val	Leu	Ala	Asn	Ala	Ser	Tyr	Gly	Tyr	Met	Gly	Trp	Ser	His	Ala	Arg
		530				535					540				
Trp	Tyr	Cys	Lys	Arg	Cys	Ala	Glu	Ala	Val	Thr	Ala	Trp	Gly	Arg	Asn
545					550					555					560
Leu	Ile	Leu	Thr	Ala	Ile	Glu	Tyr	Ala	Arg	Lys	Leu	Gly	Leu	Lys	Val
				565					570					575	
Ile	Tyr	Gly	Asp	Thr	Asp	Ser	Leu	Phe	Val	Val	Tyr	Asp	Lys	Glu	Lys
			580					585					590		
Val	Glu	Lys	Leu	Ile	Glu	Phe	Val	Glu	Lys	Glu	Leu	Gly	Phe	Glu	Ile
		595					600					605			
Lys	Ile	Asp	Lys	I											

-continued

Ile Thr Lys Leu Ile Ile Trp Lys Thr Leu Ser Lys Arg Ile Glu Glu
 690 695 700
 Tyr Glu His Asp Ala Pro His Val Met Ala Ala Arg Arg Met Lys Glu
 705 710 715 720
 Ala Gly Tyr Glu Val Ser Pro Gly Asp Lys Val Gly Tyr Val Ile Val
 725 730 735
 Lys Gly Ser Gly Ser Val Ser Ser Arg Ala Tyr Pro Tyr Phe Met Val
 740 745 750
 Asp Pro Ser Thr Ile Asp Val Asn Tyr Tyr Ile Asp His Gln Ile Val
 755 760 765
 Pro Ala Ala Leu Arg Ile Leu Ser Tyr Phe Gly Val Thr Glu Lys Gln
 770 775 780
 Leu Lys Ala Ala Ala Thr Val Gln Arg Ser Leu Phe Asp Phe Phe Ala
 785 790 795 800
 Ser Lys Lys

<210> SEQ ID NO 98
 <211> LENGTH: 784
 <212> TYPE: PRT
 <213> ORGANISM: Aeropyrum pernix

<400> SEQUENCE: 98

Met Arg Gly Ser Thr Pro Val Ile Ile Leu Trp Gly Arg Gly Ala Asp
 1 5 10 15
 Gly Ser Arg Val Val Val Phe Tyr Gly Glu Phe Arg Pro Tyr Phe Tyr
 20 25 30
 Val Leu Pro Asp Gly Ser Val Gly Leu Asp Gln Leu Ala Ala Met Ile
 35 40 45
 Arg Arg Leu Ser Arg Pro Ser Ser Pro Ile Leu Ser Val Glu Arg Val
 50 55 60
 Arg Arg Arg Phe Ile Gly Arg Glu Val Glu Ala Leu Lys Val Thr Thr
 65 70 75 80
 Leu Val Pro Ala Ser Val Arg Glu Tyr Arg Glu Ala Val Arg Arg Leu
 85 90 95
 Gly Gly Val Arg Asp Val Leu Glu Ala Asp Ile Pro Phe Ala Leu Arg
 100 105 110
 Phe Ile Ile Asp Phe Asn Leu Tyr Pro Met Arg Trp Tyr Val Ala Glu
 115 120 125
 Val Arg Glu Val Ala Val Pro His Gly Tyr Ser Val Asp Arg Ala Tyr
 130 135 140
 Thr Leu Ser Gly Asp Ile Arg Glu Asp Glu Thr Arg Ile Gln Glu Asp
 145 150 155 160
 Pro Leu Lys Gly Leu Arg Val Met Ala Phe Asp Ile Glu Val Tyr Ser
 165 170 175
 Lys Met Arg Thr Pro Asp Pro Lys Lys Asp Pro Val Ile Met Ile Gly
 180 185 190
 Leu Gln Gln Ala Gly Gly Glu Ile Glu Ile Leu Glu Ala Glu Asp Arg
 195 200 205
 Ser Asp Lys Lys Val Ile Ala Gly Phe Val Glu Arg Val Lys Ser Ile
 210 215 220
 Asp Pro Asp Val Ile Val Gly Tyr Asn Gln Asn Arg Phe Asp Trp Pro
 225 230 235 240
 Tyr Leu Val Glu Arg Ala Arg Val Leu Gly Val Lys Leu Ala Val Gly
 245 250 255

-continued

Arg	Arg	Ser	Val	Glu	Pro	Gln	Pro	Gly	Leu	Tyr	Gly	His	Tyr	Ser	Val
			260					265					270		
Ser	Gly	Arg	Leu	Asn	Val	Asp	Leu	Leu	Asp	Phe	Ala	Glu	Glu	Leu	His
	275						280					285			
Glu	Val	Lys	Val	Lys	Thr	Leu	Glu	Glu	Val	Ala	Asp	Tyr	Leu	Gly	Val
	290					295					300				
Val	Lys	Ile	Gly	Glu	Arg	Val	Thr	Leu	Glu	Trp	Trp	Gln	Ile	Gly	Glu
305					310					315					320
Tyr	Trp	Asp	Asp	Pro	Ser	Lys	Arg	Glu	Ile	Leu	Arg	Lys	Tyr	Leu	Arg
				325					330					335	
Asp	Asp	Val	Arg	Ser	Thr	Met	Gly	Leu	Ala	Glu	Lys	Phe	Leu	Pro	Phe
			340					345					350		
Gly	Ala	Glu	Leu	Ser	Gln	Val	Ser	Gly	Leu	Pro	Leu	Asp	Gln	Val	Met
	355						360					365			
Ala	Ala	Ser	Val	Gly	Phe	Arg	Leu	Glu	Trp	Arg	Leu	Ile	Arg	Glu	Ala
	370					375					380				
Ala	Lys	Leu	Gly	Glu	Leu	Val	Pro	Asn	Arg	Val	Glu	Arg	Ser	Glu	Gly
385					390					395					400
Arg	Tyr	Ala	Gly	Ala	Ile	Val	Leu	Arg	Pro	Lys	Pro	Gly	Val	His	Glu
			405						410					415	
Asp	Ile	Ala	Val	Leu	Asp	Phe	Ala	Ser	Met	Tyr	Pro	Asn	Ile	Met	Val
		420					425						430		
Lys	Tyr	Asn	Val	Gly	Pro	Asp	Thr	Leu	Val	Arg	Pro	Gly	Glu	Glu	Tyr
	435					440						445			
Gly	Glu	Glu	Glu	Val	Tyr	Thr	Ala	Pro	Glu	Val	Gly	His	Lys	Phe	Arg
	450					455					460				
Lys	Ser	Pro	Pro	Gly	Phe	Lys	Lys	Ile	Leu	Glu	Arg	Phe	Leu	Ser	
465				470					475					480	
Trp	Arg	Arg	Gln	Ile	Arg	Ser	Glu	Met	Lys	Lys	His	Pro	Pro	Asp	Ser
			485						490					495	
Pro	Glu	Tyr	Lys	Leu	Leu	Asp	Glu	Arg	Gln	Lys	Ala	Ile	Lys	Leu	Leu
			500				505						510		
Ala	Asn	Ala	Ser	Tyr	Gly	Tyr	Met	Gly	Trp	Pro	His	Ala	Arg	Trp	Tyr
	515						520					525			
Cys	Arg	Glu	Cys	Ala	Glu	Ala	Val	Thr	Ala	Trp	Gly	Arg	Ser	Ile	Ile
	530					535					540				
Arg	Thr	Ala	Ile	Arg	Lys	Ala	Gly	Glu	Leu	Gly	Leu	Glu	Val	Ile	Tyr
545				550						555				560	
Gly	Asp	Thr	Asp	Ser	Leu	Phe	Val	Lys	Asn	Asp	Pro	Glu	Lys	Val	Glu
			565						570					575	
Arg	Leu	Ile	Arg	Phe	Val	Glu	Glu	Glu	Leu	Gly	Phe	Asp	Ile	Lys	Val
		580					585						590		
Asp	Lys	Val	Tyr	Arg	Arg	Val	Phe	Phe	Thr	Glu	Ala	Lys	Lys	Arg	Tyr
	595					600						605			
Val	Gly	Leu	Thr	Val	Asp	Gly	Lys	Ile	Asp	Val	Val	Gly	Phe	Glu	Ala
	610					615				620					
Val	Arg	Gly	Asp	Trp	Ser	Glu	Leu	Ala	Lys	Glu	Thr	Gln	Phe	Lys	Val
625				630						635				640	
Ala	Glu	Ile	Val	Leu	Lys	Thr	Gly	Ser	Val	Asp	Glu	Ala	Val	Asp	Tyr
			645						650					655	
Val	Arg	Asn	Ile	Ile	Glu	Lys	Leu	Arg	Arg	Gly	Gln	Val	Asp	Met	Arg
		660						665					670		
Lys	Leu	Val	Ile	Trp	Lys	Thr	Leu	Thr	Arg	Pro	Pro	Ser	Met	Tyr	Glu
		675					680						685		

-continued

Ala Arg Gln Pro His Val Thr Ala Ala Leu Leu Met Glu Arg Ala Gly
690 695 700

Ile Lys Val Glu Pro Gly Ala Lys Ile Gly Tyr Val Val Thr Lys Gly
705 710 715 720

Ser Gly Pro Leu Tyr Thr Arg Ala Lys Pro Tyr Phe Met Ala Ser Lys
725 730 735

Glu Glu Val Asp Val Glu Tyr Tyr Val Asp Lys Gln Val Val Pro Ala
740 745 750

Ala Leu Arg Ile Leu Gln Tyr Phe Gly Val Thr Glu Lys Arg Leu Lys
755 760 765

Gly Gly Gly Arg Gln Ser Thr Leu Leu Asp Phe Met Arg Arg Gly Lys
770 775 780

<210> SEQ ID NO 99
 <211> LENGTH: 781
 <212> TYPE: PRT
 <213> ORGANISM: Archaeoglobus fulgidus

<400> SEQUENCE: 99

Met Glu Arg Val Glu Gly Trp Leu Ile Asp Ala Asp Tyr Glu Thr Ile
1 5 10 15

Gly Gly Lys Ala Val Val Arg Leu Trp Cys Lys Asp Asp Gln Gly Ile
20 25 30

Phe Val Ala Tyr Asp Tyr Asn Phe Asp Pro Tyr Phe Tyr Val Ile Gly
35 40 45

Val Asp Glu Asp Ile Leu Lys Asn Ala Ala Thr Ser Thr Arg Arg Glu
50 55 60

Val Ile Lys Leu Lys Ser Phe Glu Lys Ala Gln Leu Lys Thr Leu Gly
65 70 75 80

Arg Glu Val Glu Gly Tyr Ile Val Tyr Ala His His Pro Gln His Val
85 90 95

Pro Lys Leu Arg Asp Tyr Leu Ser Gln Phe Gly Asp Val Arg Glu Ala
100 105 110

Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala Cys
115 120 125

Met Asp Gly Ile Ala Ile Glu Gly Glu Lys Gln Gly Gly Val Ile Arg
130 135 140

Ser Tyr Lys Ile Glu Lys Val Glu Arg Ile Pro Arg Met Glu Phe Pro
145 150 155 160

Glu Leu Lys Met Leu Val Phe Asp Cys Glu Met Leu Ser Ser Phe Gly
165 170 175

Met Pro Glu Pro Glu Lys Asp Pro Ile Ile Val Ile Ser Val Lys Thr
180 185 190

Asn Asp Asp Asp Glu Ile Ile Leu Thr Gly Asp Glu Arg Lys Ile Ile
195 200 205

Ser Asp Phe Val Lys Leu Ile Lys Ser Tyr Asp Pro Asp Ile Ile Val
210 215 220

Gly Tyr Asn Gln Asp Ala Phe Asp Trp Pro Tyr Leu Arg Lys Arg Ala
225 230 235 240

Glu Arg Trp Asn Ile Pro Leu Asp Val Gly Arg Asp Gly Ser Asn Val
245 250 255

Val Phe Arg Gly Gly Arg Pro Lys Ile Thr Gly Arg Leu Asn Val Asp
260 265 270

Leu Tyr Asp Ile Ala Met Arg Ile Ser Asp Ile Lys Ile Lys Lys Leu
275 280 285

-continued

Glu Asn Val Ala Glu Phe Leu Gly Thr Lys Ile Glu Ile Ala Asp Ile
 290 295 300
 Glu Ala Lys Asp Ile Tyr Arg Tyr Trp Ser Arg Gly Glu Lys Glu Lys
 305 310 315 320
 Val Leu Asn Tyr Ala Arg Gln Asp Ala Ile Asn Thr Tyr Leu Ile Ala
 325 330 335
 Lys Glu Leu Leu Pro Met His Tyr Glu Leu Ser Lys Met Ile Arg Leu
 340 345 350
 Pro Val Asp Asp Val Thr Arg Met Gly Arg Gly Lys Gln Val Asp Trp
 355 360 365
 Leu Leu Leu Ser Glu Ala Lys Lys Ile Gly Glu Ile Ala Pro Asn Pro
 370 375 380
 Pro Glu His Ala Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Glu
 385 390 395 400
 Arg Gly Leu His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr
 405 410 415
 Pro Ser Ile Met Ile Ala Phe Asn Ile Ser Pro Asp Thr Tyr Gly Cys
 420 425 430
 Arg Asp Asp Cys Tyr Glu Ala Pro Glu Val Gly His Lys Phe Arg Lys
 435 440 445
 Ser Pro Asp Gly Phe Phe Lys Arg Ile Leu Arg Met Leu Ile Glu Lys
 450 455 460
 Arg Arg Glu Leu Lys Val Glu Leu Lys Asn Leu Ser Pro Glu Ser Ser
 465 470 475 480
 Glu Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr
 485 490 495
 Asn Ser Phe Tyr Gly Tyr Met Gly Trp Asn Leu Ala Arg Trp Tyr Cys
 500 505 510
 His Pro Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Phe Ile Arg
 515 520 525
 Thr Ser Ala Lys Ile Ala Glu Ser Met Gly Phe Lys Val Leu Tyr Gly
 530 535 540
 Asp Thr Asp Ser Ile Phe Val Thr Lys Ala Gly Met Thr Lys Glu Asp
 545 550 555 560
 Val Asp Arg Leu Ile Asp Lys Leu His Glu Glu Leu Pro Ile Gln Ile
 565 570 575
 Glu Val Asp Glu Tyr Tyr Ser Ala Ile Phe Phe Val Glu Lys Lys Arg
 580 585 590
 Tyr Ala Gly Leu Thr Glu Asp Gly Arg Leu Val Val Lys Gly Leu Glu
 595 600 605
 Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Lys Val Gln Arg Glu
 610 615 620
 Val Ile Glu Val Ile Leu Lys Glu Lys Asn Pro Glu Lys Ala Leu Ser
 625 630 635 640
 Leu Val Lys Asp Val Ile Leu Arg Ile Lys Glu Gly Lys Val Ser Leu
 645 650 655
 Glu Glu Val Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro Ser Lys Tyr
 660 665 670
 Glu Ser Met Gln Ala His Val Lys Ala Ala Leu Lys Ala Arg Glu Met
 675 680 685
 Gly Ile Ile Tyr Pro Val Ser Ser Lys Ile Gly Tyr Val Ile Val Lys
 690 695 700
 Gly Ser Gly Asn Ile Gly Asp Arg Ala Tyr Pro Ile Asp Leu Ile Glu

-continued

705	710	715	720
Asp Phe Asp Gly Glu Asn Leu Arg Ile Lys Thr Lys Ser Gly Ile Glu	725	730	735
Ile Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asp Asn Gln Ile Ile Pro	740	745	750
Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu Ala Ser Leu	755	760	765
Lys Gly Ser Ser Gln Met Ser Leu Asp Ser Phe Phe Ser	770	775	780

<210> SEQ ID NO 100

<211> LENGTH: 773

<212> TYPE: PRT

<213> ORGANISM: Desulfurococcus saccharovorans

<400> SEQUENCE: 100

Met Ile Leu Asp Ala Asp Tyr Ile Thr Glu Asp Gly Lys Pro Val Ile	1	5	10	15
Arg Val Phe Lys Lys Glu Lys Gly Glu Phe Lys Ile Asp Tyr Asp Arg	20	25	30	
Asp Phe Glu Pro Tyr Ile Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile	35	40	45	
Glu Asp Ile Lys Lys Ile Thr Ala Glu Arg His Gly Thr Thr Val Arg	50	55	60	
Val Thr Arg Ala Glu Arg Val Lys Lys Lys Phe Leu Gly Arg Pro Val	65	70	75	80
Glu Val Trp Lys Leu Tyr Phe Thr His Pro Gln Asp Val Pro Ala Ile	85	90	95	
Arg Asp Lys Ile Arg Glu His Pro Ala Val Val Asp Ile Tyr Glu Tyr	100	105	110	
Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Arg Gly Leu Ile Pro	115	120	125	
Met Glu Gly Asp Glu Glu Leu Arg Met Leu Ala Phe Asp Ile Glu Thr	130	135	140	
Leu Tyr His Glu Gly Glu Glu Phe Gly Glu Gly Pro Ile Leu Met Ile	145	150	155	160
Ser Tyr Ala Asp Glu Glu Gly Ala Arg Val Ile Thr Trp Lys Asn Ile	165	170	175	
Asp Leu Pro Tyr Val Glu Ser Val Ser Thr Glu Lys Glu Met Ile Lys	180	185	190	
Arg Phe Leu Lys Val Ile Gln Glu Lys Asp Pro Asp Val Leu Ile Thr	195	200	205	
Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Ser Glu	210	215	220	
Met Leu Gly Val Lys Phe Ile Leu Gly Arg Asp Gly Ser Glu Pro Lys	225	230	235	240
Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile	245	250	255	
His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr	260	265	270	
Tyr Thr Leu Glu Thr Val Tyr Glu Pro Val Phe Gly Gln Pro Lys Glu	275	280	285	
Lys Val Tyr Ala Glu Glu Ile Ala Arg Ala Trp Glu Ser Gly Glu Gly	290	295	300	
Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Ala Thr Tyr				

-continued

305	310	315	320
Glu Leu Gly Lys	Glu Phe Phe Pro Met	Glu Ala Gln Leu Ser Arg	Leu
	325	330	335
Val Gly Gln Ser	Leu Trp Asp Val Ser Arg Ser Ser Thr Gly Asn Leu		
	340	345	350
Val Glu Trp Phe	Leu Leu Arg Lys Ala Tyr Glu Arg Asn Asp Val Ala		
	355	360	365
Pro Asn Lys Pro Asp	Glu Arg Glu Leu Ala Arg Arg Thr Glu Ser Tyr		
	370	375	380
Ala Gly Gly Tyr	Val Lys Glu Pro Glu Lys Gly Leu Trp Glu Asn Ile		
	385	390	395
Val Tyr Leu Asp	Tyr Lys Ser Leu Tyr Pro Ser Ile Ile Ile Thr His		
	405	410	415
Asn Val Ser Pro Asp	Thr Leu Asn Arg Glu Gly Cys Arg Glu Tyr Asp		
	420	425	430
Val Ala Pro Gln	Val Gly His Arg Phe Cys Lys Asp Phe Pro Gly Phe		
	435	440	445
Ile Pro Ser Leu	Leu Gly Asp Leu Leu Glu Glu Arg Gln Lys Val Lys		
	450	455	460
Lys Lys Met Lys	Ala Thr Val Asp Pro Ile Glu Arg Lys Leu Leu Asp		
	465	470	475
Tyr Arg Gln Arg	Ala Ile Lys Ile Leu Ala Asn Ser Tyr Tyr Gly Tyr		
	485	490	495
Tyr Ala Tyr Ala	Asn Ala Arg Trp Tyr Cys Arg Glu Cys Ala Glu Ser		
	500	505	510
Val Thr Ala Trp	Gly Arg Gln Tyr Ile Glu Thr Thr Met Arg Glu Ile		
	515	520	525
Glu Glu Lys Phe	Gly Phe Lys Val Leu Tyr Ala Asp Thr Asp Gly Phe		
	530	535	540
Phe Ala Thr Ile	Pro Gly Ala Asp Ala Glu Thr Val Lys Asn Lys Ala		
	545	550	555
Lys Glu Phe Leu	Asn Tyr Ile Asn Pro Arg Leu Pro Gly Leu Leu Glu		
	565	570	575
Leu Glu Tyr Glu	Gly Phe Tyr Arg Arg Gly Phe Phe Val Thr Lys Lys		
	580	585	590
Lys Tyr Ala Val	Ile Asp Glu Glu Asp Lys Ile Thr Thr Arg Gly Leu		
	595	600	605
Glu Ile Val Arg	Arg Asp Trp Ser Glu Ile Ala Lys Glu Thr Gln Ala		
	610	615	620
Arg Val Leu Glu	Ala Ile Leu Lys His Gly Asp Val Glu Glu Ala Val		
	625	630	635
Arg Ile Val Lys	Glu Val Thr Glu Lys Leu Ser Arg His Glu Val Pro		
	645	650	655
Pro Glu Lys Leu	Val Ile Tyr Glu Gln Ile Thr Arg Asp Leu Arg Ser		
	660	665	670
Tyr Arg Ala Thr	Gly Pro His Val Ala Val Ala Lys Arg Leu Ala Ala		
	675	680	685
Arg Gly Ile Lys	Ile Arg Pro Gly Thr Val Ile Ser Tyr Ile Val Leu		
	690	695	700
Lys Gly Pro Gly	Arg Val Gly Asp Arg Ala Ile Pro Phe Asp Glu Phe		
	705	710	715
Asp Pro Ala Lys	His Arg Tyr Asp Ala Glu Tyr Tyr Ile Glu Asn Gln		
	725	730	735

-continued

Val Leu Pro Ala Val Glu Arg Ile Leu Arg Ala Phe Gly Tyr Arg Lys
740 745 750

Glu Asp Leu Arg Tyr Gln Lys Thr Lys Gln Ala Gly Leu Gly Ala Trp
755 760 765

Leu Lys Pro Lys Thr
770

<210> SEQ ID NO 101

<211> LENGTH: 775

<212> TYPE: PRT

<213> ORGANISM: Thermococcus sp.

<400> SEQUENCE: 101

Met Ile Leu Asp Thr Asp Tyr Ile Thr Glu Asn Gly Lys Pro Val Ile
1 5 10 15

Arg Val Phe Lys Lys Glu Asn Gly Glu Phe Lys Ile Glu Tyr Asp Arg
20 25 30

Thr Phe Glu Pro Tyr Phe Tyr Ala Leu Leu Lys Asp Asp Ser Ala Ile
35 40 45

Glu Asp Val Lys Lys Val Thr Ala Lys Arg His Gly Thr Val Val Lys
50 55 60

Val Lys Arg Ala Glu Lys Val Gln Lys Lys Phe Leu Gly Arg Pro Ile
65 70 75 80

Glu Val Trp Lys Leu Tyr Phe Asn His Pro Gln Asp Val Pro Ala Ile
85 90 95

Arg Asp Arg Ile Arg Ala His Pro Ala Val Val Asp Ile Tyr Glu Tyr
100 105 110

Asp Ile Pro Phe Ala Lys Arg Tyr Leu Ile Asp Lys Gly Leu Ile Pro
115 120 125

Met Glu Gly Asp Glu Glu Leu Thr Met Leu Ala Phe Asp Ile Glu Thr
130 135 140

Leu Tyr His Glu Gly Glu Glu Phe Gly Thr Gly Pro Ile Leu Met Ile
145 150 155 160

Ser Tyr Ala Asp Gly Ser Glu Ala Arg Val Ile Thr Trp Lys Lys Ile
165 170 175

Asp Leu Pro Tyr Val Asp Val Val Ser Thr Glu Lys Glu Met Ile Lys
180 185 190

Arg Phe Leu Arg Val Val Arg Glu Lys Asp Pro Asp Val Leu Ile Thr
195 200 205

Tyr Asn Gly Asp Asn Phe Asp Phe Ala Tyr Leu Lys Lys Arg Cys Glu
210 215 220

Glu Leu Gly Ile Lys Phe Thr Leu Gly Arg Asp Gly Ser Glu Pro Lys
225 230 235 240

Ile Gln Arg Met Gly Asp Arg Phe Ala Val Glu Val Lys Gly Arg Ile
245 250 255

His Phe Asp Leu Tyr Pro Val Ile Arg Arg Thr Ile Asn Leu Pro Thr
260 265 270

Tyr Thr Leu Glu Ala Val Tyr Glu Ala Val Phe Gly Lys Pro Lys Glu
275 280 285

Lys Val Tyr Ala Glu Glu Ile Ala Gln Ala Trp Glu Ser Gly Glu Gly
290 295 300

Leu Glu Arg Val Ala Arg Tyr Ser Met Glu Asp Ala Lys Val Thr Tyr
305 310 315 320

Glu Leu Gly Arg Glu Phe Phe Pro Met Glu Ala Gln Leu Ser Arg Leu
325 330 335

Ile	Gly	Gln	Ser	Leu	Trp	Asp	Val	Ser	Arg	Ser	Ser	Thr	Gly	Asn	Leu	
			340					345					350			
Val	Glu	Trp	Phe	Leu	Leu	Arg	Lys	Ala	Tyr	Lys	Arg	Asn	Glu	Leu	Ala	
		355					360					365				
Pro	Asn	Lys	Pro	Asp	Glu	Arg	Glu	Leu	Ala	Arg	Arg	Arg	Gly	Gly	Tyr	
		370				375					380					
Ala	Gly	Gly	Tyr	Val	Lys	Glu	Pro	Glu	Arg	Gly	Leu	Trp	Asp	Asn	Ile	
					390					395					400	
Val	Tyr	Leu	Asp	Phe	Arg	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Ile	Thr	His	
				405					410					415		
Asn	Val	Ser	Pro	Asp	Thr	Leu	Asn	Arg	Glu	Gly	Cys	Lys	Glu	Tyr	Asp	
			420					425					430			
Val	Ala	Pro	Glu	Val	Gly	His	Lys	Phe	Cys	Lys	Asp	Phe	Pro	Gly	Phe	
		435					440					445				
Ile	Pro	Ser	Leu	Leu	Gly	Asp	Leu	Leu	Glu	Glu	Arg	Gln	Lys	Ile	Lys	
		450				455					460					
Arg	Lys	Met	Lys	Ala	Thr	Val	Asp	Pro	Leu	Glu	Lys	Lys	Leu	Leu	Asp	
					470					475					480	
Tyr	Arg	Gln	Arg	Ala	Ile	Lys	Ile	Leu	Ala	Asn	Ser	Phe	Tyr	Gly	Tyr	
				485					490					495		
Tyr	Gly	Tyr	Ala	Lys	Ala	Arg	Trp	Tyr	Cys	Lys	Glu	Cys	Ala	Glu	Ser	
			500					505					510			
Val	Thr	Ala	Trp	Gly	Arg	Glu	Tyr	Ile	Glu	Met	Val	Ile	Arg	Glu	Leu	
			515				520					525				
Glu	Glu	Lys	Phe	Gly	Phe	Lys	Val	Leu	Tyr	Ala	Asp	Thr	Asp	Gly	Leu	
		530				535					540					
His	Ala	Thr	Ile	Pro	Gly	Ala	Asp	Ala	Glu	Thr	Val	Lys	Lys	Lys	Ala	
					550					555					560	
Lys	Glu	Phe	Leu	Lys	Tyr	Ile	Asn	Pro	Lys	Leu	Pro	Gly	Leu	Leu	Glu	
				565					570					575		
Leu	Glu	Tyr	Glu	Gly	Phe	Tyr	Val	Arg	Gly	Phe	Phe	Val	Thr	Lys	Lys	
			580					585					590			
Lys	Tyr	Ala	Val	Ile	Asp	Glu	Glu	Gly	Lys	Ile	Thr	Thr	Arg	Gly	Leu	
		595					600					605				
Glu	Ile	Val	Arg	Arg	Asp	Trp	Ser	Glu	Ile	Ala	Lys	Glu	Thr	Gln	Ala	
						615					620					
Arg	Val	Leu	Glu	Ala	Ile	Leu	Lys	His	Gly	Asp	Val	Glu	Glu	Ala	Val	
					630					635					640	
Arg	Ile	Val	Lys	Glu	Val	Thr	Glu	Lys	Leu	Ser	Lys	Tyr	Glu	Val	Pro	
			645						650					655		
Pro	Glu	Lys	Leu	Val	Ile	His	Glu	Gln	Ile	Thr	Arg	Asp	Leu	Arg	Asp	
			660					665					670			
Tyr	Lys	Ala	Thr	Gly	Pro	His	Val	Ala	Val							

-continued

Leu Lys Val Lys Gly Lys Lys
770 775

<210> SEQ ID NO 102
<211> LENGTH: 781
<212> TYPE: PRT
<213> ORGANISM: Archaeoglobus fulgidus

<400> SEQUENCE: 102

Met Glu Arg Val Glu Gly Trp Leu Ile Asp Ala Asp Tyr Glu Thr Ile
1 5 10 15
Gly Gly Lys Ala Val Val Arg Leu Trp Cys Lys Asp Asp Gln Gly Ile
20 25 30
Phe Val Ala Tyr Asp Tyr Asn Phe Asp Pro Tyr Phe Tyr Val Ile Gly
35 40 45
Val Asp Glu Asp Ile Leu Lys Asn Ala Ala Thr Ser Thr Arg Arg Glu
50 55 60
Val Ile Lys Leu Lys Ser Phe Glu Lys Ala Gln Leu Lys Thr Leu Gly
65 70 75 80
Arg Glu Val Glu Gly Tyr Ile Val Tyr Ala His His Pro Gln His Val
85 90 95
Pro Lys Leu Arg Asp Tyr Leu Ser Gln Phe Gly Asp Val Arg Glu Ala
100 105 110
Asp Ile Pro Phe Ala Tyr Arg Tyr Leu Ile Asp Lys Asp Leu Ala Cys
115 120 125
Met Asp Gly Ile Ala Ile Glu Gly Glu Lys Gln Gly Gly Val Ile Arg
130 135 140
Ser Tyr Lys Ile Glu Lys Val Glu Arg Ile Pro Arg Met Glu Phe Pro
145 150 155 160
Glu Leu Lys Met Leu Val Phe Asp Cys Glu Met Leu Ser Ser Phe Gly
165 170 175
Met Pro Glu Pro Glu Lys Asp Pro Ile Ile Val Ile Ser Val Lys Thr
180 185 190
Asn Asp Asp Asp Glu Ile Ile Leu Thr Gly Asp Glu Arg Lys Ile Ile
195 200 205
Ser Asp Phe Val Lys Leu Ile Lys Ser Tyr Asp Pro Asp Ile Ile Val
210 215 220
Gly Tyr Asn Gln Asp Ala Phe Asp Trp Pro Tyr Leu Arg Lys Arg Ala
225 230 235 240
Glu Arg Trp Asn Ile Pro Leu Asp Val Gly Arg Asp Gly Ser Asn Val
245 250 255
Val Phe Arg Gly Gly Arg Pro Lys Ile Thr Gly Arg Leu Asn Val Asp
260 265 270
Leu Tyr Asp Ile Ala Met Arg Ile Ser Asp Ile Lys Ile Lys Lys Leu
275 280 285
Glu Asn Val Ala Glu Phe Leu Gly Thr Lys Ile Glu Ile Ala Asp Ile
290 295 300
Glu Ala Lys Asp Ile Tyr Arg Tyr Trp Ser Arg Gly Glu Lys Glu Lys
305 310 315 320
Val Leu Asn Tyr Ala Arg Gln Asp Ala Ile Asn Thr Tyr Leu Ile Ala
325 330 335
Lys Glu Leu Leu Pro Met His Tyr Glu Leu Ser Lys Met Ile Arg Leu
340 345 350
Pro Val Asp Asp Val Thr Arg Met Gly Arg Gly Lys Gln Val Asp Trp
355 360 365

-continued

Leu Leu Leu Ser Glu Ala Lys Lys Ile Gly Glu Ile Ala Pro Asn Pro
 370 375 380
 Pro Glu His Ala Glu Ser Tyr Glu Gly Ala Phe Val Leu Glu Pro Glu
 385 390 395 400
 Arg Gly Leu His Glu Asn Val Ala Cys Leu Asp Phe Ala Ser Met Tyr
 405 410 415
 Pro Ser Ile Met Ile Ala Phe Asn Ile Ser Pro Asp Thr Tyr Gly Cys
 420 425 430
 Arg Asp Asp Cys Tyr Glu Ala Pro Glu Val Gly His Lys Phe Arg Lys
 435 440 445
 Ser Pro Asp Gly Phe Phe Lys Arg Ile Leu Arg Met Leu Ile Glu Lys
 450 455 460
 Arg Arg Glu Leu Lys Val Glu Leu Lys Asn Leu Ser Pro Glu Ser Ser
 465 470 475 480
 Glu Tyr Lys Leu Leu Asp Ile Lys Gln Gln Thr Leu Lys Val Leu Thr
 485 490 495
 Asn Ser Phe Tyr Gly Tyr Met Gly Trp Asn Leu Ala Arg Trp Tyr Cys
 500 505 510
 His Pro Cys Ala Glu Ala Thr Thr Ala Trp Gly Arg His Phe Ile Arg
 515 520 525
 Thr Ser Ala Lys Ile Ala Glu Ser Met Gly Phe Lys Val Leu Tyr Gly
 530 535 540
 Asp Thr Asp Ser Ile Phe Val Thr Lys Ala Gly Met Thr Lys Glu Asp
 545 550 555 560
 Val Asp Arg Leu Ile Asp Lys Leu His Glu Glu Leu Pro Ile Gln Ile
 565 570 575
 Glu Val Asp Glu Tyr Tyr Ser Ala Ile Phe Phe Val Glu Lys Lys Arg
 580 585 590
 Tyr Ala Gly Leu Thr Glu Asp Gly Arg Leu Val Val Lys Gly Leu Glu
 595 600 605
 Val Arg Arg Gly Asp Trp Cys Glu Leu Ala Lys Lys Val Gln Arg Glu
 610 615 620
 Val Ile Glu Val Ile Leu Lys Glu Lys Asn Pro Glu Lys Ala Leu Ser
 625 630 635 640
 Leu Val Lys Asp Val Ile Leu Arg Ile Lys Glu Gly Lys Val Ser Leu
 645 650 655
 Glu Glu Val Val Ile Tyr Lys Gly Leu Thr Lys Lys Pro Ser Lys Tyr
 660 665 670
 Glu Ser Met Gln Ala His Val Lys Ala Ala Leu Lys Ala Arg Glu Met
 675 680 685
 Gly Ile Ile Tyr Pro Val Ser Ser Lys Ile Gly Tyr Val Ile Val Lys
 690 695 700
 Gly Ser Gly Asn Ile Gly Asp Arg Ala Tyr Pro Ile Asp Leu Ile Glu
 705 710 715 720
 Asp Phe Asp Gly Glu Asn Leu Arg Ile Lys Thr Lys Ser Gly Ile Glu
 725 730 735
 Ile Lys Lys Leu Asp Lys Asp Tyr Tyr Ile Asp Asn Gln Ile Ile Pro
 740 745 750
 Ser Val Leu Arg Ile Leu Glu Arg Phe Gly Tyr Thr Glu Ala Ser Leu
 755 760 765
 Lys Gly Ser Ser Gln Met Ser Leu Asp Ser Phe Phe Ser
 770 775 780

-continued

```

<210> SEQ ID NO 103
<211> LENGTH: 824
<212> TYPE: PRT
<213> ORGANISM: Methanococcus voltae

<400> SEQUENCE: 103

Met Asp Leu Asp Tyr Asn Ser Lys Asp Leu Cys Ile Asp Met Tyr Tyr
1          5          10          15

Lys Asn Cys Gly Leu Lys Lys Pro Glu Ile Asn Leu Gln Lys Glu Cys
20          25          30

Glu Phe Lys Pro Tyr Phe Tyr Val Asp Thr Ser Glu Pro Lys Glu Ile
35          40          45

Tyr Asp Tyr Leu Asp Gly Leu Asn Gln Glu Ile Asp Leu Lys Lys Leu
50          55          60

Glu Pro Glu Phe Glu Asn Asn Thr Ser Leu Lys Val Gln Asp Leu Ile
65          70          75          80

Thr Asn Ile Glu Ile Ile Glu Lys Ile Val Tyr Ser Asp Tyr Ile Leu
85          90          95

Asn Gly Lys Asp Ile Ser Glu Val Ser Asp Phe Lys Asn Lys Lys Glu
100         105         110

Arg Lys Ile Cys Lys Val Tyr Val Lys Tyr Pro Asn His Val Lys Ile
115         120         125

Ile Arg Glu Tyr Phe Lys Glu Phe Gly Lys Ser Tyr Glu Phe Asp Ile
130         135         140

Pro Phe Leu Arg Arg Tyr Met Ile Asp Gln Asp Ile Val Pro Ser Ala
145         150         155         160

Lys Tyr Ser Glu Asp Asn Lys Ile Asp Asn Ser Ile Pro Glu Leu Asn
165         170         175

Cys Ile Ala Phe Asp Met Glu Leu Tyr Cys Lys Lys Glu Pro Asn Ala
180         185         190

Lys Lys Asp Pro Ile Ile Met Val Asn Leu Phe Ser Lys Asp Tyr Gln
195         200         205

Lys Val Ile Thr Tyr Lys Lys Phe Glu Asn Ser Glu Tyr Asn Gly Cys
210         215         220

Val Asp Tyr Val Lys Asp Glu Lys Glu Leu Ile Gln Lys Thr Ile Glu
225         230         235         240

Ile Leu Lys Gln Tyr Asp Val Ile Tyr Thr Tyr Asn Gly Asp Asn Phe
245         250         255

Asp Phe Pro Tyr Leu Lys Lys Arg Ala Asn Ile Tyr Glu Ile Glu Leu
260         265         270

Asp Phe Asp Asn Ala Ser Asn Ser Gln Gln Pro Gln Ile Ile Lys Ile
275         280         285

Ser Lys Gly Gly Ile Asn Arg Lys Ser Lys Ile Pro Gly Ile Ile His
290         295         300

Ile Asp Leu Tyr Pro Ile Ala Arg Lys Leu Leu Asn Leu Thr Lys Tyr
305         310         315         320

Lys Leu Glu Asn Val Val Gln Glu Leu Phe Lys Ile Asn Lys Glu Ala
325         330         335

Val Asp Tyr Gly Asp Ile Pro Lys Met Trp Glu Thr Glu Asp Thr Thr
340         345         350

Leu Leu Arg Tyr Ala Tyr Glu Asp Ala Leu Tyr Thr Tyr Lys Met Gly
355         360         365

Asn Tyr Phe Leu Pro Leu Glu Ile Met Phe Ser Arg Ile Val Asn Gln
370         375         380

Pro Leu Tyr Asp Thr Ser Arg Met Asn Ser Ser Gln Met Val Glu Phe

```

-continued

385	390	395	400
Leu Leu Leu Lys Arg Ser Phe Glu Gln Asn Met Ile Ser Pro Asn Arg	405	410	415
Pro Ser Ser Ser Ser Tyr Arg Glu Arg Ala Lys Phe Ser Tyr Glu Gly	420	425	430
Gly Tyr Val Arg Glu Pro Leu Lys Gly Ile Gln Glu Asp Ile Val Ser	435	440	445
Leu Asp Phe Met Ser Leu Tyr Pro Ser Ile Leu Ile Ser His Asn Ile	450	455	460
Ser Pro Glu Thr Val Ile Tyr Glu Glu Lys Glu Arg Glu Asn Met Glu	465	470	475
Leu Gly Ile Ile Pro Lys Thr Leu Asn Glu Leu Leu Ser Arg Arg Lys	485	490	495
His Ile Lys Met Leu Leu Lys Asp Lys Ile Gln Lys Asn Glu Phe Asp	500	505	510
Glu Glu Tyr Ser Arg Leu Glu His Glu Gln Lys Ser Ile Lys Val Leu	515	520	525
Ala Asn Ser His Tyr Gly Tyr Leu Ala Phe Pro Met Ala Arg Trp Tyr	530	535	540
Ser Asp Lys Cys Ala Glu Met Val Thr Gly Leu Gly Arg Lys Tyr Ile	545	550	555
Gln Glu Thr Ile Glu Lys Ala Glu Glu Phe Gly Phe Lys Val Ile Tyr	565	570	575
Ala Asp Thr Asp Gly Phe Tyr Ala Lys Trp Asp Tyr Asp Lys Leu Gln	580	585	590
Lys Gly Lys Lys Glu Glu Asn Asp Lys Ser Asp Lys Leu Ser Asn Leu	595	600	605
Pro Lys Leu Ser Lys Glu Glu Leu Ile Ile Leu Thr Lys Lys Phe Leu	610	615	620
Lys Gly Ile Asn Glu Glu Leu Pro Glu Gly Met Glu Leu Glu Phe Glu	625	630	635
Gly His Phe Lys Arg Gly Leu Phe Val Thr Lys Lys Lys Tyr Ala Leu	645	650	655
Ile Glu Asp Asp Gly His Ile Val Val Lys Gly Leu Glu Val Val Arg	660	665	670
Arg Asp Trp Ser Asn Ile Ala Lys Asp Thr Gln Gln Ala Val Ile Arg	675	680	685
Ala Leu Leu Glu Asp Gly Asp Val Asn Leu Ala Lys Lys Ile Ile Lys	690	695	700
Asn Thr Ile Asp Asn Leu Lys Lys Gly Asn Ile Asp Lys Asn Asp Leu	705	710	715
Leu Ile His Thr Gln Leu Thr Lys Asn Ile Glu Glu Tyr Lys Ser Thr	725	730	735
Ala Pro His Ile Glu Val Ala Lys Lys Ile Lys Gln Arg Gly Asp Ser	740	745	750
Val Arg Val Gly Asp Val Ile Ser Tyr Ile Ile Val Lys Gly Ser Arg	755	760	765
Ser Ile Ser Glu Arg Ala Glu Leu Leu Glu Tyr Ala Gly Asp Tyr Asp	770	775	780
Ile Asn Tyr Tyr Ile Asp Asn Gln Val Leu Pro Val Ile Arg Ile	785	790	795
Met Glu Ser Leu Gly Ile Ser Glu Asp Glu Leu Lys Asn Ser Gly Lys	805	810	815

-continued

Gln Phe Lys Leu Asp Gln Phe Met
820

<210> SEQ ID NO 104
<211> LENGTH: 785
<212> TYPE: PRT
<213> ORGANISM: *Pyrobaculum islandicum*

<400> SEQUENCE: 104

Met Glu Leu Lys Val Trp Pro Leu Asp Ile Thr Tyr Ala Val Val Gly
1 5 10 15
Ser Val Pro Glu Ile Arg Ile Phe Gly Ile Leu Ser Ser Gly Glu Arg
20 25 30
Val Val Leu Ile Asp Arg Ser Phe Lys Pro Tyr Phe Tyr Val Asp Cys
35 40 45
Ala Val Cys Glu Pro Ala Ala Leu Lys Thr Ala Leu Ser Arg Val Ala
50 55 60
Pro Ile Asp Asp Val Gln Ile Val Glu Arg Arg Phe Leu Gly Arg Ser
65 70 75 80
Lys Lys Phe Leu Lys Val Ile Ala Lys Ile Pro Glu Asp Val Arg Lys
85 90 95
Leu Arg Glu Ala Ala Met Ser Ile Pro Arg Val Ser Gly Val Tyr Glu
100 105 110
Ala Asp Ile Arg Phe Tyr Met Arg Tyr Met Ile Asp Met Gly Val Val
115 120 125
Pro Cys Ser Trp Asn Val Ala Glu Val Glu Glu Gly Gly Arg Leu Gly
130 135 140
Gly Ile Pro Thr Tyr Val Val Ser Gln Trp Tyr Gly Ile Asp Glu Gly
145 150 155 160
Phe Pro Pro Ser Leu Lys Val Met Ala Phe Asp Ile Glu Val Tyr Asn
165 170 175
Glu Arg Gly Ser Pro Asp Pro Ile Arg Asp Pro Val Val Met Leu Ala
180 185 190
Ile Lys Thr Asn Asp Gly His Glu Glu Val Phe Glu Ala Ser Gly Lys
195 200 205
Asp Asp Arg Gly Val Val Arg Ala Phe Val Asp Phe Ile Arg Ser Tyr
210 215 220
Asp Pro Asp Val Ile Val Gly Tyr Asn Ser Asn Gly Phe Asp Trp Pro
225 230 235 240
Tyr Leu Val Glu Arg Ala Lys Ala Val Gly Val Pro Leu Lys Val Asp
245 250 255
Arg Leu Ser Asn Pro Pro Gln Gln Ser Val Tyr Gly His Trp Ser Ile
260 265 270
Val Gly Arg Ala Asn Val Asp Leu Tyr Asn Ile Val Glu Glu Phe Pro
275 280 285
Glu Ile Lys Leu Lys Thr Leu Asp Arg Val Ala Glu Tyr Phe Gly Val
290 295 300
Met Lys Arg Glu Glu Arg Val Leu Ile Pro Gly His Lys Ile Tyr Glu
305 310 315 320
Tyr Trp Lys Asp Pro Asn Lys Arg Pro Leu Leu Lys Arg Tyr Val Leu
325 330 335
Asp Asp Val Arg Ser Thr Leu Gly Leu Ala Asp Lys Leu Leu Pro Phe
340 345 350
Leu Ile Gln Leu Ser Ser Val Ser Gly Leu Pro Leu Asp Gln Val Ala
355 360 365

Ser
785

-continued

```

<210> SEQ ID NO 105
<211> LENGTH: 844
<212> TYPE: PRT
<213> ORGANISM: Cenarchaeum symbiosum

<400> SEQUENCE: 105

Met Thr Val Gln Asp Ala Val Glu Ile Pro Pro Ser Leu Leu Val Ser
1      5      10      15

Ala Thr Tyr Asp Ser Gln Ala Gly Ala Val Val Leu Lys Phe Tyr Glu
20     25     30

Pro Glu Ser Gln Lys Ile Val His Trp Thr Asp Asn Thr Gly His Lys
35     40     45

Pro Tyr Cys Tyr Thr Arg Gln Pro Pro Ser Glu Leu Gly Glu Leu Glu
50     55     60

Gly Arg Glu Asp Val Leu Gly Thr Glu Gln Val Met Arg His Asp Leu
65     70     75     80

Ile Ala Asp Lys Asp Val Pro Val Thr Lys Ile Thr Val Ala Asp Pro
85     90     95

Leu Ala Ile Gly Gly Thr Asn Ser Glu Lys Ser Ile Arg Asn Ile Met
100    105    110

Asp Thr Trp Glu Ser Asp Ile Lys Tyr Tyr Glu Asn Tyr Leu Tyr Asp
115    120    125

Lys Ser Leu Val Val Gly Arg Tyr Tyr Ser Val Ser Gly Gly Lys Val
130    135    140

Ile Pro His Asp Met Pro Ile Ser Asp Glu Val Lys Leu Ala Leu Lys
145    150    155    160

Ser Leu Leu Trp Asp Lys Val Val Asp Glu Gly Met Ala Asp Arg Lys
165    170    175

Glu Phe Arg Glu Phe Ile Ala Gly Trp Ala Asp Leu Leu Asn Gln Pro
180    185    190

Ile Pro Arg Ile Arg Arg Leu Ser Phe Asp Ile Glu Val Asp Ser Glu
195    200    205

Glu Gly Arg Ile Pro Asp Pro Lys Ile Ser Asp Arg Arg Val Thr Ala
210    215    220

Val Gly Phe Ala Ala Thr Asp Gly Leu Lys Gln Val Phe Val Leu Arg
225    230    235    240

Ser Gly Ala Glu Glu Gly Glu Asn Gly Val Thr Pro Gly Val Glu Val
245    250    255

Val Phe Tyr Asp Lys Glu Ala Asp Met Ile Arg Asp Ala Leu Ser Val
260    265    270

Ile Gly Ser Tyr Pro Phe Val Leu Thr Tyr Asn Gly Asp Asp Phe Asp
275    280    285

Met Pro Tyr Met Leu Asn Arg Ala Arg Arg Leu Gly Val Ser Asp Ser
290    295    300

Asp Ile Pro Leu Tyr Met Met Arg Asp Ser Ala Thr Leu Arg His Gly
305    310    315    320

Val His Leu Asp Leu Tyr Arg Thr Phe Ser Asn Arg Ser Phe Gln Leu
325    330    335

Tyr Ala Phe Ala Ala Lys Tyr Thr Asp Tyr Ser Leu Asn Ser Val Thr
340    345    350

Lys Ala Met Leu Gly Glu Gly Lys Val Asp Tyr Gly Val Lys Leu Gly
355    360    365

Asp Leu Thr Leu Tyr Gln Thr Ala Asn Tyr Cys Tyr His Asp Ala Arg
370    375    380

```

-continued

Leu Thr Leu Glu Leu Ser Thr Phe Gly Asn Glu Ile Leu Met Asp Leu
 385 390 395 400
 Leu Val Val Thr Ser Arg Ile Ala Arg Met Pro Ile Asp Asp Met Ser
 405 410 415
 Arg Met Gly Val Ser Gln Trp Ile Arg Ser Leu Leu Tyr Tyr Glu His
 420 425 430
 Arg Gln Arg Asn Ala Leu Ile Pro Arg Arg Asp Glu Leu Glu Gly Arg
 435 440 445
 Ser Arg Glu Val Ser Asn Asp Ala Val Ile Lys Asp Lys Lys Phe Arg
 450 455 460
 Gly Gly Leu Val Val Glu Pro Glu Glu Gly Ile His Phe Asp Val Thr
 465 470 475 480
 Val Met Asp Phe Ala Ser Leu Tyr Pro Ser Ile Ile Lys Val Arg Asn
 485 490 495
 Leu Ser Tyr Glu Thr Val Arg Cys Val His Ala Glu Cys Lys Lys Asn
 500 505 510
 Thr Ile Pro Asp Thr Asn His Trp Val Cys Thr Lys Asn Asn Gly Leu
 515 520 525
 Thr Ser Met Ile Ile Gly Ser Leu Arg Asp Leu Arg Val Asn Tyr Tyr
 530 535 540
 Lys Ser Leu Ser Lys Ser Thr Ser Ile Thr Glu Glu Gln Arg Gln Gln
 545 550 555 560
 Tyr Thr Val Ile Ser Gln Ala Leu Lys Val Val Leu Asn Ala Ser Tyr
 565 570 575
 Gly Val Met Gly Ala Glu Ile Phe Pro Leu Tyr Phe Leu Pro Ala Ala
 580 585 590
 Glu Ala Thr Thr Ala Val Gly Arg Tyr Ile Ile Met Gln Thr Ile Ser
 595 600 605
 His Cys Glu Gln Met Gly Val Arg Val Leu Tyr Gly Asp Thr Asp Ser
 610 615 620
 Leu Phe Ile Lys Asp Pro Glu Glu Arg Gln Ile His Glu Ile Val Glu
 625 630 635 640
 His Ala Lys Lys Glu His Gly Val Glu Leu Glu Val Asp Lys Glu Tyr
 645 650 655
 Arg Tyr Val Val Leu Ser Asn Arg Lys Lys Asn Tyr Phe Gly Val Thr
 660 665 670
 Arg Ala Gly Lys Val Asp Val Lys Gly Leu Thr Gly Lys Lys Ser His
 675 680 685
 Thr Pro Pro Phe Ile Lys Glu Leu Phe Tyr Ser Leu Leu Asp Ile Leu
 690 695 700
 Ser Gly Val Glu Ser Glu Asp Glu Phe Glu Ser Ala Lys Met Arg Ile
 705 710 715 720
 Ser Lys Ala Ile Ala Ala Cys Gly Lys Arg Leu Glu Glu Arg Gln Ile
 725 730 735
 Pro Leu Val Asp Leu Ala Phe Asn Val Met Ile Ser Lys Ala Pro Ser
 740 745 750
 Glu Tyr Val Lys Thr Val Pro Gln His Ile Arg Ala Ala Arg Leu Leu
 755 760 765
 Glu Asn Ala Arg Glu Val Lys Lys Gly Asp Ile Ile Ser Tyr Val Lys
 770 775 780
 Val Met Asn Lys Thr Gly Val Lys Pro Val Glu Met Ala Arg Ala Gly
 785 790 795 800
 Glu Val Asp Thr Ser Lys Tyr Leu Glu Phe Met Glu Ser Thr Leu Asp

-continued

340						345						350					
Leu	Tyr	Lys	Phe	Phe	Phe	Asn	Arg	Ala	Val	Ser	Ile	Tyr	Ala	Phe	Glu		
		355				360					365						
Gly	Lys	Tyr	Ser	Glu	Tyr	Ser	Leu	Tyr	Ala	Val	Ala	Thr	Ala	Leu	Leu		
		370				375					380						
Gly	Ile	Ser	Lys	Val	Lys	Leu	Asp	Thr	Phe	Ile	Ser	Phe	Met	Asp	Ile		
385					390				395						400		
Asp	Lys	Leu	Ile	Glu	Tyr	Asn	Leu	Arg	Asp	Ala	Glu	Ile	Thr	Leu	Lys		
				405				410						415			
Leu	Thr	Thr	Phe	Asn	Asn	Asn	Leu	Val	Leu	Lys	Leu	Met	Val	Leu	Leu		
				420				425						430			
Ala	Arg	Ile	Ser	Lys	Leu	Gly	Leu	Glu	Glu	Leu	Thr	Arg	Thr	Glu	Val		
		435				440						445					
Ser	Thr	Trp	Ile	Lys	Asn	Leu	Tyr	Tyr	Trp	Glu	His	Arg	Lys	Arg	Asn		
		450				455						460					
Trp	Leu	Ile	Pro	Leu	Lys	Glu	Glu	Ile	Leu	Val	Arg	Ser	Asn	Gln	Val		
465						470				475				480			
Lys	Thr	Ala	Ala	Val	Ile	Lys	Gly	Lys	Lys	Tyr	Lys	Gly	Ala	Val	Val		
				485				490						495			
Ile	Asp	Pro	Pro	Ala	Gly	Val	Tyr	Phe	Asn	Val	Val	Val	Leu	Asp	Phe		
		500						505						510			
Ala	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Lys	Asn	Trp	Asn	Ile	Ser	Tyr	Glu		
		515				520						525					
Thr	Ile	Glu	Ile	Asp	Glu	Cys	Thr	Lys	Lys	Val	Trp	Val	Glu	Asp	Glu		
		530				535						540					
Thr	Gly	Glu	Lys	Leu	His	Tyr	Val	Cys	Met	Asp	Lys	Pro	Gly	Ile	Thr		
545						550				555				560			
Ala	Val	Tyr	Gln	Gly	Leu	Ile	Arg	Asp	Phe	Arg	Val	Lys	Val	Tyr	Lys		
				565				570						575			
Lys	Lys	Ala	Lys	Tyr	Ser	Asn	Ile	Ser	Glu	Glu	Gln	Arg	Ser	Leu	Tyr		
		580						585						590			
Asp	Val	Val	Gln	Arg	Ala	Met	Lys	Val	Phe	Ile	Asn	Ala	Thr	Tyr	Gly		
		595				600						605					
Val	Phe	Gly	Ala	Glu	Asn	Phe	Pro	Leu	Tyr	Ala	Pro	Ala	Val	Ala	Glu		
		610				615						620					
Ser	Val	Thr	Ala	Ile	Gly	Arg	Tyr	Ile	Ile	Thr	Thr	Thr	Tyr	Lys	Gln		
625						630				635				640			
Ala	Glu	Lys	Leu	Asn	Leu	Lys	Val	Ile	Tyr	Gly	Asp	Thr	Asp	Ser	Leu		
				645				650						655			
Phe	Leu	Tyr	Asn	Pro	Thr	Lys	Asp	Lys	Leu	Glu	Glu	Leu	Ile	Lys	Phe		
				660				665						670			
Val	Lys	Gln	Asn	Phe	Asn	Leu	Asp	Leu	Glu	Val	Asp	Asn	Thr	Tyr	Lys		
		675				680						685					
Tyr	Val	Ala	Tyr	Ser	Gly	Leu	Lys	Lys	Asn	Tyr	Phe	Gly	Val	Tyr	Pro		
		690				695						700					
Asp	Gly	Lys	Thr	Glu	Ile	Lys	Gly	Met	Leu	Ala	Lys	Lys	Arg	Asn	Thr		
705						710				715				720			
Pro	Glu	Phe	Ile	Lys	Lys	Glu	Phe	Ala	Glu	Ile	Lys	Asn	Met	Leu	Ala		
				725				730						735			
Ser	Leu	Asn	Ser	Pro	Asn	Asp	Ile	Pro	Glu	Val	Lys	Asn	Lys	Leu	Glu		
		740						745						750			
Ile	Lys	Ile	Lys	Asp	Ile	Tyr	Tyr	Lys	Leu	Arg	Asn	Lys	Gly	Tyr	Asn		
		755				760						765					

-continued

Leu Asp Asp Leu Ala Phe Arg Ile Met Leu Ser Lys Pro Leu Asp Ser
 770 775 780
 Tyr Thr Lys Asn Thr Pro Gln His Val Lys Ala Gly Leu Gln Leu Arg
 785 790 795 800
 Ala Phe Gly Val Asn Val Leu Pro Arg Asp Val Ile Met Phe Val Lys
 805 810 815
 Val Lys Ser Lys Asp Gly Val Lys Ala Tyr Gln Leu Ala Lys Ile Ser
 820 825 830
 Glu Ile Asp Ile Glu Lys Tyr Val Glu Thr Leu Arg Thr Thr Phe Glu
 835 840 845
 Gln Ile Leu Lys Ala Phe Gly Ile Ser Trp Asp Glu Ile Val Ser Thr
 850 855 860
 Ile Ser Ile Asp Ser Phe Phe Gly Ser Lys Lys
 865 870 875

<210> SEQ ID NO 107
 <211> LENGTH: 872
 <212> TYPE: PRT
 <213> ORGANISM: Sulfurisphaera ohwakuensis

<400> SEQUENCE: 107

Met Ala Arg Gln Ile Thr Leu Phe Asp Phe Thr Leu Lys Lys Glu Gln
 1 5 10 15
 Asn Lys Asp Glu Ser Arg Lys Glu Glu Ile Pro His Ala Asn Ile Asn
 20 25 30
 Glu Glu Arg Arg Lys Pro Lys Glu Trp Ile Lys Glu Ala Glu Glu Gly
 35 40 45
 Lys Ser Tyr Phe Leu Leu Gln Val Asp Tyr Asp Gly Lys Lys Ser Lys
 50 55 60
 Ala Ile Cys Lys Leu Tyr Asp Lys Glu Thr Lys Lys Ile Tyr Ile Leu
 65 70 75 80
 Tyr Asp Asn Thr Gly His Lys Pro Tyr Phe Leu Thr Asp Ile Asp Pro
 85 90 95
 Glu Lys Val Asn Lys Ile Pro Lys Val Val Arg Asp Pro Ser Phe Asp
 100 105 110
 His Leu Glu Thr Val Ile Lys Ile Asp Pro Tyr Ser Gly Asn Lys Ile
 115 120 125
 Lys Leu Thr Lys Ile Val Val Lys Asp Pro Leu Ala Val Arg Arg Met
 130 135 140
 Arg Asn Ser Val Pro Lys Ala Tyr Glu Ala His Ile Lys Tyr Phe Asn
 145 150 155 160
 Asn Tyr Ile Tyr Asp Leu Gly Leu Ile Pro Gly Leu Pro Tyr Val Val
 165 170 175
 Lys Lys Gly Lys Leu Glu Gln Leu Arg Pro Glu Leu Lys Gly Glu Glu
 180 185 190
 Val Asp Glu Ile Arg Lys Ala Phe Ala Asp Ser Asp Glu Met Thr Lys
 195 200 205
 Glu Ala Val Asn Asp Trp Ile Pro Ile Phe Glu Ser Glu Val Pro Asp
 210 215 220
 Val Lys Arg Val Ala Ile Asp Ile Glu Val Tyr Thr Pro Ile Lys Gly
 225 230 235 240
 Arg Ile Pro Asp Pro Glu Lys Ala Glu Phe Pro Ile Ile Ser Ile Ser
 245 250 255
 Leu Ala Gly Asn Asp Gly Thr Lys Arg Val Leu Val Leu Leu Arg Glu
 260 265 270

-continued

Asp	Val	Asn	Ser	Gln	Ile	Thr	Lys	His	Asp	Val	Ile	Val	Glu	Thr	Phe
	275						280					285			
Lys	Ser	Glu	Arg	Glu	Leu	Ile	Arg	Arg	Phe	Phe	Asp	Ile	Ile	Leu	Asp
	290					295					300				
Tyr	Pro	Ile	Ile	Leu	Thr	Phe	Asn	Gly	Asp	Asp	Phe	Asp	Ile	Pro	Tyr
305					310				315					320	
Ile	Tyr	Tyr	Arg	Ala	Leu	Lys	Leu	Asn	Phe	Thr	Pro	Glu	Glu	Ile	Pro
			325						330					335	
Phe	Asp	Ile	Ile	Asn	Asp	Glu	Gly	Lys	Tyr	Leu	Ala	Gly	Ile	His	Ile
		340						345					350		
Asp	Leu	Tyr	Lys	Phe	Phe	Phe	Asn	Arg	Ala	Ile	Arg	Asn	Tyr	Ala	Phe
	355						360					365			
Glu	Gly	Lys	Tyr	Asn	Glu	Tyr	Asn	Leu	Asp	Ala	Val	Ala	Thr	Ala	Leu
	370					375					380				
Leu	Gly	Met	Ser	Lys	Val	Lys	Leu	Asp	Thr	Leu	Ile	Ser	Phe	Leu	Asp
385					390					395					400
Leu	Asp	Lys	Leu	Ile	Glu	Tyr	Asn	Ser	Arg	Asp	Ala	Glu	Ile	Thr	Leu
			405						410					415	
Lys	Leu	Thr	Thr	Phe	Asn	Asn	Asn	Leu	Val	Trp	Lys	Leu	Ile	Ile	Leu
		420					425						430		
Leu	Ala	Arg	Ile	Ser	Lys	Met	Gly	Leu	Glu	Glu	Leu	Thr	Arg	Thr	Glu
	435						440					445			
Val	Ser	Thr	Trp	Ile	Lys	Asn	Leu	Tyr	Tyr	Trp	Glu	His	Arg	Arg	Arg
450					455						460				
Asn	Trp	Leu	Ile	Pro	Leu	Lys	Glu	Glu	Ile	Leu	Thr	Arg	Ser	Ser	Gln
465				470						475					480
Ile	Lys	Thr	Ala	Ala	Ile	Ile	Lys	Gly	Lys	Arg	Tyr	Lys	Gly	Ala	Val
			485					490						495	
Val	Ile	Asp	Pro	Pro	Ala	Gly	Val	Phe	Phe	Asn	Val	Val	Val	Leu	Asp
		500					505					510			
Phe	Ala	Ser	Leu	Tyr	Pro	Ser	Ile	Ile	Arg	Asn	Trp	Asn	Ile	Ser	Tyr
	515						520					525			
Glu	Thr	Val	Asp	Val	Glu	Asn	Cys	Lys	Asn	Lys	Glu	Tyr	Val	Arg	Asp
	530					535					540				
Glu	Thr	Gly	Glu	Val	Leu	His	Tyr	Ile	Cys	Lys	Asp	Lys	Pro	Gly	Ile
545				550					555					560	
Thr	Ala	Val	Ile	Thr	Gly	Leu	Leu	Arg	Asp	Phe	Arg	Val	Lys	Val	Tyr
			565					570					575		
Lys	Lys	Lys	Ala	Lys	Ser	Gln	Asn	Ile	Ser	Glu	Glu	Gln	Arg	Ser	Val
			580				585					590			
Tyr	Asp	Val	Val	Gln	Arg	Ala	Met	Lys	Val	Phe	Ile	Asn	Ala	Thr	Tyr
	595					600						605			
Gly	Val	Phe	Gly	Ala	Glu	Asn	Phe	Pro	Leu	Tyr	Ala	Pro	Ala	Val	Ala
	610					615					620				
Glu	Ser	Val	Thr	Ala	Ile	Gly	Arg	Tyr	Val	Ile	Thr	Thr	Thr	Val	Asn
625				630					635					640	
Tyr	Cys	Arg	Ser	Ile	Gly	Leu	Gln	Val	Leu	Tyr	Gly	Asp	Thr	Asp	Ser
			645					650					655		
Met	Phe	Leu	Trp	Asn	Pro	Ser	Lys	Glu	Lys	Leu	Glu	Glu	Ile	Ile	Lys
		660					665						670		
Phe	Val	Lys	Gly	Lys	Phe	Gly	Leu	Asp	Leu	Glu	Val	Asp	Lys	Val	Tyr
	675						680					685			
Lys	Phe	Val	Ala	Phe	Ser	Gly	Leu	Lys	Lys	Asn	Tyr	Leu	Gly	Val	Tyr
	690					695					700				

-continued

Pro Asp Gly Lys Thr Asp Ile Lys Gly Met Leu Ala Lys Lys Arg Asn
 705 710 715 720
 Thr Pro Glu Phe Ile Lys Lys Glu Phe Asn Glu Val Lys Gln Leu Val
 725 730 735
 Thr Thr Ile Asn Ser Pro Asp Asp Ile Pro Lys Ile Arg Asp Gln Leu
 740 745 750
 Glu Tyr Lys Ile Lys Glu Ile Tyr Glu Lys Leu Arg His Lys Gly Tyr
 755 760 765
 Asn Leu Asp Glu Leu Ala Phe Arg Val Met Leu Ser Lys Pro Leu Glu
 770 775 780
 Ser Tyr Thr Lys Asn Thr Pro Gln His Val Lys Ala Ala Leu Gln Leu
 785 790 795 800
 Arg Ser Tyr Gly Val Met Val Leu Pro Arg Asp Ile Ile Met Phe Val
 805 810 815
 Lys Val Lys Ser Lys Asp Gly Val Lys Pro Val Gln Leu Ala Lys Leu
 820 825 830
 Ser Glu Ile Asp Val Asp Lys Tyr Ile Asp Ala Val Arg Ser Thr Phe
 835 840 845
 Glu Gln Ile Leu Lys Ala Phe Gly Leu Ile Gly Ala Asn Leu Leu Gln
 850 855 860
 Leu Leu Ser Ile Leu Ser Leu Thr
 865 870

<210> SEQ ID NO 108

<211> LENGTH: 882

<212> TYPE: PRT

<213> ORGANISM: Sulfolobus solfataricus

<400> SEQUENCE: 108

Met Thr Lys Gln Leu Thr Leu Phe Asp Ile Pro Ser Ser Lys Pro Ala
 1 5 10 15
 Lys Ser Glu Gln Asn Thr Gln Gln Ser Gln Gln Ser Ala Pro Val Glu
 20 25 30
 Glu Lys Lys Val Val Arg Arg Glu Trp Leu Glu Glu Ala Gln Glu Asn
 35 40 45
 Lys Ile Tyr Phe Leu Leu Gln Val Asp Tyr Asp Gly Lys Lys Gly Lys
 50 55 60
 Ala Val Cys Lys Leu Phe Asp Lys Glu Thr Gln Lys Ile Tyr Ala Leu
 65 70 75 80
 Tyr Asp Asn Thr Gly His Lys Pro Tyr Phe Leu Val Asp Leu Glu Pro
 85 90 95
 Asp Lys Val Gly Lys Ile Pro Lys Ile Val Arg Asp Pro Ser Phe Asp
 100 105 110
 His Ile Glu Thr Val Ser Lys Ile Asp Pro Tyr Thr Trp Asn Lys Phe
 115 120 125
 Lys Leu Thr Lys Ile Val Val Arg Asp Pro Leu Ala Val Arg Arg Leu
 130 135 140
 Arg Asn Asp Val Pro Lys Ala Tyr Glu Ala His Ile Lys Tyr Phe Asn
 145 150 155 160
 Asn Tyr Met Tyr Asp Ile Gly Leu Ile Pro Gly Met Pro Tyr Val Val
 165 170 175
 Lys Asn Gly Lys Leu Glu Ser Val Tyr Leu Ser Leu Asp Glu Lys Asp
 180 185 190
 Val Glu Glu Ile Lys Lys Ala Phe Ala Asp Ser Asp Glu Met Thr Arg
 195 200 205

-continued

Gln Met Ala Val Asp Trp Leu Pro Ile Phe Glu Thr Glu Ile Pro Lys
 210 215 220
 Ile Lys Arg Val Ala Ile Asp Ile Glu Val Tyr Thr Pro Val Lys Gly
 225 230 235 240
 Arg Ile Pro Asp Ser Gln Lys Ala Glu Phe Pro Ile Ile Ser Ile Ala
 245 250 255
 Leu Ala Gly Ser Asp Gly Leu Lys Lys Val Leu Val Leu Asn Arg Asn
 260 265 270
 Asp Val Asn Glu Gly Ser Val Lys Leu Asp Gly Ile Ser Val Glu Arg
 275 280 285
 Phe Asn Thr Glu Tyr Glu Leu Leu Gly Arg Phe Phe Asp Ile Leu Leu
 290 295 300
 Glu Tyr Pro Ile Val Leu Thr Phe Asn Gly Asp Asp Phe Asp Leu Pro
 305 310 315 320
 Tyr Ile Tyr Phe Arg Ala Leu Lys Leu Gly Tyr Phe Pro Glu Glu Ile
 325 330 335
 Pro Ile Asp Val Ala Gly Lys Asp Glu Ala Lys Tyr Leu Ala Gly Leu
 340 345 350
 His Ile Asp Leu Tyr Lys Phe Phe Phe Asn Lys Ala Val Arg Asn Tyr
 355 360 365
 Ala Phe Glu Gly Lys Tyr Asn Glu Tyr Asn Leu Asp Ala Val Ala Lys
 370 375 380
 Ala Leu Leu Gly Thr Ser Lys Val Lys Val Asp Thr Leu Ile Ser Phe
 385 390 395 400
 Leu Asp Val Glu Lys Leu Ile Glu Tyr Asn Phe Arg Asp Ala Glu Ile
 405 410 415
 Thr Leu Gln Leu Thr Thr Phe Asn Asn Asp Leu Thr Met Lys Leu Ile
 420 425 430
 Val Leu Phe Ser Arg Ile Ser Arg Leu Gly Ile Glu Glu Leu Thr Arg
 435 440 445
 Thr Glu Ile Ser Thr Trp Val Lys Asn Leu Tyr Tyr Trp Glu His Arg
 450 455 460
 Lys Arg Asn Trp Leu Ile Pro Leu Lys Glu Glu Ile Leu Ala Lys Ser
 465 470 475 480
 Ser Asn Ile Arg Thr Ser Ala Leu Ile Lys Gly Lys Gly Tyr Lys Gly
 485 490 495
 Ala Val Val Ile Asp Pro Pro Ala Gly Ile Phe Phe Asn Ile Thr Val
 500 505 510
 Leu Asp Phe Ala Ser Leu Tyr Pro Ser Ile Ile Arg Thr Trp Asn Leu
 515 520 525
 Ser Tyr Glu Thr Val Asp Ile Gln Gln Cys Lys Lys Pro Tyr Glu Val
 530 535 540
 Lys Asp Glu Thr Gly Glu Val Leu His Ile Val Cys Met Asp Arg Pro
 545 550 555 560
 Gly Ile Thr Ala Val Ile Thr Gly Leu Leu Arg Asp Phe Arg Val Lys
 565 570 575
 Ile Tyr Lys Lys Lys Ala Lys Asn Pro Asn Asn Ser Glu Glu Gln Lys
 580 585 590
 Leu Leu Tyr Asp Val Val Gln Arg Ala Met Lys Val Phe Ile Asn Ala
 595 600 605
 Thr Tyr Gly Val Phe Gly Ala Glu Thr Phe Pro Leu Tyr Ala Pro Ala
 610 615 620
 Val Ala Glu Ser Val Thr Ala Leu Gly Arg Tyr Val Ile Thr Ser Thr

-continued

625	630	635	640
Val Lys Lys Ala Arg Glu Glu Gly Leu Thr Val Leu Tyr Gly Asp Thr	645	650	655
Asp Ser Leu Phe Leu Leu Asn Pro Pro Lys Asn Ser Leu Glu Asn Ile	660	665	670
Ile Lys Trp Val Lys Thr Thr Phe Asn Leu Asp Leu Glu Val Asp Lys	675	680	685
Thr Tyr Lys Phe Val Ala Phe Ser Gly Leu Lys Lys Asn Tyr Phe Gly	690	695	700
Val Tyr Gln Asp Gly Lys Val Asp Ile Lys Gly Met Leu Val Lys Lys	705	710	715
Arg Asn Thr Pro Glu Phe Val Lys Lys Val Phe Asn Glu Val Lys Glu	725	730	735
Leu Met Ile Ser Ile Asn Ser Pro Asn Asp Val Lys Glu Ile Lys Arg	740	745	750
Lys Ile Val Asp Val Val Lys Gly Ser Tyr Glu Lys Leu Lys Asn Lys	755	760	765
Gly Tyr Asn Leu Asp Glu Leu Ala Phe Lys Val Met Leu Ser Lys Pro	770	775	780
Leu Asp Ala Tyr Lys Lys Asn Thr Pro Gln His Val Lys Ala Ala Leu	785	790	800
Gln Leu Arg Pro Phe Gly Val Asn Val Leu Pro Arg Asp Ile Ile Tyr	805	810	815
Tyr Val Lys Val Arg Ser Lys Asp Gly Val Lys Pro Val Gln Leu Ala	820	825	830
Lys Val Thr Glu Ile Asp Ala Glu Lys Tyr Leu Glu Ala Leu Arg Ser	835	840	845
Thr Phe Glu Gln Ile Leu Arg Ala Phe Gly Val Ser Trp Asp Glu Ile	850	855	860
Ala Ala Thr Met Ser Ile Asp Ser Phe Phe Ser Tyr Pro Ser Lys Gly	865	870	875
Asn Ser			

<210> SEQ ID NO 109
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR primer

<400> SEQUENCE: 109

gggaaacata tgatccttga cggttgattac

30

<210> SEQ ID NO 110
 <211> LENGTH: 31
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: PCR primer

<400> SEQUENCE: 110

gggaaaggat cctcacttct tcttccccctt c

31

What is claimed is:

1. An Archaeal DNA polymerase comprising at least one amino acid mutation in the exoI motif and an amino acid mutation at V93 of SEQ ID NO:89 or a corresponding residue in an amino acid sequence selected from SEQ ID NOs: 83-88

or SEQ ID NOs:90-102, wherein said Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

2. An Archaeal DNA polymerase comprising at least one amino acid mutation in the exoII motif and an amino acid mutation at V93 of SEQ ID NO:89 or a corresponding residue

269

in an amino acid sequence selected from SEQ ID NOs:83-88 or SEQ ID NOs:90-102, wherein said Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

3. An Archaeal DNA polymerase comprising at least one amino acid mutation in the exo III motif and an amino acid mutation at V93 of SEQ ID NO:89 or a corresponding residue in an amino acid sequence selected from SEQ ID NOs:83-88 or SEQ ID NOs:90-102, wherein said Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

4. An Archaeal DNA polymerase comprising at least one amino acid mutation in each of the exo I and exo III motifs and an amino acid mutation at V93 of SEQ ID NO:89 or a corresponding residue in an amino acid sequence selected from SEQ ID NOs:83-88 or SEQ ID NOs:90-102, wherein said Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

5. An Archaeal DNA polymerase comprising at least one amino acid mutation in each of the exo II and exo III motifs and an amino acid mutation at V93 of SEQ ID NO:89 or a corresponding residue in an amino acid sequence selected from SEQ ID NOs:83-88 or SEQ ID NOs:90-102, wherein said Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

6. An Archaeal DNA polymerase comprising at least one amino acid mutation in each of the exo I and exoII motifs and an amino acid mutation at V93 of SEQ ID NO:89 or a corresponding residue in an amino acid sequence selected from SEQ ID NOs:83-88 or SEQ ID NOs:90-102, wherein said Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

7. An Archaeal DNA polymerase comprising at least one amino acid mutation in each of the exoI, exo II, and exoIII motifs and an amino acid mutation at V93 of SEQ ID NO:89 or a corresponding residue in an amino acid sequence selected from SEQ ID NOs: 83-88 or SEQ ID NOs:90-102, wherein said Archaeal DNA polymerase is deficient in 3'-5' exonuclease activity.

8. The mutant Archaeal DNA polymerase of any of claims 1-7, wherein said mutant Archaeal DNA polymerase is selected from the group consisting of: KOD, Pfu, and JDF-3 DNA polymerase.

9. The mutant Archaeal DNA polymerase of any of claims 1-7, wherein said mutation at position V93, is a Valine to Arginine substitution, a Valine to Glutamic acid substitution, a Valine to Lysine substitution, a Valine to Aspartic acid substitution, a Valine to Glutamine substitution, or a Valine to Asparagine substitution.

10. The mutant Archaeal DNA polymerase of any of claims 1-7, wherein said mutation in exo I motif is selected from the group consisting of: aspartic acid (D) to threonine (T), aspartic acid (D) to alanine (A) and glutamic acid (E) to alanine (A).

270

11. A composition comprising a mutant Archaeal DNA polymerase of any of claims 1-7.

12. The composition of claim 11, further comprising an enzyme with reverse transcriptase activity.

13. The composition of claim 12, wherein said enzyme with reverse transcriptase is a second mutant DNA polymerase.

14. The composition of claim 12, wherein said enzyme with reverse transcriptase is the mutant Archaeal DNA polymerase which contains an increased reverse transcriptase activity.

15. The composition of claim 11, further comprising a PCR additive.

16. A kit comprising a mutant Archaeal DNA polymerase of any of claims 1-7 and packaging material therefor.

17. The kit of claim 16, further comprising an enzyme with reverse transcriptase activity.

18. The kit of claim 17, wherein said enzyme with reverse transcriptase is a second mutant DNA polymerase.

19. The kit of claim 17, wherein said enzyme with reverse transcriptase is the mutant Archaeal DNA polymerase which contains an increased reverse transcriptase activity.

20. The kit of claim 16, further comprising a PCR additive.

21. A method for DNA synthesis comprising:

(a) providing a mutant Archaeal DNA polymerase of any of claims 1-7; and

(b) contacting said mutant Archaeal DNA polymerase with a polynucleotide template to permit DNA synthesis.

22. A method for determining the abundance of a polynucleotide template, comprising

(a) providing a mutant Archaeal DNA polymerase of any of claims 1-7;

(b) contacting said mutant Archaeal DNA polymerase with said polynucleotide template to produce amplified product; and

(c) determining the abundance of said amplified product, wherein said abundance of said amplified product is indicative of the abundance of said polynucleotide template.

23. The method of claim 22, wherein said polynucleotide template is a RNA molecule, and wherein said RNA molecule is reverse transcribed into cDNA before the contacting step (b).

24. The method of claim 23, wherein said RNA is reverse transcribed by an enzyme with reverse transcriptase activity.

25. The method of claim 24, wherein said RNA is reverse transcribed by said mutant Archaeal DNA polymerase which also contains an increased reverse transcriptase activity.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 8,283,148 B2
APPLICATION NO. : 10/734563
DATED : October 9, 2012
INVENTOR(S) : Joseph A. Sorge et al.


Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face page, in field (56), under "Other Publications", in column 2, line 10, delete "Archael" and insert -- Archaeal --, therefor.

On the face page, in field (56), under "Other Publications", in column 2, line 11, delete "archael" and insert -- archaeal --, therefor.

Signed and Sealed this
First Day of January, 2013

A handwritten signature in black ink, reading "David J. Kappos". The signature is written in a cursive, flowing style with a large initial "D".

David J. Kappos
Director of the United States Patent and Trademark Office